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An effective HIV vaccine remains the main hope for controlling the HIV epidemic and is a 
global health priority. The genetic diversity of the virus across the globe is a major 
impediment to developing an effective vaccine.  Whether a universal vaccine is possible 
still remain elusive. Therefore, there is need to fully characterise clusters of commonly 
targeted regions across the different HIV-1 clades. Centralized sequences have been 
suggested as vaccine immunogens and peptide reagents for assessing vaccine-induced 
responses, but their cross-reactivity has not been fully assessed in larger cohorts of subtype 
C-infection and in regions of differing HIV epidemics. In addition, the functional profile of 
HIV-specific T-cells recognizing variant epitopes has not been fully characterized. Whether 
cross-reactivity observed by IFN-γ production in an ELISpot assay can be observed at 
physiological concentrations of the peptides and for other functions of HIV-specific T-cells 
is an important question that remains to be answered. 
 
Methods 
The cross-reactivity of HIV-specific T-cells was assessed using clade-specific peptide 
reagents forming part of current candidate vaccine inserts based on the HIV-1 Gag protein 
from clades CDu422, CCH, A, B and D in 40 clade C-infected study participants using the 
IFN-γ ELISpot assay. To test the reactivity of group M consensus peptide reagents, 66 
individuals, 44 of whom were ARV naïve, were assessed for HIV-specific T cell responses 
to group M Gag and Nef peptides. A selection of these individuals was screened for HIV-
specific T-cell responses to clade CDu422 Gag peptides. Cross-reactivity of peptide variants 
was assessed at physiologically relevant peptide concentrations by functional avidity 
studies using peptide dilution IFN-γ ELISpot assays. Additionally, the cytokine profile, 
cytotoxic potential and proliferative capacity of cross-reactive peptide variants was 
characterised using multiparameter flow cytometry.  
 
Results 
The magnitude and breadth of HIV-specific T-cell responses were similar between the two 
clade-C peptide reagents in a clade C-infected population. However, the magnitude and 
breadth of responses to peptides based on clades A, B and D were significantly lower 












across the four clades investigated resided predominantly in conserved regions. 
Interestingly, there were Gag regions that were exclusively recognized in the different 
clades that had significantly lower entropy scores for the reactive variants than their non-
reactive counterparts, suggesting that the variability in targeted regions could have been 
shaped by host immune pressure. For consensus group M peptides, the magnitude and 
breadth of Gag responses were significantly higher than that of Nef in clade C-infected 
individuals. In addition, consensus group M Gag peptides had significantly lower 
magnitude and breadth of HIV-specific T-cell responses compared to clade C peptide 
reagents, suggesting loss of responses by centralised reagents despite their central nature to 
group M viruses. On the contrary, the magnitude and breadth of responses to consensus 
group M Gag peptides were comparable to that of clade-mismatched peptides, namely 
clades A, B and D, suggesting that these reagents can be used interchangeably. Peptide 
dilution assays showed that amino acid mismatches have discordant effects on functional 
avidity and that some peptides are cross-reactive at physiological concentrations. Similarly, 
discordant effects (differences in functional avidity, cytokine and cytotoxic profiles and 
proliferative capacity) of amino acid mismatches on cytokine and cytotoxic potential 
profiles as well as proliferative capacity were observed. 
 
Conclusion 
People infected by a particular HIV clade can recognize HIV peptides based on other 
clades. However, the magnitude and breadth of responses are greater for the matched clades 
compared to mismatched clades, suggesting that there may be an advantage of using 
vaccines based on matched over unmatched clades. Group M based consensus sequences 
can be recognized in HIV-infected individuals, but with a lower frequency, magnitude and 
breadth of responses compared to clade-matched peptides, suggesting a limitation of these 
peptides both as reagents and vaccine immunogens. However, the frequency, magnitude 
and breadth T-cell reponses to consensus group M peptides were comparable to clade-
mismatched responses, suggesting that these reagents may be used interchangeably. 
Furthermore, amino acid variations across corresponding viral regions have discordant 
effects on the functional avidity, cytokine profile, cytotoxic potential and proliferative 
capacity; implying that qualitative measures of cross-reactivity beyond IFN- frequencies 
need to be considered. These data may aid in the development of reagents for the 
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Worldwide, there were an estimated 34 million people living with HIV at the end of 
2010, with 17% of these having been infected since 2001 (UNAIDS Epidemic Update, 
2011). Sub-saharan Africa remains the worst affected by the HIV/AIDS epidemic, with 
68% of all HIV infections residing in this region (UNAIDS Epidemic Update, 2011). 
The degree of the burden is clearly apparent from the fact that Sub-Saharan African 
accounts for only 12% of the global population yet nearly 70% of all new HIV infections 
in 2010 were from this region. The epidemic is more severe in South Africa, which has 
the highest number of HIV infections than any other country in the world, estimated at 
5.7 million out of a population of 48 million (UNAIDS Epidemic Update, 2011). 
 
To some extent, behavior change in certain countries and greater access to antiretroviral 
treatment (ART) has recently stabilised or reduced the number of new HIV infections 
and HIV/AIDS-related deaths worldwide, respectively (UNAIDS Epidemic Update, 
2011). However, a safe and effective HIV vaccine is currently a critically important 
global health priority to halt new infections (there were still a staggering 2.7 million new 
infections in 2010; UNAIDS Epidemic Update, 2011), as well as for long-term control of 
the epidemic. The development of such a vaccine faces many challenges, the most 
important being the huge genetic diversity and plasticity the virus exhibits, our 
incomplete knowledge of what constitutes a durable and effective immune response 
against the virus, and how to generate such a response with a vaccine. Therefore, a 
greater understanding of the biology of the virus and its interaction with the immune 
system, its diversity and distribution worldwide, and immune correlates of protection in 
natural HIV infection are of major importance in the design of an effective HIV vaccine.  
This chapter provides an overview of the key concepts in HIV biology, diversity, 
immunity and vaccine design pertinent to the studies described in the thesis. 
1.1. The genetic organization and gene products of HIV 
 
The HIV genome is approximately 9.8 kilobase pairs long and is composed of nine genes 
that code for 15 proteins; three structural or enzyme polyproteins whose products are 
essential components of the viral particle (Gag, further processed into p24, p17 and p6, 
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four enzymes, namely integrase, reverse transcriptase, protease and RNase-H), two 
regulatory proteins (Tat and Rev) and four accessory proteins (Nef, Vif, Vpr and Vpu, 
Figure 1.1, http://hiv-web.lanl.gov). The genome has two long terminal repeat units 
(LTR), at the unique 5‟ (U5) and unique 3‟ (U3) ends that have control elements required 
for transcription of the viral genome (Frenza et al., 1998). Previous studies have shown 
that almost all of the expressed HIV proteins are immunogenic (Addo et al., 2003). In 
terms of variability, these proteins can vary by as much as 5-25% within a single HIV 
clade and by 10-40% between different HIV-1 clades (Kuiken et al., 2010). 
 
   
 
 
Figure 1.1. A diagrammatic representation of the genetic organization of HIV genome. The proviral 
genome is composed of nine genes that are flanked by two long terminal repeats (LTR, 5‟ and 3‟). The 
nine open reading frames code for at least 15 proteins. The gag gene is translated into the structural Gag 
precursor (Pr55
Gag
) that is cleaved into matrix, p17 (MA), capsid, CA (p24), nucleocapsid, NC (p7) and p6 
(Sp1 and Sp2 are spacer proteins). The pol gene is translated by a -1 ribosomal frameshift as a Gag-Pol 
precursor polypeptide that yields the four enzymes Reverse Transcriptase (RT), Integrase (IN), Protease 
(PR) and Ribonuclease H (RNaseH) upon cleavage. The env gene encodes the anchor structural precursor 
Env, gp160, which is cleaved into the surface (gp120) and trans-membrane (gp41) glycoproteins. The 
Gag-Pol mRNAs are spliced to encode the regulatory (Rev, Tat) and accessory (Nef, Vpr, Vpu and Vif) 




1.1.1. Structural proteins 
 
Gag 
Gag is one of the main HIV-1 proteins that this thesis focuses on. It is a 55 kD protein 
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polypeptides, namely the matrix protein (MA), capsid protein (CA), nucleocapsid protein 
(NC) and three smaller peptides, the spacer proteins 1 and 2 (SP1 and SP2) and protein 6 
(p6, Briggs et al., 2004; Henderson et al., 1992; Mervis et al., 1988), that are produced 
by the activity of the viral protease enzyme (Swanstrom and Wills, 1997; Vogt, 1997). 
These proteins function together to coordinate membrane binding and Gag-Gag lattice 
interaction in immature virions (Ganser-Pornillos et al., 2008; Scarlata et al., 2003). The 
MA that is derived from the myristylated N-terminal of p55 encompasses p17, and forms 
the scaffold between the core and the outer envelope of the capsid. This region of Gag 
also contains a nuclear localization domain that facilitates the nuclear transport of the 
viral genome and allows HIV to infect non-dividing cells (Fassati, 2006; Qi et al., 2008).   
 
The CA encompasses the p24 region of Gag and forms the conical core of viral particles 
(Gottlinger et al., 2001), and is important for proper folding of the HIV virion particle 
(Yoo et al., 1997) and also following entry into a new target cell (Gottlinger et al., 
2001). It is the region of Gag that interacts with the cellular protein Cyclophilin A 
(CyPA) and mediates its incorporation into HIV virions (Dorfman and Gottlinger, 1996; 
Lopez et al., 2011).  Cyclophilin A is a cytosolic human protein involved in protein 
folding (Zydosky et al., 1992), and previ us studies have demonstrated that decreased 
levels of virion-associated CyPA result in reduced virion infectivity (Thali et al., 1994) 
and decreased HIV replication rates in T-cell lines that lack CyPA (Braaten and Luban, 
2001). The CA protein is also involved in the incorporation of the Gag-Pol precursor, 
and therefore enzymes into the capsid (Bukovsky and Gottlinger, 1996; Huang and 
Martin, 1997; Srinivasakumar et al., 1995; Wills and Craven, 1991). 
 
The NC, also referred to as the p7 protein, Sp1, Sp2 and p6 encompass the p15 region of 
the Gag protein. The nucleocapsid protein is important for transmission and pathogenesis 
of the virus. It is responsible for specifically recognizing the packaging signal of the 
genome, and introducing two copies of the viral genome into progeny virions (Heath et 
al., 2003; Dussupt et al., 2011). This protein is highly basic and has a non-specific 
nucleic acid binding ability that is utilized during annealing reactions in the virus life 
cycle (Berkowitz et al., 1996). The p6 protein constitutes one of the most variable 
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viral life cycle. These include binding to Tsg101 and ALIX, cellular factors important 
for viral budding from infected cells (Doherty et al., 2005). In addition, p6 is a substrate 
for phosphorylation, ubiquitination and sumoylation, thereby mediating the incorporation 
of the Vpr protein into the viral particles (Paxton et al., 1993; von Schwedler et al., 
2003; Votteler et al., 2011). Spacer protein 1 (Sp1) is located between the CA and NC, 
and spacer protein 2 (Sp2) is located between NC and p6 (Bryant et al., 2011). Sp1 plays 
a major role in Gag multimerization, higher order organization of the Gag lattice and 
virus particle assembly (Datta et al., 2011; Liang et al., 2002). Sp2 plays similar roles 
and cleavage between p6 and Sp2 has been shown to be critical for the formation of fully 
infectious particles (Yu et al., 1995). Furthermore, a recent study showed that cleavage 
of the Sp2-p6 site is necessary for genome integration by the infecting virus (Coren et 
al., 2007). Overall, these cleavage processes are important for the maturation of the 
virion (Vogt, 1996; Wiegers et al., 1998).  
 
The p24 region is relatively conserved compared to the p17 and p15 regions of Gag, and 
targeting of epitopes within the p24 region of the HIV Gag protein has been shown to be 
associated with viral control (Zuniga et al., 2006). Overall, CD8+ T-cell escape 
mutations in the Gag protein, particularly p24 epitopes, have been associated with a 
fitness cost to the virus (Ammaranond et al., 2011; Martinez-Picado et al., 2006; Troyer 
et al., 2009), suggesting that Gag is a good target for inclusion in a vaccine. 
 
Pol 
The pol gene encodes four different enzymes that are involved in different processes of 
HIV replication. The enzymes are produced as a Gag-Pol precursor protein, that is 
further processed by the viral protease enzyme into the individual proteins. Reverse 
transcriptase (RT) is one of the main enzymes encoded by pol and is unique to 
retroviruses; reverse transcribing the single-stranded HIV RNA (ssRNA) to DNA 
(Kuiken et al., 2000). Another enzyme coded for by the pol gene is RNase-H, which 
breaks down the retroviral genome after infection of a cell; integrase, which integrates 
the DNA copy of the HIV genome into the host DNA (Craigie, 2001; Wang et al., 2001); 
and protease, which processes multiple polyproteins of HIV so that they can become part 
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Env 
The envelope protein is cleaved into two main proteins, a non-covalent complex of the 
external gp120 and a transmembrane glycoprotein, gp41. These proteins are synthesized 
as a precursor protein gp160 that matures through various steps, including disulphide 
bond formation (Coffin et al., 1997), extensive glycosylation, cleavage by membrane-
associated   proteases such as furin (Oliva et al., 2003), transport to the cell surfaces as a 
non-covalent membrane complex (gp120) and finally incorporation into the budding 
virus (Adamson et al., 2007). The mature gp120-gp41 proteins interact together by 
means of non-covalent interactions, with gp41 transversing through the lipid bilayer of 
membranes and gp120 on the cell surface. Gp120 is composed of five conserved 
domains, C1-C5, and five variable domains, V1-V5, and gp41 is composed of seven 
transmembrane domains. The gp120 glycoprotein, through its V3 loop, is responsible for 
cell tropism for either T-lymphocytes or primary macrophages (Landau et al., 1988), and 
contains the binding site for the CD4 receptor, interacts with CXCR4 and CCR5 
chemokine receptors (Hwang et al., 1991) and DC-SIGN on dendritic cells, which 
facilitates mucosal transmission through transportation of HIV to lymphoid tissue (Deng 
et al., 1996; Geijtenbeek et al., 2000). It is also the primary target for neutralizing 
antibodies (Feng et al., 1996). The gp41 protein contains an N-terminal fusogenic 
domain, binds to the MA protein and mediates viral and cellular membrane fusion 
(Camerini and Seed, 1990). 
 
1.1.2. Regulatory proteins 
 
These proteins regulate the transcriptional and posttranscriptional steps involved in viral 
gene expression, and have all been shown to be important for viral propagation. 
 
Tat 
HIV Tat (trans-activator) protein acts as a transcriptional regulator of viral gene 
expression that function early in viral infection. Tat binds to the trans-activating 
responsive sequence (TAR) RNA element located at the 5‟ end of the HIV RNA genome 
and initiates viral transcription and elongation from the LTR promoter by binding to P-
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factor and cofactor that prevents polymerase arrest resulting in the production of full-
length HIV-1 transcripts (He et al., 2011). This accelerates the production of HIV viral 
particles (Roy et al., 1990) and up-regulates the expression of all viral genes, promoting 
the elongation phase of HIV-1 transcription and allowing full-length transcripts to be 
produced (Feinberg et al., 1991; Kao et al., 1987). Absence of Tat results in premature 
termination of HIV-1 transcription generating short transcripts (Jones, 1997). 
 
Rev 
HIV Rev is produced from fully spliced mRNA and functions early in HIV infection. 
Rev binds to the rev responsive element (RRE; Malim et al., 1989) and regulates 
unspliced and incompletely spliced viral RNA nuclear export to the cytoplasm (Hope, 
1999). Rev has also been shown to up-regulate the expression of structural proteins 
(Gag, Pol and Env) while down regulating itself and Tat (Douglas et al., 1997), through 
down-regulation of mRNA splicing (since it is produced from fully spliced mRNA). HIV 
Rev also facilitates the transition from the early to late phase of HIV gene expression 
(Kim et al., 1989).  
 
1.1.3. Accessory or auxiliary proteins 
 
These proteins are not necessary for HIV propagation in tissue culture but they have 
been conserved in different l ntiviruses and experimental observation in in vitro studies 
suggests that they are important in vivo as they have been found to influence viral 
replication and the course of disease progression (reviewed in Kirchhoff et al., 2010). 
Overall, accessory proteins enable viral persistence, replication, dissemination and 
transmission through preventing immune-mediated or intrinsic antiviral resistance by 
modifying the infected host cell environment (Malim and Emerman, 2008). 
 
Nef 
Nef is a small (27kD) multifunctional protein that is predominantly cytoplasmic but 
through myristol residues and basic amino acids at the N-terminal of the protein, also 
associates with the cell membrane (Welker et al., 1998; Yu and Felsted, 1992). Studies 
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major functions (Alexander et al., 2003; Walk et al., 2001). Studies of HIV-1 long-term 
non-progressors have identified viruses with defective Nef, suggesting that this protein is 
essential for the efficient spread of the virus and disease progression (Brambilla et al., 
1999; Deacon et al., 1995; Rhodes et al., 2000; Salvi et al., 1998; Tolstrup et al., 2006). 
Nef down-regulates MHC class I molecules (Schwartz et al., 1996; Toussaint et al., 
2008), and this function of Nef protects infected cells from recognition and killing by 
cytotoxic T-lymphocytes (Schwartz et al., 1996). Nef has the ability to interfere with 
many cellular pathways, with the ultimate consequence of favoring virus persistence in 
infected individuals.  Some of these functions include down-regulation of a host of 
receptors from the cell surface, including CD4, CD28 and MHC class II-associated 
invariant chain (reviewed in Lindwasser et al., 2007; Kirchhoff et al., 2008).  In addition, 
Nef has been shown to down-regulate CCR5 and CXCR4, which is thought to protect 
cells from super-infection (Michel et al., 2005; 2006). Structurally, Nef has an overall 
conserved central region that is highly immunogenic and that is flanked by variable 
regions that are less immunogenic (Addo et al., 2003).  
 
Vif 
Virion infectivity factor (Vif) is a cytoplasmic protein that functions during viral particle 
assembly and inhibits the incorporation of cellular antiviral agents into viral particles. 
For example, Vif interacts with the cellular restriction factor APOBEC3G, leading to 
degradation of the protein, mediated through polyubiquitination of APOBEC3G, thus 
directing it to degradation by proteases (Opi et al., 2007).  APOBEC3G is an 
intracellular antiviral protein that results in defective virions by deaminating the minus-
strand of the viral genome, introducing numerous G to A mutations (Fan et al., 2010; Yu 
et al., 2004).  
 
Vpr 
Viral protein R (Vpr) accelerates the production of HIV proteins by promoting cell-cycle 
arrest at the G2 phase of cell cycle through activation of p34cdc2/cyclin B complex, a 
regulator of the cell cycle important for cell entry into mitosis (Ho et al., 1995; Jowett et 
al., 1995), thereby inhibiting cell division by mitosis (Planelles et al., 1995).  The 
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of p55 Gag (Bachand et al., 1999). Vpr also facilitates the formation of the pre-
integration complex that is required for the HIV genome to be integrated into the cellular 
genome (Miller & Sarver, 1997; Popov et al., 1998). Vpr can also allow infection of 
non-dividing tissue macrophages, notably terminally differentiated macrophages 
(Vodicka et al., 1998) through interaction with the nuclear transport pathway (Eckstein 
et al., 2001; Vodicka et al., 1998). This interaction leads to nuclear importation of HIV-1 
pre-integration complex (PIC) and the presence of Vpr in the cytoplasm for 
incorporation into virions, thus enhancing viral spread in these cells (Sherman et al., 
2003). Non-dividing cells constitute important reservoirs of the virus in infected 
individuals (Hockett et al., 1999; Igarashi et al., 2001).  
 
Vpu 
Vpu (viral protein U) is a transmembrane protein unique to certain lentiviruses namely 
HIV-1, its chimpanzee and gorilla precursors (Gao et al., 1999), and SIVgsm, SIVmus, 
SIVmon and SIVden (Barklow et al., 2003; Courgnand et al., 2003; Dazza et al., 2005). 
Vpu functions in promoting CD4 degradation in the endoplasmic reticulum (ER) as well 
CD4 down-regulation from the cell surface (Magadan and Bonifacino, 2012), and helps 
virion release from the plasma membrane of HIV-1 infected cells (Deora & Ratner, 
2001). Down-regulation and degradation of CD4 reduces the likelihood of a cell 
becoming super-infected. Vpu counteracts the cellular restriction factor Tetherin (BST-
2), which prevents budding of viral particles, by binding it and directing it to 
proteasomal degradation by β-TrCP2 (beta-transducin-repeat-containing protein), a 
human ubiquitin ligase that degrades proteins, (Mangeat et al., 2009; Dube et al., 2010). 
 
1.2. HIV genetic diversity and distribution 
 
One of the major characteristics of HIV relevant to vaccine immunogen design is its 
extensive and constantly changing genetic diversity, that results in different variants that 
can be categorized into distinct genetic subtypes as well as recombinant forms. These 
subtypes and recombinant forms are unevenly distributed throughout the world 
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immunogens being designed to be included in vaccines can be further understood in the 
context of the genetic diversity the virus exhibits and generates during infection. 
 
 
1.2.1. HIV classification 
 
HIV-1 is classified into four main groups, which are groups M (the main group), O (the 
outlier group), N (non-M nor O group, Ayouba et al., 2000; Gurtler et al., 1994; Rayfield 
et al., 1996; Simon et al., 1996) and the recently identified group P (Plantier et al., 2009; 
Vallari et al., 2011). It is HIV-1 group M that is responsible for the majority of HIV 
infections throughout the world, and it is further subdivided into ten phylogenetic 
subtypes designated by the letters from A-K (Figure 1.2). These subtypes are 
approximately genetically equidistant from each other, except for subtypes B and D, that 
are more closely related to each other than to other subtypes (Gao et al., 1996). The 
subtypes are classified based on phylogenetic clustering of sub-genomic regions such as 
gag, nef, pol and env of individual genes from the same isolates. In addition, advances in 
sequencing technology have enabled the use of multiple sub-genomic regions and near 
full-length genome sequence analysis for subtyping and classification of HIV-1 variants 
(Louwagie et al., 1993; Triques et al., 2000).  These studies highlight the degree to 
which recombination contributes to HIV-1 subtypes diversity, and highlight the 
limitations of using a single method or gene for classification, since some viruses are the 











Chapter 1: Literature review 11 
 
           
 
 
Figure 1.2. The different levels of HIV classification. More than 90% of HIV-1 infections worldwide 
belong to HIV-1 group M. Group O is found in west-central Africa, group N was discovered in 1998 in 
Cameroon and is exceptionally rare, and Group P was discovered in 2009 and has been described in only 
two individuals from Cameroon. 
 
 
The inter-subtype genetic distance within group M is 15% for the gag gene and as high 
as 25% for the env gene (Janssens et al., 1994; Robertson et al., 2000). Sub-subtypes 
have been identified, which are formed when viruses from the same subtypes recombine, 
and appear to be more genetically related to each other when compared to other subtypes 
(Robertson et al., 2000). Examples of sub-subtypes are A1 and A2 and F1 to F2 from 
subtypes A and F, respectively (Gao et al., 2001; Triques et al., 2000).  
 
There are also viral isolates that are a product of genetic recombination between two 
distinct subtypes (Burke et al., 1997) and are thought to originate from people multiply 
infected with viruses of two or more subtypes. Those recombinant forms that can be 
identified by full-length genome sequencing in at least three epidemiologically unlinked 
individuals have been designated circulating recombinant forms (CRFs; McCutchan, 
2006; Peeters, 2001; Robertson et al., 2000). At least 49 CRFs have been identified thus 
far (http://www.hiv.lanl.gov/), and they are identified by numbers in ascending order 
according to discovery, followed by letters of the parental subtypes. If only a single 
sequence is available, they are designated unique recombinant forms (Robertson et al., 
2000; Ragupathy et al., 2011). These recombinants are common in regions with 
HIV-1 HIV-2 
Group M Group N Group O Group P 
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multiclade epidemics, such as countries in West central Africa. CRF02_AG and 
CRF01_AE are amongst the commonly found CRFs. 
 
This extensive heterogeneity of HIV-1 is driven by different mechanisms that include the 
high error rate of reverse transcriptase enzyme during transcription (Op de Coul et al., 
2001; Roberts et al., 1988), rapid turnover of HIV-1 in vivo (Ho et al., 1995), host 
selective immune pressure (Michael, 1999) and recombination events during replication 
(Temin, 1993). 
 
The high error prone reverse transcriptase enzyme that results in the incorporation of 
incorrect nucleotides during transcription results in rapid HIV evolution (Op de Coul et 
al., 2001; Roberts et al., 1988). A huge amount of genetic variation is generated that is 
fueled by the rapid replication rates of the virus in CD4+ T lymphocytes (Ho et al., 
1995). There are studies that have shown that rapid HIV evolution correlates with rapid 
HIV disease progression (Mullins and Jensen, 2006). 
Another mechanism that generates the much genetic variation in HIV is the high rate of 
recombination. This can be on average three events per genome per round of replication 
(Hu and Temin, 1990a and 1990b). Coupled to the rapid replication rate of the virus, a 
huge amount of genetic variation is generated between and within HIV subtypes 
(Schroeder et al., 2005; Charpentier et al., 2006). 
 
HIV has been shown to evolve under immune selection pressure, with a vast amount of 
data generated suggesting that certain regions of HIV targeted by CD8+ T cells mutate in 
an effort to escape recognition by the immune system (Price et al., 1997; Borrow et al., 
1997). However, as some of these mutations may be in regions that have structural roles 
for the virus, this can result in a fitness cost that results in a reduced replicative capacity 
(Gesprasert et al., 2010; Martinez-Picado et al., 2006; Novitsky et al., 2009; Troyer et 
al., 2009). For example, the extensively studied dominant Gag TW10 escape mutation, 
T242N, has been shown to reduce viral replicative capacity (Martinez-Picado et al., 
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1.2.2. Geographic distribution of HIV-1 subtypes 
 
Except in Africa, where almost all HIV subtypes are found, other regions in the world 
show a clear, distinct pattern of HIV subtype distribution (Hemelaar et al., 2006; 2011; 
Osmanov et al., 2002). The migration of people from one place to another or a prevalent 
route of transmission favoring a certain subtype in that particular population could have 
resulted in this distribution of HIV subtypes (Buonaguro et al., 1995; McCutchan et al., 
1992a and 1992b; Myers, 1994; Naderi et al., 2006; Ou et al., 1992). However, this 
pattern is being affected by increases in global travel (Perrin et al., 2003). 
 
Recent studies have identified HIV-1 subtypes A, B and C as the most prevalent HIV-1 
subtypes globally, with subtype C accounting for almost 50% of infections worldwide 
(Hemelaar et al., 2011). Subtype A and B account for approximately 12% and 11% of 
global infections, respectively. HIV-1 subtype A viruses are the predominant subtypes in 
countries in west, central and eastern Africa (Kenya, Uganda, Tanzania, and Rwanda), 
and also make-up the eastern European epidemic (Bobkov et al., 2004, Figure 1.3). HIV-
1 subtype B is the main subtype circulating in western and central Europe, north and 
south America, and Australia, and is also common in other countries in South East Asia, 
northern Africa and the Middle East. In South Africa and Russia, subtype B is mainly 
found among men who have sex with other men (Le Vu et al., 2010). HIV-1 subtype C 
viruses are predominant in those countries with >80% of all global HIV-1 infections, 
such as southern Africa and India (Hemelaar et al., 2006; 2011; Osmanov et al., 2002). 
HIV-1 subtypes G and D each account for 5% and 2% of global HIV-1 infections 
respectively, and are commonly found in central Africa. HIV-1 subtypes F, H J and K 
together account for less than 1% of global HIV-1 infections. 
 
CRFs now account for at least 20% of HIV-1 infections worldwide, and this fact has 
increased their recognition as being relevant in the global HIV-1 pandemic (Hemelaar et 
al., 2011; Osmanov et al., 2002). CRF01_AE is the predominant local form in South 
East Asia (Motomura et al., 2000; Piyasirisilp et al., 2000), while CRF02_AG is 
predominantly found in West and West Central Africa (McCutchan et al., 1999; Peeters 
et al., 2000), as shown in Figure 1.3. These two recombinant forms account for 13% of 
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circulate, some of them dominate the epidemic; for example, in Cameroon, CRF02_AG 
is the predominant virus accounting for more infections than its parental subtypes 
(subtypes A and G) found in the that country (McCutchan et al., 2000; Carr et al., 1998; 
Kijak et al., 2004). Overall, although there was a notable increase in the contribution of 
CRFs to the global HIV-1 epidemic, their global and regional distribution is broadly 
stable (Hemelaar et al., 2011). Unique recombinant forms account for at least 30% of 
infections in regions where they circulate (Peeters et al., 2000; as reviewed in Tebit and 
Arts, 2011). Since recombination and mutation continue to occur, it is likely that new 
genetic subtypes and CRFs of HIV-1 will arise in the future. Furthermore, due to global 
travel, the current subtypes and CRFs will continue to spread to new areas as the global 
epidemic continues.  
 
In addition to the genetic diversity of HIV-1, the task of designing an effective vaccine is 
made difficult by the diverse human leukocyte antigen (HLA) genetic backgrounds of 
individuals in different populations. An important consideration in understanding cellular 
immune responses to HIV-1 infection is the role played by the HLA molecules, through 
which CD8+
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Figure 1.3. Global distribution of HIV-1 subtypes and circulating recombinant forms. (A) Africa. (B) 
South America. (C) Asia. (D) Europe. Each pie represents the contribution of the particular subtype or 
recombinant form to the total sequences in the database from the specific country from different regions, with 
the different subtypes and recombinants being color-coded. The table of names and geographical locations of 
countries were obtained from the Natural Earth Data website (www.naturalearthdata.com). Sequence data and 
information on classification of countries into regions were obtained from the HIV geography site of the Los 
Alamos Sequence database (www.hiv.lanl.gov), as of 31 December 2011. The tables were joined and 
modified and map drawn using the Arc Geographical Information System (GIS) software version 9.3.1 (Arc 
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1.3. HLA genetic diversity, distribution and association with disease progression 
 
HLA genetic diversity and distribution 
The HLA genes can be divided into three main loci, namely HLA class I, II and III (Shiina et al., 
2009). HLA class I molecules are involved in the presentation of immunogenic peptides to 
CD8+
 
T-cells, while HLA class II molecules present peptides to CD4+ T-cells (Gebe et al., 
2002). HLA class I alleles involved in peptide presentation are classified into HLA-A, -B, -C, 
while HLA class II are classified into HLA-DP, -DQ and –DR. HLA class III molecules are 
unrelated to peptide presentation. The type of peptide that binds to a particular HLA molecule 
depends on the HLA anchor residues and the sequence of that particular peptide. 
 
The genes that code for HLA molecules are highly polymorphic, with extensive allelic variation 
within the HLA class I loci (Lazaro et al., 2011a, 2011b and 2011c; Pacheco et al., 2010). At 
least 3249 HLA class I and 1198 HLA class II alleles have been described to date 
(http://www.ebi.ac.uk/imgt/hla/stats.html). Different alleles show different degrees of 
diversification, with HLA B molecules being more diverse when compared to other HLA class I 
alleles (Tian et al., 2003). There have been 965 HLA-A, 1 543 HLA-B and 625 HLA-C 
molecules identified thus far (http://www.ebi.ac.uk/imgt/hla/stats.html). These HLA alleles can 
differ by as little as one nucleotide substitution within a genomic sequence of 3300 base pairs 
(Robinson et al., 2003a and 2003b; 2009), which may result in different peptide recognition 
patterns.  
 
HLA allele variation differs between populations, with some populations exhibiting greater 
diversity compared to others. For example, Brazilians were shown to have a high variation 
within the HLA-B locus compared to Mexican, Cuban, South African Zulus, Omani and 
Singapore Chinese, with the Mexicans exhibiting the least diversity of them all (Williams et al., 
2001). Different populations and ethnicities express different HLA alleles (reviewed in Stephens 
et al., 2005), with certain alleles being dominant or even specific to certain populations. For 
example, HLA-A*02:02; A*34:02; A*36:01; A*74:01; B*15:03; B*42:01; B*57:03 and 
B*58:02 were shown to be found only in multiple African populations (Cao et al., 2004). Also, 
an allele that is common to a particular population may be rare in another population. Some 
alleles are limited to particular ethnic groups, while others are widely spread among ethnically 
distinct populations. For example, HLA-A*30:02, HLA-B*57:03 and Cw*18:01 are found in 
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B*81:01, Cw*81:01, B*15:03 and B*15:10 in Zulus and Xhosas when compared to other 
populations in South Africa (Honeyborne et al., 2006). Even in individuals of the same ethnicity, 
particular HLA alleles expressed differ among individuals (Du Toit et al., 1990). For example, 
HLA-A*03, B*49 and B*57 have relatively higher frequencies in Ethiopians than in other 
African populations (Ferrari et al., 2004). Overall, HLA-A2 is the most prevalent allele 
worldwide (Browning and Krausa, 1996). This allele has also been associated with reduced risk 
of HIV-1 acquisition in two Kenyan cohorts (McDonald et al., 2000), and so might be of interest 
in development of T-cell based HIV vaccines. Altogether, these data showing the differential 
expression of different HLA alleles in ethnically diverse populations highlight challenges in 
designing a T-cell-based HIV vaccine immunogen with high global population coverage. 
 
HLA and disease progression 
There are strong data to suggest that not all HLA alleles have a similar impact on HIV-1 control. 
Genome wide association studies (GWAS), an approach involving the identification of genetic 
variations in human genomes that are associated with any disease outcome, have generated data 
to suggest that variation attributed to HLA types is associated with differential HIV disease 
outcome. Several GWAS performed on populations of European ancestry showed that the 
B*5701 allele is strongly associated with lower viral set point (the viral load at approximately a 
year after infection) and slower CD4+ T-cell decline (Fellay et al., 2007; Limou et al., 2009; 
Dalmasso et al., 2008; Fellay et al., 2009). In addition, similar analyses in African-Americans 
identified B*57:03 to be associated with slow disease progression (Pelak et al., 2010). These 
studies are lacking in African populations. Complementing the GWAS studies mentioned above, 
certain HLA types have been associated with better diseases outcome, including HLA B*57 
(Altfeld et al., 2003), B*27 (Stephens et al., 2005), B*58:01 (Gao et al., 2001) and B63 (Frahm 
et al., 2005).  On the other hand, HLA B*35, B*58:02 and Cw*04 have been shown to 
negatively affect the outcome of disease (Walker and Korber, 2001). Studies have also shown 
that variations at the B*35Px group have different associations with disease outcome. HLA 
B*35:03 is associated with better disease outcome (Table 1.1), whilst B*35:01 does not 
significantly differ from the population average in terms of disease outcome (Kiepiela et al., 
2004; Kawashima et al., 2009). Similarly, these data extend to macaque models of SIV 
infection. For example, association between MHC class I genotypes Mamu-A*01, Mamu-A*02, 
Mamu-B*08 and Mamu-B*17 with enhanced SIV control has been demonstrated (Goulder and 
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while Mamu-B*01 and Mamu-A*08 have been observed as alleles associated with rapid disease 
progression (Goulder and Watkins, 2004). The mechanism underlying the ability of certain HLA 
types to be associated with better disease outcome was not fully understood. One possible 
mechanism is that CD8+ T-cells restricted by these protective HLA alleles are able to suppress 
regulatory T cells, which themselves would have suppressed the proliferation of these HIV-
specific T-cells (Elahi et al., 2011). This in part provides an explanation of why HIV-specific T-
cells restricted by these protective HLA alleles have a higher proliferative capacity compared to 
those restricted by non-protective alleles. However, the ability of these HLA alleles to perform 
this function, where other non-protective alleles do not, is not fully understood, and needs 
further research. It is likely that the nature of regions being targeted by these HLA alleles and the 
timing of responses are among the possible explanations. Therefore, specificity of the epitopes 
targeted by these CD8+ T-cells may also play an important role in their protective nature, since 
studies have shown that these alleles can present conserved viral epitopes, for example HLA-
B*27 has been shown to restrict a conserved epitope in Gag that is associated with viral control 
(Goulder et al., 1997), since mutation of this region in HIV Gag may result in a reduced 
replication capacity of the virus.  
 
A separate issue with HLA and disease progression is homozygosity.  Individuals homozygous 
for HLA class I alleles appear to have limited breadth of the CD8+ T-cell responses, and this 
may negatively impact disease outcome and progression (Carrington et al., 1999; Huang et al., 
2009; Qing et al., 2006). 
 
These data suggest that different HLA types may have differential contribution to immune 
control of HIV, which makes it sound to construe that HLA diversity and distribution have to be 
taken into consideration in the design of T-cell-generating vaccines, if a high degree of 
population coverage is to be attained. Previous studies have shown differential contribution by 
different HLA molecules to the total anti-HIV cellular immune response (Kiepiela et al., 2004). 
This study suggested a dominant role of HLA-B molecules in shaping the co-evolution of HIV-1 
and HLA molecules, through presentation of more epitopes when compared to HLA-A and 
HLA-C. Interestingly, several studies have shown that certain HLA molecules can present 
similar or identical viral epitopes despite their polymorphisms, and these have been grouped into 
genetic families referred to as HLA „supertypes‟, based on analysis and subsequent clustering of 
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Sydney, 1999). Therefore, knowledge of the distribution of HLA alleles within local populations 
is essential for the development of peptide-based vaccines with large population coverage.  
 
 
Table 1.1 . Table of HLA alleles commonly associated with different disease outcomes. 
 
HLA allele Supporting evidence Reference 
Protective alleles   
B*57 
Allele is over-represented in elite controllers, 
B57 CD8+ T-cells are immunodominant than 
other CD8+ T-cells 
Bailey et al., 2006; Jansen et 
al., 2005; Altfeld et al., 
2003; 2006. 
B*5801 and B*63 
Have a very similar binding motif to B57 and 
associated viral control 
Carrington et al., 2003; 
Frahm et al., 2005. 
B*27 
Present a conserved Gag epitope and is 
associated with long-term non-progression and 
escape in this epitope predicts viral load 
outcome. 
Goulder et al., 1997; 
Carrington et al., 2003; 
Ammaranond et al., 2011. 
Non protective alleles   
B*35, B*58:02, Cw*04 
and B*53 
Associated with rapid progression to AIDS. 
B35 subtypes have different associations: 
B*35:03 is associated with rapid progression 
while B*35:01 has a slightly different binding 
motif to B*35:03 but disease outcome not 
significantly different from population 
average. 
Carrington et al., 2003, Gao 





1.4. HIV escapes from immune pressure 
 
It has been established that HIV-1 can escape both the humoral and cell-mediated arms of the 
immune response. HIV-1 Env is the target for neutralization by the antibody response, but 
research has demonstrated that HIV-1 can replicate in the face of a strong antibody responses. 
This is because HIV-1 has evolved mechanisms to escape neutralization. These include 
glycosylation of regions that encompass epitopes that are targets for neutralization (Johnson et 
al., 2002; Sheehy et al., 2002), as well as mutation of regions within the variable loops of the 
gp120 without a fitness cost to the virus, that result in abrogation of neutralization (Johnson et 
al., 2002). Addressing these issues is extremely important in the light of renewed major interest 
in developing vaccines capable of generating neutralizing antibodies.  Because the HIV vaccine 
field has largely, in the last ten years, focused its efforts on developing T-cell generating 
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1.41. HIV escape from CD8+ T-cell pressure and implications for vaccine design 
 
As described in a previous section, CD8+ T-cells recognize epitopes presented to them in the 
form of an HLA class I-peptide complex. The amino acid sequence of the peptide determines the 
allele that restricts that peptide. Different HLA alleles demonstrate differential tolerance to 
amino acid variation within the peptides.  However, mutational escape which is a major 
challenge facing CD8+ T-cell-mediated recognition of HIV can be predicted based on the 
individual HLA allele background (Brumme et al., 2007; Brumme et al., 2009; Heckerman et 
al., 2010; Leslie et al., 2004; Yang et al., 2010).  
 
HIV can escape immune recognition by CD8+ T-cells by various mechanisms. Firstly, since 
there are various steps that occur during MHC class I peptide processing, mutations in the viral 
protein may result in abrogation of the peptide processing steps and subsequently loss of 
recognition by CD8+ T-cells (Koup et al., 1994). For example, mutations in the regions that 
flank the epitope may interfere with peptide processing if the residues are crucial for the 
processing steps (Milicic et al., 2005; Draenert et al., 2004). For example, the A69K, A81G and 
H87R mutations flanking the HLA-B*35-restricted VY8 Nef epitope were shown to alter 
processing of the epitope by the proteasome (Milicic et al., 2005). In addition, the A146P 
mutation flanking the IW9 HLA-B*57-restricted Gag epitope were shown to prevent the amino 
terminal trimming of the optimal epitope by the ER amino peptidase I enzyme (Draenert et al., 
2004). 
 
Secondly, escape can be a result of inhibiting or reducing HLA-peptide binding and presentation 
to the T cell receptor (TCR). Mutations in the antigenic peptide may result in conformational 
changes that abrogate binding to the HLA allele, thereby abolishing presentation of the epitope 
(McAdam et al., 1995). An example is a well-characterized epitope in p24 restricted by HLA-
B*27 (KRWIILGLNK), in which an RK or RG at the second position of the epitope was 
found to abrogate binding to HLA-B*27 molecule (Goulder et al., 1997). Lastly, mutational 
escape may involve mutations that interfere, reduce or antagonize the TCR-peptide interaction. 
An example of this is the rhesus macaque Mamu-A*02-restricted SIV Nef epitope (199RY), 
where a variant bound the MHC allele as the wild type sequence, but had reduced affinity for the 
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Mutational escape may therefore result in the virus being able to replicate without being 
recognized by specific T-cells, or without immune pressure in those viral regions. However, 
escape can in some instances be disadvantageous to the virus, in that if the targeted regions 
reside in those regions of the viral protein that have a functional or structural role for the virus, a 
mutation may result in a fitness cost or a replication-defective virus (Liu et al., 2007; Brockman 
et al., 2007; Schneidewind et al., 2007; Troyer et al., 2009). 
 
For a T cell-based HIV vaccine, targeting such immunologically vulnerable regions may be 
advantageous for controlling virus replication and hence the course of disease progression, and 
subsequently reducing transmission rates. Therefore, the design of a vaccine immunogen can 
exploit knowledge of mutations that result in a fitness cost to the virus, such that vaccine 
induced immune responses may direct HIV evolution towards a less fit virus.  However, this is 
also not a foolproof strategy; the observation of mutations either upstream or downstream of 
epitopes that have been shown to have a fitness cost to the virus if mutated has raised concerns 
about this feasibility (Crawford et al., 2007; Gonzalez-Ortega et al., 2011; Navis et al., 2007; 
Verheyen et al., 2006). Such „compensatory‟ mutations have been shown to partially or fully 
restore the virus fitness after mutating certain epitopes with a fitness role for the virus (Crawford 
et al., 2007; Gonzalez-Ortega et al., 2011).  Also, a major concern regarding this may be that 
escape mutants may accumulate at the population level, leading to a loss of recognized epitopes 
and vaccine-induced T cell responses with reduced effectiveness over time. Indeed, HIV has 
been shown to adapt at the population level in the face of immune pressure (Bunnik et al., 2010; 
Kawashima et al., 2009; Moore et al., 2002; Pond et al., 2006). In addition, much of the work on 
mutational escape has relied on epitopes from the p24 conserved region of HIV that are 
restricted by particular HLA alleles, and it is not known whether there are many other HIV 
regions outside this well characterized protein that may be suitable as vaccine immunogens, as 
well as their relevance in populations lacking these HLA alleles. Also, epitopic regions that 
undergo reversion to their wild type sequence when the virus is transmitted to HLA mismatched 
host (as the epitope will no longer be under immune pressure) might have to be taken into 
consideration in the design of a T cell-based vaccine in populations of diverse HLA backgrounds 
(Davenport et al., 2008; Gesprasert et al., 2010; Kearney et al., 2009), since these epitopes 
become lost as the epidemic progresses. However, it could be argued that these reverting 
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1.5. HIV-specific T-cell immunity 
 
Although the immune correlates of protection in HIV infection are not fully understood, 
numerous studies suggest that the induction of HIV-specific cellular immune responses is 
important for an effective vaccine against HIV. Therefore, much of the efforts of the last ten 
years have focused on developing a vaccine capable of generating T-cell responses. There is a 
wealth of evidence to show that HIV-specific CD8+ T-cells can control viraemia during acute 
HIV-1 infection (Borrow et al., 1994; Koup et al., 1994). For that reason, identification of HIV 
regions repeatedly targeted by the cellular immune response and associated with viral control 
will assist in choosing immunogens for vaccine design.  In addition, elucidating the functional 
and phenotypic nature of HIV-specific immune responses will assist in choosing which vectors, 
adjuvants and immunisation protocols are required to generate effective immune responses 
against the virus.   
 
For more than 20 years, researchers have focused on different aspects of the immune response to 
HIV in an attempt to identify the immune correlates of HIV control. Such studies have looked at 
the specificity of the response to HIV, for example which regions of HIV are frequently targeted, 
and which regions may be associated with viral control, as well as the magnitude and breadth of 
HIV-specific responses in infected individuals. Research has also focused on the functional 
attributes of HIV-specific T cells, including the range of cytokines produced by these cells, their 
cytotoxic potential, proliferative capacity, memory differentiation status, and CD8 or CD4 
phenotype. While earlier studies focused on the specificity and quantity (breadth and magnitude) 
of HIV-specific T-cell responses and their association with markers of disease progression such 
as CD4 count and plasma viral load, more recent studies have studied the quality of these 
responses (their functional nature) in trying to identify the features associated with viral control.  
 
HIV-infected individuals show broad recognition of HIV proteins and high magnitude responses 
(Addo et al., 2003; Masemola et al., 2004). These kinds of studies typically employed whole 
proteome screening of HIV-specific T-cell responses by the IFN-g ELISpot assay, and 
performed them in cross-sectional cohorts of HIV-infected individuals infected for unknown 
periods of time.  These studies on the total magnitude of HIV-specific T-cells as well as their 
breadth, indicating the number of epitopes targeted, have generated data to conclude that the 
overall magnitude of HIV-specific T-cells is not associated with viral control (measured by 
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al., 2003; Betts et al., 2001; Buseyne et al., 2002; Edwards et al., 2002; Gray et al., 2009; 
Masemola et al., 2004; Peretz et al., 2005). Several longitudinal studies have also failed to make 
a connection between the overall magnitude and breadth of responses. For example, no 
association was observed between the magnitudes of each expressed HIV protein with disease 
progression or viral set point at 12 months in a subtype C-infected cohort (Gray et al., 2009), and 
no correlation was obtained between viral load and rate of CD4 T-cell decline as when the 
magnitude or breadth of T-cell responses were compared between typical, fast and slow 
progressors (Peretz et al., 2005).  These studies suggested that whilst HIV-infected individuals 
make robust CD8+ IFN-g responses to the virus, the overall breadth and magnitude of these 
responses was not a correlate of immune control, and perhaps the specificity or quality of the 
response may be important for viral control.  
 
Masemola et al. (2004) showed that the hierarchical targeting of the HIV Gag protein, rather 
than the overall magnitude of T-cell responses to HIV proteins, was associated with viral 
control. This result was confirmed by other independent studies that showed that targeting of the 
HIV Gag protein was beneficial for viral control (Edwards et al., 2002; Kiepiela et al., 2007; 
Mori et al., 2011). In one of these studies, specifically it was the magnitude and breadth of the 
Gag p24 protein that inversely correlated with slower disease progression (Mori et al., 2011). In 
other studies, targeting of other proteins such as Nef and Env did not correlate with viral load or 
CD4 count (Edwards et al., 2002). Interestingly, one of these studies demonstrated that while 
targeting of Gag was associated with lower plasma viral loads, targeting of Env was associated 
with higher plasma viral loads (Kiepiela et al., 2007). The importance of the specificity of T-
cells in viral control has also been further supported by many other studies concluding that 
targeting of Gag is associated with lower viral loads, higher CD4 counts or slower disease 
progression (Zuniga et al., 2006; Geldmacher et al., 2007, Pereyra et al., 2008).  
 
Although studies on functional avidity of HIV-specific T-cells have not been conclusive (Miura 
et al., 2009; Migueles et al., 2003; Draenert et al., 2004), the avidity of HIV-specific T-cells 
targeting specific HIV epitopes that was associated with control of virus replication (Almeida et 
al., 2007; Miura et al., 2009). Taken together, when data on HIV-specific CD8+ T-cells of 
LTNPs or elite controllers are compared to that progressors no consistent significant differences 
have been observed in terms of specificity, breadth or magnitude (as reviewed in Migueles et al., 
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Having realized that most of these studies looking at the specificity, magnitude and breadth of 
HIV-specific T-cell responses relied on quantifying response using one immunological readout, 
namely the cytokine IFN-γ, some researchers sought to exploit advances in flow cytometry and 
looked at the quality rather than quantity of virus-specific CD8+ T-cell responses. Apart from 
IFN-γ production, HIV-specific T-cells are capable of producing many other cytokines (e.g. IL-2 
and TNF-α), chemokines (e.g. MIP-1β), as well as performing other cytotoxic functions, where 
the up-regulation of perforin and granzymes can be measured, or functions such as degranulation 
(CD107a expression) have been used as a surrogate of cytotoxic potential (De Rosa et al., 2004; 
Roederer et al., 2004; Betts et al., 2006; Kannanganat et al., 2007a and 2007b; Hersperger et al., 
2010).  The proliferative capability of HIV-specific T cells can also be measured (Migueles et 
al., 2002; Lichterfeld et al., 2004; Horton et al., 2006). Initially, data generated in studies 
characterizing the quality of HIV-specific T-cells suggested that it is the polyfunctionality, i.e. 
the ability of cells to produce more than three „functions/cytokines‟ simultaneously, that may be 
important in viral control (De Rosa et al., 2004; Roederer et al., 2004 Betts et al., 2006; 
Kannanganat et al., 2007). An additional study observed that HIV-specific CD8+ T-cells from 
long term nonprogressors (LTNPs) or elite controllers were able to produce perforin 
immediately after stimulation with HIV peptides, which suggests that this might be one of the 
mechanisms by which this small group of individuals effectively control HIV during natural 
infection, as this was not observed in progressors (Hersperger et al., 2010). Further dissection 
and characterization of the different combinations of functions of these HIV-specific T-cells, 
generated data to suggest that highly functional HIV-specific T-cells are distinguished by 
perforin and IL-2 up-regulation (Makedonas et al., 2010). Furthermore recent study suggested 
that the ability of HIV-specific T-cells to perform effector functions was associated with their 
ability to express high levels of the transcription factor T-bet (Hersperger et al., 2011).  
 
There is evidence that HIV-specific T-cells from individuals showing better control of the virus 
have a higher proliferative capacity when compared to those who progress faster (Migueles et 
al., 2002; Litcherfeld et al., 2004; Horton et al., 2006), and that proliferative capacity of HIV-
specific CD8+ T-cells correlate inversely with plasma viral load (Day et al., 2007). HLA-
B*5701 restricted CD8+ T-cells demonstrated higher proliferation compared to non-HLA-
B*5701 restricted T-cells (Horton et al., 2006; Altfeld et al., 2003). Therefore, study individuals 
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through targeting those HIV regions which cannot escape CD8+ T cell pressure without fitness 
cost and generating strong T-cell responses that are highly functional and capable to proliferate. 
A recent study demonstrated the superiority of the proliferative capacity compared to the 
magnitude of IFN-γ responses in delaying HIV disease progression, showing that the magnitude 
of IFN-γ responses did not correlate with delayed disease progression, but rather the proliferative 
capacity of HIV-specific CD8+ T-cells did (McKinnon et al., 2011). In addition, the high 
magnitude of CD8+ T-cells targeting HIV Gag protein, specifically p17 and p15 with high 
proliferative capacity, was associated with low viral loads and high CD4 counts (Calarota et al., 
2008).  Therefore, magnitude to specific regions of the virus, function and proliferative capacity 
of HIV-specific T-cells may be more important than merely the overall breadth and magnitude 
of HIV-specific CD8+ T-cell responses. 
 
The presentation of antigens to CD8+ T-cells and their activation by antigen presenting cells has 
been shown to involve CD4+ T-cell help (Xiang et al., 2005). CD4+ T-cells play an important 
role in the clonal expansion and differentiation of CD8+ T-cells (Janssen et al., 2003) as well as 
maintenance of their memory (Jun & Bevan, 2003). In addition, CD4+ T-cell proliferation in the 
same way as the proliferation of CD8+ T-cells as well IL-2 production has been shown to 
correlate with HIV-1 clinical status in both humans and macaques (Rosenburg et al., 1997; 
Mckay et al., 2003). Therefore, CD4+ T-cell help may be vital for viral control, and a key 
immune function to generate with a HIV vaccine. 
 
 
1.6. Cross-reactive immunity to HIV-1 
 
The uneven distribution of HIV-1 subtypes and CRFs has led to the development of some HIV 
candidate vaccines to match subtypes circulating in specific regions (Ellenberger et al., 2003; 
Jaffray et al., 2004). However, whether regional vaccines are necessary or a universal vaccine is 
possible, is still unknown. Therefore, efforts have also focused on developing broadly cross-
reactive vaccines for global use, or for areas in which many clades and recombinants circulate. 
These different approaches are discussed in detail in the next section. Since vaccine development 
and clinical trials are lengthy, it is important to characterize the cross-reactive potential of 
vaccine immunogens that are in different stages of development in HIV-infected populations 
where different viral subtypes circulate. Although these kinds of studies have their limitations, 
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by a vaccine, they may nevertheless reveal important insights into whether vaccine immunogens 
may be sufficiently cross-reactive in a given population (with its immunogenetic diversity) with 
particular HIV-1 subtypes circulating.  
 
The extensive diversity in the HLA gene loci is one of the ways by which the immune system 
adapts to the recognition of the many variant forms of pathogens (Brennan et al., 2002), through 
promiscuous binding by HLA alleles (Sette and Sydney, 1998), and the involvement of other key 
players, such as peptide processing and presentation, and the flexibility of the T-cell receptor 
(Brennan et al., 2002; Buseyne and Riviere, 2001; Haanen et al., 1999). For that reason, T-cells 
of an individual are able to recognize an extensive array of epitopes from each viral sequence 
that can be extended by being heterozygous at HLA loci (Carrington et al., 1999).  
 
Immune responses that are cross-reactive between different HIV clades („cross-clade responses‟) 
have been consistently demonstrated in HIV-infected individuals (Aidoo et al., 2008; Currier et 
al., 2003; Gillespie et al., 2002; Keating et al., 2002). Many earlier studies relied on the use of 
peptide pools or recombinant vaccinia virus constructs expressing selected HIV-1 genes, giving 
„bulk‟ cross-reactivity response readouts of HIV proteins (McAdam et al., 1998; Ferrari et al., 
1997 and Betts et al., 1997). Recent studies have assessed cross-clade immune responses at the 
single peptide level.  
 
In one such important study, cellular immune responses to the three major HIV-1 subtypes (A, B 
and C) were determined in a cohort of 250 unvaccinated individuals from four countries with 
HIV-1 subtype A, B and C epidemics (Coplan et al., 2005). In this study, Gag, Nef, Pol, Tat and 
Rev gene products were tested in ELISpot assays, with Gag and Nef contributing most of the 
responses, which were then further characterized for cross-reactivity. The study defined „cross-
clade reactivity ratios‟ as the ratio of immune responses against a heterelogous clade (the one not 
responsible for infection) to that against a homologous clade (the one responsible for infection). 
The higher the ratio, the greater the immune response an individual could mount against that 
particular heterologous subtype. A high degree of cross-reactivity was observed, with cross-
clade reactivity ratios of 91% and 107% for A versus B (meaning that the reactivity of A was 
more than that of B, the infecting clade) and C versus B Gag proteins, respectively. Similarly, 
cross-reactivity rations were high for the Nef protein, with 95% between clades A and B and 
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cohort extended to 363 HIV-infected individuals (Gupta et al., 2006) demonstrated similar 
extensive cross-reactivity among the three HIV-1 subtypes tested for Gag and Nef.  In this larger 
cohort, cross-reactivity ratios were 99.1% between clade C and clade B Gag proteins and 97.8% 
between clades A and B Gag proteins.  
 
In a separate study, HIV-specific T-cells from clade B-infected study individuals were assessed 
for reactivity to clades B and C peptides using the IFN-γ ELISpot assay (Zhao et al., 2007). In 
this study, there were a large number of cross-reactive peptides between clade B and C peptides. 
This observation demonstrates that HIV-1 clade B infected study individuals can recognize 
peptides based on clade C sequences. A detailed analysis of reactive peptides in this study 
showed that cross reactivity was associated with a high degree of homology and lower 
variability, measured by entropy scores among corresponding peptides from the tested clades 
(Zhao et al., 2007).  Further, results from Yu et al. (2005) demonstrated that there were amino 
acid variations in the target epitopes that T-cell receptors could tolerate without loss of epitope 
recognition, hence explaining the ability of cross-recognition among corresponding but variant 
viral peptides from different clades. This implies that variation outside HLA anchor residues, 
unless it interferes with peptide processing or TCR contact, may not have a huge impact on the 
ability of HIV-specific T-cells to cross-recognize HIV epitope variants (Geels et al., 2005).  
 
Many of the studies described assessed the degree of cross-reactivity to the major circulating 
HIV-clades using peptides based on natural clades or their consensus sequences. A number of 
studies have suggested the use of sequences generated by use of bioinformatics algorithms or 
artificial sequences. Such sequences include group M consensus, center of tree (COT), most 
recent common ancestor (MRCA) and mosaic antigens that are based on potential T-cell 
epitopes (PTEs). 
 
In a study of 25 clade B HIV-infected individuals, artificial sequences based on consensus, COT 
and MRCA clade B peptides were tested together with clades A, C and consensus group M 
peptides. Although there was a slight trend towards higher number of responses for consensus B-
based peptides (16 peptides) compared to COT-B (15 peptides), ANC-B (15 peptides) and 
consensus M (15 peptides), consensus A (14 peptides) and consensus C (13 peptides), no 
significant differences in the frequency, magnitude and breadth of T-cell responses were 
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responses at the peptide level identified 16 cross-reactive peptides among clades A, B and C, 
seven of which were identical in sequence. The other nine resulted in 11 variants that had amino 
acid substitutions outside the HLA anchor residue, except in one. These data further provide 
evidence of the huge degree of cross-reactivity of HIV-specific T-cells, even to artificial 
sequences at the peptide level, and further evidence that cross-reactivity may be attributable to 
conservative or semi-conservative amino acid substitution outside HLA anchor residues across 
HIV-1 clades (Malhotra et al., 2007). This suggests that the use of conserved proteins such as 
HIV Gag or those regions conserved across group M HIV-1 clades in vaccines (Rolland et al., 
2007) may result in a high degree of cross-reactivity.  
 
When taken together, data from these studies demonstrate that HIV-1 specific T-cells from 
individuals infected with a particular HIV-1 clade can cross-recognize HIV proteins or peptides 
based on other HIV clades. However, some studies stress that even though HIV-specific T-cells 
can cross-recognize viral variants from other clades, the responses are skewed towards the 
infecting subtype (Geldmacher et al., 2007; McKinnon et al., 2005). For vaccine development, 
this may imply that there is some advantage of matching a vaccine to the infecting subtype, 
which may be the preferred approach for large mono-clade epidemics, such as that in southern 
Africa. 
 
A major caveat to the majority of studies that have assessed cross-reactive immune responses is 
that they have characterised these using the IFN-γ ELISpot assay, where excessive amounts of 
exogenously loaded peptides are used to detect HIV-specific T cell responses. Two studies have 
demonstrated that although PBMC from HIV-1 infected people demonstrate substantial cross-
recognition of HIV-1 epitope variants, in vitro viral suppression of HIV-1 by CD8+ T cells 
specific for the corresponding epitope sequence was highly impaired (Valentine et al., 2008; 
Bennett et al., 2008). In addition, relying on a single immunological readout, namely IFN-γ 
production, may also mask differences in other functions that variants epitopes may display due 
to non-optimal TCR contact, for example reduced production of other cytokines, or the ability to 
stimulate T cell proliferation less well. A recent study suggested that some variant forms of 
peptides may elicit functions other than IFN-γ from specific T cells, and that amino acid 
mismatches across peptides variants may result in a different functional profile of HIV-specific 
T-cell responses to these peptide variants (Richmond et al., 2011).  In the context of a vaccine, 
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of the T cell response is affected by variants binding less well and not stimulating cytokine 
production from particular T cell clones, this may also have an impact on the effectiveness of 
that response. Thus, there is need to characterize the cross-reactivity of HIV-specific T-cells to 
particular variant epitopes by measuring more than one cytokine or function of these cells.  
 
 
1.7. The significance of HIV-1 genetic variation to vaccine design  
 
Despite the recent failures of a proof-of-concept T-cell based clinical trial in the USA 
(Buchbinder et al., 2008) and South Africa (Gray et al., 2011), as well as modest success of the 
RV144 clinical trial in Thailand in which CD4 T-cell responses targeting mainly Env gp120 and 
two correlates of risk associated with infection rate (IgG antibodies binding to V1-V2 correlated 
negatively with infection rate and Env binding to plasma IgA correlated positively with infection 
rate) in vaccinees were identified (Rerks-Ngarm et al., 2009), a T cell-generating vaccine is still 
considered important for protection, slowing or preventing disease in those who become 
infected, and reducing secondary HIV transmission. Much of the recent effort has focused on the 
generation of effective and cross-reactive CD8+ T cell responses specific for HIV (Martinez-
Picado et al., 2006; Frahm et al., 2006).  
 
The current focus on developing CTL-based vaccines is in part due to the failure of generating 
effective vaccines that can generate neutralizing antibodies. For example, the first empirical 
approach to neutralizing antibody vaccines, the Vaxgene AIDSVax, was a recombinant form of 
HIV envelope gp120 protein that failed to protect volunteers from infection because the vaccine 
did not induce broadly neutralizing antibodies (Johnston et al., 2007). This failure to induce 
broadly neutralizing antibodies is due mainly to the high variability in the envelope protein of 
HIV, and the fact that broadly neutralizing antibody epitopes are conformationally masked 
(Burton et al., 2004). This failure, and the challenges that it highlighted for developing a vaccine 
that can induce neutralizing antibodies, shifted the focus to the development of T cell-based 
vaccines. This shift in focus to T-cell vaccnes is further supported by the phenomenon of HLA-
driven viral evolution that was illustrated recently with the first evidence of vaccine-driven T-
cell footprints on viral sequences reported in breakthrough infections in the STEP trial (Rolland 
et al., 2011). This section will discuss the efforts underway to cater for the huge genetic diversity 











Chapter 1: Literature review 30 
 
sequences as single or multi-clade vaccine immunogens, centralized sequences, multi-variant or 
mosaics sequences as well as targeting regions (Table1.2). 
 
 
1.7.1. Inserting natural sequence as single or multi-clade vaccines 
 
The variability of HIV-1 raises concerns about whether HIV-specific T-cell responses would be 
cross-reactive enough to develop a universal vaccine that would be protective against all the 
different HIV-1 genetic subtypes and recombinants. Therefore, vaccines based on inserting 
single or multi-clade natural sequences based on HIV clades circulating in particular regions 
have been developed. Two vaccines based on this strategy involving sequences from clades B 
and E is the ALVAC candidate vaccine used as the prime in the RV144 trial in Thailand and the 
AIDSVAX protein used as the booster in the same trial (Rerks-Ngarm et al., 2009). The ALVAC 
vaccine is a recombinant canarypox vector vaccine based on Gag and Protease from HIV-1 clade 
B (LAI strain) and a gp120 from HIV-1 CRF01_AE (92TH023) linked to a trans-membrane 
gp41 from clade B LAI strain (Rerks-Ngarm et al., 2009). AIDSVAX B/E is a bivalent HIV-1 
gp120 glycoprotein vaccine from the same two clades, namely B and E (Pitisuttithum et al., 
2006; Rerks-Ngarm et al., 2006; 2009). When these vaccines were used in a prime-boost 
regimen in Thailand, modest protection from HIV acquisition (31.2%) was observed (Rerks-
Ngarm et al., 2009). Another example of a vaccine based on the use of natural sequences is the 
single clade-based Merck Adenovirus serotype-5 clade B gag/pol/nef (Buchbinder et al., 2008). 
This vaccine was tested in r gions with predominantly clade B epidemics, namely North 
America, the Caribbean, South America and Austria where it was referred to as the STEP Phase 
IIb trial (Buchbinder et al., 2008), as well as in a predominantly clade C epidemic (South Africa) 
in the Phambili Phase IIb trial (Gray et al., 2010; 2011). Although these trials were discontinued 
due to an increase HIV acquisition in the vaccine group compared to the placebo group, the 
South African trial showed that 12 % fewer vaccinees mounted a response to clade C peptides 
compared to clade B, with a 35 % reduction in the overall magnitude of the responses 
(Buchbinder et al., 2008; Gray et al., 2011). An important consideration in this type of vaccine 
design approach is the selection of a vaccine sequence that closely matches the circulating 
viruses in a given region. It was evident from the STEP study that differences between the 
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Based on regional variation of HIV-1. 
Either single clades or multiple clades 
can be incorporated into the vaccine 
immunogen. 
The two vaccines used as the prime and boost in the RV144 Phase III trial, ALVAC 
and AIDSVAX, based on clades B and AE that are the circulating types in Thailand. 
Merck Ad5 gag/pol/nef vaccine tested in STEP and Phambili Phase IIb trials (clade B-
based) 
Pitisuttithum et al., 2006; Rerks-Ngarm 
et al., 2009; Buchbinder et al., 2008 
Gray et al., 2011. 
Centralized sequences Sequences used are derived using 
phylogenetic inferences and can be 
center-of-tree, most recent common 
ancestor, or consensus sequences. 
The HIV-1 sequences can be clade-
specific when the input sequences 
are from the same HIV-1 clade, or 
they can be for a group of clades or 
for all group M HIV-1 clades.  
Clade C Env immunogen consensus and ancestral sequences elicited responses of 
comparable magnitude and breadth and group M Env immunogens elicited responses 
comparable to wild type clades A, B and C. Consensus group M responses were 
comparable to intra-clade responses but higher than inter-clade responses in murine 
models. 
 
Four studies that tested the concept of centralized sequences as immunogens using 
PBMCs from HIV infected individuals and stimulating them with peptides 
demonstrated that ancestral, center-of-tree and consensus group M peptides reagents 
are equally recognized compared to clade-specific centralized peptides reagents in 
clade infected individuals. However, in a few clade C infected individuals, group M 
peptide reagents were equally but preferentially recognized compared clade-matched 
and clade-mismatched peptide reagents, respectively except in Env protein where 
consensus group M was had significantly higher magnitude of response compared to 
clade-matched peptide reagents.  






Frahm et al., 2008; Bansal et al., 2006; 




Based on computer algorithms to 
generate and optimize sequences 
that have a greater depth or coverage 
of potential T cell epitopes. 
Rhesus macaque and human studies have showed that mosaic antigens can be 
expressed and presented to MHC class I and class II molecules and elicited broader 
T-cell responses of greater magnitude than consensus M, consensus B, consensus C 
and natural C immunogens. 
Barouch et al., 2010; Santra et al., 
2010; Ndhlovu et al., 2011 
Conserved regions Based on conserved regions of HIV 
across different HIV-1 clades that 
contain epitopes covering all HLA 
supertypes.  
Humanized mice vaccinated with a vaccine based on 14 conserved regions of HIV 
proteome elicited HIV-specific T cell responses similar to those observed in natural 
HIV infection and vaccine trial participants. 
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Other examples of using natural sequences to closely match viruses in a given region are the 
vaccines being developed for South Africa, where clade C viruses are predominant. These 
vaccines are based on the Du422 isolate, an R5 virus that was selected based on its similarity 
(>98%) to a South Africa subtype C consensus sequence (Williamson et al., 2003). Indeed, a 
DNA prime followed by MVA boost regimen based on HIV-1 clade C gag, rt, tat, nef and env in 
non-human primates generated potent, broad, multifunctional CD4 and CD8 T-cell responses 
(Burgers et al., 2009).  
 
1.7.2. Centralized sequences 
 
Unlike developing vaccines using natural sequences, bioinformatics approaches have been used 
to design vaccines based on centralized sequences or sequences representative of the different 
HIV-1 subtypes or strains. Such vaccine immunogens are artificially designed using 
phylogenetic approaches in three main ways, namely consensus group M which is representative 
of all the HIV-1 group M viruses sequenced to date (Gaschen et al., 2002; Kothe et al., 2006), 
the center-of-tree (COT), which is a sequence equidistant from all sequences used to construct a 
phylogenetic tree (Nickle et al., 2003; Nicle et al., 2007; Rolland et al., 2007), and sequence 
based on the most recent common ancestor (MCRA) of the sequences of interest (Doria-Rose et 
al., 2005; Kothe et al., 2006). While the COT and MRCA are based on the root of a tree in 
phylogenetic analyses, they are different in that if there are outlier sequences in a sample, the 
algorithm that generates the MRCA can be biased away from the majority of the sample 
sequences while the algorithm for generating the centre-of-tree will control for this while still 
maintaining the biological properties of the virus (Rolland et al., 2007). Theoretically, in all 
these methods, the sequence can be generated for a single HIV-1 clade, a selected group of HIV-
1 clades, or for all the global HIV-1 clades.  
 
Most of the work performed to test central sequences as T-cell vaccines has been performed in 
primate studies, using mainly HIV-1 Env immunogens. The magnitude and breadth of IFN-γ 
responses were comparable between ancestral and consensus clade C Env sequences in mice 
immunized with ancestral C and consensus C env DNA vaccines (Kothe et al., 2006). In a 
separate study, there different strains of mice were immunized with consensus group M and 
clades A, B and C env immunogens in a DNA prime-recombinant vaccinia virus boost regimen 
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induced T-cell responses greater of breadth and magnitude than any other wild subtype A, B or 
C, but similar to polyvalent immunogen, when the immunogens were administered together 
(Weaver et al., 2006, 2010). Characterization of these responses showed that T-cell responses to 
the consensus group M vaccine immunogen were comparable to intra-clade responses but 
significantly greater than inter-clade responses (Weaver et al., 2006, 2010).   
 
Although there are no similar studies like these murine-model studies in humans yet, measuring 
HIV-specific T-cell responses to centralized immunogens in HIV-1 infected persons using 
assays such as the IFN-γ ELISpot assay are the kinds of theoretical studies to predict whether 
consensus sequences may be better. Four studies to date have tested the reactivity of at least one 
of clade-specific central sequences (consensus, center-of-tree and ancestral for clade A, B and C) 
and compared them to at least one of the group M central sequences (consensus, center-of-tree 
and ancestral) based on HIV-1 Gag, Nef or Env proteins mainly in clade-B infected study 
individuals and few a few clade-C infected individuals (Bansal et al., 2006; Frahm et al., 2008; 
Malhotra et al., 2007; Rutebemberwa et al., 2005). In one of these studies, group M peptide 
reagents were less frequently targeted in clade B infected individuals; contrary to this, clade C 
infected individuals from the same study found comparable recognition between group M based 
peptides and clade C based peptides (Frahm et al., 2008). In two of these four studies, magnitude 
and breadth of T-cell responses was comparable among clade-specific peptides based on 
centralized sequences and group M centralized peptide reagents (Bansal et al., 2006; Malhotra et 
al., 2007), except in a few clade C infected individuals in one in which although not significantly 
different, there was a trend towards preferential recognition of clade C and group M compared to 
central sequences based on mismatched clades. Overall, the three studies demonstrated that 
consensus group M based peptide reagents are equally recognized compared to clade-matched 
peptide reagents and this recognition is more than that to clade-mismatched peptide reagents. On 
the other hand, the fourth study demonstrated that consensus group M peptides have 
significantly 2-fold higher magnitude of T-cell response compared to clade-matched consensus 
peptides (consensus B) or clade matched strain specific peptides (HIVMN, Rutebemberwa et al., 
2005). However, the fact that this fourth study was based on Env, a more variable protein 
compared to Gag and Nef that were investigated in at least one of other three studies is possibly 
an explanation for the difference. However, an important consideration about central sequences 
generated using phylogenetic means is that these sequences are artificial and depend on the 
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Furthermore, the phylogenetic models employed in generating these central sequences do not 
take into consideration events that occur during natural infection such as recombination 
(reviewed in Arenas et al., 2010) and dual infection that might require the use of more than one 
sequence from the same individual for use in generating these sequences. The mosaic vaccine 
approach discussed below tries to cater for such events as recombination using computerized 
algorithms to generate mosaic antigens by combination of different sequences. 
 
1.7.3. Multi-variant or mosaic vaccines 
 
Mosaic antigens are immunogens that are produced by combining sequences from different HIV 
variants or clades using artificial recombination methods designed to mimic the recombination 
process that occur during natural HIV evolution. Vaccines based on the mosaic approach utilize 
computerized algorithms to generate and optimize sequences similar to naturally circulating HIV 
sequences such that in their combination, demonstrate a greater depth or coverage of HIV-1 
potential T-cell epitopes (PTEs) for different in HIV proteins (Fischer et al., 2007; Thurmond et 
al., 2008; Corey and McElrath, 2010). Therefore, theoretically, the optimization process can be 
performed for a single HIV-1 clade or for the entire group M HIV-1 clades. Preliminary data on 
this approach suggests that the mosaic approach algorithm provides enhanced coverage of 9-
mers when compared to the COT approach when the same data set was used (Fischer et al., 
2008). Mosaic vaccines encompass the concept of polyvalency, but at the epitope level, since 
corresponding variants of different epitopes from different clades are included. 
 
Studies in rhesus macaques (Barouch et al., 2010; Santra et al., 2010) and humans (Ndhlovu et 
al., 2011) have demonstrated that mosaic antigens can be expressed and presented to MHC class 
I and class II molecules in these models. Mosaic antigens in these studies generated responses of 
greater magnitude and breadth than consensus reagents (Barouch et al., 2010; Santra et al., 
2010). These macaques were either immunized with plasmid DNA prime and recombinant 
vaccinia virus boost containing constructs that express Gag and Nef based on either consensus or 
mosaic antigens (Santra et al., 2010), or with Gag, Pol and Env based on natural, consensus or 
mosaic antigens expressed by replication incompetent adenovirus serotype 26 (Ad26) vectors 
(Barouch et al., 2010). The studies showed that mosaic vaccines, compared to consensus or 
natural immunogens, elicited CD8+ T-cell responses to more epitopes and more variant 
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in humans. However, in ICS and tetramer staining assays using PBMC from HIV-1 subtype B 
and subtype C infected study individuals transduced by a bivalent mosaic Gag vaccine expressed 
by replication incompetent Ad26 vector, mosaic antigens were expressed and presented to CD8+ 
T-cells and elicited T-cell responses of great magnitude, breadth, depth function compared to 
natural clade B and C Gag immunogens (Ndhlovu et al., 2011). It is important to note that this 
study only evaluated this in clade B and C infected individuals, and the utility of this approach in 
other epidemics, for example where multiple diverse clades co-circulate, may require further 
testing. Overall, mosaic antigens result in a greater breadth of responses, and an important 
feature of this approach is the representation of many variant forms of the same epitope.  
 
Studies on HLA-associated amino acid changes in populations sequences have generated data to 
show that HLA class I-restricted CD8+ T-cell pressure not only results in escape from immune 
recognition (Carlson et al., 2008; Leslie et al., 2004), but also in the formation of new CD8+ T-
cell epitopes (Bhattacharya et al., 2007). This may imply an evolutionary advantage to the virus 
rather than the host. Of note is the data generated by a recent study that demonstrated that 
although these newly formed epitopes („neo-epitopes‟) could elicit higher avidity and more 
potent IFN-γ-producing CD8+ T-cells than their parent epitopes, the responses were not more 
cytotoxic than their parent epitope variants (Keane et al., 2011). This ability to make responses 
to new epitopes may increase the positive impact on CTL cross-reactivity. Since the presence of 
neo-epitopes and their parent variants are variant forms of corresponding epitopic regions, 
mimicking a mosaic antigen, it is logical to think that mosaic vaccines might elicit broad 
responses of high magnitude than other vaccine formulations but the responses might not 
necessarily have antiviral capacity. Furthermore, partial escape occurs frequently, and new T cell 
responses are mounted repeatedly in vivo with data being generated providing evidence of 
continuous T-cell recruitment during chronic HIV infection (Allen et al,. 2005). TCR vary 
widely over time as some clones die, and others are recruited. This likely has a dramatic impact 
on CTL cross-reactivity over time. 
 
1.7.4. Targeting conserved regions 
  
Despite the huge HIV variability within and between populations, there are regions of the virus 
that are invariable, possibly due to the fact that these regions have structural and functional roles 
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regions would suggest that these regions are less likely to be mutated, and escape in these 
regions might result in a decrease in viral fitness, as been demonstrated in a number of studies 
(Fernandez et al., 2005; Martinez-Picado et al., 2006; Leslie et al., 2004). There are previous 
studies that have suggested targeting of conserved regions as possible vaccine immunogens 
(Altfeld et al., 2006; Kent et al., 2005). 
 
One group (Rolland et al., 2007) that proposes the use of conserved regions suggest a vaccine 
which they referred to as a conserved elements (CE)–vaccine, that is composed of 45 discrete 
viral segments of at least eight amino acids (resembling the minimum length of a CD8+ T-cell 
epitope) that fulfill a certain conservation criteria. This analysis resulted in identification of first 
tier segments in which there was 98% conservation of a single amino acid at a single position 
across the group M sequences, and second tier segments in which there was 99% conservation of 
two variant amino acids at a single position across group M sequences. The segments 
encompassed motifs in Gag and Pol proteins that covered all nine HLA supertypes (B7, A3, A2, 
A24, B44, B27, B62 and B58), thus potentially providing 80% coverage regardless of ethnicity 
(Rolland et al., 2007). In another study, a gene coding for the 14 most conserved regions of the 
HIV proteome (HIVCONSV) was designed (Letourneau et al., 2007). The three most studied 
vaccine vectors, namely plasmid DNA, human Ad5 and MVA were used, and induced HIV-
specific T-cells in mice producing IFN-γ, IL-2, TNF-α and capable of killing target cells 
(Letourneau et al., 2007). Together with data generated using PBMC samples from an HIV 
vaccine clinical trial and from healthy donors, the study demonstrated that the vaccine based on 
this approach primed subdominant CD4 and CD8 + T-cell responses to conserved epitopes in 
natural infection (Letourneau et al., 2007). In another study, full length HIV-1 proteins were 
characterized for variation using Shannon entropy for four major HIV-1 clades, namely A1, B, C 
and D and four highly conserved regions rich in previously described CD8+ T-cell epitopes 
(Yang et al., 2009). Subsequent testing of this immunogen in chronically HIV-infected 
individuals demonstrated that these regions are commonly immunogenic, that is, targeted in 
multiple individuals (Yang et al., 2009). A detailed characterization of conserved regions in a 
more recent study using a technique known as random matrix theory showed that there are HIV-
1 conserved regions that are immunologically vulnerable which they termed „HIV sectors‟, 
which may be important as vaccine immunogens (Dahirel et al., 2011). These regions have 
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located in the HIV-1 Gag protein that co-evolve independent of each other and of the rest of the 
Gag protein (Dahirel et al., 2011).  
 
Of course, all these vaccine design approaches are theoretical and which approaches are superior 
can only be resolved by demonstration of efficacy in different human populations with different 
viral clades circulating. This requires Phase III vaccine trials, a lengthy and expensive process. 
However, using advancements in immunological techniques such as ELISpot and flow 
cytometry, it is possible to predict the ability of these vaccine immunogens to cross-react to 
different viral variants and clades, and examine the quality of responses produced, using test 
reagents based on the different vaccine antigens in HIV-infected people.  This is the approach 
employed in this thesis. 
1.8. Aims and objectives of the thesis 
 
It is not questionable that the huge genetic diversity of HIV has made effective vaccine design 
extremely challenging. The question of whether region-specific vaccines are necessary, or a 
universal vaccine is feasible, still needs to be answered. Due to increased global travel of people 
coming from regions with different clade epidemics, and its associated HIV risk, it is likely that 
the frequencies of different clades and their distribution in different regions are going to change 
over time. This calls for vaccines with cross-clade immunity for wider protection at the 
population level. Nevertheless, there are a number of HIV vaccine candidates based on specific 
HIV-1 subtypes that are currently in development, some in pre-clinical stages and some in 
clinical trials, and it is important to predict whether these vaccines may be effective in 
unmatched populations where different HIV-1 subtypes are circulating. Vaccine trials are the 
only means to definitively answer whether a vaccine is effective in a particular population, but 
these trials are laborious and lengthy, and before or while they are underway, clues to the 
potential cross-reactive nature of particular immunogens can be obtained by assessing the 
identity, degree and nature of cross-reactive HIV-specific T-cell responses in the laboratory, 
using immunological techniques such as the ELISpot assay. It is also possible to describe the 
quality of these responses by assessing the functions of the cells beyond IFN-γ production. 
While these studies are very useful to evaluate cross-reactivity in natural infection, it should be 
noted that these in vitro cross-reactive responses may differ from actual vaccine induced 
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are cross-reactive, assess the degree of cross-reactivity, as well as determine the effect of 
sequence differences (in cross-reactive but variant epitopes) on the functional nature of cross-




To assess the degree of cross-reactive immune responses in subtype C-infected individuals using 
subtype-specific peptides from five different peptide variants based on two vaccine inserts for 
two subtype C (South African subtype C and a Chinese subtype C) and three consensus 
subtypes, A, B and D. 
 
Rationale 
South Africa has one of the world‟s highest HIV prevalence rates and a number of phase I and II 
trials and one phase IIb efficacy trials have taken place using clade A and B-based candidate 
vaccines. Further clinical trials are likely to follow using clade C-based immunogens.  Although 
a number of studies have assessed the cross-reactivity of HIV-specific T-cells using various 
clade-based peptide sequences in HIV-infected individuals, the cross reactivity of these T-cells 
to sequences based on actual vaccine inserts has not been performed. The ability of candidate 
vaccines that are based on particular clades to elicit cross-reactive T cell immunity may be 
predicted by testing reagents based on these vaccine sequences in HIV-infected people using 
laboratory methods, such as the ELISpot assay. 
 
Specific objective  
 
To determine and characterize reactive peptides in HIV-1 subtype C infected individuals in an 
IFN- ELISpot assay using Gag peptides based on consensus subtypes A, B, D and two subtype 
C peptide sequences, one from China (CCH), and the other one from South Africa (CDu422), as 
well as identifying regions within the Gag protein that are exclusively and mutually recognized 




To characterize cross-clade immune responses in HIV-1 infected individuals using HIV-1 Gag 
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Rationale 
Africa has regions that demonstrate differential predominance of HIV-1 subtypes and circulating 
recombinant forms. For example, West/Central Africa has the greatest assemblage of HIV 
subtypes, circulating recombinant forms and unique recombinant forms, while other regions 
such as southern and East Africa have particular subtypes dominating. This aim was part of a 
multi-center study involving five African countries, namely South Africa, Ethiopia, Cameroon, 
Kenya and Uganda. These countries demonstrate different epidemics with Cameroon and 
Uganda demonstrating multiclade epidemics with almost all HIV-1 subtypes circulating in 
Cameroon, and Uganda mainly subtypes A, D and A/D recombinants. South Africa and Ethiopia 
demonstrate distinct subtype C epidemics, and Kenya mainly HIV-1 subtype A epidemic, with a 
few recombinant sequences from A, C and D. The five-center study aimed to define genetic 
variation of HIV in these countries participating in or preparing for vaccine clinical trials, and 
evaluate T cell responses to group M consensus Gag and Nef peptide reagents in order to 
identify responses that are cross-reactive across HIV-1 clades in ethnically diverse populations 
where different HIV-1 clades are circulating. This aim reports on work performed by the South 
African part of this network, in an effort to address the effect of HIV genetic diversity on cross-
clade HIV-specific responses to group M-based peptide reagents. 
 
Specific objective  
 
To characterize the T-cell immune responses to HIV-1 Gag and Nef consensus group M peptides 
in HIV-1 infected individuals from South Africa, determine the relationship with the infecting 
viral sequences, and compare responses to group M and subtype C reagents. 
Aim 3 
 
To determine whether sequence variation in cross-reactive T-cell epitopes affects the qualitative 
nature of the HIV-specific T-cell immune response. 
 
Rationale 
The majority of studies characterizing cross-reactivity of HIV-specific T-cells have used a single 
immunological readout, the IFN-γ ELISpot assay, using excessive, non-physiological amounts 
of peptides. However, there are previous studies that have demonstrated the importance of other 
functions of T cells in protective responses, such as cytokine production, cytotoxicity and 
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not been assessed in the context of these other functions. Therefore, this study aimed to measure 
in more detail the true cross-reactive potential of HIV-specific T-cells recognizing 
corresponding HIV-1 peptides with amino acid mismatches, using peptide dilution assays and 




To characterize the cytokine profile (IFN-, IL-2, TNF- and MIP-1) and cytotoxic potential 
(perforin, granzyme B and CD107a expression), as well as proliferative capacity, of HIV-
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The development of a safe, globally effective and affordable vaccine offers the best hope for 
the future control of the HIV pandemic. One of the major challenges in developing such a 
vaccine is the high degree of genetic diversity the virus exhibits.  The extensive genetic 
variation of HIV is fuelled by high mutation, recombination and replication rates, partly 
driven by host cellular and humoral immune pressure (Choisy et al., 2004; Wolinsky et al., 
1996). It is anticipated that the next generation phase IIb and phase III vaccines will contain 
inserts matched to the dominant clade C and E viruses circulating in targeted populations of 
Southern Africa and Thailand respectively (Glenda Gray; AIDS Vaccine 2011, Thialand; 
AIDS Vaccine Clinical Trials Update).  However, the long and expensive process of product 
development, together with the high diversity of the global pandemic, makes matching 
vaccines to circulating viruses difficult.  It is thus likely that candidate vaccines designed for 
one clade will be tested in epidemics where multiple subtypes and recombinant forms co-
circulate. It is therefore important to predict cross-clade epitope coverage. 
T-cell immunity has been found to play a role in HIV control (Frahm et al., 2006; Martinex-
Picado et al., 2006; Miura et al., 2009). The importance of responses to Gag is well 
documented, with studies showing that the magnitude of anti-Gag CD8+ T-cell responses 
inversely correlates with plasma viral load, (Edwards et al., 2002; Kiepiela et al., 2007), and 
that preferential targeting of this protein during infection correlates positively with lower viral 
load (Edwards et al., 2002; Masemola et al., 2004; Zuniga et al., 2006). Other studies have 
shown that the breadth of anti-Gag T-cell responses is associated with lower viral loads 
Geldmacher et al., 2007; Kiepiela et al., 2007). Collectively, these data strongly implicate 
Gag as an important target of HIV-specific T-cells for inclusion in candidate preventative 
vaccines. Of major importance for preventative vaccine development is the identity of regions 
within the HIV-1 proteome that can be targeted by T-cells and that are cross-reactive between 
different viral clades. Previous studies that examined cross-clade HIV-1 Gag T-cell immune 
responses in an environment of multiple circulating clades (Geels et al., 2005; 
Gudmundsdotter et al., 2008; Gupta et al., 2006) have found that HIV-infected individuals 
can mount robust cross-clade HIV-specific T-cell immune responses, but with a preference 
for the predominant circulating or infecting clade (Geldmacher et al., 2007; McKinnon et al., 
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South Africa has a high incidence of HIV-1, with clade C accounting for over 95% of 
infections (Iweriebor et al., 2011; Musyoki et al., 2011; van Harmelen et al., 1997).  A 
number of phase I and II trials and one phase IIb efficacy trial have taken place here, testing 
constructs based on clade A, B and C-based candidate vaccines (Gray et al., 2011; Peters et 
al., 2007; Vardas et al., 2010).  Following on from the first demonstration of vaccine-induced 
protection from HIV-1 acquisition in the RV144 trial in Thailand (Rerks-Ngarm et al., 2009), 
follow-up trials in high incidence settings such as South Africa are currently being planned.   
A vaccine will need to protect against the high degree of HIV diversity and it is thus 
imperative to be able to predict the level of T-cell coverage and cross-reactivity. In this study, 
examined intra- and inter-clade cross-reactivity of HIV-1-specific T-cell responses to Gag 
was examined, using peptides matching candidate South African and Chinese clade C vaccine 
constructs, and compared these with clades A, B and D consensus-based peptides.  The South 
African and Chinese gag genes have been included in candidate HIV-1 vaccines that have 
been tested for safety in phase I clinical trials (Kresge, 2009; Vasan et al., 2010a; Vasan et 
al., 2010b. This study was performed in a South African clade C-infected population, where 
the infecting virus from each individual was sequenced and T-cell responses assessed to the 
different peptide sets. This allowed two inter-related aims to be explored: a) to identify the 
location of commonly and exclusively targeted epitope regions in Gag and relate these to the 
level of virus variability; b) to identify the extent of intra- and inter-clade recognition using 
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Forty HIV-1 infected individuals were recruited for the study from HIV clinics located in 
Johannesburg and Cape Town in South Africa. Eligibility criteria were willing and able to 
provide informed consent, clinically asymptomatic, ART naïve, and with a peripheral blood 
CD4 count that was above 350 cells/mm
3
. The study was approved by the ethical review 
boards of the University of Cape Town and University of the Witwatersrand and each study 
participant provided written informed consent.  CD4 counts were determined using the 
FlowCARE PLG CD4 monoclonal antibody reagent kit (Beckman Coulter, CA, USA) 
according to the manufacturer‟s instructions. Plasma HIV-1 RNA (viral loads in copies/ml) 
was determined using the NucliSENS EasyQ
®
 HIV-1 (version 2.0, BioMerieux SA, Lyon, 
France) according to manufacturer‟s instructions. This kit has a limit of detection of 50 
copies/ml of HIV-1 RNA. 
 
2.2.2. PBMC processing 
 
Sixty ml of blood was drawn by venipuncture in Acid-Citrate-Dextrose (ACD) tubes.  
Peripheral Blood Mononuclear Cells (PBMCs) were isolated using standard Ficoll-Hypaque 
density gradient centrifugation. Firstly, the Ficoll-Hypaque was allowed to reach room 
temperature and 15ml was added into 50ml Leucosep tubes (Sigma-Aldrich, USA). This was 
centrifuged at 1000g for 10 minutes (Heraeus 1.0R Centrifuge). Study participants‟ blood in 
the ACD vacutainers was mixed gently and 30ml poured onto the separating disc. This was 
centrifuged for 15 minutes at 1000g as before. The centrifugation process resulted in four 
distinct layers, first the red blood cells, granulocytes and dense solution at the bottom of the 
tube, secondly the disc separating red blood cells from PBMC, thirdly the ficoll layer 
containing PBMC and lastly the plasma layer on top. Plasma was removed without disturbing 
the PBMC layer and stored at -80
0
C.  The PBMC layer was carefully transferred to a 50ml 
falcon tube, diluted to 50ml using phosphate-buffered saline (PBS) with 1% foetal calf serum 
(FCS; Invitrogen, USA) and centrifuged at 250g for 10 minutes. The supernatant was 
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counted using a Guava personal counter (Guava Technologies, USA) and stored at 10-20 x 
10
6




A total of 540 peptides were used, 120 each for CDu422, CCH and B and 90 peptides each for 
the A and D sets used. The clade C and B peptides spanned the full length of the Gag protein 
while clade A and D peptides covered the p17, p24 and p2 regions. Peptides corresponding to 
p15 were excluded from data comparisons between peptide sets because this region was 
omitted from the A and D sets. The peptide sets were derived from HIV-1 Gag clades A, D, 
consensus B, and vaccine insert matched peptides from CDu422 clade C (South Africa) and a 
Chinese clade C strain (CCH). Table 2.1 details preclinical and clinical trials in which vaccines 
containing the CDu422, CCH and A sequences were tested. All peptides sets were provided by 
the International AIDS Vaccine Initiative, apart from the clade B peptides, which were 
provided by the National Institutes of Health AIDS Research and Reference Reagent 
Repository.  
 
2.2.4. HLA typing 
 
Professor Clive Gray perform d high resolution HLA class I A, B and C typing and the 
results provided for analysis. This was done using sequence specific PCR. Briefly, DNA was 
extracted using the QIAGEN DNA isolation kit for blood (QIAGEN, Chatsworth, CA). High-
resolution HLA class I genotyping was performed by sequencing of exons 2, 3 and 4 using 



















Chapter 2: Investigating Intra- and Inter-clade Cross-Reactive HIV-specific T-cell responses 46 
 
 
Table 2.1. Gag peptide sets and sequences 
 
Peptide set name HIV sequence information and references Vaccine trials and 
references 
Clade A Gag A p24/p17 consensus 
Hanke et al., 2000  
Peters et al., 2007 
Jaoko et al., 2008  
Clade B  Gag B Consensus 
Catalogue # 8116 NIH AIDS Research 
Reference Reagent Program  
https://www.aidsreagent.org 
Not Applicable  
South Africa clade C 
(CDu422) 
CDu422 Williamson et al., 2003 
GenBank: AF544010 
Burgers et al., 2009 
China clade C (CCH) C/B‟ synthetic 
Huang et al., 2008 
Vasan et al., 2010a, b, 2011 
Clade D  Gag D p24/p17 consensus 





2.2.5. IFN-γ ELISpot assay 
 
T-cell responses were assessed by IFN-γ ELISpot assay as previously described (Masemola et 
al., 2004). Briefly, PBMC were plated in 96-well polyvinyledene difluoride-backed plates 
(Microsep, Millipore Products, France) that had been coated previously with 50µl of anti-
IFN-γ mAb 1-D1K (5mg/ml, Mabtech, Sweden) overnight at 4
o
C. The unbound antibody was 
washed away three times with 200µl/well of sterile PBS. Peptides arranged in 5 different 
pools and 24 matrix pools for each of the five peptide sets, were added (50µl/well) directly 
into the wells in duplicate for the pools and singly for the 24 matrices at a final concentration 
of 1.5µg/ml. Fifty microlitres of 8-11-mer Cytomegalovirus Epstein bar virus and Flu virus 
(CEF) peptide pool (National Institute of Health AIDS Research and Reagent Repository) 
were added at a final concentration of 1.5µg/ml, and 50µl of Phytohaemagglutinin (PHA, BD 
Biosciences, USA). PBMC were added at 100 000 cells/well and incubated overnight at 5% 
CO2, 37
o
C. On the following day, the plates were washed six times with 200µl/well of PBS 
containing 0.05% Tween 20 (PBS-Tween, Sigma, USA). Fifty microlitres per well of 
biotinylated anti-human IFN-γ monoclonal antibody clone 7-B6-1 (mAb7-B6-1, MabTech 
Sweden) diluted to 2µg/ml in PBS-10% FCS was added and the plates were incubated for 3 
hours at room temperature. The plates were washed again six times with 200µl/well PBS 
0.05% Tween and Streptavidin-Horse-Radish Peroxidase (HRP) (BD Pharmingen, Canada) at 
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The plates were washed for the third time, six times with 200µl/well of PBS-Tween. The 
development step was performed with 100µl/well of Nova Red substrate (Vector 
Laboratories, CA, USA) for six minutes in the dark. Emptying the wells and rinsing them in 
cold tap water stopped the reaction. Spots were counted on a CTL Analyzer (CTL 
Technologies, Cleveland, USA) and expressed as spot forming units per million (SFU/10
6
) 
PBMC. A response was considered positive if the SFU/10
6
 exceeded 100 after background 
subtraction. An assay passed if there were <5 spots in each of the media control wells, not 
>100 spots in each of the media and cell (background) wells and >400 spots in the PHA 
control wells. Single peptide reactivity was confirmed after deconvoluting the pool/matrix 
reactive peptides in the initial screen. The number of epitopes was determined after taking 
into consideration overlapping peptides. Two consecutive reactive peptides were considered 
as one response and three consecutive reactive peptides as two responses.   
 
2.2.6. Epitope prediction, peptide mapping, binding affinity and processing prediction  
 
Epitope prediction within confirmed reactive peptides was determined using the Epitope 
Location Finder (ELF) tool on the Los Alamos HIV database (www.hiv.lanl.gov) and the 
NetMHC version 3.2 server (www.cbs.dtu.dk/services/NetMHC). The tool predicts binding of 
peptides to a number of different HLA alleles using a novel approximation algorithm that 
employs artificial neural networks and weight matrices (Nielsen et al., 2003). The peptide 
map was generated using the PepMap tool on the Los Alamos HIV database 
(www.hiv.lanl.gov). The tool maps an input of peptides on the HIV reference sequence HXB2. 
All the reactive peptides in the study were loaded onto the tool and mapped onto the HXB2 
reference sequence. 
 
Binding affinities were predicted using NetMHC3.2. To further characterize why some 
peptide variants may be more cross-reactive than others, the effect of amino acid mutations 
on the different steps involved in epitope processing and presentation by their respective HLA 
alleles was investigated by predicting proteasomal cleavage scores, transport by transport 
associated with antigen processing (TAP) and MHC class I binding scores  using a 
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reactive in the study and the proteasome, TAP, MHC processing and total scores were 
predicted as well as the MHC IC50.   
 
 
2.2.7. Statistical analyses 
 
Statistical analyses were performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Prism Software, San Diego, CA, USA). All data were analyzed by use of non-
parametric statistics. The Friedman one-way ANOVA test for matched pairs followed by the 
Dunn‟s post-test was performed to test for any significant differences in genetic distances, 
magnitude and breadth of responses among the different peptide sets. The non-parametric 
Kruskal-Wallis test for unmatched pairs was performed to test for differences in the median 
entropies of peptides in different recognition categories and for differences in scores from 
epitope prediction algorithm. All tests were two-tailed and p < 0.05 was considered 
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2.3. RESULTS 
2.3.1. Characteristics of study individuals  
 
Immunological data were available for 39 participants. The median age was 28 years (range 
22-47 years). The median CD4 count was 492 cells/mm
3
; (range 295-1437 cells/mm
3
; Table 
2.2). The study cohort had a median viral load of 11 000 copies/ml (range 200-260 000). 
Thirty-six participants had a response to at least one Gag peptide from one of the five peptide 
sets used. Seventeen study participants who had Human Leukocyte Antigen (HLA) A and B 
typing data available (Table 2.3) had their reactive peptides further characterized. 
 
Table 2.2. Summary of clinical data of study participants 
 
Characteristic Median (Range)     
Age (Years) 28 (22-47)     
Plasma HIV RNA (Copies/ml) 11000 (200-260000)     
CD4 Count (cells/µl) 492 (295-1437)     
Frequency of HIV-specific T-cell responses CDu422 CCH B A D 








N (number of participants) = 40. N=39 participants were screened for immunological responses 
and 36 had responses to at least one Gag peptide. CDu422: South African clade C, CCH: Chinese 
clade C; A, B and D are clades A, B, and D sequences. 
 
2.3.2. Genetic relatedness and epitope coverage of infecting virus by ELISpot peptide 
reagents 
 
The peptide reagents used in the ELISpot assays are detailed in Table 2.1. The genetic 
distance between these reagent sequences from infecting viral sequences from each of the 
study participants was determined.  These results have been reported previously (Lycias 
Zembe MSc thesis, UCT, 2007) and are provided in Appendix B for reference. Briefly, all 
study participants were confirmed as being infected with HIV-1 clade C (Figure B3.1, 
Appendix B3 and Figure B4.1 Appendix B4). Genetic distances for the peptide sets South 
African clade CDu422 and Chinese clade C (a synthetic B/C recombinant, CCH) and clade B 
peptide sets were based on the full-length Gag amino acid sequences, whilst those for the 
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N = 17 had complete HLA typing for loci A and B. N = 2 had no compl te HLA typing for C locus. Suffix N denotes HLA alleles whose protein is known not to be expressed 









HLA-A HLA-B HLA-C 
CC05 32 610 3900 A29:02 A30:02 B42:01 B42:01 C17:01 C17:01 
CC12 47 536 11000 A 30:01 A30:02 B07:02:01 B58:01 C03:02 C07:02 
CC15 27 452 180000 A 02:01 A29:02 B08:01:01 B42:01 C17:01 C17:01 
CC17 40 884 43000 A 02:05 A26:01 B51:01 B14:01 n/a C18:04 
CC19 23 569 7800 A 30:02 A74:01; A74:02 B07:02:01 B15:03; B95:03 C02:02; C02:10 C07:02 
CC22 31 420 15000 A 23:01 A33:03 B08:01; B08:03 B53:01; B35:29 n/a n/a 
CC23 31 565 72000 A02:01 A30:02 B08:01:01 B45:01 n/a C16:01 
ST03 29 578 21000 A30:01 A74:01; A74:02 B42:01 B58:01 C03:02 C17:01 
NM06 27 1321 130000 A30:02 A43:01 B15:10 B57:03:01 C04:01; C04:09N C18:01; C18:02 
NM07 35 1010 18000 A01:01 A30:01 B15:03; B95:03 B45:01 C04:01; C04:09N C06:02 
BN08 28 1437 740 A01:01 A30:01 B15:03; B95:03 B45:01 C04:01; C04:09N 06:02 
MT09 33 605 2700 A23:01;A23:04 A2902; A29:03 B15:03; B95:03 B42:01 C02:10 C17:01 
RL12 19 628 3500 A23:01; A23:01 A29:02:01;A29:03 B51:01:01 B14:01 C07:02 C07:27 
TM16 29 702 15000 A23:01 A23:01 B08:01 B45:01 C06:02; C06:11 C03:04; C03:07 
ER17 35 999 2000 A29:01 A34:04 B18:01; B18:17N B8101; B81:02 C07:04; C07:11 C08:04 
HN18 29 471 11000 A29:02 A74:01 B1503;B9503 B58:02 C02:10; C02:02 C06:02 
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and CCH peptide sequences to the infecting viral sequences of the participants were similar, with a 
median amino acid distance for CDu422 of 5.5%, and for CCH of 6% (range 4-15%, Figure B3.2, 
Appendix B3). However, the genetic distance between the peptide sets matching consensus 
clades A, B and D with the infecting clade C sequence was significantly greater (p<0.0001), with 
median distances of 13%, 12% and 11%, respectively (Figure B3.2, Appendix B3). 
Differences in antigenic potential of the sequences were investigated next, by examining the 
proportion of matching T-cell epitope-length peptides within the infecting viral sequences, 
compared to the peptide sets being tested. The coverage of putative 9mer epitopes within 
infecting sequences was similar for CDu422 and CCH (55.28% and 53.30% respectively, Figure 
2.1A, red bars). When 9mers were aligned that differed by one amino acid, there was a similar 
trend and an increased frequency of epitope coverage, at 85%, 81%, 63%, 64% and 71% for 
peptide sets CDu422, CCH, A, B and D, respectively (Figure 2.1A, orange bars). Inclusion of 9mer 
that differed by two amino acids further increased the coverage in all peptide sets, 94.2%, 93%, 
79%, 81%, 86% and 96% for CDu422, CCH, A, B, D and all peptide reagents combined, 
respectively (Figure 2.1A, yellow bars). Consistent with the increased amino acid divergence in 
peptide sets A, B and D from the infecting virus (Figure B3.2, Appendix B3), matched epitope 
coverage was lower for these peptide sets, at 33.21%, 30.35% and 37.39% respectively (Figure 
2.1A). Conversely, the proportion of mismatched epitopes (by one or 2 amino acids) was higher 
for the subtype B peptide reagent and least for the subtype C peptide sets (Figure 2.1C). In 
addition, the proportion of mismatched epitopes was reduced by use of all the five peptide 
reagent sequences together (Figure 2.1C, also evident in Figure 2.1A). These data suggest that 
intra-clade T-cell reactivity may be similar due to lower genetic divergence compared to between 
clades. 
 
Epitope coverage analysis was dissected to the single amino acid level across the alignment to see 
the positional epitope coverage of subtype C-viruses by the five peptide sets. Consistent with 
genetic distance data and epitope coverage above, these subtype C-sequences were equally 
covered by the two clade C vaccine inserts, CDu422 and CCH (Figure 2.1B and C). The use of only 
CDu422 vaccine candidate had lower coverage; at 55.28% (Figure 2.1D and E) when compared to 
using a combination of all the five reagent sequences as shown by the higher overall coverage at 
68.31% (Figure 2.1F and G). Overall, 9-mer matched coverage was high within the p24 region 
















Figure 2.1. The coverage of putative epitopes of current vaccine inserts and consensus sequences in 39 HIV-1 
subtype-C infected study participants. (A) Epicover: Epitope coverage of 39 HIV-1 subtype C viruses by two 
vaccine candidates (CDu244 and CCH), subtype B and two consensus sequences (A and D). (B-G) Posicover: (B) Nine-
mers matched to of five peptide sets in the 39 study participants ranked by coverage. (C) Nine-mers missed by use of 
the five peptides sets in the 39 study participants ranked by coverage. (D) Nine-mers matched in their natural 
position and (E) ranked by coverage, by using CDu422 vaccine candidate. (F) Nine-mers matched for five peptide sets 
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2.3.3. Preferential recognition of the infecting clade by HIV-specific T-cells 
 
The first level of cross-clade analysis involved identification of whether the magnitude of 
ELISPOT responses was equally distributed between the different peptide sets tested. All 
comparisons between peptide sets were based on the p17p24p2 region of the Gag protein. For the 
CDu422 and CCH sets, there was no difference between the median magnitude of response 
expressed as SFU/10
6
 PBMC, at 2690 (range 0 to 24550) for CDu422 and 2828 (range 0 to 19407) 
for CCH (p > 0.05; Figure 2.2A). Conversely, the magnitude of responses to other clades were 
significantly lower, at 750, 810 and 1390 for clades A, B and D respectively (p<0.05; Figure 
2.2A). A similar trend was observed for the breadth of responses, with a larger median number of 
reactive peptides being recognized in the two clade C based peptide reagents, CDu422; 4 (range 1-
11) and CCH; 4 (range 0-10) when compared to clades A; 1 (range 0-6), B; 2 (range 0-6) and D; 3 
(range 0-8) peptide sets (Figure 2.2B). Collectively, these data show that peptides more closely 
matched to the infecting autologous sequence result in high magnitude responses and wider 
breadth of coverage, consistent with the predicted epitope coverage shown in Figure 2.1. 
The second level of cross-clade analysis involved assessing the reactivity of each peptide at the 
single study individual level and the contribution of each peptide set to the total response. An 
example is shown for study individual CC23 (Figure 2.3). This study individual demonstrated 
substantial cross-reactivity to different peptides, recognizing a total of 11 peptides. When the 
sequences of these peptides were taken into consideration, the 11 peptides made up 39 different 
variants, of which 22 variants were reactive. Six out of eleven peptides were cross reactive 
(recognized in at least two peptide sets) with differing degrees of cross reactivity.  Each peptide 
set contributed the following responses; 8, 7, 4, 5 and 8 for CDu422, CCH, A, B and D, respectively. 
Peptides 19, 63 and 80 were the most cross-reactive peptides in this individual, being recognized 
in all the four clades, with two variants having the same sequence for peptides 63 and 80. In 
addition, these two peptides had the highest magnitude of response in this study individual (6670 
SFU/10
6
 PBMC and 7470 SFU/10
6
 PBMC, respectively, Figure 2.3). The reasons for different 
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Figure 2.2. Recognition of HIV-1 Gag peptides from clades A, B, CDu422, CCH and D sequences in HIV-1 
clade C infected individuals from South Africa. (A) Total magnitude of Gag-specific T-cells (SFU/10
6
 PBMC) 
against individual peptides for each study individual. Values are shown in log scale. (B) The minimum number of 
responses per peptide set for each study individual. Data is based on the p17p24p2 region of the Gag protein. 
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Figure 2.3. Comprehensive assessment of HIV-1-specific T-cells cross-reactive among the clades A, B, CDu422, 
CCH and D sequences at the single peptide level. The recognition of peptides from the clade A, B, CCH, CDu422 and 




Similar analysis was performed for all study individuals and for all peptides that were reactive in 
the study. In the test peptides used for the ELISpot assay (a total of 540 peptides), there were 26 
peptides that had similar sequences between two variants (6 between A and D, 6 between CDu422 
and CCH, 1 between CCH and B. 2 between CDu422 and D, 5 between CDu422 and A, 6 between 
CDu422 and CCH and between A and D peptide variants). A total of 22 peptides had similar 
sequences among three variants (8 between CDu422, CCH and D variants, 3 between CDu422, CCH 
and A variants, 6 between Du422 CCH and B variants and 5 between CDu422, A and D variants).  
 
Peptide reactivity was normalized for the size of the protein into p17, p24 and p15 (for peptides 
sets CDu422, CCH and B which had p15).  Overall, reactivity normalized per amino acid was higher 
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 per peptide 
c





 per peptide 
       
p17 (MA) 131 30 24 0.80 0.18 2.5 
p24 (CA) 231 59 47 0.79 0.20 3.2 
p15 (NC) 137 22 14 0.67 0.10 2.0 
a
The number of amino acids making up the Gag region. 
b
The proportion of peptides that are reactive given all the peptides tested for that particular region. 
c
The reactivity of the Gag region normalized to per amino acid making up that particular region. 
d
The average number of variants recognized per peptide for that particular region. 
  
 
Reactive peptides that were recognized by at least five study participants were classified as 
immunodominant peptides and are shown in Table 2.5. The location of these peptides in the three 
regions of the Gag protein and the previously determined restricting HLA alleles in the study 
individuals are shown. A total of 15 immunodominant peptides were identified in the study using 
this analysis. The magnitude of response of these immunodominant peptides ranged from 480-
10150 SFU/10
6
 PBMC (Table 2.5). Four out of 15 (27%) of these peptides were from the p17 
region of the Gag protein and 11/15 (73%) were from the p24 region of Gag protein. There were 
no peptides from the p15 region of Gag that were classified as immunodominant peptides. 
Peptides 10 and 33 contain epitopes restricted by HLA alleles previously shown to be protective, 
while peptide 77 has an epitope restricted by an allele previously shown to be associated with 
rapid progression. Of these peptides, 13/15 (87%) were low entropy peptides and 2/15 (13%) 
were high entropy peptides (data not shown). 
 
2.3.4. Peptide variability and cross-reactivity 
 
The second level of analysis consisted of identifying the numbers of mutually (cross-reactive) 
and exclusively recognized (recognition by one clade only) peptides within the five peptide sets 
tested for reactivity. The study participants recognized a total of 84 peptides, with 29 peptides 
being exclusively recognized in one clade only. Nineteen peptides were exclusive to clade C 
(either CDu422 or CCH), 8 to clade B, and one peptide each to clades A and D peptide sets (Figure 
2.4A). Between the two clade C peptide sets, 6/19 peptides were recognized exclusively in the 
CDu422 peptide set and 13/19 peptides were common between the two peptide sets. There were 17 
peptides that were mutually recognized across all four clades. Of these, 7 were positioned in p17 
and 10 within the p24 region of the Gag protein (Figure 2.4B). The remainder of the peptides was 
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5 KIRLRPGGKKHYMLK p17 Cw*4 5 660 Geels et al., 2005 
6 RPGGKKHYMLKHIV p17 A*2301 3 1360 Kiepiela et al., 2007 
10 SRELERFALNPGLLE p17 B*27 4 1750 Shellens et al., 2008 
19 ELKSLYNTVATLYCV p17 A*2902 4 5375 Llano et al., 2009 
33 PIVQNLQGQMVHQAI p24 B*13 4 2130 Llano et al., 2009 
35 MVHQAISPRTLNAWV p24 Cw*0602 5 1120 Allen et al., 2005a 
37 RTLNAWVKVIEEKAF p24 A*0201 4 1090 Schaubert et al., 2007 
44 GATPQDLNTMLNTVG p24 B*4201 4 6430 Day et al., 2007 
61 EQIAWMTSNPPIPV p24 A*0201 3 480 McKinney et al., 2004 
53 PPIPVGDIYKRWILL p24 B*0801 5 6670 Gillespie et al., 2007 
73 RDYVDRFFKTLRAEQ p24 B*1510 5 10150 Gray et al., 2009 
74 DRFFKTLRAEQATQE p24 B*1401 5 6965 Mathews et al., 2008 
75 KTLRAEQATQEVKNW p24 Cw*0304 4 3990 Masemola et al., 
2004a 77 TQEVKNWMTDTLLVQ p24 B*53 2 520 Kaul et al., 2001a 
83 LRALGPGATLEEMMT p24 B*7 3 3830 Perez et al., 2008 
 
a
The restricting HLA allele in the individual that gave the highest magnitude of response to the peptide out of 
the individuals who responded to the peptide. 
b
The cross-reactivity is given by the number of variants recognized for that particular peptide 
c
The magnitude of IFN-γ response shown in the table is the magnitude of response to the variant that gave the 
highest response for that particular peptide out of all variants that were reactive in the study individuals. 
 
 
In an attempt to understand the basis of mutual or exclusive recognition of peptides, we compared 
the Shannon entropy score for the 17 peptides cross-recognized and the 19 peptides exclusively 
recognized from the clade C peptide sets (Figure 2.5A). It was evident that peptides exclusively 
recognized had significantly higher entropy than the mutually recognized peptides (p = 0.0128). 
The bulk of these high entropy peptides were also the least recognized within the cohort (Figure 
2.5B). These data suggest that exclusive recognition of peptides is related to clade C-specific 
variability within the epitopes. Not all peptides exhibited this pattern of low entropy and mutual 
recognition or high entropy and exclusive recognition, and Table 2.6 shows a representative 
example of an individual in the cohort (CC23) recognizing 11 peptides, in some cases despite 
extensive amino acid variability. Peptides 63 and 80 are examples of mutually recognized 
peptides regardless of amino acid change D→E and T→S within the each of the peptides, 
respectively (Table 2.6). These variations are most likely tolerated as they fall outside HLA 
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Figure 2.4. Characterization of reactive peptides. (A) The contribution of each clade-specific peptide set to the overall HIV-specific T-cell responses. Shown in each 
portion of the Venn diagram are the numbers of peptides recognized in each clade and those common among the different combination of clades. (B) HIV-1 Gag cross-
reactive epitope hotspots.  The Gag region in which the peptides are located is shown and drawn to scale, MBR: membrane binding region; NLS: nuclear localization 
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r = - 0.3723



























ns p < 0.05












Figure 2.5. Characterization of peptide cross-reactivity and the basis for mutual and exclusive recognition. 
(A) Comparison of entropy scores between peptides recognized exclusively by clade C peptide reagents (red) and 
those mutually recognized in all the four clades tested (blue). (B) Frequency of responders to epitopes recognized 
by clade C reagents (red) compared to those mutually recognized in all four clades (blue). (C) Comparison of 
entropy score of peptides with different levels of cross-reactivities. Peptides were categorized into those 
recognized in one (red), two (blue) or three or more (green) variants of the peptide sets. (D) Association between 
number of variants recognized and entropy score, determined by Spearman correlation. The non-parametric one 
way ANOVA and Kruskal-Wallis test was used to test for differences in the median entropy scores among the 
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exclusively recognized due to variation in residues important for recognition, and hence not 
cross-reactive (Table 2.6). Peptides that were reactive despite differences from the infecting 
viral sequence may have had variations in „tolerated‟ residues for peptide binding and 
conformation, or the epitopes may indeed have been presented in infected persons as a result of 
minor viral variants that we did not detect by population sequencing of the dominant virus. 
 
To have an overall picture of the pattern of recognition of reactive peptides in the study, all the 
reactive peptides from the study were categorized into those that are recognized in 1, 2 or ≥3 
variants and their entropy scores compared. Reactive peptides recognized in 2 or ≥3 
corresponding variants had significantly lower entropy scores when compared to peptides 
recognized in only one peptide variant (p < 0.0001 and p < 0.05 respectively, Figure 2.5C). 
Furthermore, there was a significant negative correlation between the entropy score and 
number of variants recognized for each peptide when all reactive peptides in the study were 
assessed (r = -0.3723, p = 0.0005, Figure 2.5D). 
 
A graphical representation of these analyses for all the peptides recognized in the study, 
showing the number of responders to each reactive peptide, the number of variants recognized 
for each reactive peptide and the entropy score of the particular reactive peptide is shown in 
Figure 2.6A, B and C respectively. It is evident from this representation that there is no general 
trend for the number of responders to each reactive peptide in relation to entropy or number of 
corresponding variants recognized (Figure 2.6A). In other words, there was no correlation 
between immunodominance of peptides and their entropy (r = 0.0238, p = 0.8297; data not 
shown). However, peptides that were recognized in more variants (generally three or more) 
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Table 2.6. Reactive and corresponding non-reactive peptides in study individual CC 23 
 
Peptide number Name Sequence Restricting HLA SFU/10
6
 PBMC 
a7 Autologous GKKRYMLKHIVWASRE A*0201  
CDu422  KKHYMLKHIVWASRE  1750 
CCH  KKHYMLKHLVWASRE  940 
B GKKKYKLKHIVWASR  0 
A  KKKYRLKHLVWASRE  0 
D  KKKYRLKHLVWASRE  0 
a11 Autologous  EKFALNPGLLETSDG A*0201  
CDu422  ERFALNPGLLETSEG  130 
CCH  ERFALNPGLLETSEG  130 
B LERFAVNPGLLETSE  0 
A  ERFALNPSLLETAEG  0 
D  ERFALNPGLLETSEG  130 
15 Autologous  KQIIKQLQPALQTGT A*02  
CDu422  KQIMKQLQPALQTGT  0 
CCH  KQIIKQLQPALQTGT  0 
B CRQILGQLQPSLQTG  120 
A CQQIMEQLQSALKTSE  0 
D  KQIIGQLQPAIQTGS  0 
19 Autologous EELKSLFNTVATLYCV B*0801  
CDu422  ELKSLYNTVATLYCV  0 
CCH  ELRSLFNTVATLYCV  1280 
B EELRSLYNTVATLYC  520 
A   LKSLFNTVATLYCVH  2353 
D  ELRSLYNTVATLYCV  480 
b32 Autologous SQVSQNYPIVQNLQGQMV Unknown  
CDu422    SQNYPIVQNLQGQMV  0 
CCH    SQNYPIVQNLQGQMV  0 
B    SQNYPIVQNLQGQMV  0 
A  KVSQNYALKHRAYEL  0 
D SQVSQNYPIVQNLQG  160 
38 Autologous NAWVKVIEEKAFSPEI B*4501  
CDu422  AWVKVIEEKAFSPEV  470 
CCH  AWVKVIEEKAFSPEV  470 
B NAWVKVVEEKAFSPE  0 
A  AWVKVIEEKAFSPEV  470 
D  AWVKVIEEKAFSPEV  470 
59 Autologous AGTTSTLQEQIAWMTS A*0201  
CDu422  GTTSTLQEQIAWMTS  150 
CCH  GTTSTLQGQIAWMTS  0 
B AGTTSTLQEQIGWMT  0 
A  GTTSTLQEQIGWMTS  0 
D  GTTSTLQEQIAWMTS  150 
63 Autologous NPPIPVGEIYKRWIIL B*0801  
CDu422  PPIPVGDIYKRWIIL  6670 
CCH  PPVPVGEIYKRWIIL  5980 
B NPPIPVGEIYKRWII  5320 
A  PPIPVGDIYKRWIIL  6670 
D  PPIPVGEIYKRWIIL  5520 
80 Autologous LLTQNANPDCKTILRA B*0801  
CDu422  LVQNANPDCKTILRA  7470 
CCH  LVQNANPDCKTILRA  7470 
B LLVQNANPDCKTILK  3920 
A  LVQNANPDCKSILRA  2653 
D  LVQNANPDCKTILKA  1240 
89 Autologous GHKARVLAEAMSQVGH A*0201  
CDu422  HKARVLAEAMSQTNS  110 
CCH  HKARVLAEAMSQANG  0 
B GHKARVLAEAMSQVT  0 
A  HKARVLGTGARASVL  0 
D  HKARVLAEAMSQATN  200 
107 Autologous FLGKIWPSHKGRPGN A*0201  
CDu422 FLGKIWPSHKGRPGN  450 
CCH FLGKIWPSHKGRPGN  450 
B FLGKIWPSHKGRPGN  450 
A Not available
c
  N/A 
D Not available  N/A 
 
aThe previously described HLA allele to restrict the epitope was absent in the individual, however HLA A*0201 was found to be a strong 
binder to the epitope within this peptide with a binding affinity of 5nM for peptide 7 and a weak binder with an affinity of 135nM for peptide 
11, using NetMHC. bNo epitope described nor predicted to bind to HLA alleles of this participant in this peptide.  cClades A and D had no p15 
region of the Gag protein. Some peptide variants with substitutions in regions flanking the epitope showed discordant recognition patterns 
regardless of matching epitope sequence, possibly due to additional non hydrophobic amino acids at the C-terminal or N-terminal that are not 
well tolerated by class I alleles [63]. ELISPOT reactivity is shown for variants that were reactive, while 0 denotes those that were not reactive. 
Red letters in the peptide sequence indicate amino acid mismatches between that peptide variant and the CDu422 sequence. The green letters 
show amino acid mismatches between the peptide variant sequence and the infecting virus. The predicted epitope in each variant is underlined. 











































































































































































































































Figure 2.6. Reactive peptides from all the study individuals. (A) Number of individuals responding to each peptide. (B) Number of peptide variants recognized for each reactive 
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2.3.5. The Impact of Host HLA on Epitope Recognition by HIV-1-specific T-cells 
  
To test the hypothesis that the level of peptide recognition was most likely governed by 
mutations in key residues that are associated with peptide processing and binding to restricting 
HLA molecules, an algorithm prediction tool was applied (www.immuneepitope.org). The tool 
assesses predicted scores for Transport Associated with Antigen Processing (TAP) binding (an 
estimate of the affinity of the peptide with the TAP molecule), MHC binding scores (an 
estimate of the efficiency of binding to an MHC molecule), proteasome scores (an estimate of 
cleavage site usage) and processing scores (an estimate of the quantity of peptide present in the 
endoplasmic reticulum that is available for MHC binding, from a combination of cleavage and 
transport predictions), and was applied to those participants whose HLA class I A and B alleles 
were typed in this study and were also available in the database (Table 2.3).  
The total epitope score, which is a summary of the proteasomal, TAP and MHC scores, as well 
as the MHC IC50 of the epitopes restricted by the predicted HLA, are shown in Table 2.7 (shown 
for study individual CC23). There were higher scores for proteasome activity, TAP and MHC 
binding, and lower MHC IC50 in peptide variants that were recognized in the IFN-γ ELISPOT 
assay. Overall, when peptide variants were classified into those that were recognized in the 
ELISPOT assay and those that were not, MHC binding score of reactive peptides was 
significantly higher than that of non-reactive variants (p<0.0001, Figure 2.7A). In addition, 
proteasomal cleavage scores (Figure 2.7B), TAP scores (Figure 2.7C) and processing scores 
(Figure 2.7D) were significantly higher for reactive peptide variants compared to their non-
reactive counterparts (p=0.0102, p=0.0427 and p=0.0161, respectively). When all these scores 
were summated, the total score of the reactive peptides was significantly higher than non-
reactive peptide variants (p=0.0001, Figure 2.7E). Furthermore, MHC IC50 scores of the 
reactive variants were significantly lower for reactive variants when compared to their 
corresponding non-reactive variants (p<0.0001, Figure 2.7F).  Thus, non-recognized peptides, 
with higher entropy, may have at some stage mutated under immune-mediated selection 
pressure, showing that variability in key residues is important for MHC presentation and 
recognition by the TCR. Overall, these data provide support for the notion that different clades 
of HIV-1 may have been shaped by class I HLA restricted epitope diversity through probable 
selective immune pressures in different populations. However, it cannot be discounted that the 
non-reactivity of these peptides might be due to random sequence variability, unrelated to 
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Figure 2.7. Characterization of peptide processing and MHC class I presentation of epitopes and their 
variants. Comparison of (A) Major Histocompatibility Complex (MHC) binding score, (B) proteasome cleavage 
score, (C) transporter associated with antigen processing (TAP) score, (D) processing score, which combines 
proteasomal cleavage and TAP transport scores, (E) total epitope score, and (F) MHC IC50, in nM.  The total 
epitope score is a summary of the proteasomal, TAP and MHC binding scores and between reactive peptide 
variants (red) and their corresponding non-reactive variants (purple). Peptides binding to HLA class I A and B 
alleles had their total processing scores and MHC IC50 predicted using the Immune Epitope Database 
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 PBMC Proteasome score TAP score MHC binding 
score 
Processing score Total score MHC 
IC50 
7 CDu422 -KKHYMLKHIVWASRE 1750 1.1 -0.23 0.7 0.87 1.57 0.20 
 CCH -........L...... 940 1.1 -0.23 0.7 0.86 1.56 0.20 
 B G..K.K......... 0 1.1 -0.24 -1.12 0.86 -0.25 13.1 
 A -..K.R...L...... 0 1.1 -0.19 -1.21 0.90 -0.30 16.1 
 D -..K.R...L...... 0 1.1 -0.19 -1.21 0.90 -0.30 16.1 
11 CDu422 -ERFALNPGLLETSEG 130 0.97 -0.29 -0.59 0.67 0.08 3.9 
 CCH -............... 130 0.97 -0.29 -0.59 0.67 0.08 3.9 
 B L....V......... 0 0.97 -0.27 -1.09 0.70 -0.39 12.3 
 A -.......S....A.. 0 0.96 -0.29 -0.63 0.67 0.04 4.3 
 D -............... 130 0.97 -0.29 -0.59 0.67 0.08 3.9 
15 CDu422 -KQIMKQLQPALQTGT 0 0.84 -0.35 -1.35 0.48 -0.87 22.4 
 CCH -...I........... 0 0.84 -0.35 -1.35 0.48 -0.87 22.4 
 B CR..LG....S.... 120 1.01 -0.65 -1.47 0.36 -1.12 29.6 
 A CQ...E...S..K.SE 0 0.87 -0.73 -1.52 0.14 -1.38 33.1 
 D -...IG.....I...S 0 0.90 -1.02 -1.50 -0.13 -1.63 31.9 
19 CDu422 -ELKSLYNTVATLYCV- 0 1.15 0.05 -0.38 1.20 0.82 2.40 
 CCH -..R..F......... 1280 1.15 0.07 0.52 1.22 1.75 0.30 
 B E..R........... 520 1.15 0.07 -0.40 1.22 0.83 2.50 
 A --....F.........H 2353 1.15 0.05 0.40 1.20 1.60 0.40 
 D -..R............ 480 1.15 0.07 -0.40 1.22 0.83 2.50 
38 CDu422 -AWVKVIEEKAFSPEV 470 1.03 0.05 0.52 1.08 1.61 0.30 
 CCH -............... 470 1.03 0.05 0.52 1.08 1.61 0.30 
 B N.....V........ 0 0.41 -0.73 -0.88 -0.32 -1.20 7.50 
 A -............... 470 1.03 0.05 0.52 1.08 1.61 0.30 
 D -............... 470 1.03 0.05 0.52 1.08 1.61 0.30 
63 CDu422 -PPIPVGDIYKRWIIL 6670 1.54 0.45 -0.44 1.99 1.95 1.10 
 CCH -..V...E........ 5980 1.54 0.44 0.22 1.98 2.20 0.60 
 B N......E....... 5320 1.54 0.44 0.22 1.98 2.20 0.60 
 A -............... 6670 1.54 0.45 -0.44 1.99 1.95 1.10 
 D -......E........ 5520 1.54 0.44 0.22 1.98 2.20 0.60 
80 CDu422 -LVQNANPDCKTILRA 7470 1.67 0.39 -0.71 2.06 1.35 5.20 
 CCH -............... 7470 1.67 0.39 -0.71 2.06 1.35 5.20 
 B L.............K 3920 1.67 0.39 -0.71 2.06 1.35 5.20 
 A -..........S.... 2653 1.17 0.25 -1.26 1.42 0.16 18.4 
 D -.............K. 1240 1.67 0.39 -0.71 2.06 1.35 5.20 
89 CDu422 -HKARVLAEAMSQTNS 110 0.94 -0.94 -0.22 -0.01 0.22 0.60 
 CCH -............A.G 0 0.77 -0.54 0.12 0.22 0.35 0.80 
 B G............VT 0 1.05 0.32 1.41 0.72 0.68 25.6 
 A -......GTGARASVL 0 1.52 0.33 -1.76 1.85 0.08 58.0 
 D -............ATN 200 0.98 -0.50 0.15 0.47 0.63 0.70 
107 CDu422 FLGKIWPSHKGRPGN 450 0.58 -1.10 0.46 -0.53 -0.13 0.40 
 CCH ............... 450 0.58 -1.10 0.46 -0.53 -0.13 0.40 
 B ............... 450 0.58 -1.10 0.46 -0.53 -0.13 0.40 
The different stages of epitope processing were predicted using algorithms for MHC class I T-cell epitope processing for reactive peptides in the study. Results shown in the 















Immunogens designed to elicit T-cell responses remain a major focus of HIV vaccine 
development. Because of the significant sequence variation that exists between HIV-1 clades 
(7-15%, (Korber et al., 2001), there is an acknowledgement that the HIV clades on which 
vaccines are based will have an impact on the immune response elicited, and very likely the 
subsequent efficacy of vaccines. 
The predicted correlates of protection (neutralizing antibodies and CTL) might be changing 
with correlates analysis from the RV144 trial, which has shown that V2 binding antibodies and 
CD4 responses were present in those vaccinated and protected from infection (Haynes et al., 
2012).  These data highlight the need for empirical studies. A vaccine to prevent infection has 
to address the issue of the high mutation rate of HIV and hence the huge genetic diversity of 
the virus. Therefore approaches that can predict possible mutation states and highly mutable 
regions of HIV will be useful for designing these kinds of vaccines. Using such methods, 
perhaps it will be possible to predict which regions are likely to mutate to which amino acids 
in people expressing particular HLA alleles, and then design immunogens that address that. 
The concept of cross-reactivity is important for both vaccine designs as in either case a vaccine 
has to encompass the ever increasing genetic diversity of the virus. Therefore, testing HIV-
infected persons serves as a proxy for assessing T-cell cross-reactivity of highly immunogenic 
vaccines. It is useful for determining whether HIV-specific responses that particular 
populations with specific HLA alleles mount, and their degree of cross-reactivity to vaccine 
sequences that may be tested in that region; infecting viruses represent future „challenge‟ 
viruses that vaccine trial volunteers may encounter. Previous studies have shown that HIV-
infected individuals can mount cross-reactive T-cell responses against different HIV-1 clades 
(Buseyne et al., 1998; Cao et al., 2000; Currier et al., 2003; Ferrari et al., 1997). While early 
studies focused on a limited number of selected epitopes, and relied on the use of pools of 
peptides or cells infected with recombinant vaccinia virus expressing HIV proteins, more 
recent studies have assessed the degree of cross-clade recognition at the peptide or epitope 
level Aidoo et al., 2008; Gupta et al., 2006; Yu et al., 2005). This chapter describes a study 
which is the first to comprehensively look at the ability of clade C infected individuals to 
recognize peptides included in vaccines currently being tested, and to investigate both intra-
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This study investigated T-cell reactivity in 39 individuals where the sequence of the infecting 
virus was determined by population sequencing of the dominant virus, and high resolution 
HLA typing was performed in a sub-group of these individuals.  Although it was not directly 
shown that responses were due to CD8+ T-cells, reactivity was assumed to be CD8-mediated 
as previous studies have shown that ELISpot responses are predominantly CD8+ T-cell 
mediated (Addo et al., 2003; Bansal et al., 2003). However, it cannot be ruled out that some of 
the responses may have been CD4-mediated. In this study, responses against Gag peptides 
from five sequence variants, clade CDu422 from South Africa based on the Du422 sequence 
(Williamson et al., 2003), CCH (Chinese clade C, for intra-clade responses), and clades B, A 
and D, at the single peptide level were assessed and were in the same order as predicted by 
coverage algorithms with slight differences possibly due to the fact that recognition of peptides 
is affected by many other variables in particular the HLA background of the individual. 
Although South Africa and China have genetically distinct clade C epidemics, we found that 
neither the magnitude nor the breadth of HIV-specific T-cell responses to Chinese and South 
African clade C peptide variants differed significantly. However, the magnitude and breadth of 
the responses to these two clade C peptide variants was significantly higher than that of Gag 
peptide reagents based on clades B, A and D sequences. Although D is closer to B than C, D 
was recognized with higher magnitude and breadth than other clade-mismatched peptides. 
Perhaps the greater variability in D does not reside in immunogenic regions and therefore 
preferential recognition of D compared to clades A and B. Overall, the data is further 
corroboration of results from previous studies which have shown that HIV-specific T-cells are 
cross-reactive among differ nt HIV clades but with a preference for the infecting clade 
(Geldmacher et al., 2007; McKinnon et al., 2005).  A similar reduction in epitope breadth for 
non-infecting clade peptide sets of approximately 50-70% was observed in a clade B-infected 
population when comparing recognition of clade B peptides to C and A peptides sets spanning 
the whole HIV genome (Yu et al., 2005). These data suggest that vaccines based on other 
clades may be cross-reactive and therefore warrant their testing in HIV-1 clade C-epidemic 
regions.  However, whilst vaccines based on non-matching HIV clades may still induce cross-
reactive responses, this reactivity may be less than that for clade-matched vaccines.  Indeed, 
Gray et al (2011) demonstrated recently in the Phambili phase IIb trial of a clade B-based Ad5 
immunogen in a South African population that 12% fewer vaccinees mounted a response to 
clade C peptides compared to clade B, with a 35% reduction in the overall magnitude of the 
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a clade B-infected population (Buchbinder et al., 2008), so no conclusions can be drawn 
regarding the lower clade C-specific responses and vaccine efficacy.  Clade-matching vaccines 
may represent a viable approach for regions where single clades circulate, such as Southern 
Africa, but this approach is highly limited for regions where multiple clades circulate, and 
increasing global HIV-1 diversity is a major challenge (Hemelaar et al., 2011).   
The results from this study demonstrate that within a single individual, some HIV peptides 
were exclusively recognized in the clade C sequence variants (CDu422 and CCH), whilst others 
were uniquely recognized in the clades B, A and D peptide variant. The recognition of clades 
B, A and D peptide variants and not the corresponding clade C peptide variants is of 
importance, as it demonstrates that using a single peptide reagent set leads to a considerable 
number of responses being missed when investigating T-cell immune responses (Frahm et al., 
2007; Rolland et al., 2011).  Of course, this approach is very likely still an underestimation of 
actual responses, since using peptide reagents matching the autologous virus demonstrates an 
increase in detectable T-cell responses of 29%, even in more conserved parts of the genome 
such as p24 (Altfeld et al., 2003).  Importantly, an even greater increase of 37% in detectable 
epitopic regions was demonstrated when using a clade B Nef PTE (potential T-cell epitope) 
peptide set compared to clade B consensus peptides (Malhotra et al., 2007); indeed, preclinical 
vaccine studies show that these synthetic mosaic immunogens based on the PTE approach 
expand both the breadth and depth of T-cell responses (Barouch et al., 2010; Kong et al., 
2009; Santra et al., 2010), as discussed in chapter one. Whether these increases in cross-
reactive breadth are sufficient to be cross-protective remains to be elucidated in clinical trials. 
It was surprising to note that only 14% of the reduction in cross-reactivity could be explained 
by the variability in peptide sequences. Although this was a low predictive value, it was 
significant and but suggested that there could be many other variables involved including HLA 
alleles that could be affecting cross-reactivity of these peptides. Therefore further 
characterization of reactive peptides in the study identified highly cross-reactive peptides with 
low intra- and inter-clade diversity, as shown by their lower entropy scores. Peptides that were 
recognized in two or more variant forms had significantly lower entropy scores when 
compared to peptides recognized once across the peptide sets.  The pattern of recognition 
observed in the mutually recognized peptides may imply that HLA alleles restricting these 
peptides are driving mutations in the epitopes, as shown by loss of recognition of certain 
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factors including TAP and MHC binding and proteasomal cleavage as playing a role in the 
recognition of specific variants and not others. This may illustrate the evolution of HIV due to 
T-cell pressure in HLA class I-restricted epitopes (Allen et al., 2004; Carlson et al., 2008; 
Dong et al., 2011; Kawashima et al., 2009; Kiepiela et al., 2004; Rolland et al., 2011), which 
is evidenced by HLA footprints observed in specific regions of the viral proteome containing 
HIV-specific HLA class I restricted T-cell epitopes (John et al., 2010; Moore et al., 2002). 
This phenomenon of HLA-driven viral evolution was illustrated recently with the first 
evidence of vaccine-driven T-cell footprints on viral sequences reported in breakthrough 
infections in the STEP trial (Rolland et al., 2011).  
Overall, these data further corroborate previous findings which suggest that within the clades 
A, B, C and D sequences, some corresponding viral regions share a similar degree of 
conservation, possibly due to structural constraints that prevent sequence mutations in specific 
parts of the viral genome (Woo et al., 2010). This is further supp rted by the finding that most 
of the highly cross-recognized peptides were from the p24 region of the Gag protein which is 
known to be highly conserved and play a structural role in the HIV proteome. Yet, cross-clade 
recognition of peptides with considerable differences in their amino acid composition was also 
observed; most of the amino acid changes were semi-conserved, that is between amino acids 
with closely related side chains, and therefore did not have a significant impact on the 
processing of the epitopes for presentation by HLA alleles. This suggests that T-cell receptors 
of HIV-specific T-cells as well as HLA molecules can tolerate some degree of amino acid 
substitution in their epitopes without total loss of epitope recognition or binding as previously 
found in other studies (Addo et al., 2003; Geels et al., 2005; McKinney et al., 2004). 
Interestingly, even the same peptide was recognized to different degrees of cross-reactivity in 
different individuals, showing that different HLA molecules tolerate amino acid changes to 
different extents. Furthermore, use of different T-cell clonotypes through different TCR 
recruitment might have impacted recognition (Litcherfeld et al., 2007). Together, these effects 
of HLA and TCR have to be noted when designing vaccine immunogens that elicit cross-
reactive responses in different populations. In addition, measuring cross-reactivity by 
performing viral inhibition assays could be an alternative way of performing these studies, 
than to reply on the use of immunological readouts as surrogates of predicting cross-reactivity. 
In conclusion, the results in this chapter have shown that clade C HIV-infected individuals 
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that intra-clade variability from diverse geographic regions may not necessarily be an 
impediment to vaccine designed to elicit T-cell responses. However, while extensive cross-
clade recognition was detected, the total magnitude was lower and the breadth of T-cell 
recognition narrower when compared with intra-clade C T-cell responses suggesting that 
vaccine-induced T-cell immunity of clade-mismatched vaccines would result in lower 
immunogenicity at the epitope level.  
 A range of approaches are currently being pursued to develop cross-reactive HIV vaccines, 
including those containing only conserved regions of the HIV proteome among clades 
(Letourneau et al., 2007; Rolland et al., 2007; Rosario et al., 2010), as well as mosaic 
approaches that seek to represent the majority of the diversity within clades (Fischer et al., 
2007). Immunogens containing conserved regions would serve to focus the T-cell vaccine-
induced response towards regions that are less likely to mutate due to structural constraints, 
and specifically exclude responses to variable regions that may be easily escapable, have little 
consequence on viral control, and may even act as decoys masking responses to conserved 
regions (Li et al., 2011).  
 The identification in this study of mutually reactive epitopes within conserved regions of the 
Gag protein support vaccine design strategies that incorporate conserved regions of the viral 
genome. Alternatively, T-cell mosaic antigens seek to increase cross-clade reactivity by 
maximizing the T-cell epitope coverage for most variants (Fischer et al., 2007). Ultimately, 
only testing these different vaccine approaches in clinical efficacy trials will inform us of what 
the best approach is for long-term protection from HIV acquisition or disease and the data 
from this part of the study support the use of conserved regions in developing cross-reactive 
vaccines. However, whether there are enough conserved regions for inclusion in vaccine or 
whether true cross-reactivity will be an issue is unknown, since it remains to be determined 
how many epitopes are needed to confer protection from infection or disease progression. The 
concept of HLA supertypes, where groups of HLA alleles can restrict the same epitopes, and 
the demonstration of HLA promiscuity, where many HLA alleles can restrict more than one 
epitope or tolerate epitope variants, might provide possibilities for good MHC coverage in 
different populations by conserved epitopes. Since similar analyses have not been extensively 
performed on HLA class II alleles, it is not known whether this could be the case with CD4 
epitopes. From the observation that some long term non-progressors may target a single 
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periods, one could speculate that a handful of conserved epitopes that result in a fitness cost to 
the virus and that were promiscuous in their binding to multiple common HLA could be 
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The high level of genetic diversity of HIV-1 poses a major challenge for global vaccine 
development (Garber et al., 2004). The use of centralized sequences in HIV vaccine immunogen 
design has been proposed in order to minimise the genetic distance to multiple clades, and 
potentially maximise cross-clade reactivity. Central sequences can be derived using various 
approaches, including (i) consensus (the most frequent base at a given position across 
corresponding viral sequences); (ii) centre-of-tree (COT; the point in a phylogenetic tree that 
minimizes the evolutionary distances to all sampled viruses); or (iii) most recent common 
ancestor (MRCA; the derived progenitor to a set of sequences; Ellenberger et al., 2002; Gaschen 
et al., 2002; Korber et al., 2001; Mullins et al., 2004; Nickle et al., 2003; Novitsky et al., 2002; 
Rolland et al., 2007).  A detailed characterization of these centralized sequences, particularly 
consensus sequences based on group M viruses, has not been performed in large data sets of 
clade C infected individuals.  
 
Several studies have investigated the feasibility of vaccines based on centralized sequences in 
murine or non-human primate models (Doria-Rose et al., 2005; Kothe et al., 2006; Rolland et 
al., 2007). In a murine model, broader HIV-specific T-cell responses were detected against 
group M consensus Env immunogens than against any single wild type subtype A, B and C Env 
immunogens tested (Weaver et al., 2006). In a non-human primate study, a candidate vaccine 
expressing a group M consensus Env immunogen that was optimized using phylogenetic 
approaches for a shorter variable region compared to wild type Env (Weaver et al., 2010) 
elicited T-cell responses that were significantly broader compared to single clade vaccine 
sequences based on clades A, C and G (Santra et al., 2008). To date, candidate vaccine 
immunogens based on group M consensus sequences have not been tested in human vaccine 
trials, so their potential for eliciting broad immune responses and for providing protection 
against multiple clades from group M is unknown.    
 
One way to evaluate cross-clade reactivity is to assess HIV-specific T-cell responses to these 
centralized reagents in HIV-infected individuals using the IFN- ELISPOT assay. There have 
been several studies that have characterised the immunogenicity of group M consensus 
sequences in comparison to subtype-specific sequences. One such study of 43 subtype B-
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Gag peptide reagents, including peptides based on clade B consensus, subtype B isolate HXB2, 
ancestral group M, ancestral subtype B, and consensus A, C and group M (Bansal et al., 2006). 
Out of the 42 reactive peptides identified, 29 (69%) peptides demonstrated cross-reactivity 
among all the seven Gag peptide reagents tested in at least one of the study individuals 
investigated. Cross-reactivity was highest for p24 Gag (71%), followed by p15 (67%) and lastly 
p17 (63%).  This study also evaluated responses to these peptide reagents in a limited number of 
subtype C-infected participants from Zambia (n=13) of which reactive peptides were only 
confirmed in six individuals. Overall, when subtype B and subtype C infected populations were 
assessed, the subtype consensus peptides that matched the infecting virus clade detected 
responses of similar magnitude and breadth to consensus M and ancestral M reagents, and these 
were higher than responses to clade consensus peptides that were not matched to the infecting 
virus (Bansal et al., 2006). However, this cross reactivity was far lower when evaluating 
reagents based on the more variable HIV proteins such as Env.  In a study of 17 subtype B-
infected participants, Rutebemberwa et al. (2005), found limited cross-reactivity (only 6% 
compared to 69% from the Bansal et al. study) between consensus B, consensus group M and 
HIV-1MN (clade B strain-specific) sequences using the Env protein.  In this study, 16, 14 and 11 
individuals responded to HIV-1MN, consensus clade B and consensus group M peptide sets, 
respectively (Rutebemberwa et al., 2005). In addition, out of the 32 unique responses detected 
by the three peptide sets, 7/32 were common between consensus clade B and consensus group 
M, 10/32 were common between HIV-1MN and consensus clade B, no peptides were unique to 
HIV-1MN and consensus group M peptides, and only two peptides were cross reactive across 
the three peptide sets. Seventeen peptides were exclusively recognized in the HIV-1MN peptide 
set and one peptide each exclusively in the consensus group M and consensus clade B peptide 
set (Rutebemberwa et al., 2005).   
 
A more recent study evaluated responses in subtype B infected individuals from Boston, Peru 
and Barbados (n=54), and clade C infected South Africans (n = 10) to consensus and ancestral 
clades B and C Gag and Nef peptide sets, as well as centre-of-tree for clade B, Consensus M and 
centre-of-tree for group M (Frahm et al., 2008).  HIV-1 specific T cell responses were equally 
well detected in terms of both magnitude and breadth of responses by each clade-specific central 
sequence. Although not significantly different, the number of targeted peptides to these 
centralised peptide sets was lower for Peru and Barbados compared to the US (Frahm et al., 
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the phylogenetic design of these centralised reagents, suggesting that lack of adequate 
representation of population sequences in centralised sequences may limit detectable responses. 
In addition, in clade C infected individuals, the breadth of clade B peptides was reduced 
significantly compared to consensus clade C peptides (p = 0.0039), while the number of targeted 
peptides to group M and clade C sequences did not differ significantly (p > 0.05), Frahm et al., 
2008). Even among the clade B based peptides, ancenstral B responses were broader compared 
to consensus B, possibly due to the fact that ancestral B is more central and thus closer to clade 
C sequences than the consensus clade B sequence. Also, detailed assessment of the data from 
this study demonstrated that the number of targeted peptides to group M were higher in clade C- 
than in clade B-infected individuals (Frahm et al., 2008). Overall, there was a significant 
increase in the breadth of responses when sequences were combined (p < 0.0001), with 
individuals having double the number of responses detected.  
 
A fourth study, of 25 early HIV-1 clade B-infected individuals, similarly evaluated HIV-1 Gag-
specific T-cell responses to CON (consensus)-, COT (centre-of-tree)- and ANC (ancestral)-clade 
B.  As in previous studies, they found responses were similar in terms of magnitude, breadth, 
frequency and epitope specificites of reactive peptides (Malhotra et al., 2007). However, clade-
mismatched consensus peptides based on clades A and C had slightly lower magnitude, 
specificity and breadth of responses compared to clade-matched consensus reagents (Malholtra 
et al., 2007). Detailed sequence charaterization of the detected epitopes identified 16 distinct 
epitopes; with almost half (seven) being invariant across the three clades tested, and 15/16 
epitopes were cross-reactive with at least two clades (A, C or both). Amino acid substitutions in 
9/16 epitopes were located outside HLA anchor residues (Malhotra et al., 2007).  
 
These four studies illustrate the value of investigating different types of centralised or clade-
specific peptide reagents to assess the effect of genetic diversity on HIV-specific T-cell 
responses in infected individuals. To summarise these findings, in some cases there was 
preferential recognition of clade-matched peptide reagents compared to group M or ancestral-
based peptides in terms of both magnitude and breadth of the responses, and in other cases these 
were equally recognised or group M preferentially recognized compard to clade-mismatched 
peptides. The results are consistent with the fact that the genetic distance between group M 
consensus sequences and circulating viruses ranges from 5-15%, which is approximately half the 
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ancestral sequences detect broader responses than consensus sequences of that clade, 
highlighting the importance of evaluating the different approaches proposed for generating these 
centralized sequences.  However, most of these studies were performed in predominantly clade 
B-infected populations, with a limited number of clade C-infected individuals. Furthermore, it is 
important to consider in all these studies that the HLA background of the population under study 
plays an important role in epitope recognition. 
 
This chapter reports on a study, which forms part of a five-country investigation into HIV-1 
diversity and immunity in Africa through the African AIDS Vaccine Programme, involving 
South Africa, Cameroon, Uganda, Kenya and Ethiopia. The overall aim of the study was to 
characterize HIV-specific T-cell responses to group M consensus Gag and Nef proteins in HIV-
infected individuals living in diverse geographical regions in Africa, where different HIV-1 
clades are circulating, and ethnically-diverse population live. Countries were selected based on 
the different subtypes responsible for their HIV epidemics: Cameroon has one of the greatest 
assemblage of HIV-1 subtypes, circulating recombinant forms and unique recombinant forms in 
the world; South Africa and Ethiopia have mainly a subtype C epidemic; and subtypes A and D 
circulate in Kenya and Uganda, with a high proportion of recombinants from clades A, C and D 
(Figure 3.1).  The results from Uganda have recently been published (Serwanga et al., 2011), 
and this chapter reports on the results from South Africa. In this study, two HIV proteins, Gag 
and Nef, were chosen for investigating sequence diversity and cellular immune responses, as 
HIV-infected individuals commonly respond to these proteins, and the conserved and variable 
regions intrinsic to these proteins enable the effect of viral diversity to be evaluated. In this 
chapter, two interrelated aims were investigated, namely: a) characterization of HIV-specific T-
cell immune responses to consensus group M Gag and Nef peptide reagents; and b), comparison 
of these responses to those generated against the near to consensus clade CDu422 peptide reagent 
in an HIV-1 clade C-infected cohort.  These results were related to the sequences of the peptide 



















Figure 3.1. Map showing the HIV epidemics of five selected African countries. South Africa and Ethiopia 
demonstrate predominantly mono-clade epidemics, while multiple clades circulate in Uganda, Kenya and 
Cameroon, with the latter demonstrating extensive diversity of the virus. Table of names and geographical 
locations of countries were obtained from Natural Earth Data website (www.naturalearthdata.com).  Sequence data 
for the five countries was obtained from the HIV geography site of the Los Alamos Sequence database 
(www.hiv.lanl.gov) as of 17 January 2011. The tables were joined and modified and map drawn using the Arc 
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3.2. MATERIALS AND METHODS 
3.2.1. Study participants 
 
Eligibility criteria for the study were willingness and ability to provide informed consent and a 
CD4 count >200 cells/mm
3
. For those who were on the ART start criteria was CD4 count 
<200cells/µl according to South Africa national guidelines.The ethical review board of the 
University of Cape Town approved the study and each study participant provided written 
informed consent. CD4 counts and viral loads were performed as for the study participants 
described in Chapter 2. CD4 count data was unavailable for five study participants and viral 
load data was not available for one individual. Peripheral Blood mononuclear Cells (PBMCs) 
were isolated using standard Ficoll-Hypaque density gradient centrifugation, and plasma 
isolated, as described in Chapter 2.  
 
3.2.2. HIV-1 gag and nef sequencing 
 
HIV RNA was extracted from plasma samples using the Magna-Pure Compact Nucleic Acid 
extractor (Roche). HIV gag cDNA was generated using the Invitrogen Thermoscript
TM
 RT-PCR 
system (Invitrogen). cDNA from the RT step was amplified in a first round polymerase chain 
reaction (PCR) using sequence-specific primers, Gag D forward HXB2 position 5”….3” 626-
644 and Gag D reverse HXB2 position 5”….3” 2402-2382.  Full length gag was amplified 
using Gag A forward 5”….3”, HXB2 683-704, and Gag C reverse, HXB2 position 5”….3” 
2356-2334 in a second round PCR. From the same extracted RNA, HIV nef cDNA was 
generated using Invitrogen Thermoscript
TM
 RT-PCR system (Invitrogen). The cDNA from the 
RT step was amplified in a first round using sequence specific primers namely Nef OR primer, 
HXB position 5”….3” 9608-9625 and SQ15FC, HXB position  5”….3” 8561-8578 and then in 
a second round using Nef F, HXB position,  5”….3” 8754-8776 and Nef R, HXB position 
5”….3” 9443-9461 (Bredell et al., 2007). Primer sequences and cycling conditions are shown in 
Appendix B, B1 and B2 for Gag and Nef, respcetively. The amplified products were “bulk” 
sequenced (i.e. sequenced the major population) in both 5‟ and 3‟ directions on an automated 
DNA sequencer in six separate reactions for each study participant. The resulting sequences 
were assembled using ChromasPro or Sequencher, aligned using BioEdit and phylogenetic 



















Group M consensus Gag and Nef 15-mer peptides overlapping by 11 amino acids from the NIH 
AIDS Reference Reagent Repository were used to test for immune reactivity in 66 HIV infected 
individuals. There were a total of 129 Gag and 53 Nef peptides. The peptides were arranged in 
protein specific and matrix pools, where a peptide appeared once in each protein-specific pool 
and once in each matrix pools, to allow for predictive single peptide mapping (Appendix D1). 
Peptides were arranged in 12 Gag pools, five Nef pools and 12 Matrix pools, as shown in the 
ELISpot plate layout sheet in Appendix D1. In some individuals, HIV Gag clade CDu422 peptides 
with were tested with consensus group M Gag and as well as group M Nef peptides using a 
different layout (Appendix D2). Peptide pools were tested in duplicate except in individuals 
where clade CDu422 peptides were included (Appendix D2, Table D2.4) and matrix pools in 
single wells, at a final concentration of 1μg/ml. Single peptides that were predicted to be 
reactive after deconvoluting the pool/matrix layout from the initial screen were tested at the 
same concentration in a confirmatory ELISpot assay. In 17 study participants, an additional set 
of Gag peptides based on subtype CDu422 from the NIH AIDS Reference Reagent Repository 
was used. These peptides were arranged into 12 pools and 10 matrix pools, and tested and 
confirmed as described above. The CEF peptide pool (obtained from the NIH AIDS Reference 
Reagent Repository) was used as a positive control for each sample, as well as for testing of a 
quality control sample on each plate. This peptide pool, which consisted of 32 8-11-mer CMV, 
EBV and Flu virus epitopes recognized by CD8+ T-cells (Currier et al., 2002), was used at a 
final concentration of 1μg/ml. 
 
3.2.4. IFN-γ ELISpot assay  
 
HIV-specific T-cell responses were assessed by an IFN-γ ELISpot assay, as previously 
described in Chapter 2 of this thesis. 
  
3.2.5. Statistical analyses 
 
Statistical analyses were performed using two-tailed distribution free or non-parametric 
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California USA). Total magnitude of responses to each individual reactive peptide in the Gag 
and Nef proteins were compared using the Mann-Whitney test for unpaired independent 
measures. The total number of peptides recognized by each study individual was compared 
between Gag and Nef proteins using the Wilcoxon signed rank test for matched pairs. The 
magnitude and number of peptides recognized by each subject were compared between 
consensus Gag and subtype CDu422 using the Wilcoxon signed rank test when matched, or 
Mann-Whitney test where data from chapter 2 where compared. The overall number of 
responses to the peptide sets used was tested for differences using the Kruskal-Wallis test 
followed by Dunn‟s post-test for multiple comparisons. The Mann-Whitney test was used to test 
for differences between ARV positive and negative subjects for each protein and within each 
protein. Correlation analyses were performed using the Spearman correlation method. In all 
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3.3. RESULTS 
3.3.1. Characteristics of study participants 
 
In total, 66 participants were included in the study of which 44 ARV-naïve participants and 22 
study individuals who were on ARV treatment were included (Table 3.1).  The median viral 
load of untreated participants was 13000 copies/ml (range <50 to 490000), which was 
significantly higher than that of the individuals who were on ARV treatment (median <400 
copies/ml, range <50-580000, p = 0.0019). Inclusion criteria for this study was a CD4 count ≥ 
200, and there were no significant differences in the median CD4 counts between the two 
groups, with medians of 441 cells/µl (range 215-931) and 537 cells/µl (range 290-1306, p = 
0.1553), respectively. Overall, there were 14 study individuals whose viral load was lower than 
detectable levels, 11 of whom were on treatment and three who were not.  
 
All 66 study individuals were screened for HIV-specific T-cell responses using consensus group 
M Gag and Nef peptides using the IFN-g ELISPOT assay. Fifty-three participants had positive 
responses to at least one Gag or Nef pool, with the remainder not responding to any of the 
peptides tested. Out of the 53, single peptide confirmation was performed in 43 study 
individuals, 37 of whom were not on treatment. In a subset of 17 study individuals, responses to 
Gag clade CDu422 were assayed.  This reagent was based on the subtype CDu422 sequence tested 
in Chapter 2 of this thesis.   
 
3.3.2. Phylogenetic analysis of gag and nef sequences 
 
To identify the infecting subtype, as well as to determine how these infecting viral sequences 
were related to the peptide reagents used in the ELISpot assays, full-length gag sequences were 
generated from 23 participants and nef sequence data from 19 participants.  All study 
participants were infected with pure HIV-1 subtype C viruses in both the gag and nef regions 
(Figure 3.2A and B).  There were four clusters observed in the gag region of two sequences 
each (boostrap values > 85%), namely NY 133 and NY 155; NY 032 and NY 021; NY 264 and 
NY 163; and NY 138 and NY 162. These clusters suggest a relatively recent common ancestor 
for each pair, which is possible since these individuals were recruited from the same 














Chapter 3: Characterization of HIV-specific T-cell responses to consensus and subtype-specific peptide sets 82 
 
Table 3.1. Clinical characteristics of study participants 
 









NY172 316 100000 no NY040 322 7600 no 
ZA006 618 10728 no NY123 343 8700 no 
NY166 217 11000 no ZA034 469 ldl no 
NY155 441 110000 no NY140 782 ldl no 
NY167 405 120000 no ZA011 923 ldl no 
NY133 448 1500 no ZA029 448 nd no 
NY234 680 15000 no ZA023 547 nd no 
NY221 317 16000 no ZA028 553 nd no 
NY210 333 160000 no ZA031 635 nd no 
NY219 551 170000 no ZA030 877 nd no 
NY145 nd 21000 no ZA022 931 nd no 
NY032 534 21000 no NY248 473 1000 yes 
NY164 665 240000 no NY273 768 20000 yes 
ZA021 607 2544 no NY270 650 230000 yes 
NY233 nd 2600 no NY030 705 2400 yes 
NY138 401 27000 no NY062 407 26000 yes 
ZA035 394 2772 no NY028 547 320 yes 
NY163 388 330 no NY279 316 530 yes 
ZA026 517 3539 no NY263 nd 580000 yes 
NY130 322 39811 no NY240 340 5900 yes 
ZA025 614 40438 no NY066 563 84000 yes 
ZA033 379 460 no NY293 nd ldl yes 
NY294 nd 490000 no NY002 290 ldl yes 
NY122 215 500 no NY074 390 ldl yes 
NY157 225 50000 no NY292 423 ldl yes 
NY055 335 510 no NY029 439 ldl yes 
NY264 251 56000 no NY045 530 ldl yes 
ZA002 352 5845 no NY267 545 ldl yes 
ZA024 378 59696 no NY139 554 ldl yes 
NY057 384 6400 no NY039 582 ldl yes 
ZA001 492 64617 no NY076 640 ldl yes 
NY165 258 69000 no NY044 1306 ldl yes 
NY162 461 7100 no NY277 395 nd yes 
 
nd- not done or data not available 





























































Figure 3.2. Phylogenetic relatedness of infecting viral sequences. (A) Gag gene sequences (~ 1500 bp). (B) Nef 
gene sequences (~700 bp) (next page). Phylogenetic analysis was performed on full-length gag and nef sequences 
and is based on the Neighbour-Joining method. The reliability of internal branches is based on 1000 bootstrap 
replicates. The scale bar indicates 10% genetic distance. Study participants infecting virus sequences are shown 
with blue squares. The Du422 sequence is shown with a red triangle while the consensus group M sequence with 
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3.3.3. Amino acid distances between infecting viruses and ELISpot peptide reagents 
 
Amino acid distances were generated to determine the relationship between sequences of 
infecting viruses and ELISpot peptide reagents. In the Nef region, amino acid distances    
between infecting viral sequences and consensus group M reagent were slightly higher than 
compared to subtype CDu422 reagent at a median of 15.5% (range 12.1-17%) and 14.4% (range 
9.5-22.7%), respectively. However, this difference was not statistically significant (p = 0.7239, 
Figure 3.3A).  However, amino acid distances in the Gag region were significantly higher 
between infecting viral sequences and consensus group M reagent when compared to the 
subtype CDu422 peptide reagent 11% (range 8.8-15%) and 6.7% (range 4.1-10.4%), respectively 
(p < 0.0001).  
 
We then estimated the number of 9mers that were matched between the infecting virus and 
either Group M reagents or subtype CDu422 peptide reagents.  We found, as expected, that 
epitope coverage was higher for Gag compared to Nef (Figure 3.3), and coverage was also 
higher for the subtype CDu422 reagent when compared to the consensus M peptide reagents. In 
the Gag protein, when considering exact matches, epitope coverage was 53.88% for the subtype 
CDu422 peptide reagent compared to 41.94% for the consensus group M peptide reagent, a 1.3-
fold increase (Figure 3.3B). In the Nef protein, when considering exact matches, epitope 
coverage by CDu422 peptide reagent was 24.11%, and by the consensus M peptide reagent it was 
18.75% (Figure 3.3B). Overall, the consensus M peptide reagents had lower predicted epitope 
coverage even when epitopes with 1 or 2 amino acid mismatches were taken into consideration, 
suggesting that a group M consensus immunogen would give poorer coverage compared to a 
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Figure 3.3. Characterization of infecting viral sequence and ELISpot peptide reagent sequences. (A) The 
amino acid distance between infecting viral sequences and ELISpot peptide reagent sequence.  (B) Predicted 
epitope coverage of infecting viral sequences by ELISpot peptide reagent sequences. Epitope coverage was 
determined using the Epicover (www.hiv.lanl.gov) for Gag (N = 63, 40/70 sequences from Chapter 2) and Nef (N 
= 19). (C-F) The predicted positional epitope coverage of infecting viral sequences by ELISpot peptide reagent 
sequences. Matched epitope coverage ranked by coverage for Gag (C) and Nef (D).   Missed epitope coverage 
ranked by coverage for Gag (E) and Nef (F). Reagent peptides were derived from CDu422-South African subtype C 
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Next, the proportion of matched or mismatched epitopes was investigated using Posicover 
(www.hiv.lanl.gov) (Figure 3.3C to F). Consistent with the above data, the proportion of matched 
epitopes was higher for Gag compared to Nef (Figure 3.3C and D, respectively) and conversely, 
the proportion of mismatched epitopes was lower for Gag compared to Nef (Figure 3.3E and F, 
respectively). Furthermore, subtype CDu422 peptide reagent had a higher proportion of matched 
epitopes when compared to group M consensus peptide reagent and this was consistent for both 
Gag and Nef proteins (Figure 3.3C and D). 
 
We then determined the variability of each pepide using the Shannon entropy score to determine 
which regions of the protein were more likely to be cross-reactive. Higher variability was 
observed for p17 (amino acids 1-145) and p15 (amino acids 379-520) Gag regions, and lower 
for the p24 (amino acids 146-378) region (Figure 3.4A). For the Nef protein, lower entropy 
scores (less variability) were observed in the central region (amino acids 80-164, Figure 3.4B).   
 
3.3.4. Magnitude and breadth of Consensus M Gag- and Nef-specific T-cells 
 
To assess the reactivity of HIV-1 group M consensus peptides in the 44 ARV untreated study 
participants, the frequency, magnitude and breadth of HIV-specific T-cells recognizing group M 
consensus Gag and Nef peptides were investigated. Study participants on treatment were 
excluded from this analysis as previous studies showed that HIV-specific T-cell responses are 
reduced in these individuals (Addo et al., 2003; Stranford et al., 2001), and also to allow for 
comparison with data from Chapter 2 of this thesis, where all study participants investigated 
were not on treatment. 
 
Based on reactivity to the peptide pools, 81.8% (36/44) of study participants had a response to 
at least one peptide from group M consensus Gag or Nef, with 18.2% (8/44) individuals not 
recognizing any of the Group M peptides tested. Out of the 36 study individuals responding to 
consensus M Gag or Nef, 33 (91.7%) responded to at least one Gag peptide, while 29/36 
(80.6%) responded to at least one Nef peptide. Confirmation of reactive peptides was performed 
in 29 responders. For these participants, 26/29 (90%) responded to Gag peptides, while 17/29 
(59%) responded to Nef peptides. The magnitude and breadth of HIV-specific T-cell responses 
















Figure 3.4. Entropy scores showing variation across protein sequences of study individuals’ infecting viral sequences. (A) Gag protein, N = 23.  (B) Nef protein, N= 19. The 
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The median magnitude of responses was significantly different between the two proteins, with 
Gag having a median of 1180 SFU/10
6
 PBMC (range 0-7810) and Nef having a median of 195 
SFU/10
6
 PBMC (range 0-3730), respectively (p = 0.0013; Figure 3.5A). The median breadth of 
responses (the median number of epitopes targeted after taking into consideration consecutive 
peptides) was significantly higher for Gag, with a median of 2 (range 0-10) compared to the Nef 
protein, with a median of 1 (range 0-6) response (p = 0.0017; Figure 3.5B).  
 
The two artificial proteins tested for reactivity in this study, HIV-1 group M consensus Gag and 
Nef, are characterized by a relatively conserved p24 and variable p17 and p15 regions for Gag, 
and a conserved central region in the Nef protein, with relatively variable outer regions. We 
assessed the relationship between immunodominance and location on the protein.  Overlapping 
reactive peptides in the same individual were only counted as one response.  A total of 50 
different peptides were recognised in consensus M Gag (Figure 3.6A), out of 129 peptides 
making up Gag.  There were nine peptides that were recognized in ≥3 study individuals for the 
Gag protein (18%), 14 in two individuals, and the majority, 27/50 peptides (54%) recognised in 
only one individual. The recognition of peptides was spread throughout the Gag protein, 
although the majority of the highly reactive peptides (7/9; 77.8%) were from the conserved p24 
region of the protein, and 1/9 (11.1%) peptide each from the p17 and p15 regions of Gag. For 
remaining peptides that were recognised in only two individuals, 78.6% (11/14) were from p24, 
and for those recognised in only one individual, 70.4% (19/27) were from p24.  The recognition 
of Nef was focused on 16 peptides (Figure 3.6B), out of 53 peptides spanning the protein, 
representing 30%. There were six Nef peptides that were recognized in ≥3 study participants 
(37.5%). Four out of these six peptides (66.7%) were from the conserved central region of the 
protein, while 2/6 (33.3%) peptides were from the amino terminus of the protein. There were 
four peptides that were recognized in only two individuals, 75% located in the central region of 
Nef, and six peptides recognized in only one study individual, 50% of which were located in the 
central conserved region of the protein. It was interesting to note that no peptide from the 
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Figure 3.5. Total HIV-1-specific IFN-γ producing T-cells against group M consensus Gag and Nef proteins. 
(A) Total magnitude of responses to Gag and Nef individual peptides recognized in 29 study individuals. Each dot 
represents an individual. (B) Total number of peptides recognized in Gag or Nef proteins for 29 individuals. The 
number of responses is the minimum responses after taking into consideration consecutive peptides, as described in 

































































































































































































































































































































Figure 3.6. The immunodominance of HIV-1 specific T-cell responses to consensus group M peptides. (A) The number of individuals responding to each Gag, and (B) 
the number of individuals responding to each Nef peptide. The number of participants responding to each reactive Gag or Nef peptide for 29 study participants is indicated. In 
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3.3.5. Comparison of reactivity of Consensus M and subtype C peptides in a clade C 
population 
 
To compare the reactivity of consensus group M Gag to clade C Gag, 17 responding study 
individuals were tested for T cell responses both to consensus M Gag and clade CDu422 Gag 
peptides. There was preferential recognition of the clade C Gag peptide reagents, with a median 
magnitude of 2005 SFU/10
6
 PBMC (range, 0-10933) compared to consensus group M peptides, 
with a median of 1283 SFU/10
6
 PBMC (range, 0-5911; Figure 3.7A). This difference was 
significant (p = 0.0317). In terms of the number of responses, clade C peptides were 
preferentially recognized in terms of breadth, with a median number of response of 3 (range, 0-
11), however there was no significant difference in the median number of consensus group M 
peptides recognised, namely 2.5 (range, 0-10, p = 0.1121; Figure 3.7B) in these 17 study 
individuals. 
 
To increase our power we performed additional comparisons using data generated from Chapter 
2, in an unmatched analysis. Here we included Gag-specific T-cell responses to consensus M 
(n=29) and to clade CDu422 peptides (n=17) from this Chapter, and Gag-specific T-cell responses 
to clade CDu422 peptides from 39 individuals from Chapter 2.  CD4 counts and viral loads were 
compared between individuals assessed for Group M reactivity (29) and those with clade C 
reactivity data (56), and no significant differences were found between these two groups of 
participants.  Median CD4 counts were 547.0 cells/μl and 448.0 cells/μl, and viral loads 16000 
copies/ml and 5845 copies/ml for group of the two groups of study participants, respectively (p = 
0.0798 and p = 0.3840, Figure D3.1, Appendix D3). Consistent with genetic distance data and 
epitope coverage analysis, as well as the above analysis on the matchted group, the magnitude of 
responses was significantly higher (1.8-fold) for subtype CDu422 peptides compared to consensus 
group M-based peptides, with a median of 2078 SFU/10
6
 PBMC (range 0-24550) and 1180 
SFU/10
6
 PBMC (range 0-7810) for subtype CDu422 Gag and consensus group M peptides, 
respectively in this larger cohort (p = 0.0244, Figure 3.8A). Using these increased numbers of 
participants we now found a significant difference in the median breadth to clade C and 
consensus M peptides.  The breadth of responses was double for the clade C (CDu422) peptide 
reagent, with a median of 4 responses (range 0-11), compared to consensus group M peptides, 
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The trend in the magnitude or breadth of HIV-specific T-cells between clade C compared to 
group M consensus peptides was investigated and denoted by trend arrows joining matching 
cases (Figure 3.8A and B). In 75% (12/16) of the cases that had detectable Gag T-cell responses, 
the detected response was higher for the clade C peptide reagent compared to consensus group 
M reagent (p = 0.0317, Figure 3.8A). The remaining 25% had a lower magnitude of responses to 
the clade C peptides compared to consensus group M peptides. The breadth of responses 
followed a similar pattern, in which more reactive peptides were identified for the clade C 
peptide reagent compared to consensus group M petide reagent in 62.5% (10/16) of the cases 
(Figure 3.8B). The remaining 12.5% and 25% had equal and fewer reactive peptides detected by 
clade C reagent compared to group M reagent, respectively (Figure 3.8B). These data 
demonstrate that within a single individual, clade-matched HIV-Gag peptide reagents detect 
HIV-specific T-cells of higher magnitude and breadth than Gag reagents based on group M 
consensus sequences. 
 
Altogether, these data suggest that although consensus group M based peptide reagents are 
recognized in HIV-1 clade C-infected individuals, they recognise fewer responses with a lower 
magnitude compared to clade-matched peptide reagent, in this case subtype CDu422. This may 
have implications for the use of central sequences as vaccine immunogens. 
 
 In Chapter 2, it was demonstrated that the reagent matching the infecting clade is recognized 
with higher magnitude and breadth of responses when compared to clade-mismatched peptides 
reagents, namely consensus A, B and D. In this Chapter, peptides matching the infecting clade 
were recognized with higher frequency (36/39, 92% versus 33/44, 75%), magnitude and breadth 
when compared to consensus group M based peptide reagents. Therefore, data on inter-clade 
responses from Chapter 2 were compared with data from matched clade and consensus group M 
reagents. Only Gag reactivity was considered, since no Nef reactivity data was available for 






























































































































Figure 3.7. Matched comparison of magnitude and breadth of HIV Gag T-cell responses. (A) The total 
magnitude of HIV-specific T-cells recognizing consensus group M and clade C peptide reagents in clade C infected 
study participants. (B) The minimum number of consensus group M and clade C HIV Gag peptides recognized by 
HIV-specific T-cells in clade C infected study individuals. N=17. Each dot represents an individual. Differences 




























































































Figure 3.8. Comparison of total HIV-1 specific T-cells responding to group M consensus and subtype C Gag 
peptides. (A) Total magnitude of Gag responses.  (B) Total number of peptides recognized. For CDu422, individuals 
from Chapter 2 were included for analysis. Each dot represents an individual. Gag response data were available for 
37 individuals for the Con M and for 56 (17 who had matched data plus 39 from Chapter 2) study individuals for the 




Interestingly, the magnitude of responses were comparable between the consensus group M 
peptide reagents and the clade-mismatched reagents (Figure 3.9A), with a median of 1180 
SFU/10
6
 PBMC (range 0-7810) for consensus M, and inter-clade based consensus reagents 
based on subtypes A, B and D having medians of 750 SFU/10
6
 PBMC (range 0-23817), 810 
SFU/10
6
 PBMC (range 0-11360) and 1390 SFU/10
6
 PBMC (range 0-19474), respectively. 
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peptide sets (Figure 3.9B, p > 0.05).  In terms of frequency of responses, group M peptide 
reagent had detectable responses in 75% of individulas (33/44), and was comparable to that of 
mismatched clades of 76.9% (35/40), 71.7% (28/40) and 84.6% (33/40) for clades A, B and D, 
respectively. However, the frequency of recognition of Gag peptides was higher by 15.6% when 
clade-matched reagents were used compared to consensus group M Gag reagents, at 92.3% 
compared to 76.7% for clade C and consensus group M, respectively. These data suggest that, at 
least for Gag, consensus group M based peptide reagents can be used interchangeably with 
clade-mismatched reagents in the assessment of vaccine induced HIV-specific T-cell responses, 
and may imply that vaccine candidates based on consensus M spanning relatively conserved 
viral regions such as HIV-1 Gag, have no advantage over clade mismatched vaccines in a 
monoclade epidemic.  
 
3.3.6. Comparison of the immune responses between untreated and treated individuals 
 
Previous studies that have shown that HIV-specific T-cell responses are reduced in individuals 
on antiretroviral treatment, compared to those untreated.  Since a portion of our study 
participants (22/66) were treated, the HIV-specific T-cell responses to Gag and Nef in study 
participants who were on treatment (n=16), compared to those who were not (n=29), were 
examined. The total magnitude of responses to Gag was significantly reduced in treated 
individuals compared to untreated individuals (p = 0.0008; Figure 3.10A). The responses ranged 
from 0-12585 and 5330 SFU/10
6
 PBMC; with medians of 635 and 0 SFU/10
6
 PBMC for 
untreated and treated individuals, respectively. Total HIV-specific T-cells against the Nef 
protein showed a similar trend, ranging from 0-4660 and 936 SFU/10
6
 PBMC, with medians of 
195 and 136 SFU/10
6
 PBMC for untreated and treated study participants, respectively (Figure 
3.10A). In contrast to the Gag responses, this difference was not statistically significant (p = 
0.3377, Figure 3.10A). The median number of responses to the Gag protein was significantly 
higher for untreated study participants 2 (range 0-10) compared to treated study participants (1, 
range 0-6; p = 0.0081; Figure 3.10B). On the other hand, there was no significant difference in 
the median number of Nef responses between the treated and untreated study individuals (p = 
0.2834, Figure 3.10). These data demonstrate that antigen load increases the magnitude and 
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Figure 3. 9. Comparison of recognition of consensus group M peptides with subtype specific peptide reagents 
based on clades CDu422, A, B and D. (A) Magnitude of responses. (B) Breadth of responses. Data from Chapter 2 
were included in the analysis to compare consensus group M reagent to inter-clade consensus reagents namely A, B 
and D, as well as intra-clade based peptide reagent namely CDu422. For CDu422 peptide set, total of 56 study 
individuals were included (17 from Chapter 3 and 39 from Chapter 2). For Con M (N=37), and for A, B and D 
(N=39) for each clade. Con M is the consensus group M peptide reagent. Mann-Whitney test for unmatched data 
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Figure 3. 10. Comparison of HIV-specific T-cell responses between participants on treatment (ARV+) and 
those not on treatments (ARV–). (A) The magnitude of HIV-specific T-cell responses to Gag and Nef proteins. 
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3.3.7. Immunodominant peptides identified by consensus group M peptides 
 
Peptides that were recognized in at least four study individuals were classified as 
immunodominant. In total, eight immunodominant peptides were identified in the study (Table 
3.2). There were three such reactive peptides recognized within the Gag protein, and five within 
the Nef protein (Table 3.2). All (3/3) immunodominant reactive Gag peptides were located 
within the p24 region of the protein and the predescribed epitopes within these peptides were 
identical in sequence to their corresponding clade C variants. For Nef protein, all five 
immunodominant peptides were located in the conserved central region of the protein. All 
immunodominant peptides recognized contained previously described epitopes (Table 3.2). In 
addition, these peptides were also identified or reactive using the clade C peptide reagents. 
Sequence comparison between clade C and consensus M showed that previously defined 
epitopic regions were identical in 4/5 peptides (18, 19, 31 and 34) and different in 1/5 peptides.    
The dominant response to the TL9 epitope (peptide 47) could be due to the fact that this epitope 
is restricted by B*7 supertype (B*0702) which comprises about 15% of the South African 
population (Paximadis et al., 2011). HIV Gag peptides 48 and 78 (Table 3.2) were also 
identified as immunodominant in chapter 2 using clade-specific reagents. 
 
 










47 SEGATPQDLNTMLNT p24 5 B*40:01 (B60) Altfeld et al., 2000 
48 TPQDLNTMLNTVGG
H 
p24 7 B*0702 (B7) Jin et al., 2000 




Central 5 B*07:02 (B7) Haas et al., 1996 
19 RPQVPLRPMTYKAA
L 
Central 4 B*35:01 (B35) Culmann et al., 1991 
28 KKRQEILDLWVYHT
Q 




Central 4 B*15:01 (B62) Culmann et al., 1989 
34 TPGPGIRYPLTFGW  
 
Central 4 A*24:02 (A24) Goulder et al., 1997 
The underlined region denotes the pre-described epitope. The HLA in brackets denotes the supertype of the 
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3.3.8. Reactive peptide maps of Gag and Nef  
 
Reactive peptide maps were drawn to show differential epitope clustering across Gag and Nef 
protein regions with the peptides that were recognised using consensus M reagents (Figure 3.11).  
As mentioned, there was a higher peptide density in the relatively conserved p24 region of the 
Gag protein when compared to p17 or p15 (Figure 3.11A). Similarly, the more conserved central 
region of Nef protein had a higher reactive peptide density when compared to the outer regions 








Figure 3.11. Reactive T-cell peptides mapped to within a region of 15 amino acids on the HIV proteins. (A) 
Reactive peptides identified using consensus group M Gag peptides. The locations of the reactive peptides identified 

























































Given the high degree of diversity in Africa, it is not possible to make vaccines matched to all 
the subtypes circulating in different geographical regions.  One way to overcome this problem is 
to design an immunogen based on a centralized sequence derived from the Group M HIV-1 
viruses.  However, this could come at a cost, as subtype coverage may be greater and this 
approach may result in a reduced number of responses at the subtype level compared to a clade-
matched vaccine. In this chapter, we examined the reactivity of peptide sequences based on 
HIV-1 group M consensus sequences, and compared these to peptides based on subtype C 
(Du422 strain) in HIV-1 chronically infected individuals from a subtype C epidemic. This study 
focused on looking at cross-clade responses to Gag and Nef, as Gag has been associated with 
lower viral loads or better disease outcome (Edwards et al., 2002; Kiepiela et al., 2007), while 
Nef is the most immunodominant protein, at least in early subtype C infection (Gray et al., 
2009).   
 
As expected in this study, all the study individuals whose virus was characterized were infected 
with HIV-1 subtype C viruses. Previous studies have documented the South African HIV 
epidemic as being a monoclade epidemic, attibutable in >95% of cases to subtype C viruses 
(Iweriebor et al., 2011, Musyoki et al., 2011), although a minority of non-subtype C have 
recently been identified in South Afr ca (such as A1, B, F1, AD, AG and AC; Wilkinson and 
Engelbrecht, 2009).   The median amino acid distance between the infecting viral sequences and 
the Gag subtype C peptide reagent compared to the Nef subtype C reagent was 6.7% and 14.4%, 
respectively, with the viruses being 1.6-fold more closely related to the subtype CDu422 sequence, 
a South African near-to C consensus isolate (Williamson et al., 2003), compared to the 
consensus group M sequence in the Gag protein (median amino acid difference of 6.7% and 
11.0%, respectively).  Furthermore, analysis of potential epitope coverage by these peptides 
predicted that subtype CDu422 reagents would detect 1.3-fold the breadth of consensus group M-
specific T-cell responses for both Gag and Nef peptide reagents.   
 
To determine how these differences would affect cross-clade reactivity, this study tested the 
ability of consensus group M and clade C peptides based on Gag and Nef to detect responses in a 
study population from South Africa, where the dominant circulating virus is clade C. We found 
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magnitude and breadth of HIV-specific T-cell responses was 1.8-fold and 2-fold, respectively 
higher for the clade C reagent compared to the consensus group M Gag peptide reagent and 
higher than the 1.3-fold predicted by epitope coverage assessment tools. This suggests that group 
M-based peptide reagents can miss responses. Because the group M consensus sequence is 
central to all HIV-1 group M viruses, we would expect similar targeting of these proteins in the 
conserved regions across all group M viruses compared to the variable regions that have 
diversified in other subtypes. In this study we do find this, in that the immunodominant peptides 
were located in the more conserved regions of the proteins, namely the p24 for Gag and the 
central regions of Nef.   Our findings are very similar to those generated from our partners in this 
multicentre study in Ugandan study (Serwanga et al., 2011).  They found that 39% (50/129) and 
34% (18/53) of clade A1 and D HIV-1 infected individuals recognised consensus group M Gag 
and Nef peptides respectively, compared to 39%  (50/129) and 34% 18/53 in our study.  
Furthermore, they identified four peptides that were identified in this chapter as 
immunodominant, including two from Gag p24, TPQDLNTMLNTVGGH and 
RDYVDRFFKTLRAEQ, and two from the central core of Nef, PGIRYPLTFGWCFKL and 
KKRQEILDLWVYHTQ.  However, unlike the study reported herein where the magnitude and 
breadth of responses differed significantly between Gag and Nef proteins, Serwanga et al. 
(2011) did not find significant differences in the magnitude and breadth of responses between 
the two proteins, possibly due to other factors such as HLA background and clinical 
characteristics of study participants since previous studies have shown that magnitude and 
breadth of HIV T-cell responses may be affected by antigen load (Geldmacher et al., 2007).  
 
When the reactivity of consensus M Gag peptides was compared to that of inter-clade peptides, 
there was no significant difference observed in terms of magnitude and breadth. These data 
suggest that consensus group M Gag peptide reagents can be used inter-changeably with clade-
mismatched reagents in the assessment of HIV-specific T-cell responses.  However, they are less 
reactive in frequency, magnitude and breadth compared to clade-matched peptide reagents.  This 
is in contrast to previous data from clade C-infected individuals in which consensus group M 
Gag and Nef peptide reagents performed better than inter-clade peptide reagents, and performed 
as well as the clade matching the infecting clade (Frahm et al., 2008).  However, this could be 
due to the fact that the previous study had limited number of participants (only had 10 clade C-
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In agreement with this study, and in contrast to our results, in another study (Bansal et al., 2006) 
peptides based on the clade matching the infecting clade (clade B) were shown to elicit 
responses of similar frequency (79%) compared to consensus group M (79%) and ancestral 
sequences (79%). However, although the frequency of recognition of clade B reagents was 
similar, in clade C infected participants they found that consensus sequences based on the clade 
not matching the infecting clade were less well targeted in terms of magnitude of responses 
compared to clade-matched, consensus and ancestral sequences.  This was supported by a further 
study that compared the reactivity of HIV-specific T-cells among clade-specific reagents and 
centralised reagents, the frequency of recognition was equal (60%, 15/25 individuals) among the 
consensus B, centre of tree B, ancestor B, consensus M and consensus C peptide reagents 
(Malhotra et al., 2007). Only consensus A was less frequently recognised (48%, 12/25 
individuals) when compared to the other peptide reagents, and this was attributable to lack of 
recognition of the TW10 epitope of the consensus A peptide set.  The differences in results, 
together with loss of responses to specific epitopes, could to a certain extent be attributed to 
different HLA compositions in different populations, which have been shown to affect 
immunodominance (reviewed in Goulder and Watkins, 2008). Another possible reason for 
differences to two published studies that have looked at Gag responses to M consensus and 
compared them to infecting clades and mismatched clades is that these studies had limited 
sample sizes for clade C-infected individuals. Differences between their clade B infected 
individuals and our clade C infected individuals could be because M consensus reacts differently 
in these different epidemics, as pointed out by the study of (Frahm et al., 2008, where M 
consensus reactivity (magnitude and breadth) is higher in clade C infected individuals than in 
clade B infected individuals. In addition, differences in stages of infection, viral load and CD4 
count could have also resulted in the observed differences in results between this study and 
previous studies.  Our study has focused on Gag, which is a conserved protein, and Nef, and 
these results may not be applicable to more variable proteins such as Env.  Overall, the protein 
being characterised and the diversity of the epidemic under study (i.e. which and how many 
virus clades are circulating) may influence the outcome of studies assessing the performance of 
group M consensus peptide reagents compared to other centralised peptide reagents such as 
centre-of-tree, ancestral and clade-specific peptide reagents.   
 
The goal of this part of the multicentre African study was to assess the reactivity of group M 
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results will be combined with those from other countries with different epidemics and HLA 
backgrounds within the populations. 
 
 The present study demonstrated that HIV-1 clade C-infected individuals can recognize peptides 
based on consensus group M Gag and Nef peptides. The magnitude and breadth of responses 
were higher for Gag compared to Nef. In addition, the pattern of recognition could be explained 
by the genetic relatedness of infecting viral sequences to peptide reagent sequences, in which 
Gag was more closely related to the infecting virus sequences compared to Nef. Furthermore, 
clade C (the clade-matched reagent) was significantly more highly recognized (in terms of 
magnitude and number of responses) compared to consensus group M peptide reagent.  
 
Preliminary comparison with data from Uganda, another country involved in the multi-centre 
study, showed no significant differences when comparing the total magnitude and breadth of 
Gag and Nef responses; however the magnitude of responses may be related to time of infection, 
viral load and other factors. On the other hand, similarities were observed in terms of 
immunodominant peptides targeted between the two studies. This is also in line with 
unpublished results from Cameroon, a country demonstrating one of the greatest diversities of 
HIV-1, who is also participating in the multi-centre study (Tongo, Zembe, Burgers et al., 
manuscript in preparation). In that study 75% of individuals recognized at least one peptide from 
Gag and/or Nef and frequency of Nef recognition was slightly higher than Gag, at 82.5% 
compared to 79% for gag. Overall, there were no significant differences in the total magnitude of 
Gag and Nef responses. Interestingly, two Gag and four Nef peptides defined as 
immunodominant from Cameroon were also identified in our study as immunodominant (Marcel 
Tongo, personal communication). Overall, taking these three studies together, it is evident that 
individuals from diverse epidemics with different HLA backgrounds have T-cells that recognize 
certain regions of HIV that are conserved across group M viruses, as detected by consensus 
group M peptide reagents. This suggests the possibility of group M conserved regions as vaccine 
immunogens in populations of differing HLA background and HIV epidemics.  
 
An important point to note, and a limitation of these types of studies, is that reactivity was 
attributable to a single immunological readout, namely IFN-γ production as measured by the 
ELISpot assay. HIV-specific T-cells have the ability to produce other cytokines and perform 
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ability. Also, it is not known whether the specific epitopes targeted would translate to antiviral 
activity in vivo. Therefore, further studies such as viral inhibition assays and multicolor flow 
cytometry assays to explore other functions and characterize the identity of T-cells specific for 
immunodominant, cross-reactive central sequences are important for assessing their true cross-
reactive and antiviral ability.  The present study is the first to assess reactivity of group M 
peptides reagents and compare them to clade-matched and mismatched reagents in a large cohort 
of clade C infection from South Africa, and comprehensive anaylsis of the combined results of 
the five countries participating in the multi-centre African study will identify important regions 
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HIV-1 exhibits a high degree of sequence variability, and this poses a major challenge to the 
development of an effective vaccine against the virus.  A range of studies have described 
cross-clade responses, that is, epitopes that differ between HIV clades but remain 
recognizable and able to stimulate HIV-specific memory T-cells in in vitro assays (Geels et 
al., 2005; Geldmacher et al., 2007; Gupta et al., 2006; McKinnon et al., 2005; Yu et al., 
2005). Indeed, Chapters 2 and 3 of this thesis described matching peptides from different 
HIV clades with variant amino acid sequences that are recognized by T-cells despite variation 
in the epitopes. However, the vast majority of these studies, including those described in this 
thesis, measure cross-reactivity using the IFN-γ ELISpot assay, thus relying on measuring the 
reactivity of peptides by exogenously-added peptides (often in vast excess to physiological 
levels), and relying on one function of T-cells, namely cytokine production of IFN-γ.  
 
In an attempt to understand immune correlates of favourable disease outcome or viral control 
in natural HIV infection, data from several studies comparing HIV-specific adaptive immune 
responses suggest that there are other aspects of the T-cell immune response to HIV that may 
require further elucidation apart from IFN-γ production. HIV-specific memory T-cells are 
capable of producing other cytokines such as IL-2 and TNF-α, chemokines for example MIP-
1β, cytotoxicity through upregulation of perforin and/or granzyme B as well as degranulation 
through CD107a production (Betts et al., 2006; De Rosa et al., 2004; Roederer et al., 2004). 
On that note, previous studies have shown that polyfunctional CD8+ T-cells are found in 
significantly higher frequencies in LTNPs compared to chronic progressors (Betts et al., 
2006). In that study, the quality of CD8+ T-cells were assessed by measuring five functions, 
namely degranulation, IFN-γ, MIP-1β, TNF-α and IL-2 simultaneously in chronically HIV-
infected individuals and compared to elite controllers. The proportion and numbers of CD8+ 
T-cells with more functions inversely correlated with viral load in the progressors, showing 
that the quality of HIV-specific CD8+ T-cells is important in immune control of HIV 
infection (Betts et al., 2006). Additional studies have further assessed the function of CD8+ 
T-cells and identified the upregulation of a cytotoxic molecule, namely perforin, as a 
correlate of HIV elite control (Hesperger et al., 2010). In this cross-sectional study of 
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upregulate perforin consistently compared to viremic controllers, chronic progressors and 
viremic nonprogressors (Hesperger et al., 2010). 
 
Other studies have shown that proliferation of T cells in response to HIV-1 antigens is 
associated with less progressive HIV-1 infection (Huang et al., 2008; Migueles et al., 2002; 
Younes et al., 2003). In one of these studies, it was the proliferative capacity of CD4+ T-cells 
before treatment interruption that correlated with CD4+ T-cell count decline during treatment 
interruption (Huang et al., 2008). In another study, CD4+ T-cell Gag- and Nef-proliferative 
responses were higher in aviremic compared to viremic study individuals (Younes et al., 
2003). Furthermore, a separate study showed that the proliferative capacity of CD8+ T-cells 
of non-progressors is maintained compared to that of progressors (Migueles et al., 2002). 
Interestingly, this study also demonstrated that this was coupled to increased perforin 
production. This data may suggest that it is the combination of specific qualitative aspects of 
HIV-specific CD8+ T-cell functions that is associated with immune control of HIV infection.  
A number of studies have suggested that in addition to polyfunctionality and proliferative 
capacity of HIV-specific T-cells being important in immune control of HIV, other aspects of 
HIV-specific T-cells, such as their functional avidity for the epitopes recognized, may be a 
major factor in the ability of these T-cells to produce more than one function and to suppress 
HIV replication in slow disease progressors (Almeida et al., 2009). These authors showed 
that CD8+ T-cells that had higher polyfunctionality and suppressive activity were highly 
sensitive to antigen, that is, they had higher avidity compared to less polyfunctional and less 
suppressive HIV-specific CD8+ T-cells. Because this study used purified CD8+ T-cell clones 
specific for one epitope restricted by HLA*B27:05, there were no artefacts due to 
heterogeneity in terms of different specificities and restriction by different HLA alleles of 
different T-cell clones, as might have been the case for previous studies that found 
contrasting results on the importance of antigen sensitivity on the functional profile of CD8+ 
T-cells (Ueno et al., 2004; Yang et al., 2003). Functional avidity has also been proposed to 
predict antiviral efficiency (Alexander-Miller et al., 1996; Berger et al., 2011; Derby et al., 
2001). 
 
Current vaccine approaches promising to cater for the divergent forms of the virus involve 
inclusion of variant forms of the viral epitopes („mosaics‟) to elicit broadly reactive T-cell 
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little is known about the ability of HIV-specific T-cells recognizing these variant epitopes to 
mediate different T-cell functions, and the nature of responses at physiologically relevant 
concentrations of the epitopes. Recent published studies indicate that despite broad cross-
reactivity to exogenously loaded HIV peptides in ELISpot assays, T-cell suppression of HIV-
1 with the corresponding epitope was significantly impaired (Bennett et al., 2008). In 
addition, the functional profile of epitope variants differed with respect to levels of cytokine 
production (Malhotra et al., 2009), and importantly, ELISpot reactivity did not necessarily 
correlate with in vitro viral suppression (Valentine et al., 2008).  
 
The hypothesis that was explored in this chapter was that HIV-specific T-cells recognizing 
corresponding epitope variants that differed in functional avidity would also differ in their 
functional profile and proliferative capacity. To test this, T-cells specific for variant HIV 
peptide pairs (e.g., a peptide from subtype C and the corresponding one from Consensus 
group M that had amino acid mismatches but both detected HIV-specific responses in the 
ELISPOT assay) were assessed for their cytokine production profiles by measuring IFN-γ, 
IL-2, TNF-α and MIP-1β; their ability to up-regulate cytotoxic molecules, namely granzyme 
B, perforin and the degranulation marker CD107a; as well as their proliferative capacity, in a 
flow cytometry-based proliferation assay. The results from this study may shed more light on 
the true cross-reactive nature of HIV-specific CD8+ T-cells, which may be important for 
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4.1. MATERIALS AND METHODS 
4.1.1. Study participants 
 
Seventeen HIV-1 infected study participants were involved in this part of the study. These 
were all study individuals described in Chapters 2 and 3. The clinical characteristics of these 
individuals have been provided in these chapters. The individuals were first screened for 
HIV-1 consensus group M- and subtype C-specific T-cell responses using a pool and matrix 
IFN-γ ELISpot assay. Responses were mapped to individual reactive peptides and 
corresponding reactive peptides in each study individual were selected for subsequent 




Peptides that gave a positive response in the IFN-γ ELISpot assay were selected and their 
corresponding variants that were available in the laboratory were tested for reactivity in a 
second IFN-γ ELISpot assay. Peptide variant pairs that were reactive with amino acid 
mismatches within and in flanking regions of pre-described epitopes were used to stimulate 
the same donor PBMC in peptide dilution ELISpot assays, for intracellular cytokines staining 
assays and proliferation assays. Apart from peptide dilution assays, where a range of 
concentrations was used, peptides were used at a final concentration of 1μg/ml in all assays. 
  
4.1.3. Peptide dilution IFN-γ ELISpot assay 
 
Predicted reactive peptides determined from the pool and matrix ELISpot screening assays 
were tested individually to confirm their reactivity. Limiting dilution ELISpot assays were 
performed on 16 study individuals with 17 peptide variant pairs using the IFN-γ ELISpot 
assay as described in Chapter 2 section 2.2.5, in order to investigate whether amino acid 
changes had an effect on functional avidity of the peptides, and whether functional avidity 
was related to the magnitude of response to the recognized peptides. The peptide variants 
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and were performed in duplicate. A functional avidity of ≥2-fold between peptide variants 
was empirically considered different. 
 
4.1.4. Antibodies and reagents 
 
Costimulatory antibodies, anti-CD28 and anti-CD49d (BD Biosciences; San Diego, 
California) and Golgi transport inhibitor, Brefeldin A (Sigma-Aldrich; St. Louis, MO) were 
used at the beginning of each of the stimulation. For the cytokine staining panel, an antibody 
cocktail for surface staining included anti-CD4 FITC, and anti-CD8 PerCP Cy5.5 in a total of 
50μl with 1% wash buffer per reaction. The intracellular staining (ICS) antibody cocktail 
included anti-CD3 APC Cy7, anti-IFN-γ Alexa 700, anti-IL-2 APC, anti-TNF-α PE Cy7 and 
anti-MIP-1β PE in a total of 50µl of 1 x Perm Wash buffer (BD Biosciences; San Jose, 
California). 
 
For the cytotoxic panel, anti-CD107a FITC (BD Biosciences; San Jose, California) was 
included at the beginning of the stimulation in addition to costimulatory antibodies.  The 
cocktail for surface staining included anti-CD4 PE Cy7, and anti-CD8 PerCP Cy5.5 in a total 
of 50μl 1% wash buffer (PBS containing 1% FCS; Fischer Scientific; Pittsburgh, 
Pennsylvania) and 0.1% sodium azide (Fischer Scientific; Pittsburgh, Pennsylvania) per 
reaction. The intracellular cytokine staining antibody cocktail included anti-CD3 APC Cy7, 
anti-IFN-γ Alexa Fluor 700, anti-Perforin PE (clone B-D48 that can recognize perforin in its 
various conformations and therefore can also detect newly formed perforin, Hesperger et al., 
2008) and anti-Granzyme B Alexa 647 in a total of 50µl of 1 x Perm Wash buffer (BD 
Biosciences; San Jose, California) per reaction. All antibodies were titered to optimal 
concentrations for the assays. 
 
Pairs of corresponding peptides with amino acid mismatches used in ELISpot peptide dilution 
assays were used for stimulations. The same concentration (1µg/ml) that gave a positive IFN-γ 
response during screening and confirmatory IFN-γ ELISpot assay was used for stimulations 


















The stimulation mix included 4.5ml Rosewell Park Memorial Institute (RPMI) medium with 
10% FCS, anti-CD28 and anti-CD49d at final concentrations of 0.004μg/ml and 0.001μg/ml 
respectively, and DNase (0.2mg/ml). After resting for at least 4 hours, PBMC were 
centrifuged for 10 minutes at 1200rpm and the pellet re-suspended the stimulation mix and 
divided into half, for staining with a cytokine panel a cytotoxic panel. For the cytokine panel, 
approximately 10
6
 cells (in 195µl) were plated into v-bottomed wells and 5µl of peptide 
added into each stimulation at a final concentration of 1μg/ml, and set up in duplicate. An 
equal volume of RPMI containing 10% FCS and co-stimulatory antibodies was added to the 
negative, unstimulated well. For the cytotoxic panel, 193µl of cells were plated into each well 
and the same peptides added as for the cytokine panel. Anti-CD107a FITC was added to each 
well, as this needs to be included during stimulation. Cells were mixed and the plate was 
incubated at 37
0
C and 5% CO2 for 16 hours. 
 
4.1.6. Intracellular cytokine staining 
 
After 16 hours of stimulation, cells were washed twice with PBS by centrifugation at 1000g 
for 3 minutes at 4
0
C. Pre-titered LIVE/DEAD Fixable Violet Dead Cell Stain (Vivid, Applied 
Biosystems, Invitrogen, USA), a viability marker was added in a total volume of 50μl and 
cells incubated in the dark for 20 minutes, after which they were washed twice with FACS 
wash buffer at 1000g for 3 minutes at 4
0
C. Surface antibody cocktail, containing anti-CD4 
FITC and anti-CD8 PerCP Cy5.5 in a total of 50μl FACS wash buffer for the cytokine panel 
and containing anti-CD4 PE Cy7, anti-CD8 PerCP Cy5.5 in a total of 50µl FACS wash buffer 
for the cytotoxic panel, were added to each well and incubated in the dark for 20 minutes. 
Cells were washed twice with FACS wash buffer at 1000g for 3 minutes and 4
0
C. 
Cytofix/Cytoperm (100μl, BD Biosciences; San Jose, California) was added and cells 
incubated for 20 minutes in the dark, after which they were washed twice with Permwash 
buffer (BD Biosciences; San Jose, California) and stained with 50µl of intracellular cytokine 
antibody cocktail for 20 minutes in the dark. For the cytokine panel, the antibody cocktail 
included anti-CD3 APC Cy7, anti-IFN-γ Alexa Fluor 700, anti-IL-2 APC, anti-TNF-α PE 
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cocktail included anti-CD3 APC Cy7 (stained intracellularly due to internalization upon 
stimulation by antigen), anti-IFN-γ Alexa Fluor 700, anti-Perforin PE and anti-Granzyme B 
Alexa 647 in a total of 50µl of FACS wash buffer per well. Cells were washed twice with 
Permwash buffer at 1000g for 3 minutes at 4
0
C and were resuspended in 150µl Cell Fix (BD 
Biosciences; San Jose, California) and then acquired on an LSRII flow cytometer (BD 
Biosciences; San Jose, California). 
 
 4.1.7. Oregon Green proliferation assay 
 
After resting for at least 6 hours, PBMC were washed twice with PBS.  CellTrace Oregon 
Green 488 (10µg/ml, Molecular Probes, Invitrogen, USA) was added to 1 x 10
7
 cells and 
incubated for 4 minutes in the dark. Cells were mixed and incubated for another 3 minutes in 
the dark, after which they were vortexed at high speed for 10 seconds and an equal volume of 
PBS was added, followed by a further incubation for 3 minutes in the dark. PBS was added 
up to 15 ml and the cells were centrifuged at 571g for 10 minutes. The cells were 
resuspended in RH10 (RPMI with 10% human AB serum, Sigma-Aldrich; St. Louis, MO) 
such that 195µl of cells could be plated per well with 200 000 cells/well, with four wells for 
each peptide variant. Corresponding peptide pairs with amino acid mismatches were used to 
stimulate cells at a final concentration of 1µg/ml in a 200µl reaction volume. A negative 
control well was included, to which RH10 was added in the place of peptide. Cells were 
incubated at 37
0
C, 5% CO2 for 6 days. On day 6, four wells were combined for each peptide 
stimulation and centrifuged at 857g for 5 minutes. Cells were stained for surface markers 
namely CD4 and CD8, as well as for CD3 intracellularly, as described in the previous 
section. Samples were then acquired on an LSRII flow cytometer (BD Biosciences; San Jose, 
California) 
 
4.1.7. Data acquisition and statistical analyses 
 
Approximately 500 000 events were acquired for each stimulation on a three-laser LSRII 
flow cytometer using BD FACS DIVA software (BD Biosciences, San Jose, California). Data 
were analysed using FlowJo version 9.3 (TreeStar, Ashland, Oregon) and Spice version 5.2 
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B, the perforin or granzyme gates were copied into either the CD107a gate or IFN-γ gate, so 
that perforin or granzyme produced together with either CD107a or IFN-γ could be identified. 
Results reported are background subtracted. A response was considered positive if it was 
twice above background and above 0.025% after background subtraction, and with more than 


















4.2.1. Functional avidity of corresponding peptide variants 
 
Although amino acid mutations in corresponding epitope variants have been suggested to be 
key factors leading to loss of recognition of these epitope variants, the effect of these 
mutations in corresponding peptide variants that remain recognized by T-cells has not been 
well characterized. Firstly, the effect of amino acid mismatches on the functional avidity of 
HIV-specific T-cells was investigated. Functional avidity was defined as the peptide 
concentration that gave rise to half the maximum IFN-γ response. 
 
Functional avidity, shown in Figure 4.1-4.3, was classified into three categories. Firstly, 8/17 
(47%) of corresponding peptide pairs with amino acid mismatches had differences in the 
magnitude of HIV-specific IFN-γ T-cell responses, and subsequently a more than 2-fold 
difference in their functional avidity (Figure 4.1). Three out of these seven (38%) peptide 
pairs had amino acid mismatches involving non-conservative mutations, in participants 
ZA023, ZA030 and ZA033 (Figure 4.1). There were 5/8 (63%) of these whose functional 
avidities were different despite conservative amino acid mutations between peptide pairs, that 
is, the amino acid mismatch involved substitution by an amino acid with a closely related side 
chains (ZA031, ZA035, ZA034, TM16 and ZA029, Figure 4.1). 
 
In the second category were 3/17 (18%) of peptide pairs that had differences in the magnitude 
of IFN-γ T-cell responses but did not show differences in their functional avidity (Figure 4.2). 
Further assessment of these four peptide pairs showed that 2/3 (67%) of them had amino acid 
mismatches involving very closely related amino acids (TM16 and NM07), while in 1/3 
(33%) peptide pairs the mismatch involved distantly related amino acids (ZA006, Figure 4.2). 
It was interesting to note that NM07 recognized the variant with higher magnitude than the 
infecting sequence (Figure 4.2). This could possiblly be due to the fact that the sequence that 
is now a variant sequence in the individual represents the original sequence that was in the 
transmitting host and had an epitope that is more avid than the infecting sequence in NM07 or 


















































































































































































































































2000 C73:  RDYVDRFFKTLRAEQ
D41:  RDYVDRFYKTLRAEQ
Infecting: RDYVDRFFKTLRAEQ























































































































Figure 4.1. Peptide dilution assay for corresponding peptide pairs that differed in magnitude and 
functional avidity. IFN-γ responses were determined by ELISPOT assay at five peptide concentrations. The 
number at the top of each figure shows the sample tested. Functional avidity was defined as the peptide 
concentration giving rise to half the maximum IFN-γ response, and is denoted by the dotted lines. A difference 
in functional avidity was defined as >2-fold. The underlined region of the peptide (indicated by the peptide 
number shown before the sequence) denotes the predicted epitope. The red letters denote amino acid mismatch 
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In the third category, 6/17 (35%) of tested peptide variant pairs had a similar magnitude of 
response at almost all peptide concentrations tested (Figure 4.3) and no difference in 
functional avidity. Only 2/6 (33%) of these peptide pairs had amino acid mismatches 
involving non-conservative mutations (MM15 and ZA011) while the majority involved 
closely related amino acids (ZA001, ZA028, ZA035, ZA023, Figure 4.3). 
 
Interestingly, in one case where the same peptide variant pairs were recognised in different 
individuals (C45 and A13 in ZA006 and ZA023), these peptides behaved distinctly, in one 
case showing similar avidity, and in the other very different avidity. This may suggest that 
different HLA alleles were restricting the same peptides in these two people, and the amino 
acid changes affected them differently, or the T cell receptor usage was different between 
them. 
 
In summary, these results show that corresponding peptides that are both recognized and even 
have similar magnitude of T-cell responses in an ELISpot assay at the standard, high 
concentrations typically employed in these assays, may have different functional avidities, 
and suggests that some of these peptides may not be recognized in vivo, for example, in 
ZA035 the M78 variant continues to stimulate a response at low peptide concentrations while 
the corresponding variant D41 ceases to be detectable (Figure 4.1). A summary of the results 
for the participants that had samples available for further study is shown in Table 4.1, and 
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TM 16






500 CDu422 7: KKHYMLKHIVWASRE
CCH7: KKHYMLKHLVWASRE
Infecting: KKHYNLKHLVWASRE































































































































Figure 4.2. Functional avidity of corresponding peptide pairs that demonstrated similar functional avidity 
despite differences in total magnitude of IFN-γ response. Similar functional avidity was defined as that 
which is <2-fold between corresponding peptide pairs. Functional avidity is denoted by dotted lines. The 
infecting virus sequence was available for participants TM16 and NM07. The underlined region denotes the 
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Figure 4.3. Functional avidity of peptide variants which demonstrated similar functional avidity and 
magnitude of IFN-γ response. Dotted lines denote functional avidities, which is the peptide concentration 
yielding half maximum IFN-γ response. Amino acid mismatches are denoted by red letters and the underlined 
region denotes the pre-described epitopic region within the tested peptides. The infecting virus sequence was 
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Table 4.1. Summary of functional avidities of peptide pairs investigated in the study 
 









356 Gillespie et al., 2002 
A13 PQDLNMMLNIVGGHQA 0.004 





3 Reche et al., 2006 
D42 DRFYKTLRAEQASQD 0.447 





10 Bhattacharya et al., 2001 
C59 GTTSTLQGQIAWMTS 0.016 





23 Boutwell et al., 2007 
C20 LFNTVATLYCVHEGI 0.316 





1.8 Gillespie et al., 2002 
C45 PQDLNTMLNTVGGHQA 0.224 





1.33 Thakar et al., 2005 
A19 INEEAAEWDRLHPVHA 0.003 





1.41 Boutwell et al., 2007 
C20 LFNTVATLYCVHEGI 3.162 
        
ZA011 C06 RPGGKKHYMLKHIVW 
p17 B*24:02 
0.102 
1.95 Llano et al., 2009 
 A06 RPGGKKKYRLKHLVW 0.199 
        




Reche et al., 2006 
 D41 RDYVDRFYKTLRAEQ 1.259  
 
The letters in red denote the amino acid mismatch between corresponding peptide pairs. The underlined region shows the predicted epitope region based on data in Los 
Alamos National Laboratory (LANL) immunology database (http://www.hiv.lanl.gov/content/immunology). Fold difference in avidity was obtained by dividing the larger 
EC50 by the smaller EC50 for each peptide pair, where EC50 is the peptide concentration yielding a half maximum peptide-specific IFN-γ response in a peptide dilution 
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4.2.2. Cytokine production by HIV-specific T-cells 
 
 
Having observed that amino acid mismatches in peptide variants had a differential effect on 
the magnitude of IFN-γ responses and functional avidity, peptide variant pairs were selected 
(Table 4.1) and the cytokine profiles of their specific T-cells were investigated. Samples were 
selected based on PBMC availability. The cytokine profile of these peptide variants was 
assessed using intracellular cytokine staining and multiparameter flow cytometry, measuring 
four cytokines, namely IFN-γ, IL-2, MIP-1β and TNF-α. The gating strategy is shown in 
Figure 4.4 and a layout for each study participant is shown in Appendix E1, Figures E1.1-
E1.7.  
 
Only HIV-specific responses by CD8+ T cells were detected, with no CD4 responses 
detected in the samples and peptides that were studied. Responses were not detected in one 
study individual (ZA011), possibly due the fact that the responses were below the level of 
detection of ICS assays, leaving seven individuals for analysis. Overall, HIV-specific CD8+ 
T-cell responses were highest for MIP-β with a median of 0.27% (range 0.09-2.04%), 
followed by IFN-γ, with a median of 0.23% (range 0.08-1.35%; data not shown). IL-2 and 
TNF-α production were the weakest responses in the study, both with a median of 0.05% 
(range 0-0.83% and 0-0.06%, respectivel ). 
  
We next determined whether there were differences in the cytokines produced in response to 
each peptide variant. Peptide pairs demonstrated discordant effects of amino acid mismatches 
on the cytokine profile of HIV-specific T-cells recognizing them. In 4/7 study individuals, 
namely ZA006, ZA021, ZA028 and ZA033 (Figure 4.5), similarities were observed in the 
profile of cytokines produced in response to each peptide variant. Interestingly, 3/4 of these 
study individuals demonstrated similar functional avidities of HIV-specific T-cells 
recognizing their respective peptides pairs, with only ZA033 exhibiting more than a log 
difference in functional avidity (Table 4.1).  
 
On the other hand, three study individuals demonstrated differences in the profile of 
cytokines produced by their HIV-specific T-cells upon stimulation by peptide variants. These 
individuals, namely ZA023, ZA029 and ZA030, had HIV-specific T-cells producing different 
combinations of cytokines in response to their respective peptide variants. In two cases 
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response that was not produced in response to the lower avidity variant (Figure 4.5).  ZA023 
was an interesting case, where the higher avidity peptide A13 detected higher MIP-1 and 







































































































































































































































IL-2 MIP-1B TNF-a  
 
Figure 4. 4. Cytokine profiles of HIV-specific CD8+ T-cells in response to corresponding peptide variants 
with amino acid mismatches. HIV-specific T-cells were assessed for their cytokine production profiles in 
response to peptide variants. The upper row of flow plots demonstrates the gating strategy. This is a 
representative figure for study individual ZA029 after 16 hour stimulation with two corresponding Gag peptide 
variants A42 and D42. The proportion of cytokine producing CD8+ T-cells is indicated in each plot. The last 
row of the bottom panel shows unstimulated cells (Unstim). This result is representative of two independent 
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ZA006













































































Figure 4.5. The cytokine profile of HIV-specific T-cells in response to stimulation with peptide pairs with 
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Having observed discordant effects of avidity and amino acid mismatches on the cytokine 
profile of HIV-specific T-cells recognizing these peptides, the median fluorescence intensity 
(MFI) of intracellular cytokines was compared (Figure 4.6). The MFI indicates the amount of 
cytokine produced by each responding cell. There were no significant differences in the per-
cell cytokine producing capacity for the peptide pairs for all the cytokines investigated, 






































































































Figure 4.6. Comparison of MFI values of cytokines produced in response to corresponding peptide 
variants in seven study individuals. Each study individual is colour coded and for each study individual, 
variant 1 is the peptide variant that had a higher functional avidity, while variant 2 is the corresponding variant 
that had a lower functional avidity. Responses that did not qualify for positive criteria had their MFI set to zero 
if the other variant was positive. When both variants were negative for a particular cytokine, that cytokine was 
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4.2.3. Polyfunctionality of cross-reactive HIV-specific T-cells 
 
The next level of characterization of the cytokine profile of HIV-specific T-cells recognizing 
epitope variants was the investigation of the polyfunctionality of these cells, or the ability to 
produce multiple or combinations of cytokines simultaneously. Only 1/7 study individuals 
(ZA023) had HIV-specific T cells that produced all the three cytokines and one chemokine 
(four functions) tested in response to one of the peptide variants (Appendix E1). Four out of 
seven individuals had HIV-specific T cells producing three functions. These functions were 
predominantly (in 3/4) IFN-γ, MIP-1β and TNF-α, while in 1/4 individuals, IFN-γ, IL-2 and 
MIP-1β were produced. There were 2/7 individuals who demonstrated two functions from 
their HIV-specific T cells, namely IFN-γ and MIP-1β production. Overall, all study 
individuals (7/7) produced IFN-γ (as expected from the ELISPOT assay), as well as MIP-1β 
(Appendix E1). 
 
There were 4/7 study individuals who had similar polyfunctionality between peptide variants, 
for example, ZA006 (Figure 4.7), where both peptide variants (C45 and A13) elicited similar 
proportions of CD8+ T-cells producing MIP-1β and IFN-γ or MIP-1β only (Figure 4.7B). On 
the other hand, 3/7 study individuals demonstrated differences in the proportions of cytokine 
combinations produced in response to peptide variants, as shown for ZA023 (Figure 4.8).  
Here, HIV-specific CD8+ T-cells recognizing the C45 peptide variant produced IL-2, which 
was absent for the A13 peptide variant. In addition, the C45 peptide variant elicited single 
cytokine producing cells for IFN-γ, TNF-α and IL-2. The only single cytokine producing 
cells in the A13 variant were MIP-1β-producing cells, which were not present in the C45 
variant, where all MIP-1β-producing cells were dual cytokine producing cells with MIP-1β 
and IFN-γ (Figure 4.8B). Taken together, the data suggest that amino acid mismatches 
between peptides variants may lead to differences in the profile of cytokines produced by the 

























Figure 4.7. A representative figure of an individual showing similar polyfunctionality of HIV-1 specific T-
cells recognizing HIV-1 peptide variants (ZA006). (A) Pie charts showing the proportion of HIV-specific T-
cells producing specific cytokines. (B) Bar graph showing the proportion of CD8+ T-cells producing the 
different combinations of cytokines. Each arc shows the proportion of CD8+ T-cells producing the colour-coded 

























Figure 4.8. Representative figure of an individual (ZA023) showing differences in polyfunctionality 
between HIV-1 specific T-cells recognizing HIV peptide variants. (A) Pie charts showing the proportion of 
HIV-1specific T-cells producing specific cytokines. (B) Bar graph showing the proportion of CD8+ T-cells 
producing the different combinations of cytokines. Each arc shows the proportion of CD8+ T-cells producing 
the colour-coded cytokine as a fraction of total responding CD8+ T-cells. 
 
 
4.2.4. Cytotoxic potential of cross-reactive HIV-specific T-cells 
 
 
HIV-specific T-cells can perform other functions apart from cytokine production, including 
degranulation (CD107a expression), have specific cytotoxic potential (measured by perforin 
and/or granzyme B). Therefore, the effect of amino acid mismatches in peptide variants on 
the cytotoxic potential of T-cells recognizing these peptides was investigated, by measuring 
CD107a, IFN-γ, perforin and granzyme B by flow cytometry. To determine the proportions 
of HIV-specfic cells expressing perforin and granzyme, since there are large intracellular 
stores of these proteins, perforin and granzyme were gated together with IFN-γ and/or 
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Figure 4.9. Cytotoxic potential of HIV-specific CD8+ T-cells stimulated with corresponding peptide 
variants with amino acid mismatches. A representative figure from study individual ZA023 showing the 
expression of IFN-γ, perforin, granzyme B and CD107a after 16-hour stimulation with two corresponding Gag 
peptide variants, A13 and C45. The upper row flow plots are showing the gating strategy. The bottom panel 
shows thew cytotoxic profile for each peptide variant.  Granzyme B and Perforin were co-gated with IFN- to 
exclude non-antigen-specific cells with endogenous stores of these proteins. The last row of the bottom panel 
shows the unstimulated sample. The proportion of CD8+ T-cells producing each cytotoxic molecule is shown in 




Firstly, the cross-reactive cytotoxic potential of these peptide variants was investigated by 
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express perforin or granzyme B in HIV-specific cells. Specific perforin or granzyme B were 
defined as the sum of that which is constitutively produced with IFN-γ and/or CD107a. A 
representative example of the gating strategy is shown for study individual ZA023 (Figure 
4.9). In this study individual, both perforin and granzyme B were upregulated to at least one 
peptide variant tested. In addition, CD107a was expressed (Figure 4.9). 
 
Figure 4.10 summarise the results of all seven individuals tested. An uneven pattern of the 
quality and quantity of CD107a production and perforin and granzyme B in HIV-sepcfic cells 
was observed. Peptide-specific CD8+ T cells in ZA028 and ZA033 express perforin to both 
rvariants demonstrating a similar quality of cytotoxic potential. .In ZA006, CD107a and 
granzyme B were both expressed at identical frequencies. However, in this individual, the 
level of perforin upregulation was different between peptide variants, with A13 upregulating 
perforin in 50% and C45 in 30% (1.7-fold) of CD107a and/ IFN-γ producing CD8+ T-cells. 
In ZA021 and ZA029, the cytotoxic potential was similar between the tested peptide variants. 
However, different frequencies of T cells producing or expressing the different molecules 
were observed. For example, in ZA021, the A19 variant detected more granzyme B positive 
cells than the C51 variant (1.8-fold more, Figure 4.10). Similary, in ZA029, A42 detected 
consistently higher frequencies of CD8+ T-cells producing CD107a and granzyme B than 
D42. On the other hand, ZA023 and ZA030 demonstrated differences in the quality of 
cytotoxic potential between peptide variants. In ZA023, when CD107a and granzyme B were 
both expressed, the proportions were higher in CD107a, 34% for A13 and 20% for C45 
variant (1.8-fold), and comparable in granzyme B.  
  
When combinations of cytotoxic molecules were assessed, polycytotoxic potential of HIV-
specific CD8+ T-cells recognizing the different peptides variants differed in some individuals 
and not in the others. For example, in study individual ZA021, the quality of polycytotoxic 
potential was similar for the peptide variants A19 and C51 (Figure 4.11). On the other hand, 
ZA023 demonstrated differences in the quality of polycytotoxic potential of CD8+ T-cells 
recognizing peptide variants A13 and C45 (Figure 4.12). In the response detected to the one 
peptide variant, A13, perforin was up regulated, but this was not the case for the other peptide 
variant. Interestingly, in this individual, using the cytokine panel, it was the C45 peptide 
variant that detected T cells that could produce additional cytokines produced compared to 
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Figure 4.10. The profile of cytotoxicity potential of HIV-1 specific T-cells recognizing HIV peptide 
variants. Responses are corrected for background. Perforin and granzyme B responses refer to the upregulation 





















Figure 4.11. A representative example of an individual (ZA021) showing similarities in cytotoxic potential 
of HIV-1 specific T-cells recognizing HIV peptide variants. (A) Pie chart showing the proportion of HIV-
1specific T-cells producing specific cytotoxic molecules. (B) Bar graph showing the proportion of CD8+ T-cells 
producing the different combinations of cytotoxic molecules. The pie arcs shows the proportion of perforin 
and/or granzyme B positive CD8+ T-cells producing IFN-γ and/or CD107a, that is CD8+ T-cells upregulating 
perforin and or granzyme B. 
 
 
Overall, 2/7 study individuals (ZA023 and ZA030) demonstrated differences in the cytotoxic 
potential profile (Appendix E2). In these two study individuals, the peptide variant with 
greater avidity upregulated perforin, namely A13 (for ZA023) and C59 (for ZA030), which 
was not observed with the peptide with lower avidity (Appendix E2). On the other hand, 5/7 
individuals demonstrated similarities in the profile or quality of cytotoxic potential 
(Appendix E2). Overall, 5/7 individuals had HIV-specific T-cell degranulation (as measured 
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(Appendix E2). However, it was interesting to note that 2/7 individuals upregulated perforin 
but did not demonstrate degranulation (ZA028 and ZA033). Furthermore, not all HIV-
specific T-cells upregulated both cytotoxic molecules upon stimulation. There were 5/7 
individuals who up regulated perforin and an equal number of subjects who upregulated 
granzyme B. There were 3/7 individuals who upregulated both perforin and granzyme B 














































Figure 4.12. A representative example of an individual (ZA023) showing differences in cytotoxic potential 
of HIV-1 specific T-cells recognizing HIV peptide variants. (A) Pie chart showing the proportion of HIV-
1specific T-cells producing specific cytotoxic molecules. (B) Bar graph showing the proportion of CD8+ T-cells 
producing the different combinations of cytotoxic molecules. The pie arcs shows the proportion of perforin 
and/or granzyme B positive CD8+ T-cells producing IFN-γ and/or CD107a, that is CD8+ T-cells upregulating 
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4.2.5. Proliferative capacity of cross-reactive HIV-specific T-cells 
 
The next level of characterization of the functional cross-reactive potential of HIV epitope 
variants was investigation of the proliferative capacity of HIV-specific T-cells recognizing 
corresponding peptide variants. This was performed using a 6 day Oregon Green proliferation 
assay in four study individuals due to limited sample availability. Figure 4.13 shows the 
gating strategy for detecting proliferating CD8+ T cells in response to the peptide variants 
tested, and the four individuals studied. 
 
Two participants with reactive peptide variants with different functional avidity (ZA030 and 
ZA035) and two participants with reactive peptide variants with similar functional avidity 
(ZA021 and ZA028, less that 1.5 times difference in avidity between variants) were studied, 
as shown in Figure 4.13.  „Variant 1‟ indicates the peptide with the greater avidity for ZA030 
and ZA035, which were both 10 fold greater than Variant 2.  Net proliferative responses are 
shown in Fig 4.14A. Peptide variants demonstrated differences in the effects of amino acid 
mismatches on the proliferative capacity of HIV-specific T-cells recognizing them. 
Participants ZA030 and ZA035 demonstrated higher proliferative responses for the reactive 
peptides with greater functional avidity (C59 and M78).  Interestingly, the A27 (variant 2) 
reactive peptide did not stimulate any proliferation in ZA30, indicating that it might be 
reactive with T cell clones that could not proliferate, despite being reactive in the ELISPOT 
assay and secreting multiple cytokines.   Strikingly, for ZA028 and ZA021, despite the 
peptides having similar avidity, giving very similar ELISPOT responses and producing the 
same repertoire of cytokines, their proliferative capacity differed considerably (Figure 
4.14A). The differences in proliferative capacity were not statistically significant, most likely 
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Figure 4.13. The proliferative capacity of HIV-specific T-cells in response to stimulation by 
corresponding peptide variants with amino acid mismatches.  The top row shows the gating strategy and the 
remainder of the panels show results of the four study individuals tested, showing proliferation of CD8+ T cells 
in response to the peptide pair with variant amino acids. The peptides used for stimulation are indicated, and the 
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Figure 4.14. HIV-specific T-cell proliferative capacity in response to peptide variants with amino acid 
mismatches. (A) The net percentage of CD8+ T-cells proliferating in response to peptide variants in four study 
individuals. (B) Matched pairs comparison of the frequency of CD8+ T-cells proliferating in response to 
stimulation with peptide variants. PBMC were labelled with Oregon Green and stimulated with corresponding 
peptide variants for 6 days after which proliferation was analysed by flow cytometry. The p value was obtained 
using the non-parametric Wilcoxon matched T test. 
 
 
Results from the four assays, namely functional avidity, cytokine production, cytotoxic 
potential and proliferative capacity, are combined into Table 4.2.  It was noted that the 
majority (3/4) of individuals that demonstrated functional avidity differences that also had 
cytokine profile data available had differences in their cytokine profile in response to 
stimulation with peptide variants. In 2/3 of the individuals (ZA029 and ZA030), the peptide 
variant with higher avidity resulted in more cytokines being produced compared to the 
peptide variant with higher functional avidity, and this difference in TNF-α production for 
ZA029, and in the case of ZA030, CD107a and granzyme B production (Table 4.2). The third 
individual with cross-reactive peptides with vastly differential avidity (ZA023, 356-fold 
difference) had some functions of peptide-specific cells in common, namely IFN-, MIP-1, 
CD107a, and granzyme B, whilst the higher avidity peptide additionally detected HIV-speific 
cells expressing perforin, and the low avidity peptide stimulated IL-2 and TNF- production.  
There was one case where peptide variants that demonstrated functional avidity differences 
did not show differences in cytokine profile, in individual ZA033. On the other hand, three 
study individuals that demonstrated little or no functional avidity differences between peptide 
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CD8+ T-cell they detected (ZA006, ZA021 and ZA028). Interestingly, for the four 
individuals that had CD8+ proliferation data, 2/4 individuals (ZA028 and ZA021) that 
demonstrated no differences in functional avidities, cytokine and cytotoxic profiles had 
marked differences in proliferative capacity of HIV-specific T-cells recognizing the peptide 
variants (3-fold and 6-fold, respectively). For the remaining two individuals (ZA030 and 
ZA035), differences in functional avidity translated into differences in proliferative capaicy, 
where the peptide with the higher avidity stimulated more cells to proliferate.   
 
Together, the data suggest that using one immunological readout, such as the IFN- 
ELISPOT assay, may not reveal functional differences exhibited by HIV-specific T-cells 
recognizing epitope variants, and in the context of a vaccine, amino acid mismatches between 
peptide variants may result in differences in functional avidity and/or discordant effects on 
the functional profile of HIV-specific T-cells they elicit. 
 
Seventy-five per cent (3/4) pairs of peptides recognized by HIV-specific T-cells with similar 
functional profiles had conservative amino acid substitution between their corresponding 
variants. In one case (ZA006), a similar profile was observed but with non-conservative 
amino acid substitutions between the peptide variants (Table 4.2). On the other hand, 67% 
(2/3) peptide pairs recognized by HIV-specific T-cells exhibiting different functional profiles 
between the variants had non-conservative amino acid substitutions. Only one case (1/3) was 
a different functional profile observed but with a conservative amino acid substitution 
between the peptide variants (Table 4.2). Overall, there is a trend towards different functional 
profiles of HIV-specific T-cells recognizing HIV epitope variants with non-conservative 
amino acid substitutions, and a trend towards similarities in functional profile if the peptide 
pairs differed in conservative amino acid substitutions or closely related side chains. This 
suggests that the different HLA alleles and TCR contact sites in different individuals 
restricting these epitopes have differing degrees of tolerating amino acid changes resulting in 
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Cytokine profile Cytotoxicity potential 
Proliferative 
capacity (%) 






0.398        nd 
C45 PQDLNTMLNTVGGHQA 0.224         
   




0.016        1.160 
A27 GTTSTLQEQIAWMTS 0.158        0.000 
   




1.259        nd 
A13 PQDLNMMLNIVGGHQA 0.004         
   




0.004        0.985 
A19 INEEAAEWDRLHPVHA 0.003        0.166 
   




4.467        0.270 
D78 LYNTVATLYCVHERI 3.162        0.083 
   




0.014        nd 
C20 LFNTVATLYCVHEGI 0.316         
             




0.447        nd 
D42 DRFYKTLRAEQASQD 0.141         
   




0.102 Responses not detected by flow cytometry nd 
A06 RPGGKKKYRLKHLVW 0.199  




0.126 nd 1.213 
D41 RDYVDRFYKTLRAEQ 1.259 0.773 
 
The underlined region denotes the pre-described epitope.  Amino acid mismatches are denoted in red. Conservative and non-conservative classification of amino acid changes means amino acid 
substitution by an amino acid with a related or un-related side chain, respectively. Functional avidity was defined as the peptide concentration giving half maximum T-cell response by the IFN-γ 
ELISpot assay. Results are based on CD8+ T-cell responses detected. Where positive CD8+ T-cell responses were detected, the different functions are color-coded. Blank cells represent where the 
function was not detected as positive for that particular peptide variant. Nd denotes not done. For ZA11, no responses were detectable by flow cytometry and for ZA35, cytokine and cytotoxic 
production experiments were not performed. Perforin and granzyme B are based on upregulation of these two cytotoxic molecules in combination with CD107a and/or IFN-γ. Bolded functional 

















The importance of HIV-specific T-cells in the control of virus replication during natural 
HIV-1 infection is well documented (Borrow et al., 1994; Koup et al., 1994). Yet there is a 
need to better understand the HIV-specific T-cell functional correlates of cell-mediated 
control of HIV. Moreover, the role played by the huge genetic diversity of the virus requires 
deeper understanding, as these immune correlates of cell-mediated control of HIV are 
unravelled. One way of doing this is to functionally characterize HIV-specific T-cells with 
the ability to cross-recognize epitope variants from the virus. 
 
There are previous studies that have assessed the ability of HIV-specific T-cells to cross-
recognize different HIV-1 clades both in regions of single (Geldmacher et al., 2007; 
McKinnon et al., 2005) and multiple circulating clade epidemics (Gudmundsdotter et al., 
2008; Gupta et al., 2006). These studies reached a consensus that HIV-specific T-cells have 
the ability to cross-recognize HIV variants or clades but there is preference for the 
recognition of peptides matching the infecting clade. Furthermore, different HIV epitopes 
demonstrated different degrees of cross-reactivity (Yu et al., 2005). However, these studies 
relied on the use of a single immunological readout, namely the production of IFN-γ in an 
ELISpot assay, to measure „cross-reactivity‟. A characteristic feature of this assay is that it 
relies on the use of exogenously loaded HIV peptides that are in excess of physiologically 
relevant concentrations of these peptides in vivo. Therefore, whether the T-cells identified as 
cross-reactive in these studies are truly cross-reactive in vivo remains elusive. Additionally, 
whether the cross-reactive responses exhibit antiviral suppressive activity still needs further 
investigation. In one previous study, cross-clade activity of HIV-specific CD8+ T-cells 
identified in an ELISpot assay was compared to results from an in vitro viral replication assay 
(Bennett et al., 2008). CD8+ T-cells that demonstrated substantial cross-reactivity in the 
peptide-based ELISpot assay measuring IFN-γ production only had antiviral activity to the 
autologous clade B, and not other clades tested, in the viral inhibition assay. Similar finding 
were observed in SIV-infected macaques in which a significant impairment of CD8+ T-cells 
to kill infected cells was observed, despite broad cross-clade responses by the exogenous 
peptide based IFN-γ ELISpot assay (Valentine et al., 2008). Another recent study 
demonstrated that vaccine induced CD8+ T-cells equally recognize wild type and variant SIV 
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demonstrated that these T-cells elicit suboptimal cytokine production on recognition of 
variant epitopes compared to wild type epitopes, suggesting limited cross-reactivity when 
other T-cell functions are taken into consideration. 
 
This study was undertaken in an attempt to investigate further the cross-reactivity of cross-
reactive epitopes identified in the studies in this thesis. The first stage of this investigation 
involved testing whether corresponding peptide variants with amino acid mismatches that 
were cross-recognized at high concentrations of exogenously loaded peptides, were still 
cross-recognized at low or physiologically relevant concentrations of the peptide variants, 
using the IFN-γ ELISpot peptide dilution assay. This allowed us to test whether amino acid 
mismatches between cross-recognized corresponding peptide variants affected the functional 
avidity of the T-cells recognizing them.  
 
Functional avidity is a measure of T-cell responsiveness to peptide (Bennett et al., 2007). 
Therefore a peptide variant with higher avidity will be one that requires less peptide to elicit a 
response equal in magnitude to its corresponding variant or counterpart. In this study, the 
results of the relationship between magnitude of IFN-γ response and functional avidity could 
be categorized into those HIV-specific T-cells that differed in magnitude and functional 
avidities, those that demonstrated similar functional avidities despite observed differences in 
magnitude of IFN-γ T-cell responses, and those that had similar functional avidity and similar 
magnitude of responses. The differences observed in some peptide pairs in their magnitude 
and functional avidity could be as a result of differential strength of binding to TCR or their 
restricting HLA alleles. Interestingly, further characterization of the nature of amino acid 
mismatches showed that the majority of peptide pairs in this category had amino acid 
mismatches between distantly related amino acids (non-conservative amino acid 
substitutions), implying that in natural HIV infection, these amino acids may be involved in 
either peptide processing, binding to restricting HLA or TCR contact sites during the 
recognition of these peptides by HIV-specific T-cells. This result is in line with data from 
previous studies suggesting that even single amino acid mutations between peptide variants 
was sufficient to alter their functional avidity, illustrating the importance of variation in 
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The fact that the nature of amino acid substitution might be having an effect on other key 
players involved in the presentation of these peptides to T-cells was further supported by the 
result that those peptide variants with conservative substitutions between variants had a 
similar magnitude of IFN-γ T-cell responses and similar functional avidities. Non-
conservative substitutions that did not result in differences in magnitude or functional 
avidities among different individuals suggest that HLA alleles or TCR contact sites in these 
individuals have different degrees of sensitivity to amino acid changes, or that these changes 
did not affect either. However, the effect of other factors such as stability of these peptides in 
the cytosol and physiological factors cannot be neglected (Lazaro et al., 2011). Therefore, the 
recognition of both peptide pairs at lower peptide concentrations suggests that cross-
reactivity observed at high peptide concentration in a standard ELISpot assay measuring IFN-
γ production may also be identified in vivo. The loss of recognition of one variant and not the 
other for other peptide pairs suggest that for some epitopes, cross-reactivity is lost at 
physiological concentrations of these peptides and possibly in vivo. 
 
The functional cross-reactive potential of these HIV peptide variants was investigated by 
characterizing cytokine profiles measuring IFN-γ, IL-2, MIP-1β and TNF-α, cytotoxic 
potential measuring upregulation of perforin and granzyme B and the degranulation marker 
CD107a, as well as proliferative capacity of HIV-specific T-cells recognizing these peptide 
variants using flow cytometry. This allowed us to test the hypothesis that amino acid 
mismatches and avidity differences between corresponding peptide variants would result in 
differences in the functional profile of CD8+ T-cells recognizing them. 
 
Highly discordant effects of amino acid substitutions on these measured parameters were 
observed, and few patterns emerged, with no clear relationship between functional avidity 
and multiple cytokines secreted or a greater cytotoxic or proliferative potential.  Relatively 
few peptide pairs tested limited our study, and a larger study may reveal consistent 
differences. The identification of a subset of CD8+ T-cells degranulating but without 
producing IFN-γ suggest the need to include more parameters in the measurement of HIV-
specific T-cells, as some responses are missed by the use of one marker such as IFN-γ. 
Furthermore, the data suggest that there are qualitative differences observed in the CD8+ T-
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may not be detected by using a limited number of parameters, as has been suggested 
previously (Richmond et al., 2011).  
 
Antigen sensitivity or functional avidity of HIV-specific T-cells has been shown to influence 
the functional profile of T-cells (Almeida et al., 2009). Polyfunctionality of HIV-specific T-
cells decreased with decreasing peptide concentration and decreasing functional avidity of the 
T-cells recognizing the peptides tested. In the study presented in this chapter, although 
polyfunctionality was assessed at only a single peptide concentration due to sample 
availability, and in limited number of individuals certain peptides that had similar functional 
avidities at that particular concentration still demonstrated differences in their profile of 
cytokine production and cytotoxic potential, future studies with a larger dataset would go 
beyond descriptive value and allow for a more rigorous analysis of avidity and its 
relationship with T cell function. Furthermore, some peptide pairs that had differences in 
functional avidities also had differences in their profile of cytokines, cytotoxic potential and 
proliferative capacity. This is in line with previous findings that demonstrated that cross-
reactivity of T-cells differs between overnight IFN-γ assays and longer proliferation assays 
(McKinnon et al., 2007). These results again highlight of the fact that HIV-specific T-cells 
recognizing epitope variants cannot be fully understood by using a single technique or by 
measuring a single function. In other words, avidity predicts function but only in a subset of 
individuals. Although this was not a correlates study, there are previous studies that have 
highlighted the importance of other functions of HIV-specific T-cells (Betts et al., 2006; De 
Rosa et al., 2004; Hesperger et al., 2010; Roederer et al., 2004), hence the necessity to 
characterize them to fully understand whether particular epitope variants might still mount 
effective responses in the context of vaccines. 
 
It is important to note that this study made the assumption that cytotoxic potential may be a 
surrogate for potential viral suppression in vivo, which in fact can only be shown using viral 
suppression assays.  Although in a previous study (Bennett et al., 2008) it was only IFN-γ 
production by ELISpot assay that did not translate to actual viral suppression, it is still 
possible that it might be the case with other functions that were measured in this study. In 
addition, the TCR repertoire of responding cells was not characterized in this study to 
determine whether there were differences in T-cell clonotypes and TCR usage of the 
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clonotypes. Therefore, additional studies looking at TCR usage and viral replication 
inhibition assays (Saez-Cirion et al., 2007) using CD8+ T-cells specific for the peptide 
variants studied and larger datasets  may be important in drawing conclusions about the effect 
of amino acid mismatches on the true cross-reactive nature of HIV-specific T-cells and 
drawing clear-cut overall correlation analysis in these datasets. Also, the differences in assay 
sensitivity among various assay methods may affect the classification of responses being 
discordant or not.  The fact that continual antigen exposure has an effect on the expression of 
perforin, proliferative capacity and polyfunctionality makes it difficult to make conclusive 
interpretation of this data. Because of this, it is possible that VL, CD4 counts and period of 
infection might have affected the predicted cross-reactivity. One way to overcome this could 
be to perform longitudinal studies in which study individuals are followed up from acute to 
chronic infection and their polyfunctional cross-reactive potential assessed and analysed 
together with clinical data and period of infection to predict the best correlate of cross-
reactivity. However, there is no evidence as to whether increased cross-reactivity prevents or 
delys disease progression. Further studies will be required that characterize cross-reactivity in 
controllers and progressors. 




















The development of a globally effective HIV vaccine is a major health priority. Developing a 
vaccine that can elicit responses that will protect against the diversity of HIV-1 strains 
responsible for the HIV-1 pandemic remains a major challenge in the field.  It is generally 
accepted that an effective vaccine will need to elicit both broadly cross-neutralizing antibody 
responses, and well as effective CD8+ T cell responses.  While the recently discovered 
broadly cross-neutralizing antibodies are effective against approximately 80% (Pejchal et al., 
2010; Walker et al., 2010) of viruses from different clades, there is some evidence in natural 
infection of clade specificity (Li et al., 2011; Pejchal et al., 2011; Seaman et al., 2010).   
 
There is a wealth of evidence to support the role of CD8+ T cells in controlling HIV 
replication.  Studies have shown that the emergence of virus-specific CD8+ T-cells during 
primary HIV infection coincides with initial drop in peak viraemia (Borrow et al., 1994; 
Goonetilleke et al., 2009; Koup et al., 1994).  Furthermore, studies in macaques have shown 
CD8+ T-cell depletion results in an increase in viraemia in SIV infected macaques (Friedrich 
et al., 2007; Jin et al., 1999; Lifson et al., 2001; Schmitz et al., 1999). Strong evidence of the 
role of CD8+ T cells was provided by genome-wide association studies that demonstrated 
that polymorphisms in the HLA class I gene loci were associated with differential effects on 
disease outcome (Fellay et al., 2007; Pereyra et al., 2010). Therefore, there has been a major 
focus on HIV vaccine immunogen designed to elicit cellular immunity. 
 
HIV exhibits an enormous genetic variability and challenges faced due to the huge genetic 
diversity of the virus cannot be neglected.  Although there have been some recent vaccine 
trials testing the mosaic immunogens which are designed to minimize the distance between 
vaccine immunogen and the circulating viruses (phase 1 clinical trial IAVI B003/IPCAVD-
004 by Barouch et al began in Boston, USA, http://www.iavi.org/archives/2010), vaccines 
going forward into Phase III trials in South Africa still contain wild type virus sequences 
(Glenda Gray; AIDS Vaccine 2011, Thialand; AIDS Vaccine Clinical Trials Update).  Thus, 
evaluating the potential effectiveness of these types of vaccine immunogens against the 
global strains remains relevant to understand whether they will induce virus-specific CD8+ 
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have potent antiviral activity. Evaluation of cross-clade efficacy can only be directly 
addressed by performing human clinical HIV vaccine trials in different populations with 
different HLA genetic backgrounds, and where people are likely to encounter different HIV-1 
clades. However this process is very costly and laborious and insight into these issues may be 
obtained by assessing the ability of cells from individuals infected with a particular HIV-1 
clade to recognize peptides using laboratory based assays. It is most relevant to test this using 
sequences representing vaccines that are likely to be tested in South Africa.   
 
The goal of the first study described in this thesis was to investigate inter- and intra-clade 
cross-reactivity of HIV-specific CD8+ T-cells using peptides based on current candidate HIV 
vaccine inserts. This study provides more relevant data than previous studies where cross-
reactivity of HIV-specific T-cells relied on the use of peptides that were not based on 
candidate vaccine immunogen sequences. Our data corroborated previous findings that HIV-
infected individuals can recognize HIV peptide variants based on other clades not matching 
the ones infecting them (Geels et al., 2005; Geldmacher et al., 2007; Gudmundsdotter et al., 
2008; Gupta et al., 2006; McKinnon et al., 2005), and also provides novel evidence of 
responses in South African subtype C-infected individuals that both exclusively, and 
commonly, target clades A, B, C (China), and D peptides.  The substantial cross-reactivity 
obtained with clades A, B and D suggests that vaccines based on these clades would provide 
some protection in a clade C epidemic. However, we found preferential recognition of clade 
C peptide reagents suggesting that there is an advantage of matching a vaccine to the 
infecting clade. Furthermore, there was no increased recognition of South African clade C 
peptides compared to Chinese clade C peptides suggesting no further advantage of matching 
vaccines to viruses circulating in the region.  
 
We found that cross-reactive peptides were commonly located in highly conserved, 
functionally important regions, particularly the p24 region of the Gag protein. Studies have 
suggested that there are segments in p24 that are highly targeted by virus-specific CD8+ T-
cells which the virus is not able to mutate and therefore evade immune pressure int hese 
regions due to functional constraints (Dahirel et al., 2011). These highly targeted regions that 
show extensive cross reactivity would serve as important regions to include in a vaccine 
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An important consideration for vaccine development is not only whether regions included in 
vaccines will be cross-reactive to a range of clades globally, but also whether the immune 
responses they generate will provide protection against HIV. Further insights into CD8+ T-
cell responses that may be beneficiary in slowing disesase progression and may be 
subsequently lower HIV transmission rates can be predicted by calculating a protective ratio 
(PR; Mothe et al. 2011). In this study, the PRs served as a surrogate for the ability of each 
peptide to elicit protective T-cell responses and were calculated by dividing median viral 
loads of responders by that of non-responders. PRs were classified as beneficial if the PR >1. 
We compared all beneficial Gag peptides identified by Mothe et al. (2011) from a clade B 
cohort with peptides reactive in the study reported in this thesis, and found that all of them 
(10/10) were reactive in the individuals studied in this thesis, with 3/10 (30%) being 
classified as immunodominant peptides using the near to consensus clade CDu422 vaccine 
insert. In addition, of the 18 beneficial peptides that Mothe et al. (2011) identified in the 
clade C infected individuals, 17/18 (94 %) were recognized in our study, with 7/18 (39%) 
being identified as immunodominant. Furthermore, these beneficial peptides showed similar 
clustering patterns to the cross-reactive peptides we identified (Figure D4.1A and B, 
Appendix D4), further supporting the protective potential of these T-cell responses.  
 
After establishing that HIV-1 subtype C infected individuals can mount cross-reactive HIV-
specific CD8+ T-cell responses to the four major circulating HIV clades, the reactivity of 
centralized sequences based on consensus group M Gag and Nef peptides was assessed. As 
centralized sequences have been suggested as potential future candidate vaccine immunogens 
for a globally relevant vaccine, as well as their use as reagents to assess vaccine induced 
responses in individuals infected by different HIV clades, it was important to assess their 
performance in a mono-clade epidemic of subtype C viruses. Although the overall goal of 
this part of the study was to compare the reactivity of these reagents to that obtained in 
regions where multiple clades circulate such as Cameroon and Uganda, for the purposes of 
this thesis, the reactivity of these peptides was compared to those obtained for the four clades 
described above. We found that Group M peptides detected fewer responses compared to 
peptides matched to the infecting clade, and were comparable to clade-mismatched peptide.   
Poorer recognition of centralized sequences compared to clade-matched peptides suggests 
that they are not an ideal reagent for assessing HIV-specific T-cell responses in a mono-clade 
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analysis of combined data. However, data from the Ugandan study where clade A, D and 
recombinant viruses predominate, suggest that responses to these peptides reagents are 
focused towards a few immunodominant epitopes (Serwanga et al., 2011).  
 
Previous cross-clade studies, including the ones reported in this thesis, have relied on using 
exogenously loaded peptides at high concentrations (possibly exceeding physiological levels) 
to measure the ability of HIV-specific T-cells to recognize them. Although this approach will 
identify CD8+ T-cells recognizing the peptide variants, whether these are detected at 
physiological concentrations of the antigens in vivo remains to be answered.   Furthermore, 
the IFN- ELISPOT assay, while showing that CD8+ T-cells can recognize the peptides, does 
not prove that these T-cells have antiviral activity in vivo.  One way to predict the efficiency 
of the interaction between CD8+ T-cells and virus infected target cells is by measuring the 
functional avidity of the T-cells (Almeida et al., 2009).  Here we report on seventeen HLA 
class I-restricted peptide pairs that were assessed for functional avidity using a peptide 
dilution assay. This study allowed us to test whether amino acid mismatches between 
corresponding peptide variants resulted in differences in functional avidities. Interestingly, 
most peptides tested (23/34) were still recognizable at low peptides concentrations, with the 
recognition of other variants (11/34) being lost at physiologically relevant concentrations. 
Therefore, amino acid mismatches may have discordant effects on the „true‟ cross-reactivity 
of peptides variants. Although it is known that in general, CD8+ T-cell populations exhibit 
several clonotypes that are specific for the same antigenic complex (Wilson et al., 1998), a 
recent study showed no preference in use of a particular clonotype in recognizing KK10, an 
HLA-B*27-restricted epitope from HIV Gag (Almeida et al., 2007). We did not perform 
molecular analysis of TCRB gene usage, to assess if use of certain CDR3 motifs resulted in 
higher functional avidity in one of the tested peptide variants or amino acid mismatches 
resulted in differential modes of binding to the same motif.  
 
HIV-specific T-cells able to mediate multiple functions („polyfunctional‟ cells) have been 
found at higher frequencies in individuals who control HIV (Betts et al., 2006). Similarly, 
polyfunctional HIV-specific CD8+ T-cells have been shown to demonstrate a more potent 
HIV suppressive activity than those that exhibit less polyfunctionality (Saez-Cirion et al., 
2007). We investigated whether amino acid mismatches in cross-reactive peptide pairs 
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recognizing them, beyond IFN- secretion identified in the ELISpot assay. We found that 
amino acid mismatches between peptides had discordant effects on the profile of cytokines 
and chemokines produced their cytotoxic potential as well as proliferative capacity. Peptide 
variants that had similar functional avidity also demonstrated similar functional profiles, 
while some that had differences in functional avidity exhibited both different and similar 
functional profiles. These results suggest that the development of „mosaic‟ immunogens that 
include multiple variants of single epitopes to elicit not only broad coverage of HIV-1, but 
also broad functional responses is a good approach, as proposed by others (Malhotra et al., 
2009).  These results also emphasise that we need to define „cross-reactive‟ responses in a 
more detailed, qualitative manner, rather than just quantity of IFN- responses. 
 
There were several limitations to our study and to similar studies in general that could be 
addressed in future studies.  Although the infecting viruses may represent future viruses the 
individuals may encounter, testing vaccine peptides in HIV infected invidivuals is quite 
different from using the same vaccine sequences to induce vaccine responses in HIV 
uninfected individuals who will encounter HIV. For example it is not know whether cross-
reactivity will be affected by level of CD4 count or presence or absence of CD4 help, 
immune activation and viral load. In addition, in an HIV infected person, continual antigen 
exposure has a huge impact on perforin expression, proliferative capacity as T-cell approach 
exhaustion and polyfunctionality. The advantage of vaccine iduced responses as compared to 
testing vaccine antigens in people already infected is that vaccine induced T-cells precede 
HIV exposure. Furthermore, functional studies were performed at a single peptide 
concentration, and therefore the effect of antigen concentration on the profile of functions 
could not be characterized. In addition, IFN-γ ELISPOT readout was used as the criteria for 
reactive peptides. It is possible that some peptides might not produce IFN-γ, but other 
cytokines or chemokines. Initial screening of reactive peptides using other readouts, such as a 
perforin ELISPOT or high throughput proliferation assays, could be performed in future 
studies.  Also, clonal analysis of HIV-specific CD8+ T-cells was not performed, since it was 
possible that clones with different TCRB gene usage resulted in differences in functions 
between peptide variants. We did not measure viral suppression, that is, measuring the 
ultimate function of CD8+ T-cells to eliminate virus-infected cells using a viral suppression 
assay (Saez-Cirion et al., 2010), which may provide more insight into whether the cross-
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translated to antiviral cross-reactivity. However, a limitation of these types of studies 
performed in HIV-infected humans is the difficult of knowing whether a „good‟ functional 
profile is the cause or consequence of viral control. These types of studies need to be 
performed in vaccine trials of candidate HIV vaccines 
 
In conclusion, in a monoclade subtype C epidemic, we found that HIV-infected individuals 
mounted robust inter- and intra-clade cross-reactive HIV-specific T-cell responses, 
suggesting that vaccines based on these clades may work equally well. However, preferential 
of recognition of clade C-based peptide reagents suggest some advantage of matching a 
vaccine to the infecting clade. Moreover, despite the central nature of consensus group M 
Gag and Nef peptide reagents, their use to evaluate HIV-specific T-cell responses or as 
immunogens may be limited due to mismatches with particular clades. Overall, the cross-
reactive qualitative and quantitative aspects of the HIV-specific T-cell response is a complex 
phenomenon to de-convolute that is related to the functional avidity of the CD8+ T-cell 
specific for a particular HLA class I-restricted epitope, and is affected by amino acid 
mismatches between peptide variants. These data may advance the development of an 
effective cross-reactive HIV vaccine immunogen, an urgent and critical need both in South 





















1. Adamson, C. S., and E. O. Freed. 2007. Human immunodeficiency virus type 1 
assembly, release, and maturation. Adv Pharmacol 55:347-87. 
2. Addo, M. M., X. G. Yu, A. Rathod, D. Cohen, R. L. Eldridge, D. Strick, M. N. 
Johnston, C. Corcoran, A. G. Wurcel, C. A. Fitzpatrick, M. E. Feeney, W. R. 
Rodriguez, N. Basgoz, R. Draenert, D. R. Stone, C. Brander, P. J. Goulder, E. S. 
Rosenberg, M. Altfeld, and B. D. Walker. 2003. Comprehensive epitope analysis of 
human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed 
against the entire expressed HIV-1 genome demonstrate broadly directed responses, 
but no correlation to viral load. J Virol 77:2081-92. 
3. Aidoo, M., S. Sawadogo, E. C. Bile, C. Yang, J. N. Nkengasong, and J. M. 
McNicholl. 2008. Viral, HLA and T cell elements in cross-reactive immune 
responses to HIV-1 subtype A, CRF01_AE and CRF02_AG vaccine sequence in 
Ivorian blood donors. Vaccine 26:4830-9. 
4. Alexander, L., P. O. Illyinskii, S. M. Lang, R. E. Means, J. Lifson, K. Mansfield, 
and R. C. Desrosiers. 2003. Determinants of increased replicative capacity of serially 
passaged simian immunodeficiency virus with nef deleted in rhesus monkeys. J Virol 
77:6823-35. 
5. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective 
expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive 
immunotherapy. Proc Natl Acad Sci U S A 93:4102-7. 
6. Allen, T. M., M. Altfeld, S. C. Geer, E. T. Kalife, C. Moore, M. O'Sullivan K, I. 
Desouza, M. E. Feeney, R. L. Eldridge, E. L. Maier, D. E. Kaufmann, M. P. 
Lahaie, L. Reyor, G. Tanzi, M. N. Johnston, C. Brander, R. Draenert, J. K. 
Rockstroh, H. Jessen, E. S. Rosenberg, S. A. Mallal, and B. D. Walker. 2005. 
Selective escape from CD8+ T-cell responses represents a major driving force of 
human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals 
constraints on HIV-1 evolution. J Virol 79:13239-49. 
7. Allen, T. M., M. Altfeld, X. G. Yu, K. M. O'Sullivan, M. Lichterfeld, S. Le Gall, 
M. John, B. R. Mothe, P. K. Lee, E. T. Kalife, D. E. Cohen, K. A. Freedberg, D. 
A. Strick, M. N. Johnston, A. Sette, E. S. Rosenberg, S. A. Mallal, P. J. Goulder, 
C. Brander, and B. D. Walker. 2004. Selection, transmission, and reversion of an 
antigen-processing cytotoxic T-lymphocyte escape mutation in human 
immunodeficiency virus type 1 infection. J Virol 78:7069-78. 
8. Allen, T. M., X. G. Yu, E. T. Kalife, L. L. Reyor, M. Lichterfeld, M. John, M. 
Cheng, R. L. Allgaier, S. Mui, N. Frahm, G. Alter, N. V. Brown, M. N. Johnston, 
E. S. Rosenberg, S. A. Mallal, C. Brander, B. D. Walker, and M. Altfeld. 2005. 
De novo generation of escape variant-specific CD8+ T-cell responses following 
cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 















9. Almeida, J. R., D. A. Price, L. Papagno, Z. A. Arkoub, D. Sauce, E. Bornstein, T. 
E. Asher, A. Samri, A. Schnuriger, I. Theodorou, D. Costagliola, C. Rouzioux, H. 
Agut, A. G. Marcelin, D. Douek, B. Autran, and V. Appay. 2007. Superior control 
of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, 
and clonal turnover. J Exp Med 204:2473-85. 
10. Almeida, J. R., D. Sauce, D. A. Price, L. Papagno, S. Y. Shin, A. Moris, M. 
Larsen, G. Pancino, D. C. Douek, B. Autran, A. Saez-Cirion, and V. Appay. 
2009. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and 
HIV-suppressive activity. Blood 113:6351-60. 
11. Altfeld, M., M. M. Addo, E. S. Rosenberg, F. M. Hecht, P. K. Lee, M. Vogel, X. 
G. Yu, R. Draenert, M. N. Johnston, D. Strick, T. M. Allen, M. E. Feeney, J. O. 
Kahn, R. P. Sekaly, J. A. Levy, J. K. Rockstroh, P. J. Goulder, and B. D. Walker. 
2003. Influence of HLA-B57 on clinical presentation and viral control during acute 
HIV-1 infection. AIDS 17:2581-91. 
12. Altfeld, M., M. M. Addo, R. Shankarappa, P. K. Lee, T. M. Allen, X. G. Yu, A. 
Rathod, J. Harlow, K. O'Sullivan, M. N. Johnston, P. J. Goulder, J. I. Mullins, E. 
S. Rosenberg, C. Brander, B. Korber, and B. D. Walker. 2003. Enhanced 
detection of human immunodeficiency virus type 1-specific T-cell responses to highly 
variable regions by using peptides based on autologous virus sequences. J Virol 
77:7330-40. 
13. Altfeld, M., E. T. Kalife, Y. Qi, H. Streeck, M. Lichterfeld, M. N. Johnston, N. 
Burgett, M. E. Swartz, A. Yang, G. Alter, X. G. Yu, A. Meier, J. K. Rockstroh, T. 
M. Allen, H. Jessen, E. S. Rosenberg, M. Carrington, and B. D. Walker. 2006. 
HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to 
the Initial CD8(+) T Cell Response against HIV-1. PLoS Med 3:e403. 
14. Ammaranond, P., D. J. van Bockel, K. Petoumenos, M. McMurchie, R. 
Finlayson, M. G. Middleton, M. P. Davenport, V. Venturi, K. Suzuki, L. Gelgor, 
J. M. Kaldor, D. A. Cooper, and A. D. Kelleher. 2011. HIV immune escape at an 
immunodominant epitope in HLA-B*27-positive individuals predicts viral load 
outcome. J Immunol 186:479-88. 
15. Arenas, M., and D. Posada. 2010. Computational design of centralized HIV-1 genes. 
Curr HIV Res 8:613-21. 
16. Ayouba, A., S. Souquieres, B. Njinku, P. M. Martin, M. C. Muller-Trutwin, P. 
Roques, F. Barre-Sinoussi, P. Mauclere, F. Simon, and E. Nerrienet. 2000. HIV-1 
group N among HIV-1-seropositive individuals in Cameroon. AIDS 14:2623-5. 
17. Bachand, F., X. J. Yao, M. Hrimech, N. Rougeau, and E. A. Cohen. 1999. 
Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct 
interaction with the p6 domain of the p55 gag precursor. J Biol Chem 274:9083-91. 
18. Bailey, J. R., T. M. Williams, R. F. Siliciano, and J. N. Blankson. 2006. 
Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors 















19. Bansal, A., E. Gough, D. Ritter, C. Wilson, J. Mulenga, S. Allen, and P. A. 
Goepfert. 2006. Group M-based HIV-1 Gag peptides are frequently targeted by T 
cells in chronically infected US and Zambian patients. AIDS 20:353-60. 
20. Bansal, A., S. Sabbaj, B. H. Edwards, D. Ritter, C. Perkins, J. Tang, J. J. 
Szinger, H. Weiss, P. A. Goepfert, B. Korber, C. M. Wilson, R. A. Kaslow, and 
M. J. Mulligan. 2003. T cell responses in HIV type 1-infected adolescent minorities 
share similar epitope specificities with whites despite significant differences in HLA 
class I alleles. AIDS Res Hum Retroviruses 19:1017-26. 
21. Barouch, D. H., K. L. O'Brien, N. L. Simmons, S. L. King, P. Abbink, L. F. 
Maxfield, Y. H. Sun, A. La Porte, A. M. Riggs, D. M. Lynch, S. L. Clark, K. 
Backus, J. R. Perry, M. S. Seaman, A. Carville, K. G. Mansfield, J. J. Szinger, 
W. Fischer, M. Muldoon, and B. Korber. 2010. Mosaic HIV-1 vaccines expand the 
breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16:319-
23. 
22. Bennett, M. S., H. L. Ng, A. Ali, and O. O. Yang. 2008. Cross-clade detection of 
HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity. 
J Infect Dis 197:390-7. 
23. Berger, C. T., N. Frahm, D. A. Price, B. Mothe, M. Ghebremichael, K. L. 
Hartman, L. M. Henry, J. M. Brenchley, L. E. Ruff, V. Venturi, F. Pereyra, J. 
Sidney, A. Sette, D. C. Douek, B. D. Walker, D. E. Kaufmann, and C. Brander. 
2011. High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted 
Gag-derived epitopes associated with relative HIV control. J Virol 85:9334-45. 
24. Berkowitz, R., J. Fisher, and S. P. Goff. 1996. RNA packaging. Curr Top Microbiol 
Immunol 214:177-218. 
25. Betts, M. R., D. R. Ambrozak, D. C. Douek, S. Bonhoeffer, J. M. Brenchley, J. P. 
Casazza, R. A. Koup, and L. J. Picker. 2001. Analysis of total human 
immunodeficiency irus (HIV)-specific CD4(+) and CD8(+) T-cell responses: 
relationship to viral load in untreated HIV infection. J Virol 75:11983-91. 
26. Betts, M. R., J. Krowka, C. Santamaria, K. Balsamo, F. Gao, G. Mulundu, C. 
Luo, N. N'Gandu, H. Sheppard, B. H. Hahn, S. Allen, and J. A. Frelinger. 1997. 
Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte 
responses in HIV-infected Zambians. J Virol 71:8908-11. 
27. Betts, M. R., M. C. Nason, S. M. West, S. C. De Rosa, S. A. Migueles, J. 
Abraham, M. M. Lederman, J. M. Benito, P. A. Goepfert, M. Connors, M. 
Roederer, and R. A. Koup. 2006. HIV nonprogressors preferentially maintain highly 
functional HIV-specific CD8+ T cells. Blood 107:4781-9. 
28. Bhattacharya, T., M. Daniels, D. Heckerman, B. Foley, N. Frahm, C. Kadie, J. 
Carlson, K. Yusim, B. McMahon, B. Gaschen, S. Mallal, J. I. Mullins, D. C. 
Nickle, J. Herbeck, C. Rousseau, G. H. Learn, T. Miura, C. Brander, B. Walker, 
and B. Korber. 2007. Founder effects in the assessment of HIV polymorphisms and 















29. Bobkov, A. F., E. V. Kazennova, A. L. Sukhanova, M. R. Bobkova, V. V. 
Pokrovsky, V. V. Zeman, N. G. Kovtunenko, and I. B. Erasilova. 2004. An HIV 
type 1 subtype A outbreak among injecting drug users in Kazakhstan. AIDS Res Hum 
Retroviruses 20:1134-6. 
30. Borrow, P., H. Lewicki, B. H. Hahn, G. M. Shaw, and M. B. Oldstone. 1994. 
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of 
viremia in primary human immunodeficiency virus type 1 infection. J Virol 68:6103-
10. 
31. Borrow, P., H. Lewicki, X. Wei, M. S. Horwitz, N. Peffer, H. Meyers, J. A. 
Nelson, J. E. Gairin, B. H. Hahn, M. B. Oldstone, and G. M. Shaw. 1997. 
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during 
primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 
3:205-11. 
32. Braaten, D., and J. Luban. 2001. Cyclophilin A regulates HIV-1 infectivity, as 
demonstrated by gene targeting in human T cells. EMBO J 20:1300-9. 
33. Brambilla, A., L. Turchetto, A. Gatti, C. Bovolenta, F. Veglia, E. Santagostino, 
A. Gringeri, M. Clementi, G. Poli, P. Bagnarelli, and E. Vicenzi. 1999. Defective 
nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 
infection. Virology 259:349-68. 
34. Brennan, F., and A. Foey. 2002. Cytokine regulation in RA synovial tissue: role of T 
cell/macrophage contact-dependent interactions. Arthritis Res 4 Suppl 3:S177-82. 
35. Briggs, J. A., M. N. Simon, I. Gross, H. G. Krausslich, S. D. Fuller, V. M. Vogt, 
and M. C. Johnson. 2004. The stoichiometry of Gag protein in HIV-1. Nat Struct 
Mol Biol 11:672-5. 
36. Brockman, M. A., A. Schneidewind, M. Lahaie, A. Schmidt, T. Miura, I. 
Desouza, F. Ryvkin, C. A. Derdeyn, S. Allen, E. Hunter, J. Mulenga, P. A. 
Goepfert, B. D. Walker, and T. M. Allen. 2007. Escape and compensation from 
early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human 
immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J 
Virol 81:12608-18. 
37. Browning, M., and P. Krausa. 1996. Genetic diversity of HLA-A2: evolutionary 
and functional significance. Immunol Today 17:165-70. 
38. Brumme, Z. L., C. J. Brumme, D. Heckerman, B. T. Korber, M. Daniels, J. 
Carlson, C. Kadie, T. Bhattacharya, C. Chui, J. Szinger, T. Mo, R. S. Hogg, J. S. 
Montaner, N. Frahm, C. Brander, B. D. Walker, and P. R. Harrigan. 2007. 
Evidence of differential HLA class I-mediated viral evolution in functional and 
accessory/regulatory genes of HIV-1. PLoS Pathog 3:e94. 
39. Brumme, Z. L., M. John, J. M. Carlson, C. J. Brumme, D. Chan, M. A. 
Brockman, L. C. Swenson, I. Tao, S. Szeto, P. Rosato, J. Sela, C. M. Kadie, N. 















Harrigan, D. Heckerman, and S. Mallal. 2009. HLA-associated immune escape 
pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 4:e6687. 
40. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, 
P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, M. J. McElrath, D. R. 
Casimiro, K. M. Gottesdiener, J. A. Chodakewitz, L. Corey, M. N. Robertson, 
and T. Step Study Protocol. 2008. Efficacy assessment of a cell-mediated immunity 
HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-
of-concept trial. Lancet 372:1881-93. 
41. Bukovsky, A., and H. Gottlinger. 1996. Lack of integrase can markedly affect 
human immunodeficiency virus type 1 particle production in the presence of an active 
viral protease. J Virol 70:6820-5. 
42. Bunnik, E. M., Z. Euler, M. R. Welkers, B. D. Boeser-Nunnink, M. L. Grijsen, J. 
M. Prins, and H. Schuitemaker. 2010. Adaptation of HIV-1 envelope gp120 to 
humoral immunity at a population level. Nat Med 16:995-7. 
43. Buonaguro, L., E. Del Guadio, M. Monaco, D. Greco, P. Corti, E. Beth-Giraldo, 
F. M. Buonaguro, and G. Giraldo. 1995. Heteroduplex mobility assay and 
phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 
1 isolates from Gulu, northern Uganda. The Italian-Ugandan Cooperation AIDS 
Program. J Virol 69:7971-81. 
44. Burgers, W. A., G. K. Chege, T. L. Muller, J. H. van Harmelen, G. Khoury, E. G. 
Shephard, C. M. Gray, C. Williamson, and A. L. Williamson. 2009. Broad, high-
magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA 
and modified vaccinia Ankara vaccine containing human immunodeficiency virus 
type 1 subtype C genes in baboons. J Gen Virol 90:468-80. 
45. Burke, D. S. 1997. Recombination in HIV: an important viral evolutionary strategy. 
Emerg Infect Dis 3:253-9. 
46. Burton, D. R., R. C. Desrosiers, R. W. Doms, W. C. Koff, P. D. Kwong, J. P. 
Moore, G. J. Nabel, J. Sodroski, I. A. Wilson, and R. T. Wyatt. 2004. HIV vaccine 
design and the neutralizing antibody problem. Nat Immunol 5:233-6. 
47. Buseyne, F., M. L. Chaix, B. Fleury, O. Manigart, M. Burgard, S. Blanche, C. 
Rouzioux, and Y. Riviere. 1998. Cross-clade-specific cytotoxic T lymphocytes in 
HIV-1-infected children. Virology 250:316-24. 
48. Buseyne, F., and Y. Riviere. 2001. The flexibility of the TCR allows recognition of a 
large set of naturally occurring epitope variants by HIV-specific cytotoxic T 
lymphocytes. Int Immunol 13:941-50. 
49. Buseyne, F., D. Scott-Algara, F. Porrot, B. Corre, N. Bellal, M. Burgard, C. 
Rouzioux, S. Blanche, and Y. Riviere. 2002. Frequencies of ex vivo-activated 
human immunodeficiency virus type 1-specific gamma-interferon-producing CD8+ T 
















50. Calarota, S. A., A. Foli, R. Maserati, F. Baldanti, S. Paolucci, M. A. Young, C. 
M. Tsoukas, J. Lisziewicz, and F. Lori. 2008. HIV-1-specific T cell precursors with 
high proliferative capacity correlate with low viremia and high CD4 counts in 
untreated individuals. J Immunol 180:5907-15. 
51. Cale, E. M., H. S. Bazick, T. A. Rianprakaisang, S. M. Alam, and N. L. Letvin. 
2011. Mutations in a dominant Nef epitope of simian immunodeficiency virus 
diminish TCR:epitope peptide affinity but not epitope peptide:MHC class I binding. J 
Immunol 187:3300-13. 
52. Camerini, D., and B. Seed. 1990. A CD4 domain important for HIV-mediated 
syncytium formation lies outside the virus binding site. Cell 60:747-54. 
53. Cao, H., I. Mani, R. Vincent, R. Mugerwa, P. Mugyenyi, P. Kanki, J. Ellner, and 
B. D. Walker. 2000. Cellular immunity to human immunodeficiency virus type 1 
(HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda. J Infect Dis 182:1350-6. 
54. Cao, K., A. M. Moormann, K. E. Lyke, C. Masaberg, O. P. Sumba, O. K. 
Doumbo, D. Koech, A. Lancaster, M. Nelson, D. Meyer, R. Single, R. J. 
Hartzman, C. V. Plowe, J. Kazura, D. L. Mann, M. B. Sztein, G. Thomson, and 
M. A. Fernandez-Vina. 2004. Differentiation between African populations is 
evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue 
Antigens 63:293-325. 
55. Carlson, J. M., Z. L. Brumme, C. M. Rousseau, C. J. Brumme, P. Matthews, C. 
Kadie, J. I. Mullins, B. D. Walker, P. R. Harrigan, P. J. Goulder, and D. 
Heckerman. 2008. Phylogenetic dependency networks: inferring patterns of CTL 
escape and codon covariation in HIV-1 Gag. PLoS Comput Biol 4:e1000225. 
56. Carr, A., and D. A. Cooper. 1998. HIV and AIDS. Gap between biology and reality 
in AIDS. Lancet 352 Suppl 4:SIV16. 
57. Carrington, M., G. W. Nelson, M. P. Martin, T. Kissner, D. Vlahov, J. J. 
Goedert, R. Kaslow, S. Buchbinder, K. Hoots, and S. J. O'Brien. 1999. HLA and 
HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283:1748-
52. 
58. Charpentier, C., T. Nora, O. Tenaillon, F. Clavel, and A. J. Hance. 2006. 
Extensive recombination among human immunodeficiency virus type 1 quasispecies 
makes an important contribution to viral diversity in individual patients. J Virol 
80:2472-82. 
59. Choisy, M., C. H. Woelk, J. F. Guegan, and D. L. Robertson. 2004. Comparative 
study of adaptive molecular evolution in different human immunodeficiency virus 
groups and subtypes. J Virol 78:1962-70. 
60. Coffin, J. M., S. H. Hughes, and H. E. Varmus. 1997. The Interactions of 















61. Coplan, P. M., S. B. Gupta, S. A. Dubey, P. Pitisuttithum, A. Nikas, B. Mbewe, E. 
Vardas, M. Schechter, E. G. Kallas, D. C. Freed, T. M. Fu, C. T. Mast, P. 
Puthavathana, J. Kublin, K. Brown Collins, J. Chisi, R. Pendame, S. J. Thaler, 
G. Gray, J. McIntyre, W. L. Straus, J. H. Condra, D. V. Mehrotra, H. A. Guess, 
E. A. Emini, and J. W. Shiver. 2005. Cross-reactivity of anti-HIV-1 T cell immune 
responses among the major HIV-1 clades in HIV-1-positive individuals from 4 
continents. J Infect Dis 191:1427-34. 
62. Coren, L. V., J. A. Thomas, E. Chertova, R. C. Sowder, 2nd, T. D. Gagliardi, R. 
J. Gorelick, and D. E. Ott. 2007. Mutational analysis of the C-terminal gag cleavage 
sites in human immunodeficiency virus type 1. J Virol 81:10047-54. 
63. Corey, L., and M. J. McElrath. 2010. HIV vaccines: mosaic approach to virus 
diversity. Nat Med 16:268-70. 
64. Craigie, R. 2001. HIV integrase, a brief overview from chemistry to therapeutics. J 
Biol Chem 276:23213-6. 
65. Crawford, H., J. G. Prado, A. Leslie, S. Hue, I. Honeyborne, S. Reddy, M. van 
der Stok, Z. Mncube, C. Brander, C. Rousseau, J. I. Mullins, R. Kaslow, P. 
Goepfert, S. Allen, E. Hunter, J. Mulenga, P. Kiepiela, B. D. Walker, and P. J. 
Goulder. 2007. Compensatory mutation partially restores fitness and delays reversion 
of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope 
in chronic human immunodeficiency virus type 1 infection. J Virol 81:8346-51. 
66. Currier, J. R., W. E. Dowling, K. M. Wasunna, U. Alam, C. J. Mason, M. L. 
Robb, J. K. Carr, F. E. McCutchan, D. L. Birx, and J. H. Cox. 2003. Detection of 
high frequencies of HIV-1 cross-subtype reactive CD8 T lymphocytes in the 
peripheral blood of HIV-1-infected Kenyans. AIDS 17:2149-57. 
67. Dahirel, V., K. Shekhar, F. Pereyra, T. Miura, M. Artyomov, S. Talsania, T. M. 
Allen, M. Altfeld, M. Carrington, D. J. Irvine, B. D. Walker, and A. K. 
Chakraborty. 2011. Coordinate linkage of HIV evolution reveals regions of 
immunological vulnerability. Proc Natl Acad Sci U S A 108:11530-5. 
68. Dalmasso, C., W. Carpentier, L. Meyer, C. Rouzioux, C. Goujard, M. L. Chaix, 
O. Lambotte, V. Avettand-Fenoel, S. Le Clerc, L. D. de Senneville, C. Deveau, F. 
Boufassa, P. Debre, J. F. Delfraissy, P. Broet, I. Theodorou, and A. G. W. 
Association. 2008. Distinct genetic loci control plasma HIV-RNA and cellular HIV-
DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS 
One 3:e3907. 
69. Datta, S. A., F. Heinrich, S. Raghunandan, S. Krueger, J. E. Curtis, A. Rein, and 
H. Nanda. 2011. HIV-1 Gag extension: conformational changes require simultaneous 
interaction with membrane and nucleic acid. J Mol Biol 406:205-14. 
70. Davenport, M. P., L. Loh, J. Petravic, and S. J. Kent. 2008. Rates of HIV immune 















71. Day, C. L., P. Kiepiela, A. J. Leslie, M. van der Stok, K. Nair, N. Ismail, I. 
Honeyborne, H. Crawford, H. M. Coovadia, P. J. Goulder, B. D. Walker, and P. 
Klenerman. 2007. Proliferative capacity of epitope-specific CD8 T-cell responses is 
inversely related to viral load in chronic human immunodeficiency virus type 1 
infection. J Virol 81:434-8. 
72. Dazza, M. C., M. Ekwalanga, M. Nende, K. B. Shamamba, P. Bitshi, D. 
Paraskevis, and S. Saragosti. 2005. Characterization of a novel vpu-harboring 
simian immunodeficiency virus from a Dent's Mona monkey (Cercopithecus mona 
denti). J Virol 79:8560-71. 
73. De Rosa, S. C., F. X. Lu, J. Yu, S. P. Perfetto, J. Falloon, S. Moser, T. G. Evans, 
R. Koup, C. J. Miller, and M. Roederer. 2004. Vaccination in humans generates 
broad T cell cytokine responses. J Immunol 173:5372-80. 
74. Deacon, N. J., A. Tsykin, A. Solomon, K. Smith, M. Ludford-Menting, D. J. 
Hooker, D. A. McPhee, A. L. Greenway, A. Ellett, C. Chatfield, V. A. Lawson, S. 
Crowe, A. Maerz, S. Sonza, J. Learmont, J. S. Sullivan, A. Cunningham, D. 
Dwyer, D. Dowton, and J. Mills. 1995. Genomic structure of an attenuated quasi 
species of HIV-1 from a blood transfusion donor and recipients. Science 270:988-91. 
75. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, 
S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. 
Littman, and N. R. Landau. 1996. Identification of a major co-receptor for primary 
isolates of HIV-1. Nature 381:661-6. 
76. Deora, A., and L. Ratner. 2001. Viral protein U (Vpu)-mediated enhancement of 
human immunodeficiency virus type 1 particle release depends on the rate of cellular 
proliferation. J Virol 75:6714-8. 
77. Derby, M., M. Alexander-Miller, R. Tse, and J. Berzofsky. 2001. High-avidity 
CTL exploit two complementary mechanisms to provide better protection against 
viral infection than low-avidity CTL. J Immunol 166:1690-7. 
78. Doherty, R. S., T. De Oliveira, C. Seebregts, S. Danaviah, M. Gordon, and S. 
Cassol. 2005. BioAfrica's HIV-1 proteomics resource: combining protein data with 
bioinformatics tools. Retrovirology 2:18. 
79. Dong, T., Y. Zhang, K. Y. Xu, H. Yan, I. James, Y. Peng, M. E. Blais, S. 
Gaudieri, X. Chen, W. Lun, H. Wu, W. Y. Qu, T. Rostron, N. Li, Y. Mao, S. 
Mallal, X. Xu, A. McMichael, M. John, and S. L. Rowland-Jones. 2011. Extensive 
HLA-driven viral diversity following a narrow-source HIV-1 outbreak in rural China. 
Blood 118:98-106. 
80. Dorfman, T., and H. G. Gottlinger. 1996. The human immunodeficiency virus type 
1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811. 
J Virol 70:5751-7. 
81. Doria-Rose, N. A., G. H. Learn, A. G. Rodrigo, D. C. Nickle, F. Li, M. 















W. Barnett, N. L. Haigwood, and J. I. Mullins. 2005. Human immunodeficiency 
virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing 
antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J 
Virol 79:11214-24. 
82. Douglas, N. W., G. H. Munro, and R. S. Daniels. 1997. HIV/SIV glycoproteins: 
structure-function relationships. J Mol Biol 273:122-49. 
83. Doytchinova, I. A., P. Guan, and D. R. Flower. 2004. Identifiying human MHC 
supertypes using bioinformatic methods. J Immunol 172:4314-23. 
84. Draenert, R., S. Le Gall, K. J. Pfafferott, A. J. Leslie, P. Chetty, C. Brander, E. 
C. Holmes, S. C. Chang, M. E. Feeney, M. M. Addo, L. Ruiz, D. Ramduth, P. 
Jeena, M. Altfeld, S. Thomas, Y. Tang, C. L. Verrill, C. Dixon, J. G. Prado, P. 
Kiepiela, J. Martinez-Picado, B. D. Walker, and P. J. Goulder. 2004. Immune 
selection for altered antigen processing leads to cytotoxic T lymphocyte escape in 
chronic HIV-1 infection. J Exp Med 199:905-15. 
85. Draenert, R., C. L. Verrill, Y. Tang, T. M. Allen, A. G. Wurcel, M. Boczanowski, 
A. Lechner, A. Y. Kim, T. Suscovich, N. V. Brown, M. M. Addo, and B. D. 
Walker. 2004. Persistent recognition of autologous virus by high-avidity CD8 T cells 
in chronic, progressive human immunodeficiency virus type 1 infection. J Virol 
78:630-41. 
86. du Toit, E. D., J. C. Emmanuel, G. West, D. G. Taljaard, and M. Oudshoorn. 
1990. HLA frequencies in black Zimbabweans. Tissue Antigens 36:122-4. 
87. Dube, M., B. B. Roy, P. Guiot-Guillain, J. Binette, J. Mercier, A. Chiasson, and 
E. A. Cohen. 2010. Antagonism of tetherin restriction of HIV-1 release by Vpu 
involves binding and sequestration of the restriction factor in a perinuclear 
compartment. PLoS Pathog 6:e1000856. 
88. Dussupt, V., P. Sette, N. F. Bello, M. P. Javid, K. Nagashima, and F. Bouamr. 
2011. Basic residues in the nucleocapsid domain of Gag are critical for late events of 
HIV-1 budding. J Virol 85:2304-15. 
89. Eckstein, D. A., M. P. Sherman, M. L. Penn, P. S. Chin, C. M. De Noronha, W. 
C. Greene, and M. A. Goldsmith. 2001. HIV-1 Vpr enhances viral burden by 
facilitating infection of tissue macrophages but not nondividing CD4+ T cells. J Exp 
Med 194:1407-19. 
90. Edwards, B. H., A. Bansal, S. Sabbaj, J. Bakari, M. J. Mulligan, and P. A. 
Goepfert. 2002. Magnitude of functional CD8+ T-cell responses to the gag protein of 
human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J 
Virol 76:2298-305. 
91. Elahi, S., W. L. Dinges, N. Lejarcegui, K. J. Laing, A. C. Collier, D. M. Koelle, 
M. J. McElrath, and H. Horton. 2011. Protective HIV-specific CD8+ T cells evade 















92. Ellenberger, D., Bage, S., Butera, S., Folks, T., Kraiseburd, E., Lanier, N., Li, B., 
Martinez, M., McNicholl, J., Moss, B., Otten, R., Robinson, H., Rodriguez, I., 
Sariol, C., Smith, J., Wyatt, L., Yi, H. 2003. Fellows and New Investigators 
Workshop on HIV Vaccine Development: Immunological and Biological Challenges: 
Twenty Years of HIV Research: From Discovery to Understanding, p. 134, Keystone 
Symposia, Silverthone. 
93. Ellenberger, D. L., B. Li, L. D. Lupo, S. M. Owen, J. Nkengasong, M. S. Kadio-
Morokro, J. Smith, H. Robinson, M. Ackers, A. Greenberg, T. Folks, and S. 
Butera. 2002. Generation of a consensus sequence from prevalent and incident HIV-1 
infections in West Africa to guide AIDS vaccine development. Virology 302:155-63. 
94. Fan, J., G. Ma, K. Nosaka, J. Tanabe, Y. Satou, A. Koito, S. Wain-Hobson, J. P. 
Vartanian, and M. Matsuoka. 2010. APOBEC3G generates nonsense mutations in 
human T-cell leukemia virus type 1 proviral genomes in vivo. J Virol 84:7278-87. 
95. Fassati, A. 2006. HIV infection of non-dividing cells: a divisive problem. 
Retrovirology 3:74. 
96. Feinberg, M. B., D. Baltimore, and A. D. Frankel. 1991. The role of Tat in the 
human immunodeficiency virus life cycle indicates a primary effect on transcriptional 
elongation. Proc Natl Acad Sci U S A 88:4045-9. 
97. Fellay, J., D. Ge, K. V. Shianna, S. Colombo, B. Ledergerber, E. T. Cirulli, T. J. 
Urban, K. Zhang, C. E. Gumbs, J. P. Smith, A. Castagna, A. Cozzi-Lepri, A. De 
Luca, P. Easterbrook, H. F. Gunthard, S. Mallal, C. Mussini, J. Dalmau, J. 
Martinez-Picado, J. M. Miro, N. Obel, S. M. Wolinsky, J. J. Martinson, R. 
Detels, J. B. Margolick, L. P. Jacobson, P. Descombes, S. E. Antonarakis, J. S. 
Beckmann, S. J. O'Brien, N. L. Letvin, A. J. McMichael, B. F. Haynes, M. 
Carrington, S. Feng, A. Telenti, D. B. Goldstein, and N. C. f. H. A. V. 
Immunology. 2009. Common genetic variation and the control of HIV-1 in humans. 
PLoS Genet 5:e1000791. 
98. Fellay, J., K. V. Shianna, D. Ge, S. Colombo, B. Ledergerber, M. Weale, K. 
Zhang, C. Gumbs, A. Castagna, A. Cossarizza, A. Cozzi-Lepri, A. De Luca, P. 
Easterbrook, P. Francioli, S. Mallal, J. Martinez-Picado, J. M. Miro, N. Obel, J. 
P. Smith, J. Wyniger, P. Descombes, S. E. Antonarakis, N. L. Letvin, A. J. 
McMichael, B. F. Haynes, A. Telenti, and D. B. Goldstein. 2007. A whole-genome 
association study of major determinants for host control of HIV-1. Science 317:944-7. 
99. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry 
cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled 
receptor. Science 272:872-7. 
100. Ferrari, G., J. R. Currier, M. E. Harris, S. Finkelstein, A. de Oliveira, D. 
Barkhan, J. H. Cox, M. Zeira, K. J. Weinhold, N. Reinsmoen, F. McCutchan, D. 
L. Birx, S. Osmanov, and S. Maayan. 2004. HLA-A and -B allele expression and 
ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected 















101. Ferrari, G., W. Humphrey, M. J. McElrath, J. L. Excler, A. M. Duliege, M. L. 
Clements, L. C. Corey, D. P. Bolognesi, and K. J. Weinhold. 1997. Clade B-based 
HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected 
volunteers. Proc Natl Acad Sci U S A 94:1396-401. 
102. Fischer, W., H. X. Liao, B. F. Haynes, N. L. Letvin, and B. Korber. 2008. Coping 
with viral diversity in HIV vaccine design: a response to Nickle et al. PLoS Comput 
Biol 4:e15; author reply e25. 
103. Fischer, W., S. Perkins, J. Theiler, T. Bhattacharya, K. Yusim, R. Funkhouser, 
C. Kuiken, B. Haynes, N. L. Letvin, B. D. Walker, B. H. Hahn, and B. T. Korber. 
2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global 
HIV-1 variants. Nat Med 13:100-6. 
104. Frahm, N., S. Adams, P. Kiepiela, C. H. Linde, H. S. Hewitt, M. Lichterfeld, K. 
Sango, N. V. Brown, E. Pae, A. G. Wurcel, M. Altfeld, M. E. Feeney, T. M. Allen, 
T. Roach, M. A. St John, E. S. Daar, E. Rosenberg, B. Korber, F. Marincola, B. 
D. Walker, P. J. Goulder, and C. Brander. 2005. HLA-B63 presents HLA-
B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low 
human immunodeficiency virus load. J Virol 79:10218-25. 
105. Frahm, N., D. E. Kaufmann, K. Yusim, M. Muldoon, C. Kesmir, C. H. Linde, W. 
Fischer, T. M. Allen, B. Li, B. H. McMahon, K. L. Faircloth, H. S. Hewitt, E. W. 
Mackey, T. Miura, A. Khatri, S. Wolinsky, A. McMichael, R. K. Funkhouser, B. 
D. Walker, C. Brander, and B. T. Korber. 2007. Increased sequence diversity 
coverage improves detection of HIV-specific T cell responses. J Immunol 179:6638-
50. 
106. Frahm, N., P. Kiepiela, S. Adams, C. H. Linde, H. S. Hewitt, K. Sango, M. E. 
Feeney, M. M. Addo, M. Lichterfeld, M. P. Lahaie, E. Pae, A. G. Wurcel, T. 
Roach, M. A. St John, M. Altfeld, F. M. Marincola, C. Moore, S. Mallal, M. 
Carrington, D. Heck rman, T. M. Allen, J. I. Mullins, B. T. Korber, P. J. 
Goulder, B. D. Walker, and C. Brander. 2006. Control of human 
immunodeficiency virus replication by cytotoxic T lymphocytes targeting 
subdominant epitopes. Nat Immunol 7:173-8. 
107. Frahm, N., D. C. Nickle, C. H. Linde, D. E. Cohen, R. Zuniga, A. Lucchetti, T. 
Roach, B. D. Walker, T. M. Allen, B. T. Korber, J. I. Mullins, and C. Brander. 
2008. Increased detection of HIV-specific T cell responses by combination of central 
sequences with comparable immunogenicity. AIDS 22:447-56. 
108. Friedrich, T. C., L. E. Valentine, L. J. Yant, E. G. Rakasz, S. M. Piaskowski, J. 
R. Furlott, K. L. Weisgrau, B. Burwitz, G. E. May, E. J. Leon, T. Soma, G. 
Napoe, S. V. Capuano, 3rd, N. A. Wilson, and D. I. Watkins. 2007. Subdominant 
CD8+ T-cell responses are involved in durable control of AIDS virus replication. J 
Virol 81:3465-76. 
109. Ganser-Pornillos, B. K., M. Yeager, and W. I. Sundquist. 2008. The structural 















110. Gao, F., E. Bailes, D. L. Robertson, Y. Chen, C. M. Rodenburg, S. F. Michael, L. 
B. Cummins, L. O. Arthur, M. Peeters, G. M. Shaw, P. M. Sharp, and B. H. 
Hahn. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 
397:436-41. 
111. Gao, F., S. G. Morrison, D. L. Robertson, C. L. Thornton, S. Craig, G. Karlsson, 
J. Sodroski, M. Morgado, B. Galvao-Castro, H. von Briesen, S. Beddows, J. 
Weber, P. M. Sharp, G. M. Shaw, and B. H. Hahn. 1996. Molecular cloning and 
analysis of functional envelope genes from human immunodeficiency virus type 1 
sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation 
and Characterization. J Virol 70:1651-67. 
112. Gao, F., D. L. Robertson, C. D. Carruthers, Y. Li, E. Bailes, L. G. Kostrikis, M. 
O. Salminen, F. Bibollet-Ruche, M. Peeters, D. D. Ho, G. M. Shaw, P. M. Sharp, 
and B. H. Hahn. 1998. An isolate of human immunodeficiency virus type 1 
originally classified as subtype I represents a complex mosaic comprising three 
different group M subtypes (A, G, and I). J Virol 72:10234-41. 
113. Gao, F., N. Vidal, Y. Li, S. A. Trask, Y. Chen, L. G. Kostrikis, D. D. Ho, J. Kim, 
M. D. Oh, K. Choe, M. Salminen, D. L. Robertson, G. M. Shaw, B. H. Hahn, and 
M. Peeters. 2001. Evidence of two distinct subsubtypes within the HIV-1 subtype A 
radiation. AIDS Res Hum Retroviruses 17:675-88. 
114. Gao, X., G. W. Nelson, P. Karacki, M. P. Martin, J. Phair, R. Kaslow, J. J. 
Goedert, S. Buchbinder, K. Hoots, D. Vlahov, S. J. O'Brien, and M. Carrington. 
2001. Effect of a single amino acid change in MHC class I molecules on the rate of 
progression to AIDS. N Engl J Med 344:1668-75. 
115. Garber, D. A., G. Silvestri, and M. B. Feinberg. 2004. Prospects for an AIDS 
vaccine: three big questions, no easy answers. Lancet Infect Dis 4:397-413. 
116. Gaschen, B., J. Taylor, K. Yusim, B. Foley, F. Gao, D. Lang, V. Novitsky, B. 
Haynes, B. H. Hahn, T. Bhattacharya, and B. Korber. 2002. Diversity 
considerations in HIV-1 vaccine selection. Science 296:2354-60. 
117. Gebe, J. A., E. Swanson, and W. W. Kwok. 2002. HLA class II peptide-binding and 
autoimmunity. Tissue Antigens 59:78-87. 
118. Geels, M. J., S. A. Dubey, K. Anderson, E. Baan, M. Bakker, G. Pollakis, W. A. 
Paxton, J. W. Shiver, and J. Goudsmit. 2005. Broad cross-clade T-cell responses to 
gag in individuals infected with human immunodeficiency virus type 1 non-B clades 
(A to G): importance of HLA anchor residue conservation. J Virol 79:11247-58. 
119. Geijtenbeek, T. B., D. S. Kwon, R. Torensma, S. J. van Vliet, G. C. van 
Duijnhoven, J. Middel, I. L. Cornelissen, H. S. Nottet, V. N. KewalRamani, D. R. 
Littman, C. G. Figdor, and Y. van Kooyk. 2000. DC-SIGN, a dendritic cell-specific 
HIV-1-binding protein that enhances trans-infection of T cells. Cell 100:587-97. 
120. Geldmacher, C., J. R. Currier, M. Gerhardt, A. Haule, L. Maboko, D. Birx, C. 















epidemic, the HIV-1 Gag-specific T-cell response is biased towards the infecting 
subtype. AIDS 21:135-43. 
121. Geldmacher, C., J. R. Currier, E. Herrmann, A. Haule, E. Kuta, F. McCutchan, 
L. Njovu, S. Geis, O. Hoffmann, L. Maboko, C. Williamson, D. Birx, A. 
Meyerhans, J. Cox, and M. Hoelscher. 2007. CD8 T-cell recognition of multiple 
epitopes within specific Gag regions is associated with maintenance of a low steady-
state viremia in human immunodeficiency virus type 1-seropositive patients. J Virol 
81:2440-8. 
122. Gesprasert, G., N. Wichukchinda, M. Mori, T. Shiino, W. Auwanit, B. 
Sriwanthana, P. Pathipvanich, P. Sawanpanyalert, T. Miura, P. Auewarakul, A. 
Thitithanyanont, and K. Ariyoshi. 2010. HLA-associated immune pressure on Gag 
protein in CRF01_AE-infected individuals and its association with plasma viral load. 
PLoS One 5:e11179. 
123. Gillespie, G. M., R. Kaul, T. Dong, H. B. Yang, T. Rostron, J. J. Bwayo, P. 
Kiama, T. Peto, F. A. Plummer, A. J. McMichael, and S. L. Rowland-Jones. 
2002. Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow 
progressors with B*57. AIDS 16:961-72. 
124. Gonzalez-Ortega, E., E. Ballana, R. Badia, B. Clotet, and J. A. Este. 2011. 
Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-
1. Antiviral Res 92:479-83. 
125. Goonetilleke, N., M. K. Liu, J. F. Salazar-Gonzalez, G. Ferrari, E. Giorgi, V. V. 
Ganusov, B. F. Keele, G. H. Learn, E. L. Turnbull, M. G. Salazar, K. J. 
Weinhold, S. Moore, C. C. C. B, N. Letvin, B. F. Haynes, M. S. Cohen, P. 
Hraber, T. Bhattacharya, P. Borrow, A. S. Perelson, B. H. Hahn, G. M. Shaw, B. 
T. Korber, and A. J. McMichael. 2009. The first T cell response to 
transmitted/founder virus contributes to the control of acute viremia in HIV-1 
infection. J Exp Med 206:1253-72. 
126. Gottlinger, H. G. 2001. The HIV-1 assembly machine. AIDS 15 Suppl 5:S13-20. 
127. Goulder, P. J., M. Bunce, P. Krausa, K. McIntyre, S. Crowley, B. Morgan, A. 
Edwards, P. Giangrande, R. E. Phillips, and A. J. McMichael. 1996. Novel, cross-
restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow 
progressors in HIV type 1 infection. AIDS Res Hum Retroviruses 12:1691-8. 
128. Goulder, P. J., A. Edwards, R. E. Phillips, and A. J. McMichael. 1997. 
Identification of a novel HLA-B*2705-restricted cytotoxic T-lymphocyte epitope 
within a conserved region of HIV-1 Nef. AIDS 11:536-8. 
129. Goulder, P. J., R. E. Phillips, R. A. Colbert, S. McAdam, G. Ogg, M. A. Nowak, 
P. Giangrande, G. Luzzi, B. Morgan, A. Edwards, A. J. McMichael, and S. 
Rowland-Jones. 1997. Late escape from an immunodominant cytotoxic T-















130. Goulder, P. J., and D. I. Watkins. 2004. HIV and SIV CTL escape: implications for 
vaccine design. Nat Rev Immunol 4:630-40. 
131. Gray, C. M., M. Mlotshwa, C. Riou, T. Mathebula, D. de Assis Rosa, T. 
Mashishi, C. Seoighe, N. Ngandu, F. van Loggerenberg, L. Morris, K. Mlisana, 
C. Williamson, S. A. Karim, and C. A. I. S. Team. 2009. Human 
immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay 
responses targeting specific regions of the proteome during primary subtype C 
infection are poor predictors of the course of viremia and set point. J Virol 83:470-8. 
132. Gray, G., S. Buchbinder, and A. Duerr. 2010. Overview of STEP and Phambili trial 
results: two phase IIb test-of-concept studies investigating the efficacy of MRK 
adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 5:357-
61. 
133. Gray, G. E., M. Allen, Z. Moodie, G. Churchyard, L. G. Bekker, M. Nchabeleng, 
K. Mlisana, B. Metch, G. de Bruyn, M. H. Latka, S. Roux, M. Mathebula, N. 
Naicker, C. Ducar, D. K. Carter, A. Puren, N. Eaton, M. J. McElrath, M. 
Robertson, L. Corey, J. G. Kublin, and H. P. s. team. 2011. Safety and efficacy of 
the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a 
double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet 
Infect Dis 11:507-15. 
134. Gudmundsdotter, L., D. Bernasconi, B. Hejdeman, E. Sandstrom, A. Alaeus, K. 
Lidman, B. Ensoli, B. Wahren, and S. Butto. 2008. Cross-clade immune responses 
to Gag p24 in patients infected with different HIV-1 subtypes and correlation with 
HLA class I and II alleles. Vaccine 26:5182-7. 
135. Gupta, S. B., C. T. Mast, N. D. Wolfe, V. Novitsky, S. A. Dubey, E. G. Kallas, M. 
Schechter, B. Mbewe, E. Vardas, P. Pitisuttithum, D. Burke, D. Freed, R. Mogg, 
P. M. Coplan, J. H. Condra, R. S. Long, K. Anderson, D. R. Casimiro, J. W. 
Shiver, and W. L. Straus. 2006. Cross-clade reactivity of HIV-1-specific T-cell 
responses in HIV-1-infected individuals from Botswana and Cameroon. J Acquir 
Immune Defic Syndr 42:135-9. 
136. Gurtler, L. G., P. H. Hauser, J. Eberle, A. von Brunn, S. Knapp, L. Zekeng, J. 
M. Tsague, and L. Kaptue. 1994. A new subtype of human immunodeficiency virus 
type 1 (MVP-5180) from Cameroon. J Virol 68:1581-5. 
137. Haanen, J. B., M. C. Wolkers, A. M. Kruisbeek, and T. N. Schumacher. 1999. 
Selective expansion of cross-reactive CD8(+) memory T cells by viral variants. J Exp 
Med 190:1319-28. 
138. Haynes, B. F., P. B. Gilbert, M. J. McElrath, S. Zolla-Pazner, G. D. Tomaras, S. 
M. Alam, D. T. Evans, D. C. Montefiori, C. Karnasuta, R. Sutthent, H. X. Liao, 
A. L. DeVico, G. K. Lewis, C. Williams, A. Pinter, Y. Fong, H. Janes, A. 
DeCamp, Y. Huang, M. Rao, E. Billings, N. Karasavvas, M. L. Robb, V. Ngauy, 
M. S. de Souza, R. Paris, G. Ferrari, R. T. Bailer, K. A. Soderberg, C. Andrews, 
P. W. Berman, N. Frahm, S. C. De Rosa, M. D. Alpert, N. L. Yates, X. Shen, R. 















L. Michael, and J. H. Kim. 2012. Immune-correlates analysis of an HIV-1 vaccine 
efficacy trial. N Engl J Med 366:1275-86. 
139. He, N., C. K. Chan, B. Sobhian, S. Chou, Y. Xue, M. Liu, T. Alber, M. 
Benkirane, and Q. Zhou. 2011. Human Polymerase-Associated Factor complex 
(PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on 
chromatin. Proc Natl Acad Sci U S A 108:E636-45. 
140. Heath, M. J., S. S. Derebail, R. J. Gorelick, and J. J. DeStefano. 2003. Differing 
roles of the N- and C-terminal zinc fingers in human immunodeficiency virus 
nucleocapsid protein-enhanced nucleic acid annealing. J Biol Chem 278:30755-63. 
141. Hemelaar, J., E. Gouws, P. D. Ghys, and S. Osmanov. 2006. Global and regional 
distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20:W13-23. 
142. Hemelaar, J., E. Gouws, P. D. Ghys, S. Osmanov, W.-U. N. f. H. Isolation, and 
Characterisation. 2011. Global trends in molecular epidemiology of HIV-1 during 
2000-2007. AIDS 25:679-89. 
143. Henderson, L. E., M. A. Bowers, R. C. Sowder, 2nd, S. A. Serabyn, D. G. 
Johnson, J. W. Bess, Jr., L. O. Arthur, D. K. Bryant, and C. Fenselau. 1992. Gag 
proteins of the highly replicative MN strain of human immunodeficiency virus type 1: 
posttranslational modifications, proteolytic processings, and complete amino acid 
sequences. J Virol 66:1856-65. 
144. Hersperger, A. R., J. N. Martin, L. Y. Shin, P. M. Sheth, C. M. Kovacs, G. L. 
Cosma, G. Makedonas, F. Pereyra, B. D. Walker, R. Kaul, S. G. Deeks, and M. 
R. Betts. 2011. Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite 
controllers is associated with T-bet expression. Blood 117:3799-808. 
145. Hersperger, A. R., S. A. Migueles, M. R. Betts, and M. Connors. 2011. Qualitative 
features of the HIV-specific CD8+ T-cell response associated with immunologic 
control. Curr Opin HIV AIDS 6:169-73. 
146. Hersperger, A. R., F. Pereyra, M. Nason, K. Demers, P. Sheth, L. Y. Shin, C. M. 
Kovacs, B. Rodriguez, S. F. Sieg, L. Teixeira-Johnson, D. Gudonis, P. A. 
Goepfert, M. M. Lederman, I. Frank, G. Makedonas, R. Kaul, B. D. Walker, and 
M. R. Betts. 2010. Perforin expression directly ex vivo by HIV-specific CD8 T-cells 
is a correlate of HIV elite control. PLoS Pathog 6:e1000917. 
147. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. 
Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 
infection. Nature 373:123-6. 
148. Hockett, R. D., J. M. Kilby, C. A. Derdeyn, M. S. Saag, M. Sillers, K. Squires, S. 
Chiz, M. A. Nowak, G. M. Shaw, and R. P. Bucy. 1999. Constant mean viral copy 
number per infected cell in tissues regardless of high, low, or undetectable plasma 















149. Honeyborne, I., A. Rathod, R. Buchli, D. Ramduth, E. Moodley, P. Rathnavalu, 
S. Chetty, C. Day, C. Brander, W. Hildebrand, B. D. Walker, P. Kiepiela, and P. 
J. Goulder. 2006. Motif inference reveals optimal CTL epitopes presented by HLA 
class I alleles highly prevalent in southern Africa. J Immunol 176:4699-705. 
150. Hope, T. J. 1999. The ins and outs of HIV Rev. Arch Biochem Biophys 365:186-91. 
151. Horton, H., I. Frank, R. Baydo, E. Jalbert, J. Penn, S. Wilson, J. P. McNevin, M. 
D. McSweyn, D. Lee, Y. Huang, S. C. De Rosa, and M. J. McElrath. 2006. 
Preservation of T cell proliferation restricted by protective HLA alleles is critical for 
immune control of HIV-1 infection. J Immunol 177:7406-15. 
152. Hu, W. S., and H. M. Temin. 1990. Genetic consequences of packaging two RNA 
genomes in one retroviral particle: pseudodiploidy and high rate of genetic 
recombination. Proc Natl Acad Sci U S A 87:1556-60. 
153. Hu, W. S., and H. M. Temin. 1990. Retroviral recombination and reverse 
transcription. Science 250:1227-33. 
154. Huang, J., J. J. Goedert, E. J. Sundberg, T. D. Cung, P. S. Burke, M. P. Martin, 
L. Preiss, J. Lifson, M. Lichterfeld, M. Carrington, and X. G. Yu. 2009. HLA-
B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory 
immunoregulatory impulses. J Exp Med 206:2959-66. 
155. Huang, K. H., M. R. Loutfy, C. M. Tsoukas, and N. F. Bernard. 2008. Immune 
correlates of CD4 decline in HIV-infected patients experiencing virologic failure 
before undergoing treatment interruption. BMC Infect Dis 8:59. 
156. Huang, M., and M. A. Martin. 1997. Incorporation of Pr160(gag-pol) into virus 
particles requires the presence of both the major homology region and adjacent C-
terminal capsid sequences within the Gag-Pol polyprotein. J Virol 71:4472-8. 
157. Hulot, S. L., E. M. Cale, B. T. Korber, and N. L. Letvin. 2011. Vaccine-induced 
CD8+ T lymphocytes of rhesus monkeys recognize variant forms of an HIV epitope 
but do not mediate optimal functional activity. J Immunol 186:5663-74. 
158. Hwang, S. S., T. J. Boyle, H. K. Lyerly, and B. R. Cullen. 1991. Identification of 
the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 
253:71-4. 
159. Igarashi, T., C. R. Brown, Y. Endo, A. Buckler-White, R. Plishka, N. 
Bischofberger, V. Hirsch, and M. A. Martin. 2001. Macrophage are the principal 
reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ 
T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera 
(SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A 
98:658-63. 
160. International, H. I. V. C. S., F. Pereyra, X. Jia, P. J. McLaren, A. Telenti, P. I. de 
Bakker, B. D. Walker, S. Ripke, C. J. Brumme, S. L. Pulit, M. Carrington, C. M. 















L. Gianniny, G. Crawford, J. Sullivan, E. Gonzalez, L. Davies, A. Camargo, J. 
M. Moore, N. Beattie, S. Gupta, A. Crenshaw, N. P. Burtt, C. Guiducci, N. 
Gupta, X. Gao, Y. Qi, Y. Yuki, A. Piechocka-Trocha, E. Cutrell, R. Rosenberg, 
K. L. Moss, P. Lemay, J. O'Leary, T. Schaefer, P. Verma, I. Toth, B. Block, B. 
Baker, A. Rothchild, J. Lian, J. Proudfoot, D. M. Alvino, S. Vine, M. M. Addo, T. 
M. Allen, M. Altfeld, M. R. Henn, S. Le Gall, H. Streeck, D. W. Haas, D. R. 
Kuritzkes, G. K. Robbins, R. W. Shafer, R. M. Gulick, C. M. Shikuma, R. 
Haubrich, S. Riddler, P. E. Sax, E. S. Daar, H. J. Ribaudo, B. Agan, S. Agarwal, 
R. L. Ahern, B. L. Allen, S. Altidor, E. L. Altschuler, S. Ambardar, K. Anastos, 
B. Anderson, V. Anderson, U. Andrady, D. Antoniskis, D. Bangsberg, D. 
Barbaro, W. Barrie, J. Bartczak, S. Barton, P. Basden, N. Basgoz, S. Bazner, N. 
C. Bellos, A. M. Benson, J. Berger, N. F. Bernard, A. M. Bernard, C. Birch, S. J. 
Bodner, R. K. Bolan, E. T. Boudreaux, M. Bradley, J. F. Braun, J. E. Brndjar, S. 
J. Brown, K. Brown, et al. 2010. The major genetic determinants of HIV-1 control 
affect HLA class I peptide presentation. Science 330:1551-7. 
161. Iweriebor, B. C., L. G. Mavhandu, T. Masebe, D. Rekosh, M. L. Hammarskjold, 
J. M. Mphahlele, and P. O. Bessong. 2011. Molecular epidemiology of HIV in two 
highly endemic areas of northeastern South Africa. Arch Virol. 
162. Jaffray, A., E. Shephard, J. van Harmelen, C. Williamson, A. L. Williamson, and 
E. P. Rybicki. 2004. Human immunodeficiency virus type 1 subtype C Gag virus-like 
particle boost substantially improves the immune response to a subtype C gag DNA 
vaccine in mice. J Gen Virol 85:409-13. 
163. Jansen, C. A., S. Kostense, K. Vandenberghe, N. M. Nanlohy, I. M. De Cuyper, 
E. Piriou, E. H. Manting, F. Miedema, and D. van Baarle. 2005. High 
responsiveness of HLA-B57-restricted Gag-specific CD8+ T cells in vitro may 
contribute to the protective effect of HLA-B57 in HIV-infection. Eur J Immunol 
35:150-8. 
164. Janssen, E. M., E. E. Lemmens, T. Wolfe, U. Christen, M. G. von Herrath, and S. 
P. Schoenberger. 2003. CD4+ T cells are required for secondary expansion and 
memory in CD8+ T lymphocytes. Nature 421:852-6. 
165. Janssens, W., L. Heyndrickx, K. Fransen, M. Temmerman, A. Leonaers, T. 
Ivens, J. Motte, P. Piot, and G. Van der Groen. 1994. Genetic variability of HIV 
type 1 in Kenya. AIDS Res Hum Retroviruses 10:1577-9. 
166. Jaoko, W., F. N. Nakwagala, O. Anzala, G. O. Manyonyi, J. Birungi, A. 
Nanvubya, F. Bashir, K. Bhatt, H. Ogutu, S. Wakasiaka, L. Matu, W. Waruingi, 
J. Odada, M. Oyaro, J. Indangasi, J. Ndinya-Achola, C. Konde, E. Mugisha, P. 
Fast, C. Schmidt, J. Gilmour, T. Tarragona, C. Smith, B. Barin, L. Dally, B. 
Johnson, A. Muluubya, L. Nielsen, P. Hayes, M. Boaz, P. Hughes, T. Hanke, A. 
McMichael, J. Bwayo, and P. Kaleebu. 2008. Safety and immunogenicity of 
recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr 
















167. Jin, X., D. E. Bauer, S. E. Tuttleton, S. Lewin, A. Gettie, J. Blanchard, C. E. 
Irwin, J. T. Safrit, J. Mittler, L. Weinberger, L. G. Kostrikis, L. Zhang, A. S. 
Perelson, and D. D. Ho. 1999. Dramatic rise in plasma viremia after CD8(+) T cell 
depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189:991-
8. 
168. John, M., D. Heckerman, I. James, L. P. Park, J. M. Carlson, A. Chopra, S. 
Gaudieri, D. Nolan, D. W. Haas, S. A. Riddler, R. Haubrich, and S. Mallal. 2010. 
Adaptive interactions between HLA and HIV-1: highly divergent selection imposed 
by HLA class I molecules with common supertype motifs. J Immunol 184:4368-77. 
169. Johnson, W. E., J. Morgan, J. Reitter, B. A. Puffer, S. Czajak, R. W. Doms, and 
R. C. Desrosiers. 2002. A replication-competent, neutralization-sensitive variant of 
simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol 
76:2075-86. 
170. Johnston, M. I., and A. S. Fauci. 2007. An HIV vaccine--evolving concepts. N Engl 
J Med 356:2073-81. 
171. Jones, K. A. 1997. Taking a new TAK on tat transactivation. Genes Dev 11:2593-9. 
172. Jowett, J. B., V. Planelles, B. Poon, N. P. Shah, M. L. Chen, and I. S. Chen. 1995. 
The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 
+ M phase of the cell cycle. J Virol 69:6304-13. 
173. Kangueane, P., M. K. Sakharkar, G. Rajaseger, S. Bolisetty, B. Sivasekari, B. 
Zhao, M. Ravichandran, P. Shapshak, and S. Subbiah. 2005. A framework to sub-
type HLA supertypes. Front Biosci 10:879-86. 
174. Kannanganat, S., C. Ibegbu, L. Chennareddi, H. L. Robinson, and R. R. Amara. 
2007. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to 
single-cytokine-producing cells. J Virol 81:8468-76. 
175. Kannanganat, S., B. G. Kapogiannis, C. Ibegbu, L. Chennareddi, P. Goepfert, H. 
L. Robinson, J. Lennox, and R. R. Amara. 2007. Human immunodeficiency virus 
type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three 
cytokines. J Virol 81:12071-6. 
176. Kao, S. Y., A. F. Calman, P. A. Luciw, and B. M. Peterlin. 1987. Anti-termination 
of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 
330:489-93. 
177. Kaul, R., T. Dong, F. A. Plummer, J. Kimani, T. Rostron, P. Kiama, E. Njagi, E. 
Irungu, B. Farah, J. Oyugi, R. Chakraborty, K. S. MacDonald, J. J. Bwayo, A. 
McMichael, and S. L. Rowland-Jones. 2001. CD8(+) lymphocytes respond to 
different HIV epitopes in seronegative and infected subjects. J Clin Invest 107:1303-
10. 
178. Kawashima, Y., K. Pfafferott, J. Frater, P. Matthews, R. Payne, M. Addo, H. 















Prendergast, H. Crawford, A. Leslie, Z. Brumme, C. Brumme, T. Allen, C. 
Brander, R. Kaslow, J. Tang, E. Hunter, S. Allen, J. Mulenga, S. Branch, T. 
Roach, M. John, S. Mallal, A. Ogwu, R. Shapiro, J. G. Prado, S. Fidler, J. 
Weber, O. G. Pybus, P. Klenerman, T. Ndung'u, R. Phillips, D. Heckerman, P. 
R. Harrigan, B. D. Walker, M. Takiguchi, and P. Goulder. 2009. Adaptation of 
HIV-1 to human leukocyte antigen class I. Nature 458:641-5. 
179. Keane, N. M., S. G. Roberts, C. A. Almeida, T. Krishnan, A. Chopra, E. 
Demaine, R. Laird, M. Tschochner, J. M. Carlson, S. Mallal, D. Heckerman, I. 
James, and M. John. 2011. High-avidity, high-IFNgamma-producing CD8 T-cell 
responses following immune selection during HIV-1 infection. Immunol Cell Biol. 
180. Kearney, M., F. Maldarelli, W. Shao, J. B. Margolick, E. S. Daar, J. W. Mellors, 
V. Rao, J. M. Coffin, and S. Palmer. 2009. Human immunodeficiency virus type 1 
population genetics and adaptation in newly infected individuals. J Virol 83:2715-27. 
181. Keating, S. M., R. C. Bollinger, T. C. Quinn, J. B. Jackson, and L. M. Carruth. 
2002. Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for 
vaccine design and immunodetection assays. AIDS Res Hum Retroviruses 18:1067-
79. 
182. Kent, S. J., C. S. Fernandez, C. J. Dale, and M. P. Davenport. 2005. Reversion of 
immune escape HIV variants upon transmission: insights into effective viral 
immunity. Trends Microbiol 13:243-6. 
183. Kiepiela, P., A. J. Leslie, I. Honeyborne, D. Ramduth, C. Thobakgale, S. Chetty, 
P. Rathnavalu, C. Moore, K. J. Pfafferott, L. Hilton, P. Zimbwa, S. Moore, T. 
Allen, C. Brander, M. M. Addo, M. Altfeld, I. James, S. Mallal, M. Bunce, L. D. 
Barber, J. Szinger, C. Day, P. Klenerman, J. Mullins, B. Korber, H. M. 
Coovadia, B. D. Walker, and P. J. Goulder. 2004. Dominant influence of HLA-B in 
mediating the potential co-evolution of HIV and HLA. Nature 432:769-75. 
184. Kiepiela, P., K. Ngumbela, C. Thobakgale, D. Ramduth, I. Honeyborne, E. 
Moodley, S. Reddy, C. de Pierres, Z. Mncube, N. Mkhwanazi, K. Bishop, M. van 
der Stok, K. Nair, N. Khan, H. Crawford, R. Payne, A. Leslie, J. Prado, A. 
Prendergast, J. Frater, N. McCarthy, C. Brander, G. H. Learn, D. Nickle, C. 
Rousseau, H. Coovadia, J. I. Mullins, D. Heckerman, B. D. Walker, and P. 
Goulder. 2007. CD8+ T-cell responses to different HIV proteins have discordant 
associations with viral load. Nat Med 13:46-53. 
185. Kijak, G. H., E. Sanders-Buell, N. D. Wolfe, E. Mpoudi-Ngole, B. Kim, B. 
Brown, M. L. Robb, D. L. Birx, D. S. Burke, J. K. Carr, and F. E. McCutchan. 
2004. Development and application of a high-throughput HIV type 1 genotyping 
assay to identify CRF02_AG in West/West Central Africa. AIDS Res Hum 
Retroviruses 20:521-30. 
186. Kim, S., K. Ikeuchi, R. Byrn, J. Groopman, and D. Baltimore. 1989. Lack of a 
negative influence on viral growth by the nef gene of human immunodeficiency virus 















187. Kirchhoff, F. 2010. Immune evasion and counteraction of restriction factors by HIV-
1 and other primate lentiviruses. Cell Host Microbe 8:55-67. 
188. Kirchhoff, F., M. Schindler, A. Specht, N. Arhel, and J. Munch. 2008. Role of Nef 
in primate lentiviral immunopathogenesis. Cell Mol Life Sci 65:2621-36. 
189. Kong, W. P., L. Wu, T. C. Wallstrom, W. Fischer, Z. Y. Yang, S. Y. Ko, N. L. 
Letvin, B. F. Haynes, B. H. Hahn, B. Korber, and G. J. Nabel. 2009. Expanded 
breadth of the T-cell response to mosaic human immunodeficiency virus type 1 
envelope DNA vaccination. J Virol 83:2201-15. 
190. Korber, B., B. Gaschen, K. Yusim, R. Thakallapally, C. Kesmir, and V. Detours. 
2001. Evolutionary and immunological implications of contemporary HIV-1 
variation. Br Med Bull 58:19-42. 
191. Kothe, D. L., Y. Li, J. M. Decker, F. Bibollet-Ruche, K. P. Zammit, M. G. 
Salazar, Y. Chen, Z. Weng, E. A. Weaver, F. Gao, B. F. Haynes, G. M. Shaw, B. 
T. Korber, and B. H. Hahn. 2006. Ancestral and consensus envelope immunogens 
for HIV-1 subtype C. Virology 352:438-49. 
192. Koup, R. A. 1994. Virus escape from CTL recognition. J Exp Med 180:779-82. 
193. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. 
Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses 
with the initial control of viremia in primary human immunodeficiency virus type 1 
syndrome. J Virol 68:4650-5. 
194. Kresge, K. J. 2009. South African AIDS Vaccine Initiative launches phase I trial. 
IAVI Rep 13:19. 
195. Kuiken, C., Foley, B., Hahn, B., Korber, B., Marx, PA., McCutchan, F., Mellors, 
JW., Mullins, JI., Sodroski, J., Wolinsky, S. 2000. HIV Sequence Compendium 
2000, vol. 01. Theoretical Biology and Biophysics Group, Los Alamos National 
Laboratory, Los Alamos, NM, LA-UR. 
196. Kuiken, C., Foley, B., Leitner, T., Apetrei, C., Hahn, B., Mizrachi, I., Mullins, J., 
Rambaut, A., Wolinsky, S., Korber, B. 2010. HIV Sequence Compendium 2010, 
vol. 10-03684. Published by Theoretical Biology and Biophysics Group, Los Alamos 
National Laboratory, NM, LA-UR. 
197. Landau, N. R., M. Warton, and D. R. Littman. 1988. The envelope glycoprotein of 
the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4. 
Nature 334:159-62. 
198. Lazaro, A. M., Y. Xiao, J. Henry, J. Ng, C. K. Hurley, and P. E. Posch. 2011. 
Ninety-six novel HLA class I and II alleles identified in volunteers for the National 
Marrow Donor Program Registry in 2009. Tissue Antigens 78:195-202. 
199. Lazaro, A. M., Y. Xiao, C. Masaberg, W. Y. Hwang, A. E. Yeoh, Y. Weiyan, J. 
Ng, C. K. Hurley, and P. E. Posch. 2011. Novel HLA class I and II alleles identified 















200. Lazaro, A. M., Y. Xiao, C. Masaberg, B. Tu, J. Ng, C. K. Hurley, and P. E. 
Posch. 2011. Seventy-eight novel HLA class I and II alleles identified during routine 
registry typing in 2008 and 2009. Tissue Antigens 77:54-61. 
201. Lazaro, E., C. Kadie, P. Stamegna, S. C. Zhang, P. Gourdain, N. Y. Lai, M. 
Zhang, S. A. Martinez, D. Heckerman, and S. Le Gall. 2011. Variable HIV peptide 
stability in human cytosol is critical to epitope presentation and immune escape. J 
Clin Invest 121:2480-92. 
202. Lazaro, E., L. T. Tram, P. Bellecave, G. L. Guidicelli, G. Anies, H. H. Thu, M. P. 
Debelleix, M. Vray, P. Recordon-Pinson, J. L. Taupin, T. T. Lien, and H. Fleury. 
2011. Molecular characterization of HIV-1 CRF01_AE in Mekong Delta, Vietnam, 
and impact of T-cell epitope mutations on HLA recognition (ANRS 12159). PLoS 
One 6:e26244. 
203. Le Vu, S., Y. Le Strat, F. Barin, J. Pillonel, F. Cazein, V. Bousquet, S. Brunet, D. 
Thierry, C. Semaille, L. Meyer, and J. C. Desenclos. 2010. Population-based HIV-
1 incidence in France, 2003-08: a modelling analysis. Lancet Infect Dis 10:682-7. 
204. Leslie, A. J., K. J. Pfafferott, P. Chetty, R. Draenert, M. M. Addo, M. Feeney, Y. 
Tang, E. C. Holmes, T. Allen, J. G. Prado, M. Altfeld, C. Brander, C. Dixon, D. 
Ramduth, P. Jeena, S. A. Thomas, A. St John, T. A. Roach, B. Kupfer, G. Luzzi, 
A. Edwards, G. Taylor, H. Lyall, G. Tudor-Williams, V. Novelli, J. Martinez-
Picado, P. Kiepiela, B. D. Walker, and P. J. Goulder. 2004. HIV evolution: CTL 
escape mutation and reversion after transmission. Nat Med 10:282-9. 
205. Letourneau, S., E. J. Im, T. Mashishi, C. Brereton, A. Bridgeman, H. Yang, L. 
Dorrell, T. Dong, B. Korber, A. J. McMichael, and T. Hanke. 2007. Design and 
pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2:e984. 
206. Li, F., A. C. Finnefrock, S. A. Dubey, B. T. Korber, J. Szinger, S. Cole, M. J. 
McElrath, J. W. Shiver, D. R. Casimiro, L. Corey, and S. G. Self. 2011. Mapping 
HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and 
potential impact on vaccine efficacy in the Step study. PLoS One 6:e20479. 
207. Li, Y., S. O'Dell, L. M. Walker, X. Wu, J. Guenaga, Y. Feng, S. D. Schmidt, K. 
McKee, M. K. Louder, J. E. Ledgerwood, B. S. Graham, B. F. Haynes, D. R. 
Burton, R. T. Wyatt, and J. R. Mascola. 2011. Mechanism of neutralization by the 
broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol 85:8954-67. 
208. Liang, C., J. Hu, R. S. Russell, A. Roldan, L. Kleiman, and M. A. Wainberg. 
2002. Characterization of a putative alpha-helix across the capsid-SP1 boundary that 
is critical for the multimerization of human immunodeficiency virus type 1 gag. J 
Virol 76:11729-37. 
209. Lichterfeld, M., D. E. Kaufmann, X. G. Yu, S. K. Mui, M. M. Addo, M. N. 
Johnston, D. Cohen, G. K. Robbins, E. Pae, G. Alter, A. Wurcel, D. Stone, E. S. 
Rosenberg, B. D. Walker, and M. Altfeld. 2004. Loss of HIV-1-specific CD8+ T 
cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-















210. Lifson, J. D., J. L. Rossio, M. Piatak, Jr., T. Parks, L. Li, R. Kiser, V. Coalter, B. 
Fisher, B. M. Flynn, S. Czajak, V. M. Hirsch, K. A. Reimann, J. E. Schmitz, J. 
Ghrayeb, N. Bischofberger, M. A. Nowak, R. C. Desrosiers, and D. Wodarz. 
2001. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus 
infection and resistance to rechallenge after transient early antiretroviral treatment. J 
Virol 75:10187-99. 
211. Limou, S., S. Le Clerc, C. Coulonges, W. Carpentier, C. Dina, O. Delaneau, T. 
Labib, L. Taing, R. Sladek, C. Deveau, R. Ratsimandresy, M. Montes, J. L. 
Spadoni, J. D. Lelievre, Y. Levy, A. Therwath, F. Schachter, F. Matsuda, I. Gut, 
P. Froguel, J. F. Delfraissy, S. Hercberg, J. F. Zagury, and A. G. Group. 2009. 
Genomewide association study of an AIDS-nonprogression cohort emphasizes the 
role played by HLA genes (ANRS Genomewide Association Study 02). J Infect Dis 
199:419-26. 
212. Lindwasser, O. W., R. Chaudhuri, and J. S. Bonifacino. 2007. Mechanisms of 
CD4 downregulation by the Nef and Vpu proteins of primate immunodeficiency 
viruses. Curr Mol Med 7:171-84. 
213. Liu, Y., J. McNevin, H. Zhao, D. M. Tebit, R. M. Troyer, M. McSweyn, A. K. 
Ghosh, D. Shriner, E. J. Arts, M. J. McElrath, and J. I. Mullins. 2007. Evolution 
of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-
balanced escape. J Virol 81:12179-88. 
214. Loffredo, J. T., T. C. Friedrich, E. J. Leon, J. J. Stephany, D. S. Rodrigues, S. P. 
Spencer, A. T. Bean, D. R. Beal, B. J. Burwitz, R. A. Rudersdorf, L. T. Wallace, 
S. M. Piaskowski, G. E. May, J. Sidney, E. Gostick, N. A. Wilson, D. A. Price, E. 
G. Kallas, H. Piontkivska, A. L. Hughes, A. Sette, and D. I. Watkins. 2007. CD8+ 
T cells from SIV elite controller macaques recognize Mamu-B*08-bound epitopes 
and select for widespread viral variation. PLoS One 2:e1152. 
215. Lopez, C. S., J. D. Eccles, A. Still, R. E. Sloan, R. L. Barklis, S. M. Tsagli, and E. 
Barklis. 2011. Determinants of the HIV-1 core assembly pathway. Virology 417:137-
46. 
216. Louwagie, J., F. E. McCutchan, M. Peeters, T. P. Brennan, E. Sanders-Buell, G. 
A. Eddy, G. van der Groen, K. Fransen, G. M. Gershy-Damet, R. Deleys, and et 
al. 1993. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates 
provides evidence for multiple genotypes. AIDS 7:769-80. 
217. Magadan, J. G., and J. S. Bonifacino. 2012. Transmembrane domain determinants 
of CD4 Downregulation by HIV-1 Vpu. J Virol 86:757-72. 
218. Makedonas, G., N. Hutnick, D. Haney, A. C. Amick, J. Gardner, G. Cosma, A. 
R. Hersperger, D. Dolfi, E. J. Wherry, G. Ferrari, and M. R. Betts. 2010. Perforin 
and IL-2 upregulation define qualitative differences among highly functional virus-
specific human CD8 T cells. PLoS Pathog 6:e1000798. 
219. Malhotra, U., F. Li, J. Nolin, M. Allison, H. Zhao, J. I. Mullins, S. Self, and M. J. 















1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection. J Virol 
81:5225-37. 
220. Malhotra, U., J. Nolin, H. Horton, F. Li, L. Corey, J. I. Mullins, and M. J. 
McElrath. 2009. Functional properties and epitope characteristics of T-cells 
recognizing natural HIV-1 variants. Vaccine 27:6678-87. 
221. Malhotra, U., J. Nolin, J. I. Mullins, and M. J. McElrath. 2007. Comprehensive 
epitope analysis of cross-clade Gag-specific T-cell responses in individuals with early 
HIV-1 infection in the US epidemic. Vaccine 25:381-90. 
222. Malim, M. H., J. Hauber, S. Y. Le, J. V. Maizel, and B. R. Cullen. 1989. The HIV-
1 rev trans-activator acts through a structured target sequence to activate nuclear 
export of unspliced viral mRNA. Nature 338:254-7. 
223. Mangeat, B., G. Gers-Huber, M. Lehmann, M. Zufferey, J. Luban, and V. 
Piguet. 2009. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it 
and directing its beta-TrCP2-dependent degradation. PLoS Pathog 5:e1000574. 
224. Martinez-Picado, J., J. G. Prado, E. E. Fry, K. Pfafferott, A. Leslie, S. Chetty, C. 
Thobakgale, I. Honeyborne, H. Crawford, P. Matthews, T. Pillay, C. Rousseau, 
J. I. Mullins, C. Brander, B. D. Walker, D. I. Stuart, P. Kiepiela, and P. Goulder. 
2006. Fitness cost of escape mutations in p24 Gag in association with control of 
human immunodeficiency virus type 1. J Virol 80:3617-23. 
225. Masemola, A., T. Mashishi, G. Khoury, P. Mohube, P. Mokgotho, E. Vardas, M. 
Colvin, L. Zijenah, D. Katzenstein, R. Musonda, S. Allen, N. Kumwenda, T. 
Taha, G. Gray, J. McIntyre, S. A. Karim, H. W. Sheppard, C. M. Gray, and H. 
S. Team. 2004. Hierarchical targeting of subtype C human immunodeficiency virus 
type 1 proteins by CD8+ T cells: correlation with viral load. J Virol 78:3233-43. 
226. McAdam, S., P. Kaleebu, P. Krausa, P. Goulder, N. French, B. Collin, T. 
Blanchard, J. Whitworth, A. McMichael, and F. Gotch. 1998. Cross-clade 
recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection. AIDS 12:571-9. 
227. McAdam, S., P. Klenerman, L. Tussey, S. Rowland-Jones, D. Lalloo, R. Phillips, 
A. Edwards, P. Giangrande, A. L. Brown, F. Gotch, and et al. 1995. Immunogenic 
HIV variant peptides that bind to HLA-B8 can fail to stimulate cytotoxic T 
lymphocyte responses. J Immunol 155:2729-36. 
228. McCutchan, F. E. 2006. Global epidemiology of HIV. J Med Virol 78 Suppl 1:S7-
S12. 
229. McCutchan, F. E. 2000. Understanding the genetic diversity of HIV-1. AIDS 14 
Suppl 3:S31-44. 
230. McCutchan, F. E., J. K. Carr, M. Bajani, E. Sanders-Buell, T. O. Harry, T. C. 
Stoeckli, K. E. Robbins, W. Gashau, A. Nasidi, W. Janssens, and M. L. Kalish. 
1999. Subtype G and multiple forms of A/G intersubtype recombinant human 















231. McCutchan, F. E., P. A. Hegerich, T. P. Brennan, P. Phanuphak, P. Singharaj, 
A. Jugsudee, P. W. Berman, A. M. Gray, A. K. Fowler, and D. S. Burke. 1992. 
Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses 8:1887-95. 
232. McCutchan, F. E., B. L. Ungar, P. Hegerich, C. R. Roberts, A. K. Fowler, S. K. 
Hira, P. L. Perine, and D. S. Burke. 1992. Genetic analysis of HIV-1 isolates from 
Zambia and an expanded phylogenetic tree for HIV-1. J Acquir Immune Defic Syndr 
5:441-9. 
233. McDonald, A. 2000. HIV infection, AIDS, hepatitis C, and sexually transmissible 
infections in Australia: National surveillance results to December 1998. N S W Public 
Health Bull 11:58-60. 
234. McKay, P. F., D. H. Barouch, J. E. Schmitz, R. S. Veazey, D. A. Gorgone, M. A. 
Lifton, K. C. Williams, and N. L. Letvin. 2003. Global dysfunction of CD4 T-
lymphocyte cytokine expression in simian-human immunodeficiency virus/SIV-
infected monkeys is prevented by vaccination. J Virol 77:4695-702. 
235. McKinney, D. M., R. Skvoretz, B. D. Livingston, C. C. Wilson, M. Anders, R. W. 
Chesnut, A. Sette, M. Essex, V. Novitsky, and M. J. Newman. 2004. Recognition 
of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J 
Immunol 173:1941-50. 
236. McKinnon, L. R., T. B. Ball, J. Kimani, C. Wachihi, L. Matu, M. Luo, J. 
Embree, K. R. Fowke, and F. A. Plummer. 2005. Cross-clade CD8(+) T-cell 
responses with a preference for the predominant circulating clade. J Acquir Immune 
Defic Syndr 40:245-9. 
237. McKinnon, L. R., T. B. Ball, C. Wachihi, P. J. McLaren, J. L. Waruk, X. Mao, S. 
Ramdahin, A. O. Anzala, J. Kamene, M. Luo, K. R. Fowke, and F. A. Plummer. 
2007. Epitope cross-reactivity frequently differs between central and effector memory 
HIV-specific CD8+ T c lls. J Immunol 178:3750-6. 
238. McKinnon, L. R., R. Kaul, J. Kimani, N. J. Nagelkerke, C. Wachihi, K. R. 
Fowke, T. B. Ball, and F. A. Plummer. 2011. HIV-specific CD8(+) T-cell 
proliferation is prospectively associated with delayed disease progression. Immunol 
Cell Biol. 
239. Mervis, R. J., N. Ahmad, E. P. Lillehoj, M. G. Raum, F. H. Salazar, H. W. Chan, 
and S. Venkatesan. 1988. The gag gene products of human immunodeficiency virus 
type 1: alignment within the gag open reading frame, identification of 
posttranslational modifications, and evidence for alternative gag precursors. J Virol 
62:3993-4002. 
240. Michael, N. L. 1999. Host genetic influences on HIV-1 pathogenesis. Curr Opin 
Immunol 11:466-74. 
241. Michel, N., I. Allespach, S. Venzke, O. T. Fackler, and O. T. Keppler. 2005. The 
Nef protein of human immunodeficiency virus establishes superinfection immunity by 















242. Michel, N., K. Ganter, S. Venzke, J. Bitzegeio, O. T. Fackler, and O. T. Keppler. 
2006. The Nef protein of human immunodeficiency virus is a broad-spectrum 
modulator of chemokine receptor cell surface levels that acts independently of 
classical motifs for receptor endocytosis and Galphai signaling. Mol Biol Cell 
17:3578-90. 
243. Migueles, S. A., A. C. Laborico, H. Imamichi, W. L. Shupert, C. Royce, M. 
McLaughlin, L. Ehler, J. Metcalf, S. Liu, C. W. Hallahan, and M. Connors. 2003. 
The differential ability of HLA B*5701+ long-term nonprogressors and progressors to 
restrict human immunodeficiency virus replication is not caused by loss of 
recognition of autologous viral gag sequences. J Virol 77:6889-98. 
244. Migueles, S. A., A. C. Laborico, W. L. Shupert, M. S. Sabbaghian, R. Rabin, C. 
W. Hallahan, D. Van Baarle, S. Kostense, F. Miedema, M. McLaughlin, L. Ehler, 
J. Metcalf, S. Liu, and M. Connors. 2002. HIV-specific CD8+ T cell proliferation is 
coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 
3:1061-8. 
245. Migueles, S. A., M. S. Sabbaghian, W. L. Shupert, M. P. Bettinotti, F. M. 
Marincola, L. Martino, C. W. Hallahan, S. M. Selig, D. Schwartz, J. Sullivan, 
and M. Connors. 2000. HLA B*5701 is highly associated with restriction of virus 
replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad 
Sci U S A 97:2709-14. 
246. Migueles, S. A., J. C. Tilton, and M. Connors. 2004. Advances in understanding 
immunologic control of HIV infection. Curr HIV/AIDS Rep 1:12-7. 
247. Migueles, S. A., J. C. Tilton, and M. Connors. 2006. Qualitative host factors 
associated with immunological control of HIV infection by CD8 T cells. Curr Opin 
HIV AIDS 1:28-33. 
248. Milicic, A., C. T. Edwards, S. Hue, J. Fox, H. Brown, T. Pillay, J. W. Drijfhout, 
J. N. Weber, E. C. Holmes, S. J. Fidler, H. T. Zhang, and R. E. Phillips. 2005. 
Sexual transmission of single human immunodeficiency virus type 1 virions encoding 
highly polymorphic multisite cytotoxic T-lymphocyte escape variants. J Virol 
79:13953-62. 
249. Miller, R. H., and N. Sarver. 1997. HIV accessory proteins as therapeutic targets. 
Nat Med 3:389-94. 
250. Miura, T., M. A. Brockman, A. Schneidewind, M. Lobritz, F. Pereyra, A. 
Rathod, B. L. Block, Z. L. Brumme, C. J. Brumme, B. Baker, A. C. Rothchild, B. 
Li, A. Trocha, E. Cutrell, N. Frahm, C. Brander, I. Toth, E. J. Arts, T. M. Allen, 
and B. D. Walker. 2009. HLA-B57/B*5801 human immunodeficiency virus type 1 
elite controllers select for rare gag variants associated with reduced viral replication 
















251. Moore, C. B., M. John, I. R. James, F. T. Christiansen, C. S. Witt, and S. A. 
Mallal. 2002. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a 
population level. Science 296:1439-43. 
252. Mori, M., B. Sriwanthana, N. Wichukchinda, C. Boonthimat, N. Tsuchiya, T. 
Miura, P. Pathipvanich, K. Ariyoshi, and P. Sawanpanyalert. 2011. Unique 
CRF01_AE Gag CTL epitopes associated with lower HIV-viral load and delayed 
disease progression in a cohort of HIV-infected Thais. PLoS One 6:e22680. 
253. Mothe, B., A. Llano, J. Ibarrondo, M. Daniels, C. Miranda, J. Zamarreno, V. 
Bach, R. Zuniga, S. Perez-Alvarez, C. T. Berger, M. C. Puertas, J. Martinez-
Picado, M. Rolland, M. Farfan, J. J. Szinger, W. H. Hildebrand, O. O. Yang, V. 
Sanchez-Merino, C. J. Brumme, Z. L. Brumme, D. Heckerman, T. M. Allen, J. I. 
Mullins, G. Gomez, P. J. Goulder, B. D. Walker, J. M. Gatell, B. Clotet, B. T. 
Korber, J. Sanchez, and C. Brander. 2011. Definition of the viral targets of 
protective HIV-1-specific T cell responses. J Transl Med 9:208. 
254. Mothe, B. R., J. Weinfurter, C. Wang, W. Rehrauer, N. Wilson, T. M. Allen, D. 
B. Allison, and D. I. Watkins. 2003. Expression of the major histocompatibility 
complex class I molecule Mamu-A*01 is associated with control of simian 
immunodeficiency virus SIVmac239 replication. J Virol 77:2736-40. 
255. Motomura, K., S. Kusagawa, K. Kato, K. Nohtomi, H. H. Lwin, K. M. Tun, M. 
Thwe, K. Y. Oo, S. Lwin, O. Kyaw, M. Zaw, Y. Nagai, and Y. Takebe. 2000. 
Emergence of new forms of human immunodeficiency virus type 1 intersubtype 
recombinants in central Myanmar. AIDS Res Hum Retroviruses 16:1831-43. 
256. Muhl, T., M. Krawczak, P. Ten Haaft, G. Hunsmann, and U. Sauermann. 2002. 
MHC class I alleles influence set-point viral load and survival time in simian 
immunodeficiency virus-infected rhesus monkeys. J Immunol 169:3438-46. 
257. Mullins, J. I., D. C. Nickle, L. Heath, A. G. Rodrigo, and G. H. Learn. 2004. 
Immunogen sequence: the fourth tier of AIDS vaccine design. Expert Rev Vaccines 
3:S151-9. 
258. Musyoki, A. M., K. M. Mothapo, J. N. Rakgole, A. Lukhwareni, P. Bessong, G. 
S. Selabe, C. Williamson, J. Mphahlele, and H. Bredell. 2011. Genetic 
charaterisation of HIV before widespread testing of HIV vaccine candidates at a 
clinical trial site in Pretoria, South Africa. AIDS Res Hum Retroviruses. 
259. Myers, G. 1994. Molecular investigation of HIV transmission. Ann Intern Med 
121:889-90. 
260. Naderi, H. R., M. Tagliamonte, M. L. Tornesello, M. Ciccozzi, G. Rezza, R. 
Farid, F. M. Buonaguro, and L. Buonaguro. 2006. Molecular and phylogenetic 
analysis of HIV-1 variants circulating among injecting drug users in Mashhad-Iran. 
Infect Agent Cancer 1:4. 
261. Navis, M., I. Schellens, D. van Baarle, J. Borghans, P. van Swieten, F. Miedema, 















HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol 179:3133-
43. 
262. Ndhlovu, Z. M., A. Piechocka-Trocha, S. Vine, A. McMullen, K. C. Koofhethile, 
P. J. Goulder, T. Ndung'u, D. H. Barouch, and B. D. Walker. 2011. Mosaic HIV-1 
Gag antigens can be processed and presented to human HIV-specific CD8+ T cells. J 
Immunol 186:6914-24. 
263. Nickle, D. C., M. A. Jensen, G. S. Gottlieb, D. Shriner, G. H. Learn, A. G. 
Rodrigo, and J. I. Mullins. 2003. Consensus and ancestral state HIV vaccines. 
Science 299:1515-8; author reply 1515-8. 
264. Nielsen, M., C. Lundegaard, P. Worning, S. L. Lauemoller, K. Lamberth, S. 
Buus, S. Brunak, and O. Lund. 2003. Reliable prediction of T-cell epitopes using 
neural networks with novel sequence representations. Protein Sci 12:1007-17. 
265. Novitsky, V., U. R. Smith, P. Gilbert, M. F. McLane, P. Chigwedere, C. 
Williamson, T. Ndung'u, I. Klein, S. Y. Chang, T. Peter, I. Thior, B. T. Foley, S. 
Gaolekwe, N. Rybak, S. Gaseitsiwe, F. Vannberg, R. Marlink, T. H. Lee, and M. 
Essex. 2002. Human immunodeficiency virus type 1 subtype C molecular phylogeny: 
consensus sequence for an AIDS vaccine design? J Virol 76:5435-51. 
266. Novitsky, V., R. Wang, L. Margolin, J. Baca, L. Kebaabetswe, R. Rossenkhan, C. 
Bonney, M. Herzig, D. Nkwe, S. Moyo, R. Musonda, E. Woldegabriel, E. van 
Widenfelt, J. Makhema, S. Lagakos, and M. Essex. 2009. Timing constraints of in 
vivo gag mutations during primary HIV-1 subtype C infection. PLoS One 4:e7727. 
267. Oliva, R., L. Falcigno, G. D'Auria, M. Dettin, C. Scarinci, A. Pasquato, C. Di 
Bello, and L. Paolillo. 2003. Structural investigation of the HIV-1 envelope 
glycoprotein gp160 cleavage site, 2: relevance of an N-terminal helix. Chembiochem 
4:727-33. 
268. Op de Coul, E. L., M. Prins, M. Cornelissen, A. van der Schoot, F. Boufassa, R. 
P. Brettle, L. Hernandez-Aguado, V. Schiffer, J. McMenamin, G. Rezza, R. 
Robertson, R. Zangerle, J. Goudsmit, R. A. Coutinho, V. V. Lukashov, 
European, and S. Italian Seroconverter. 2001. Using phylogenetic analysis to trace 
HIV-1 migration among western European injecting drug users seroconverting from 
1984 to 1997. AIDS 15:257-66. 
269. Opi, S., S. Kao, R. Goila-Gaur, M. A. Khan, E. Miyagi, H. Takeuchi, and K. 
Strebel. 2007. Human immunodeficiency virus type 1 Vif inhibits packaging and 
antiviral activity of a degradation-resistant APOBEC3G variant. J Virol 81:8236-46. 
270. Osmanov, S., C. Pattou, N. Walker, B. Schwardlander, J. Esparza, W.-U. N. f. H. 
Isolation, and Characterization. 2002. Estimated global distribution and regional 
spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 
29:184-90. 
271. Ou, C. Y., Y. Takebe, C. C. Luo, M. Kalish, W. Auwanit, C. Bandea, N. de la 















distribution of two subtypes of HIV-1 in Thailand. AIDS Res Hum Retroviruses 
8:1471-2. 
272. Paxton, W., R. I. Connor, and N. R. Landau. 1993. Incorporation of Vpr into 
human immunodeficiency virus type 1 virions: requirement for the p6 region of gag 
and mutational analysis. J Virol 67:7229-37. 
273. Peeters, M. 2001. The genetic variability of HIV-1 and its implications. Transfus 
Clin Biol 8:222-5. 
274. Pejchal, R., K. J. Doores, L. M. Walker, R. Khayat, P. S. Huang, S. K. Wang, R. 
L. Stanfield, J. P. Julien, A. Ramos, M. Crispin, R. Depetris, U. Katpally, A. 
Marozsan, A. Cupo, S. Maloveste, Y. Liu, R. McBride, Y. Ito, R. W. Sanders, C. 
Ogohara, J. C. Paulson, T. Feizi, C. N. Scanlan, C. H. Wong, J. P. Moore, W. C. 
Olson, A. B. Ward, P. Poignard, W. R. Schief, D. R. Burton, and I. A. Wilson. 
2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV 
glycan shield. Science 334:1097-103. 
275. Pejchal, R., L. M. Walker, R. L. Stanfield, S. K. Phogat, W. C. Koff, P. Poignard, 
D. R. Burton, and I. A. Wilson. 2010. Structure and function of broadly reactive 
antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. 
Proc Natl Acad Sci U S A 107:11483-8. 
276. Pelak, K., D. B. Goldstein, N. M. Walley, J. Fellay, D. Ge, K. V. Shianna, C. 
Gumbs, X. Gao, J. M. Maia, K. D. Cronin, S. K. Hussain, M. Carrington, N. L. 
Michael, A. C. Weintrob, H. I. V. W. G. Infectious Disease Clinical Research 
Program, A. National Institute of, and H. I. V. A. V. I. Infectious Diseases Center 
for. 2010. Host determinants of HIV-1 control in African Americans. J Infect Dis 
201:1141-9. 
277. Peretz, Y., G. Alter, M. P. Boisvert, G. Hatzakis, C. M. Tsoukas, and N. F. 
Bernard. 2005. Human immunodeficiency virus (HIV)-specific gamma interferon 
secretion directed against all expressed HIV genes: relationship to rate of CD4 
decline. J Virol 79:4908-17. 
278. Pereyra, F., M. M. Addo, D. E. Kaufmann, Y. Liu, T. Miura, A. Rathod, B. 
Baker, A. Trocha, R. Rosenberg, E. Mackey, P. Ueda, Z. Lu, D. Cohen, T. Wrin, 
C. J. Petropoulos, E. S. Rosenberg, and B. D. Walker. 2008. Genetic and 
immunologic heterogeneity among persons who control HIV infection in the absence 
of therapy. J Infect Dis 197:563-71. 
279. Perrin, L., L. Kaiser, and S. Yerly. 2003. Travel and the spread of HIV-1 genetic 
variants. Lancet Infect Dis 3:22-7. 
280. Peters, B. S., W. Jaoko, E. Vardas, G. Panayotakopoulos, P. Fast, C. Schmidt, J. 
Gilmour, M. Bogoshi, G. Omosa-Manyonyi, L. Dally, L. Klavinskis, B. Farah, T. 
Tarragona, P. A. Bart, A. Robinson, C. Pieterse, W. Stevens, R. Thomas, B. 
Barin, A. J. McMichael, J. A. McIntyre, G. Pantaleo, T. Hanke, and J. Bwayo. 















virus Ankara (MVA) with and without DNA priming: effects of dosage and route on 
safety and immunogenicity. Vaccine 25:2120-7. 
281. Pitisuttithum, P., P. Gilbert, M. Gurwith, W. Heyward, M. Martin, F. van 
Griensven, D. Hu, J. W. Tappero, K. Choopanya, and G. Bangkok Vaccine 
Evaluation. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a 
bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in 
Bangkok, Thailand. J Infect Dis 194:1661-71. 
282. Piyasirisilp, S., F. E. McCutchan, J. K. Carr, E. Sanders-Buell, W. Liu, J. Chen, 
R. Wagner, H. Wolf, Y. Shao, S. Lai, C. Beyrer, and X. F. Yu. 2000. A recent 
outbreak of human immunodeficiency virus type 1 infection in southern China was 
initiated by two highly homogeneous, geographically separated strains, circulating 
recombinant form AE and a novel BC recombinant. J Virol 74:11286-95. 
283. Planelles, V., F. Bachelerie, J. B. Jowett, A. Haislip, Y. Xie, P. Banooni, T. 
Masuda, and I. S. Chen. 1995. Fate of the human immunodeficiency virus type 1 
provirus in infected cells: a role for vpr. J Virol 69:5883-9. 
284. Plantier, J. C., M. Leoz, J. E. Dickerson, F. De Oliveira, F. Cordonnier, V. 
Lemee, F. Damond, D. L. Robertson, and F. Simon. 2009. A new human 
immunodeficiency virus derived from gorillas. Nat Med 15:871-2. 
285. Pond, S. L., S. D. Frost, Z. Grossman, M. B. Gravenor, D. D. Richman, and A. J. 
Brown. 2006. Adaptation to different human populations by HIV-1 revealed by 
codon-based analyses. PLoS Comput Biol 2:e62. 
286. Popov, S., M. Rexach, L. Ratner, G. Blobel, and M. Bukrinsky. 1998. Viral 
protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore 
complex. J Biol Chem 273:13347-52. 
287. Price, D. A., P. J. Goulder, P. Klenerman, A. K. Sewell, P. J. Easterbrook, M. 
Troop, C. R. Bangham, and R. E. Phillips. 1997. Positive selection of HIV-1 
cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci 
U S A 94:1890-5. 
288. Qi, M., R. Yang, and C. Aiken. 2008. Cyclophilin A-dependent restriction of human 
immunodeficiency virus type 1 capsid mutants for infection of nondividing cells. J 
Virol 82:12001-8. 
289. Qing, M., T. Li, Y. Han, Z. Qiu, and Y. Jiao. 2006. Accelerating effect of human 
leukocyte antigen-Bw6 homozygosity on disease progression in Chinese HIV-1-
infected patients. J Acquir Immune Defic Syndr 41:137-9. 
290. Ragupathy, V., J. Zhao, O. Wood, S. Tang, S. Lee, P. Nyambi, and I. Hewlett. 
2011. Identification of new, emerging HIV-1 unique recombinant forms and drug 
resistant viruses circulating in Cameroon. Virol J 8:185. 
291. Rayfield, M. A., P. Sullivan, C. I. Bandea, L. Britvan, R. A. Otten, C. P. Pau, D. 















Schochetman. 1996. HIV-1 group O virus identified for the first time in the United 
States. Emerg Infect Dis 2:209-12. 
292. Rerks-Ngarm, S., A. E. Brown, C. Khamboonruang, P. Thongcharoen, and P. 
Kunasol. 2006. HIV/AIDS preventive vaccine 'prime-boost' phase III trial: 
foundations and initial lessons learned from Thailand. AIDS 20:1471-9. 
293. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. 
Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, M. Benenson, S. 
Gurunathan, J. Tartaglia, J. G. McNeil, D. P. Francis, D. Stablein, D. L. Birx, S. 
Chunsuttiwat, C. Khamboonruang, P. Thongcharoen, M. L. Robb, N. L. 
Michael, P. Kunasol, J. H. Kim, and M.-T. Investigators. 2009. Vaccination with 
ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 
361:2209-20. 
294. Rhodes, D. I., L. Ashton, A. Solomon, A. Carr, D. Cooper, J. Kaldor, and N. 
Deacon. 2000. Characterization of three nef-defective human immunodeficiency 
virus type 1 strains associated with long-term nonprogression. Australian Long-Term 
Nonprogressor Study Group. J Virol 74:10581-8. 
295. Richmond, M., L. R. McKinnon, S. A. Kiazyk, C. Wachihi, M. Kimani, J. 
Kimani, F. A. Plummer, and T. B. Ball. 2011. Epitope mapping of HIV-specific 
CD8+ T cell responses by multiple immunological readouts reveals distinct 
specificities defined by function. J Virol 85:1275-86. 
296. Roberts, J. D., K. Bebenek, and T. A. Kunkel. 1988. The accuracy of reverse 
transcriptase from HIV-1. Science 242:1171-3. 
297. Robertson, D. L., J. P. Anderson, J. A. Bradac, J. K. Carr, B. Foley, R. K. 
Funkhouser, F. Gao, B. H. Hahn, M. L. Kalish, C. Kuiken, G. H. Learn, T. 
Leitner, F. McCutchan, S. Osmanov, M. Peeters, D. Pieniazek, M. Salminen, P. 
M. Sharp, S. Wolinsky, and B. Korber. 2000. HIV-1 nomenclature proposal. 
Science 288:55-6. 
298. Robinson, J., and S. G. Marsh. 2003. HLA informatics. Accessing HLA sequences 
from sequence databases. Methods Mol Biol 210:3-21. 
299. Robinson, J., M. J. Waller, S. C. Fail, H. McWilliam, R. Lopez, P. Parham, and 
S. G. Marsh. 2009. The IMGT/HLA database. Nucleic Acids Res 37:D1013-7. 
300. Robinson, J., M. J. Waller, P. Parham, N. de Groot, R. Bontrop, L. J. Kennedy, 
P. Stoehr, and S. G. Marsh. 2003. IMGT/HLA and IMGT/MHC: sequence 
databases for the study of the major histocompatibility complex. Nucleic Acids Res 
31:311-4. 
301. Roederer, M., J. M. Brenchley, M. R. Betts, and S. C. De Rosa. 2004. Flow 
















302. Rolland, M., D. C. Nickle, and J. I. Mullins. 2007. HIV-1 group M conserved 
elements vaccine. PLoS Pathog 3:e157. 
303. Rolland, M., S. Tovanabutra, A. C. deCamp, N. Frahm, P. B. Gilbert, E. 
Sanders-Buell, L. Heath, C. A. Magaret, M. Bose, A. Bradfield, A. O'Sullivan, J. 
Crossler, T. Jones, M. Nau, K. Wong, H. Zhao, D. N. Raugi, S. Sorensen, J. N. 
Stoddard, B. S. Maust, W. Deng, J. Hural, S. Dubey, N. L. Michael, J. Shiver, L. 
Corey, F. Li, S. G. Self, J. Kim, S. Buchbinder, D. R. Casimiro, M. N. Robertson, 
A. Duerr, M. J. McElrath, F. E. McCutchan, and J. I. Mullins. 2011. Genetic 
impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat 
Med 17:366-71. 
304. Rosario, M., A. Bridgeman, E. D. Quakkelaar, M. F. Quigley, B. J. Hill, M. L. 
Knudsen, V. Ammendola, K. Ljungberg, N. Borthwick, E. J. Im, A. J. 
McMichael, J. W. Drijfhout, H. Y. Greenaway, V. Venturi, D. C. Douek, S. 
Colloca, P. Liljestrom, A. Nicosia, D. A. Price, C. J. Melief, and T. Hanke. 2010. 
Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with 
superior breadth to single-gene vaccines in macaques. Eur J Immunol 40:1973-84. 
305. Roy, S., N. T. Parkin, C. Rosen, J. Itovitch, and N. Sonenberg. 1990. Structural 
requirements for trans activation of human immunodeficiency virus type 1 long 
terminal repeat-directed gene expression by tat: importance of base pairing, loop 
sequence, and bulges in the tat-responsive sequence. J Virol 64:1402-6. 
306. Saez-Cirion, A., C. Lacabaratz, O. Lambotte, P. Versmisse, A. Urrutia, F. 
Boufassa, F. Barre-Sinoussi, J. F. Delfraissy, M. Sinet, G. Pancino, A. Venet, and 
E. P. H. I. V. C. S. G. Agence Nationale de Recherches sur le Sida. 2007. HIV 
controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and 
peculiar cytotoxic T lymphocy e activation phenotype. Proc Natl Acad Sci U S A 
104:6776-81. 
307. Salvi, R., A. R. Garbuglia, A. Di Caro, S. Pulciani, F. Montella, and A. 
Benedetto. 1998. Grossly defective nef gene sequences in a human 
immunodeficiency virus type 1-seropositive long-term nonprogressor. J Virol 
72:3646-57. 
308. Santra, S., H. X. Liao, R. Zhang, M. Muldoon, S. Watson, W. Fischer, J. Theiler, 
J. Szinger, H. Balachandran, A. Buzby, D. Quinn, R. J. Parks, C. Y. Tsao, A. 
Carville, K. G. Mansfield, G. N. Pavlakis, B. K. Felber, B. F. Haynes, B. T. 
Korber, and N. L. Letvin. 2010. Mosaic vaccines elicit CD8+ T lymphocyte 
responses that confer enhanced immune coverage of diverse HIV strains in monkeys. 
Nat Med 16:324-8. 
309. Scarlata, S., and C. Carter. 2003. Role of HIV-1 Gag domains in viral assembly. 
Biochim Biophys Acta 1614:62-72. 
310. Schmitz, J. E., M. J. Kuroda, S. Santra, V. G. Sasseville, M. A. Simon, M. A. 
Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B. J. Scallon, J. Ghrayeb, M. A. 















Control of viremia in simian immunodeficiency virus infection by CD8+ 
lymphocytes. Science 283:857-60. 
311. Schneidewind, A., M. A. Brockman, R. Yang, R. I. Adam, B. Li, S. Le Gall, C. R. 
Rinaldo, S. L. Craggs, R. L. Allgaier, K. A. Power, T. Kuntzen, C. S. Tung, M. X. 
LaBute, S. M. Mueller, T. Harrer, A. J. McMichael, P. J. Goulder, C. Aiken, C. 
Brander, A. D. Kelleher, and T. M. Allen. 2007. Escape from the dominant HLA-
B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic 
reduction in human immunodeficiency virus type 1 replication. J Virol 81:12382-93. 
312. Schroeder, T. L., H. Burger, B. Weiser, V. Bengualid, J. Kimani, A. O. Anzala, 
M. M. Parker, D. Lamson, and S. M. Philpott. 2005. Characterization of 
intersubtype recombinant HIV type 1 genomes using a nonradioactive heteroduplex 
tracking assay. AIDS Res Hum Retroviruses 21:314-8. 
313. Schwartz, O., V. Marechal, S. Le Gall, F. Lemonnier, and J. M. Heard. 1996. 
Endocytosis of major histocompatibility complex class I molecules is induced by the 
HIV-1 Nef protein. Nat Med 2:338-42. 
314. Seaman, M. S., H. Janes, N. Hawkins, L. E. Grandpre, C. Devoy, A. Giri, R. T. 
Coffey, L. Harris, B. Wood, M. G. Daniels, T. Bhattacharya, A. Lapedes, V. R. 
Polonis, F. E. McCutchan, P. B. Gilbert, S. G. Self, B. T. Korber, D. C. 
Montefiori, and J. R. Mascola. 2010. Tiered categorization of a diverse panel of 
HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84:1439-
52. 
315. Serwanga, J., S. Mugaba, E. Pimego, B. Nanteza, F. Lyagoba, S. Nakubulwa, L. 
Heath, R. N. Nsubuga, N. Ndembi, F. Gotch, and P. Kaleebu. 2011. Profile of T 
Cell Recognition of HIV Type 1 Consensus Group M Gag and Nef Peptides in a 
Clade A1- and D-Infected Ugandan Population. AIDS Res Hum Retroviruses. 
316. Sette, A., and J. Sidney. 1998. HLA supertypes and supermotifs: a functional 
perspective on HLA polymorphism. Curr Opin Immunol 10:478-82. 
317. Sette, A., and J. Sidney. 1999. Nine major HLA class I supertypes account for the 
vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50:201-12. 
318. Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim. 2002. Isolation of a 
human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. 
Nature 418:646-50. 
319. Sherman, M. P., C. M. de Noronha, L. A. Eckstein, J. Hataye, P. Mundt, S. A. 
Williams, J. A. Neidleman, M. A. Goldsmith, and W. C. Greene. 2003. Nuclear 
export of Vpr is required for efficient replication of human immunodeficiency virus 
type 1 in tissue macrophages. J Virol 77:7582-9. 
320. Shiina, T., K. Hosomichi, H. Inoko, and J. K. Kulski. 2009. The HLA genomic loci 















321. Short, G. F., 3rd, A. L. Laikhter, M. Lodder, Y. Shayo, T. Arslan, and S. M. 
Hecht. 2000. Probing the S1/S1' substrate binding pocket geometry of HIV-1 
protease with modified aspartic acid analogues. Biochemistry 39:8768-81. 
322. Simon, F., I. Loussert-Ajaka, F. Damond, S. Saragosti, F. Barin, and F. Brun-
Vezinet. 1996. HIV type 1 diversity in northern Paris, France. AIDS Res Hum 
Retroviruses 12:1427-33. 
323. Srinivasakumar, N., M. L. Hammarskjold, and D. Rekosh. 1995. Characterization 
of deletion mutations in the capsid region of human immunodeficiency virus type 1 
that affect particle formation and Gag-Pol precursor incorporation. J Virol 69:6106-
14. 
324. Stephens, H. A. 2005. HIV-1 diversity versus HLA class I polymorphism. Trends 
Immunol 26:41-7. 
325. Stevens, W., A. Kamali, E. Karita, O. Anzala, E. J. Sanders, W. Jaoko, P. 
Kaleebu, J. Mulenga, L. Dally, P. Fast, J. Gilmour, B. Farah, J. Birungi, P. 
Hughes, O. Manigart, G. Stevens, S. Yates, H. Thomson, A. von Lieven, M. 
Krebs, M. A. Price, L. Stoll-Johnson, and N. Ketter. 2008. Baseline morbidity in 
2,990 adult African volunteers recruited to characterize laboratory reference intervals 
for future HIV vaccine clinical trials. PLoS One 3:e2043. 
326. Stranford, S. A., J. C. Ong, B. Martinez-Marino, M. Busch, F. M. Hecht, J. 
Kahn, and J. A. Levy. 2001. Reduction in CD8+ cell noncytotoxic anti-HIV activity 
in individuals receiving highly active antiretroviral therapy during primary infection. 
Proc Natl Acad Sci U S A 98:597-602. 
327. Swanstrom, R., and J. W. Wills. 1997. Synthesis, Assembly, and Processing of 
Viral Proteins. 
328. Tebit, D. M., and E. J. Arts. 2011. Tracking a century of global expansion and 
evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis 
11:45-56. 
329. Temin, H. M., and D. P. Bolognesi. 1993. AIDS. Where has HIV been hiding? 
Nature 362:292-3. 
330. Thali, M., A. Bukovsky, E. Kondo, B. Rosenwirth, C. T. Walsh, J. Sodroski, and 
H. G. Gottlinger. 1994. Functional association of cyclophilin A with HIV-1 virions. 
Nature 372:363-5. 
331. Thurmond, J., H. Yoon, C. Kuiken, K. Yusim, S. Perkins, J. Theiler, T. 
Bhattacharya, B. Korber, and W. Fischer. 2008. Web-based design and evaluation 
of T-cell vaccine candidates. Bioinformatics 24:1639-40. 
332. Tian, W., D. A. Boggs, G. Uko, A. Essiet, M. Inyama, B. Banjoko, T. Adewole, 
W. Z. Ding, M. Mohseni, R. Fritz, D. F. Chen, L. J. Palmer, and P. A. Fraser. 
2003. MICA, HLA-B haplotypic variation in five population groups of sub-Saharan 















333. Tolstrup, M., A. L. Laursen, J. Gerstoft, F. S. Pedersen, L. Ostergaard, and M. 
Duch. 2006. Cysteine 138 mutation in HIV-1 Nef from patients with delayed disease 
progression. Sex Health 3:281-6. 
334. Triques, K., A. Bourgeois, N. Vidal, E. Mpoudi-Ngole, C. Mulanga-Kabeya, N. 
Nzilambi, N. Torimiro, E. Saman, E. Delaporte, and M. Peeters. 2000. Near-full-
length genome sequencing of divergent African HIV type 1 subtype F viruses leads to 
the identification of a new HIV type 1 subtype designated K. AIDS Res Hum 
Retroviruses 16:139-51. 
335. Troyer, R. M., J. McNevin, Y. Liu, S. C. Zhang, R. W. Krizan, A. Abraha, D. M. 
Tebit, H. Zhao, S. Avila, M. A. Lobritz, M. J. McElrath, S. Le Gall, J. I. Mullins, 
and E. J. Arts. 2009. Variable fitness impact of HIV-1 escape mutations to cytotoxic 
T lymphocyte (CTL) response. PLoS Pathog 5:e1000365. 
336. Ueno, T., H. Tomiyama, M. Fujiwara, S. Oka, and M. Takiguchi. 2004. 
Functionally impaired HIV-specific CD8 T cells show high affinity TCR-ligand 
interactions. J Immunol 173:5451-7. 
337. Valentine, L. E., S. M. Piaskowski, E. G. Rakasz, N. L. Henry, N. A. Wilson, and 
D. I. Watkins. 2008. Recognition of escape variants in ELISPOT does not always 
predict CD8+ T-cell recognition of simian immunodeficiency virus-infected cells 
expressing the same variant sequences. J Virol 82:575-81. 
338. Vallari, A., V. Holzmayer, B. Harris, J. Yamaguchi, C. Ngansop, F. Makamche, 
D. Mbanya, L. Kaptue, N. Ndembi, L. Gurtler, S. Devare, and C. A. Brennan. 
2011. Confirmation of putative HIV-1 group P in Cameroon. J Virol 85:1403-7. 
339. van Harmelen, J., R. Wood, M. Lambrick, E. P. Rybicki, A. L. Williamson, and 
C. Williamson. 1997. An association between HIV-1 subtypes and mode of 
transmission in Cape Town, South Africa. AIDS 11:81-7. 
340. Vardas, E., P. Kaleebu, L. G. Bekker, A. Hoosen, E. Chomba, P. R. Johnson, P. 
Anklesaria, J. Birungi, B. Barin, M. Boaz, J. Cox, J. Lehrman, G. Stevens, J. 
Gilmour, T. Tarragona, P. Hayes, S. Lowenbein, E. Kizito, P. Fast, A. E. Heald, 
and C. Schmidt. 2010. A phase 2 study to evaluate the safety and immunogenicity of 
a recombinant HIV type 1 vaccine based on adeno-associated virus. AIDS Res Hum 
Retroviruses 26:933-42. 
341. Vasan, S., S. J. Schlesinger, Z. Chen, A. Hurley, A. Lombardo, S. Than, P. 
Adesanya, C. Bunce, M. Boaz, R. Boyle, E. Sayeed, L. Clark, D. Dugin, M. 
Boente-Carrera, C. Schmidt, Q. Fang, LeiBa, Y. Huang, G. J. Zaharatos, D. F. 
Gardiner, M. Caskey, L. Seamons, M. Ho, L. Dally, C. Smith, J. Cox, D. Gill, J. 
Gilmour, M. C. Keefer, P. Fast, and D. D. Ho. 2010. Phase 1 safety and 
immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-
HIV-1 B'/C candidate vaccine. PLoS One 5:e8816. 
342. Vasan, S., S. J. Schlesinger, Y. Huang, A. Hurley, A. Lombardo, Z. Chen, S. 
Than, P. Adesanya, C. Bunce, M. Boaz, R. Boyle, E. Sayeed, L. Clark, D. Dugin, 















Cox, D. K. Gill, J. Gilmour, M. C. Keefer, P. Fast, and D. D. Ho. 2010. Phase 1 
safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade 
C/B' HIV-1 candidate vaccine. PLoS One 5:e8617. 
343. Verheyen, J., E. Litau, T. Sing, M. Daumer, M. Balduin, M. Oette, G. 
Fatkenheuer, J. K. Rockstroh, U. Schuldenzucker, D. Hoffmann, H. Pfister, and 
R. Kaiser. 2006. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-
gag in therapy-naive and therapy-experienced patients. Antivir Ther 11:879-87. 
344. Vodicka, M. A., D. M. Koepp, P. A. Silver, and M. Emerman. 1998. HIV-1 Vpr 
interacts with the nuclear transport pathway to promote macrophage infection. Genes 
Dev 12:175-85. 
345. Vogt, R. L., S. Richmond-Crum, and A. Diwan. 1997. Hepatitis C virus infection in 
a human immunodeficiency virus-positive cohort in Hawaii. J Infect Dis 176:542-3. 
346. Vogt, V. M. 1996. Proteolytic processing and particle maturation. Curr Top 
Microbiol Immunol 214:95-131. 
347. von Schwedler, U. K., M. Stuchell, B. Muller, D. M. Ward, H. Y. Chung, E. 
Morita, H. E. Wang, T. Davis, G. P. He, D. M. Cimbora, A. Scott, H. G. 
Krausslich, J. Kaplan, S. G. Morham, and W. I. Sundquist. 2003. The protein 
network of HIV budding. Cell 114:701-13. 
348. Votteler, J., L. Neumann, S. Hahn, F. Hahn, P. Rauch, K. Schmidt, N. 
Studtrucker, S. M. Solbak, T. Fossen, P. Henklein, D. E. Ott, G. Holland, N. 
Bannert, and U. Schubert. 2011. Highly conserved serine residue 40 in HIV-1 p6 
regulates capsid processing and virus core assembly. Retrovirology 8:11. 
349. Walk, S. F., M. Alexander, B. Maier, M. L. Hammarskjold, D. M. Rekosh, and 
K. S. Ravichandran. 2001. Design and use of an inducibly activated human 
immunodeficiency virus type 1 Nef to study immune modulation. J Virol 75:834-43. 
350. Walker, B. D., and B. T. Korber. 2001. Immune control of HIV: the obstacles of 
HLA and viral diversity. Nat Immunol 2:473-5. 
351. Walker, L. M., M. D. Simek, F. Priddy, J. S. Gach, D. Wagner, M. B. Zwick, S. 
K. Phogat, P. Poignard, and D. R. Burton. 2010. A limited number of antibody 
specificities mediate broad and potent serum neutralization in selected HIV-1 infected 
individuals. PLoS Pathog 6:e1001028. 
352. Wang, J. Y., H. Ling, W. Yang, and R. Craigie. 2001. Structure of a two-domain 
fragment of HIV-1 integrase: implications for domain organization in the intact 
protein. EMBO J 20:7333-43. 
353. Weaver, E. A., Z. T. Camacho, and F. Gao. 2010. Similar T-cell immune responses 
induced by group M consensus env immunogens with wild-type or minimum 
consensus variable regions. AIDS Res Hum Retroviruses 26:577-84. 
354. Weaver, E. A., Z. Lu, Z. T. Camacho, F. Moukdar, H. X. Liao, B. J. Ma, M. 















Haynes, and F. Gao. 2006. Cross-subtype T-cell immune responses induced by a 
human immunodeficiency virus type 1 group m consensus env immunogen. J Virol 
80:6745-56. 
355. Welker, R., M. Harris, B. Cardel, and H. G. Krausslich. 1998. Virion 
incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite 
membrane-targeting signal: analysis of its role in enhancement of viral infectivity. J 
Virol 72:8833-40. 
356. Wiegers, K., G. Rutter, H. Kottler, U. Tessmer, H. Hohenberg, and H. G. 
Krausslich. 1998. Sequential steps in human immunodeficiency virus particle 
maturation revealed by alterations of individual Gag polyprotein cleavage sites. J 
Virol 72:2846-54. 
357. Williams, F., A. Meenagh, C. Darke, A. Acosta, A. S. Daar, C. Gorodezky, M. 
Hammond, E. Nascimento, and D. Middleton. 2001. Analysis of the distribution of 
HLA-B alleles in populations from five continents. Hum Immunol 62:645-50. 
358. Williamson, C., L. Morris, M. F. Maughan, L. H. Ping, S. A. Dryga, R. Thomas, 
E. A. Reap, T. Cilliers, J. van Harmelen, A. Pascual, G. Ramjee, G. Gray, R. 
Johnston, S. A. Karim, and R. Swanstrom. 2003. Characterization and selection of 
HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum 
Retroviruses 19:133-44. 
359. Wills, J. W., and R. C. Craven. 1991. Form, function, and use of retroviral gag 
proteins. AIDS 5:639-54. 
360. Wolinsky, S. M., K. J. Kunstman, J. T. Safrit, R. A. Koup, A. U. Neumann, and 
B. T. Korber. 1996. Response: HIV-1 Evolution and Disease Progression. Science 
274:1010-1. 
361. Woo, J., D. L. Robertson, and S. C. Lovell. 2010. Constraints on HIV-1 diversity 
from protein structure. J Virol 84:12995-3003. 
362. Xiang, J., H. Huang, and Y. Liu. 2005. A new dynamic model of CD8+ T effector 
cell responses via CD4+ T helper-antigen-presenting cells. J Immunol 174:7497-505. 
363. Yang, O. O. 2009. Candidate vaccine sequences to represent intra- and inter-clade 
HIV-1 variation. PLoS One 4:e7388. 
364. Yang, O. O., P. T. Sarkis, A. Trocha, S. A. Kalams, R. P. Johnson, and B. D. 
Walker. 2003. Impacts of avidity and specificity on the antiviral efficiency of HIV-1-
specific CTL. J Immunol 171:3718-24. 
365. Yang, Y., J. Huang, I. Toth, M. Lichterfeld, and X. G. Yu. 2010. Mutational 
escape in HIV-1 CTL epitopes leads to increased binding to inhibitory 
myelomonocytic MHC class I receptors. PLoS One 5:e15084. 
366. Yant, L. J., T. C. Friedrich, R. C. Johnson, G. E. May, N. J. Maness, A. M. Enz, 
J. D. Lifson, D. H. O'Connor, M. Carrington, and D. I. Watkins. 2006. The high-















with control of simian immunodeficiency virus SIVmac239 replication. J Virol 
80:5074-7. 
367. Yoo, S., D. G. Myszka, C. Yeh, M. McMurray, C. P. Hill, and W. I. Sundquist. 
1997. Molecular recognition in the HIV-1 capsid/cyclophilin A complex. J Mol Biol 
269:780-95. 
368. Younes, S. A., B. Yassine-Diab, A. R. Dumont, M. R. Boulassel, Z. Grossman, J. 
P. Routy, and R. P. Sekaly. 2003. HIV-1 viremia prevents the establishment of 
interleukin 2-producing HIV-specific memory CD4+ T cells endowed with 
proliferative capacity. J Exp Med 198:1909-22. 
369. Yu, G., and R. L. Felsted. 1992. Effect of myristoylation on p27 nef subcellular 
distribution and suppression of HIV-LTR transcription. Virology 187:46-55. 
370. Yu, Q., R. Konig, S. Pillai, K. Chiles, M. Kearney, S. Palmer, D. Richman, J. M. 
Coffin, and N. R. Landau. 2004. Single-strand specificity of APOBEC3G accounts 
for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11:435-42. 
371. Yu, X. F., Z. Matsuda, Q. C. Yu, T. H. Lee, and M. Essex. 1995. Role of the C 
terminus Gag protein in human immunodeficiency virus type 1 virion assembly and 
maturation. J Gen Virol 76 ( Pt 12):3171-9. 
372. Yu, X. G., M. Lichterfeld, B. Perkins, E. K life, S. Mui, J. Chen, M. Cheng, W. 
Kang, G. Alter, C. Brander, B. D. Walker, and M. Altfeld. 2005. High degree of 
inter-clade cross-reactivity of HIV-1-specific T cell responses at the single peptide 
level. AIDS 19:1449-56. 
373. Zhao, S., S. Zhai, Y. Zhuang, S. Wang, D. Huang, W. Kang, X. Li, X. G. Yu, B. 
D. Walker, M. A. Altfeld, and Y. Sun. 2007. Inter-clade cross-reactivity of HIV-1-
specific T cell responses in human immunodeficiency virus type 1 infection in China. 
Curr HIV Res 5:251-9. 
374. Zuniga, R., A. Lucchetti, P. Galvan, S. Sanchez, C. Sanchez, A. Hernandez, H. 
Sanchez, N. Frahm, C. H. Linde, H. S. Hewitt, W. Hildebrand, M. Altfeld, T. M. 
Allen, B. D. Walker, B. T. Korber, T. Leitner, J. Sanchez, and C. Brander. 2006. 
Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with 
human immunodeficiency virus control. J Virol 80:3122-5. 
375. Zydowsky, L. D., F. A. Etzkorn, H. Y. Chang, S. B. Ferguson, L. A. Stolz, S. I. 
Ho, and C. T. Walsh. 1992. Active site mutants of human cyclophilin A separate 
peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin 
























UNAIDS epidemic update 
www.unaids.org 
Accessed 10 January 2012 
 
















Accesses 07 February 2012 
 
AIDS Vaccine 2011 Conference, Bangkok, Thianland; 12-15 September 2011 
http://www.hivvaccineenterprise.org/conference/2011/detailed-program 























Table A1. Amino acid codes 
 
Amino Acid 3-Letter Code IUB Code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cystine Cys C 
Glutamine Gln Q 
Glutamic acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenyalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 


























Table A2. Amino acids and the genetic code 
 
3-letter code Unambiguous codons IUB codons 
Ala GCT, GCC, GCA, GCG GCX 
Asp, Asn GAT, GAC, AAT, AAC RAY 
Cys TGT, TGC TGY 
Asp GAT, GAC GAY 
Glu GAA, GAG GAR 
Phe TTT, TTC TTY 
Gly GGT, GGC, GGA, GGG GGX 
His CAT, CAC CAY 
Ile ATT, ATC, ATA ATH 
Lys AAA, AAG AAR 
Leu TTG, TTA, 
CTT, CTC, CTA, CTG 
TTR 
CTX 
Met ATG ATG 
Asn AAT, AAC AAY 
Pro CCT, CCC, CCA, CCG CCX 
Gln CAA, CAG CAR 








Thr ACT, ACC, ACA, ACG ACX 
Val GTT, GTC, GTA, GTG GTX 
Trp TGG TGG 
XXX  XXX 
Tyr TAT, TAC TAY 
Glu, Gln GAA, GAG, CAA, CAG SAR 





The table shows the 20 amino acids that are found in proteins. The single and three-letter code used to represent 
these amino acids are also listed along with the 64 possible three-letter combinations of the DNA coding units 
namely T (Thymine), C (Cytosine), A (Adenine) and G (Guanine), used either to encode one of these amino 
acids or as a stop codon that signals the end of a protein. This is the information incorporated into sequence 
analysis programs used to translate viral DNA sequences into protein sequences for analyses together with 


















Appendix B. PCR and cycling conditions 
 
These conditions apply for study individuals whose data is reported in Chapter 3 for gag and 
nef sequencing. PCR conditions for study participants in Chapter 2 have already been 
reported in MSc Thesis (2007). However, the conditions are similar except that for Chapter 2 
participants, only full-length gag amplification was performed while in the following 
conditions, both gag and nef genes were amplified. In addition, different primers for gag gene 
were used that amplified the whole of the gag gene continuously while previously, the gag 
gene was amplified in three fragments A, B and C (MSc Thesis, 2007). The sequences of the 
primers for Gag and Nef amplification are shown in Table B. 
 
 
Table B1. Gag and Nef primer sequences 
 
Primer Sequence HXB2 position 
Gag D Reverse 5′-AAT TCC TCC TAT CAT TTT TGG-3′  2382 - 2402 
Gag D Forward 5′-TCT CTA GCA GTG GCG CCC G-3′  626 - 644 
Gag A Forward 5′-CTC TCG ACG CAG GAC TCG GCT T-3′  683 - 704 
Gag C Reverse 5′-TCT TCT AAT ACT GTA TCA TCT GC-3  2334 - 2356 
   
Nef O Reverse 5′-AGG CAA GCT TTA TTG AGG-3′  9608 - 9625 
Nef SQ15FC 5′-GAG AGC GGT GGA ACT TCT-3  8561 - 8578 
Nef Forward 5′-CCT AGA AGA ATA AGA CAG GGC TT-3  8754 - 8776 
Nef Reverse 5′-CCT GGA ACG CCC CAG TGG-3′  9443 - 9461 
 
 
Appendix B1. HIV-1 gag PCR and cycling conditions 
 
Table B1.1. HIV-1 gag cDNA synthesis 
 
Reagent Volume (μl) 





















Table B1.2. HIV-1 gag RT PCR 
Reagent Volume (μl) 
H2O 0.7 
Buffer (X5) 4.0 
MgCl2 4.8 
dNTPs (10mM) 1.0 
RNasin (40U/μl) 0.5 
RT Enzyme (15U/μl) 1.0 
Total 12 
 
Table B1.3. HIV-1 gag first round PCR 
Reagent Volume (μl) 
H2O 37.25 
Buffer (10X) + MgCl2 (15mM) 5.0 
dNTPs (10mM each) 1.0 
Primer Gag D Reverse (10 pmoles/μl) 1.0 
Primer Gag D Forward (10 pmoles/μl) 1.0 




Table B1.4. HIV-1 gag first round PCR cycling conditions 
 10 cycles 15 cycles   
95
0
C (2 min) 
95
0
C (15 sec) 
52
0
C (30 sec) 
72
0
C (1 min) 
95
0
C (15 sec) 
55
0
C (30 sec) 
72
0
C (1.5 min) 
72
0




Table B1.5. HIV-1 gag second round PCR 
Reagent Volume (μl) 
H2O 37.25 
Buffer (10X) + MgCl2 (15mM) 5.0 
dNTPs (10mM each) 1.0 
Primer Gag A Forward (10 pmoles/μl) 1.0 
Primer Gag C Reverse (10 pmoles/μl) 1.0 




Table B1.6. HIV-1 gag second round PCR cycling conditions 
 10 cycles 15 cycles   
95
0
C (2 min) 
95
0
C (15 sec) 
52
0
C (30 sec) 
72
0
C (1 min) 
95
0
C (15 sec) 
55
0
C (30 sec) 
72
0
C (1. min) 
72
0




















Appendix B2. HIV-1 nef PCR and cycling conditions 
 
Table B2.1. HIV-1 nef cDNA synthesis 
 
Reagent Volume (μl) 




Table B2.2. HIV-1 nef RT PCR 
Reagent Volume (μl) 
H2O 0.7 
Buffer (X5) 4.0 
MgCl2 4.8 
dNTPs (10mM) 1.0 
RNasin (40U/μl) 0.5 
RT Enzyme (15U/μl) 1.0 
Total 12 
 
Table B2.3. HIV-1 nef first round PCR 
Reagent Volume (μl) 
H2O 37.25 
Buffer (10X) + MgCl2 (15mM) 5.0 
dNTPs (10mM each) 1.0 
Primer Nef SQ15FC or E200 (10 pmoles/μl) 1.0 
Primer Nef OR (10 pmoles/μl) 1.0 




Table B2.4. HIV-1 nef first round PCR cycling conditions 
 10 cycles 15 cycles   
95
0
C (2 min) 
95
0
C (15 sec) 
53
0
C (30 sec) 
72
0
C (45 sec) 
95
0
C (15 sec) 
55
0
C (30 sec) 
72
0
C (1 min) 
72
0




Table B2.5. HIV-1 nef second round PCR 
Reagent Volume (μl) 
H2O 37.25 
Buffer (10X) + MgCl2 (15mM) 5.0 
dNTPs (10mM each) 1.0 
Primer Nef Forward (10 pmoles/μl) 1.0 
Primer Nef Reverse (10 pmoles/μl) 1.0 


















Table B2.6. HIV-1 nef second round PCR cycling conditions 
 35 cycles   
95
0
C (2 min) 
95
0
C (15 sec) 
55
0
C (30 sec) 
72
0
C (1 min) 
72
0





Appendix B3. Sequence analyses 
 
HIV-1 clade classification (subtyping) of infecting viral sequences  
 
Infecting viral HIV-1 full-length gag sequences were aligned together with reference 
sequences from the Los Alamos HIBV sequence database using BioEdit sequence alignment 
editor and phylogenetic relatedness inferred using the Neighbor-J ining method, Kimura 2-
parameter model with 1000 botstraps test of phylogeny as described in MSc Thesis, Lycias 
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Figure B3.1. Phylogenetic relationships between 
gag nucleotide sequences from South African 
HIV-1-infected individuals and representative 
viral strains from groups M, N, O and CRFs. 
The tree was drawn using the Neighbor-Joining 
method. Study sequences (N=40) are shown with 
red filled circles. Branch nodes supported by 
bootstrap values above 75% (percentage of 1000 
resamplings) are indicated at branch nodes as well 
as red arcs for isolate sequences. All subtype C 
sequences are indicated with a blue brace. 
Chimpanzee SIV gag sequence was used as an out-
















Genetic relatedness of infecting viral sequences and ELISpot peptide reagents 
 
 























Figure B3.2.  Amino Acid distances between study subject sequences and ELISpot peptide reagents. 




 (median), 75th percent quartiles and maximum values for 
each peptide set. The line in the box represents the median or 50
th
 percentile. The p value is from the non-





B4: Recombination analysis 
 
Each of the study participants‟ full length gag sequence was analyzed for recombination 
using REGA version 6.4.1, a software program which compares each nucleotide position to 
other HIV-1 pure subtype and CRF reference sequences to determine whether there is 
sufficient phylogenetic signal to classify the sequence as a pure subtype of CRF, recombinant 
















































Figure B4.1. Recombination analysis of isolate sequences using REGA. The red dotted lines represent 70% 
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Appendix C. Mosaic analysis for each peptide reagent 
 
The Mosaic Vaccine Tool 
 
This is a set of on-line tools that can be used to design candidate vaccine immunogen 
sequences as well as assessing their ability as antigens using coverage of short fragments, k-
mers (9-12 amino acids) as potential epitopes (Fischer et al., 2007). The tool is a suite made 
up of three separate tools namely, the Mosaic Vaccine Designer Tool, The Vaccine Epitope 
Coverage Tool (Epicover) and the Positional Epitope Coverage Tool (Posicover). The 
vaccine designer tool uses a computer algorithm mimicking recombination events in natural 
viral infection in a series of iterations chosen by the user to design mosaic sequences with the 
best coverage of the test set sequences (Fischer et al., 2007; Thurmond et al., 2008). The two 
tools, Epicover and Posicover are assessment tools that compute h w well a suggested set of 
peptides covers potential epitopes in a test set of natural sequences (Thurmond et al., 2008). 
The suggested set of peptides can be from the mosaic vaccine designer tool or any other 
vaccine candidate peptides for assessing T-cell responses in assays. 
 
Epicover calculates the average coverage of the test-set population by antigen-set of k-mers 
while Posicover provides detailed positional coverage information relative to a test-set 
alignment. Studies of T-cell recognition of viral peptides have shown that some peptides are 
recognized even if they have amino acid mismatches with the optimally defined epitope. 
Therefore, the tool also computes coverage based on exact matches of epitopes as well as 
those mismatching by 1 or 2 amino acids. Both tools provide graphical outputs and allow 
detailed user control for example epitope length to use (which is 9-mers by default) and the 
number of antigen sets to use for computing. In Figures C1 to Figure C5, graphical 
representations of Posicover results for individual peptide reagent (CDu422, CCH, A, B and D) 




















Figure C1. Positional epitope coverage (Posicover) of infecting viral sequences by HIV-1 clade A peptide 
reagent sequence. (A) Coverage by position in the alignment of the Gag protein (p17p24p2). (B) Coverage 
ranked. (C) Matched 9-mer epitopes and missed 9-mer epitopes coverage by natural position in the alignment. 
(D) Matched 9-mers epitopes ranked by coverage. (E) Missed 9-mers epitopes coverage by natural position 
along the Gag alignment. (F) Missed 9-mers by natural position in along the Gag alignment. (G) Missed 9-mers 

















Figure C2. Positional epitope coverage (Posicover) of infecting viral sequences by HIV-1 clade B peptide 
reagent sequence. (A) Coverage by position in the alignment of the Gag protein (p17p24p2). (B) Coverage 
ranked. (C) Matched 9-mer epitopes and missed 9-mer epitopes coverage by natural position in the alignment. 
(D) Matched 9-mers epitopes ranked by coverage. (E) Missed 9-mers epitopes coverage by natural position 
along the Gag alignment. (F) Missed 9-mers by natural position in along the Gag alignment. (G) Missed 9-mers 
















Figure C3. Positional epitope coverage (Posicover) of infecting viral sequences by HIV-1 clade C (CDu422, 
South African) peptide reagent sequence. (A) Coverage by position in the alignment of the Gag protein 
(p17p24p2). (B) Coverage ranked. (C) Matched 9-mer epitopes and missed 9-mer epitopes coverage by natural 
position in the alignment. (D) Matched 9-mers epitopes ranked by coverage. (E) Missed 9-mers epitopes 
coverage by natural position along the Gag alignment. (F) Missed 9-mers by natural position in along the Gag 
















Figure C4. Positional epitope coverage (Posicover) of infecting viral sequences by HIV-1 clade C (CCH, 
Chinese) peptide reagent sequence. (A) Coverage by position in the alignment of the Gag protein (p17p24p2). 
(B) Coverage ranked. (C) Matched 9-mer epitopes and missed 9-mer epitopes coverage by natural position in 
the alignment. (D) Matched 9-mers epitopes ranked by coverage. (E) Missed 9-mers epitopes coverage by 
natural position along the Gag alignment. (F) Missed 9-mers by natural position in along the Gag alignment. (G) 

















Figure C5. Positional epitope coverage (Posicover) of infecting viral sequences by HIV-1 clade D peptide 
reagent sequence. (A) Coverage by position in the alignment of the Gag protein (p17p24p2). (B) Coverage 
ranked. (C) Matched 9-mer epitopes and missed 9-mer epitopes coverage by natural position in the alignment. 
(D) Matched 9-mers epitopes ranked by coverage. (E) Missed 9-mers epitopes coverage by natural position 
along the Gag alignment. (F) Missed 9-mers by natural position in along the Gag alignment. (G) Missed 9-mers 
















Appendix D1. ELISpot layout, quality assurance and test acceptance criteria 
 
Peptide sets 
The peptide sets used in the cross-clade study belong to Gag subtype A, Gag subtype D, Gag 
subtype B, Gag C Du422 (South African subtype C) and Gag subtype C China. A pool and 
matrix approach was used in which five pools were made up for each of the five peptide 
variants (Table D1.1) and twenty-four matrices were designed to include all the single Gag 
peptides, which make up the five different peptide variants (Table D1.2).  The consensus Gag 
B peptides were available as 1mg lyophilized peptides while as the other four peptide-
variants were supplied at 500µg/peptide. Single peptides from the five clades were 
reconstituted to 10 µl aliquots of 10mg/ml stocks and then further reconstituted to 30µg/ml 
and stored at -80
0
C. The peptides were used at a final concentration of 1.5µg/ml in the 
ELISpot assay. Peptides were confirmed by another IFN-γ ELISpot assay using single 
peptides to identify specific epitope stretches. 
 
CEF peptide pool and PHA were used as positive controls on all tested PBMCs. The CEF 
peptide pool constituted a panel of 32 8-11-mer CMV, EBV and Flu virus peptide epitopes 
recognized by CD8
+
 T cells. The pool was reconstituted at 20µg/ml in 90% PBS/10% DMSO 






The ELISpot assays were conducted for screening of peptide responses using a panel of 
peptide described in C1 and C2. PBMC from NICD blood donor (QC sample-NICD 063) was 
used as a positive control sample for each plate. The QC sample had been tested against PHA 
and CEF and was a known responder and therefore used as a positive control. Participants‟ 
PBMCs were thawed as described in Chapter 2 and tested in duplicate against each Gag 
peptide pool, once against each Gag matrix and twice against CEF and PHA (plate layout in 
Table D1.3). Eight negative control wells, four positive control wells and four peptide control 
















The negative control wells consisted of six unstimulated PBMC and two unstimulated wells 
for the QC sample per plate. Each plate also had six wells containing R10 (media only). 
Positive control wells consisted of two PHA stimulated PBMC and two PHA stimulated 
wells for the QC sample per plate. The control wells consisted of two CEF stimulated PBMC 
and two CEF stimulated QC sample on each plate. Peptide confirmations were performed for 
those peptides that gave a positive response after the screening ELISpot assays. 
 
Test acceptance criteria 
 
A test was regarded as positive when the response was >100 SFU/10
6
 PBMC and at least 3 
times the mean background response. The positive response in the pool was supposed to 
match a response in a matrix pool that shares one of the peptides in the pool. Fail criteria for 
the ELISpot assay included any one or more of the following: 
 Greater than 100 spots in the negative control wells 
 Grater than 5 spots per well for the wells containing media only 




An ELISpot worksheet (Table D1.3) was completed with each assay performed. The plates 
were read by the CTL Immunospot Analyzer and data saved on CD plates. All completed 
worksheets and ELISpot raw data and calculated data were archived. 
 





 Pool 1 Pool 2 Pool 3 Pool 4 Pool 5 
Gag C1 Du422 1-24 25-48 49-72 73-96 97-120 
Gag C2 China 1-24 25-48 49-72 73-96 97-119 
Gag B 1-24 25-48 49-72 73-96 97-123 















 Table D1.2. Gag matrices 
 
M1 M2 M3 M4 M5 M6 M7 M8 
Gag C1-1 Gag C1-2 Gag C1-3 Gag C1-4 Gag C1-5 Gag C1-6 Gag C1-7 Gag C1-8 
Gag C1-25 Gag C1-26 Gag C1-27 Gag C1-28 Gag C1-29 Gag C1-30 Gag C1-31 Gag C1-32 
Gag C1-49 Gag C1-50 Gag C1-51 Gag C1-52 Gag C1-53 Gag C1-54 Gag C1-55 Gag C1-56 
Gag C1-73 Gag C1-74 Gag C1-75 Gag C1-76 Gag C1-77 Gag C1-78 Gag C1-79 Gag C1-80 
Gag C1-97 Gag C1-98 Gag C1-99 Gag C1-100 Gag C1-101 Gag C1-102 Gag C1-103 Gag C1-104 
Gag C2-1 Gag C2-2 Gag C2-3 Gag C2-4 Gag C2/C1-5 Gag C2/C1-6 Gag C2-7 Gag C2-8 
Gag C2-25 Gag C2-26 Gag C2-27 Gag C2-28 Gag C2-29 Gag C2-30 Gag C2-31 Gag C2/C1-32 
Gag C2/C1-49 Gag C2-50 Gag C2-51 Gag C2-52 Gag C2-53 Gag C2/C1-54 Gag C2/C1-55 Gag C2/C1-56 
Gag C2/C1-73 Gag C2-74 Gag C2-75 Gag C2-76 Gag C2-77 Gag C2/C1-78 Gag C2/C1-79 Gag C2/C1-80 
Gag C2/C1-97 Gag C2/C1-98 Gag C2/C1-99 Gag C2/C1-100/B-102 Gag C2/C1-101/B-103 Gag C2/C1-102/B-104 Gag C2/C1-103/B105 Gag C2/C1-104/B106 
Gag B-2 Gag B-3 Gag B-4 Gag B-5 Gag B-6 Gag B-7 Gag B-8 Gag B-9 
Gag B-26 Gag B-27 Gag B-28 Gag B-29 Gag B-30 Gag B-31 Gag B-32 Gag B-33 
Gag B-50 Gag B-51 Gag B-52 Gag B-53 Gag B-54 Gag B-55 Gag B-56 Gag B-57 
Gag B-74 Gag B-75 Gag B-76 Gag B-77 Gag B-78 Gag B-79 Gag B-80 Gag B-81 
Gag B-99 Gag B-100 Gag B-101 Gag B-102/C1/C2-100 Gag B-103/C1/C2-101 Gag B-104/C1/C2-102 Gag B-105/C1/C2-103 Gag B-106/C1/C2-104 
Gag B123 Gag B-95       
Gag A-17/C1/C2-49 Gag A-18/C1-50 Gag A-19/C1-51 Gag A-20 Gag A-21 Gag A-22 Gag A-23 Gag A-24/C1/C2-56 
Gag A-41/C1/C2-73 Gag A-42/C1-74 Gag A-43/C1-75 Gag A-44 Gag A-45 Gag A-46 Gag A-47 Gag A-48 
Gag A-65 Gag A-66 Gag A-67 Gag A-68 Gag A-69 Gag A-70 Gag A-71 Gag A-72 
Gag A-89 Gag A-90       
Gag D-17 Gag D-18 Gag D/A-19/C1-51 Gag D-20 Gag D-21 Gag D-22 Gag D-23 Gag D/A-24/C1/C2-56 
Gag D-41 Gag D-42 Gag D-43 Gag D-44 Gag D-45 Gag D/A-46 Gag D-47 Gag D-48 
Gag D/A-65 Gag D/A-66 Gag D/A-67      
Gag D-83 Gag D-84 Gag D-85 Gag D-86 Gag D-87 Gag D-88 Gag D-89 Gag D-90 

















Table D1.2. continued 
 
 M10 M11 M12 M13 M14 M15 M16 
Gag C1-9 Gag C1-10 Gag C1-11 Gag C1-12 Gag C1-13 Gag C1-14 Gag C1-15 Gag C1-16 
Gag C1-33 Gag C1-34 Gag C1-35 Gag C1-36 Gag C1-37 Gag C1-38 Gag C1-39 Gag C1-40 
Gag C1-57 Gag C1-58 Gag C1-59 Gag C1-60 Gag C1-61 Gag C1-62 Gag C1-63 Gag C1-64 
Gag C1-81 Gag C1-82 Gag C1-83 Gag C1-84 Gag C1-85 Gag C1-86 Gag C1-87 Gag C1-88 
Gag C1-105 Gag C1-106 Gag C1-107 Gag C1-108 Gag C1-109 Gag C1-110 Gag C1-111 Gag C1-112 
Gag C2-9 Gag C2/C1-10 Gag C2/C1-11 Gag C2/C1-12 Gag C2-13 Gag C2-14 Gag C2-15 Gag C2-16 
Gag C2/C1-33/B-34 Gag C2/C1-34 Gag C2/C1-35 Gag C2/C1-36 Gag C2/C1-37 Gag C2/C1-38 Gag C2/C1-39 Gag C2/C1-40 
Gag C2/C1-57 Gag C2-58 Gag C2-59 Gag C2-60 Gag C2-61 Gag C2-62 Gag C2-63 Gag C2-64 
Gag C2/C1-81 Gag C2-82 Gag C2-83 Gag C2-84 Gag C2-85 Gag C2-86 Gag C2-87 Gag C2-88 
Gag C2/C1-105/B107 Gag C2/C1-106/B108 Gag C2/C1-107/B109 Gag C2-108 Gag C2-109 Gag C2-110 Gag C2-111 Gag C2/C1-112 
Gag B-10 Gag B-11 Gag B-12 Gag B-13 Gag B-14 Gag B-15 Gag B-16 Gag B-17 
Gag B-34/C1/C2-33 Gag B-35 Gag B-36 Gag B-37 Gag B-38 Gag B-39 Gag B-40 Gag B-41 
Gag B-58 Gag B-59 Gag B-60 Gag B-61 Gag B-62 Gag B-63 Gag B-64 Gag B-65 
Gag B-82 Gag B-83 Gag B-84 Gag B-85 Gag B-86 Gag B-87 Gag B-88 Gag B-89 
Gag B-107/C1/C2-105 Gag B-108/C1/C2-106 Gag B-109/C1/C2-107 Gag B-110/C2-108 Gag B-111/C2-109 Gag B-112/C2-110 Gag B-113 Gag B-114 
Gag A-1 Gag A-2 Gag A-3 Gag A-4 Gag A-5/C1/C2-37 Gag A-6/C1/C2-38 Gag A-7/C1/C2-39 Gag A-8 
Gag A-25/C1/C2-57 Gag A-26 Gag A-27 Gag A-28 Gag A-29 Gag A-30/C1-62 Gag A-31/C1-63 Gag A-32/C1-64 
Gag A-49 Gag A-50 Gag A-51/C1-83 Gag A-52/C1-84 Gag A-53/C1-85 Gag A-54/C1-86 Gag A-55 Gag A-56 
Gag A-73 Gag A-74 Gag A-75 Gag A-76 Gag A-77 Gag A-78 Gag A-79 Gag A-80 
Gag D-1/C1/C2-33 Gag D-2/C1/C2-34 Gag D-3/C1/C2-35 Gag D-4/C1/C2-36 Gag D/A-5/C1/C2-37 Gag D/A-6/C1/C2-38 Gag D/A-7/C1/C2-39 Gag D/A-8 
Gag D/A-25/C1/C2-57 Gag D-26/C1-58 Gag D-27/C1-59 Gag D-28/C1-60 Gag D-29 Gag D-30 Gag D-31 Gag D-32/C2-64 
Gag D-49 Gag D-50 Gag D-51 Gag D-52 Gag D/A-53/C1-85 Gag D-54/C2-86 Gag D-55/C2-87 Gag D-56/C2-88 
 Gag D-68/C1-10 Gag D-69/C1-11 Gag D-70/C1-12 Gag D-71 Gag D-72 Gag D-73 Gag D-74 
        

















Table D1.2. continued 
 
M17 M18 M19 M20 M21 M22 M23 M24 
Gag C1-17 Gag C1-18 Gag C1-19 Gag C1-20 Gag C1-21 Gag C1-22 Gag C1-23 Gag C1-24 
Gag C1-41 Gag C1-42 Gag C1-43 Gag C1-44 Gag C1-45 Gag C1-46 Gag C1-47 Gag C1-48 
Gag C1-65 Gag C1-66 Gag C1-67 Gag C1-68 Gag C1-69 Gag C1-70 Gag C1-71 Gag C1-72 
Gag C1-89 Gag C1-90 Gag C1-91 Gag C1-92 Gag C1-93 Gag C1-94 Gag C1-95 Gag C1-96 
Gag C1-113 Gag C1-114 Gag C1-115 Gag C1-116 Gag C1-117 Gag C1-118 Gag C1-119 Gag C1-120 
Gag C2-17 Gag C2-18 Gag C2-19 Gag C2-20 Gag C2-21 Gag C2-22 Gag C2-23 Gag C2-24 
Gag C2/C1-41 Gag C2/C1-42 Gag C2/C1-43 Gag C2/C1-44 Gag C2/C1-45 Gag C2/C1-46 Gag C2/C1-47 Gag C2/C1-48 
Gag C2/C1-65 Gag C2/C1-66 Gag C2/C1-67 Gag C2-68 Gag C2-69 Gag C2-70 Gag C2-71 Gag C2/C1-72 
Gag C2-89 Gag C2-90 Gag C2-91 Gag C2-92 Gag C2-93 Gag C2-94 Gag C2-95 Gag C2/C1-96 
Gag C2/C1-113 Gag C2/C1-114 Gag C2-115 Gag C2-116 Gag C2-117 Gag C2-118 Gag C2-119 Gag B-1 
Gag B-18 Gag B-19 Gag B-20 Gag B-21 Gag B-22 Gag B-23 Gag B-24 Gag B-25 
Gag B-42 Gag B-43 Gag B-44 Gag B-45 Gag B-46 Gag B-47 Gag B-48 Gag B-49 
Gag B-66 Gag B-67 Gag B-68 Gag B-69 Gag B-70 Gag B-71 Gag B-72 Gag B-73 
Gag B-90 Gag B-91 Gag B-92 Gag B-93 Gag B-94 Gag B-96 Gag B-97 Gag B-98 
Gag B-115 Gag B-116 Gag B-117 Gag B-118 Gag B-119 Gag B-120 Gag B-121 Gag B-122 
Gag A-9 Gag A-10 Gag A-11 Gag A-12 Gag A-13 Gag A-14 Gag A-15 Gag A-16/C1/C2-48 
Gag A-33/C1/C2-65 Gag A-34/C1/C2-66 Gag A-35/C1/C2-67 Gag A-36/C1-68 Gag A-37/C1-69 Gag A-38/C1-70 Gag A-39/C1-71 Gag A-40/C1/C2-72 
Gag A-57 Gag A-58 Gag A-59 Gag A-60 Gag A-61 Gag A-62 Gag A-63 Gag A-64 
Gag A-81 Gag A-82 Gag A-83 Gag A-84 Gag A-85 Gag A-86 Gag A-87 Gag A-88 
Gag D/A-9 Gag D/A-10 Gag D-11/C1/C2-43 Gag D-12/C1/C2-44 Gag D-13/C1/C2-45 Gag D-14/C1/C2-46 Gag D-15 Gag D-16 
Gag D/A-33/C1/C2-65 Gag D/A-34/C1/C2-66 Gag D/A-35/C1/C2-67 Gag D/A-36/C1-68 Gag D/A-37/C1-69 Gag D/A-38/C1-70 Gag D/A-39/C1-71 Gag D-40 
Gag D-57 Gag D-58 Gag D/A-59 Gag D/A-60 Gag D/A-61 Gag D/A-62 Gag D/A-63 Gag D/A-64 
Gag D-75 Gag D-76 Gag D-77 Gag D-78 Gag D-79 Gag D-80 Gag D-81 Gag D-82 
        
17 17 17 18 18 18 19 17 
 
 
Common peptides between C1 (Du422) and C2 (Chinese) 
No peptide 















Table D1.3. ELISpot screening plate layout 
 
 
This table shows the ELISpot layout utilized for those individuals screened for HIV-1-specific T-cell responses to five HIV gag peptide reagents simultaneously, that is 
matched data was available for these peptide reagents in the individuals screened using this layout. Also, the data for responses to clade CDu422 peptide reagent was 

















Appendix D2. ELISpot assay layout and acceptance criteria 
 
The pooled peptides were arranged in 12 Gag pools, five Nef pools and 12 Matrix pools. Peptide pools 
were tested in duplicate (except for individuals screened for both consensus group M and clade CDu422 
Gag and Nef HIV-specific T-cell responses that were performed in single wells) and matrices in single 
wells (see ELISpot plate layout worksheet, Table D2.4).  
 
Stocks of peptide pools (40μg/ml, 25μl aliquots) were made from 1mg of lyophilized peptides. For 
matrix pools stocks, 135μl of R10 (RPMI with 10% FCS) was added to each aliquot, and for Gag and 
Nef peptide pools, 225μl of R10 was added per tube. 
 
The CEF peptide pool was used as a positive control as in previous assays (Appendix D1) for each 
sample plated as well as for testing of the QC (a known CEF responder) sample on each plate. These 
peptide pools consist of a panel of 32 8-11 mers CMV, EBV and Flu virus CD8+ T-cell epitopes. The 
60μl aliquots of these peptides were provided at 20μg/ml and were used at a final concentration of 
















Table D2.1. Peptide for different Pools 
 
1 2 3 4 5 6 7 8 9 10 11 12 
Gag 1−12 13−24 25−33 34−45 46−57 58−69 70−81 82−93 94−95 96−107 108−119 120−129 
             
Nef 1−12 13−24 25−36 37−48 49−53 
       
 
 
Table D2.2. Peptide Pool and Matrix configuration 
 
 
Matrix 1 Matrix 2 Matrix 3 Matrix 4 Matrix 5 Matrix 6 Matrix 7 Matrix 8 Matrix 9 Matrix 10 matrix 11 Matrix 12 
Gag Pool 1 Gag 1 Gag 2 Gag 3 Gag 4 Gag 5 Gag 6 Gag 7 Gag 8 Gag 9 Gag 10 Gag 11 Gag 12 
Gag Pool 2 Gag 13 Gag 14 Gag 15 Gag 16 Gag 17 Gag 18 Gag 19 Gag 20 Gag 21 Gag 22 Gag 23 Gag 24 
Gag Pool 3 Gag 25 Gag 26 Gag 27 Gag 28 Gag 29 Gag 30 Gag 31 Gag 32 Gag 33 
   
Gag Pool 4 Gag 34 Gag 35 Gag 36 Gag 37 Gag 38 Gag 39 Gag 40 Gag 41 Gag 42 Gag 43 Gag 44 Gag 45 
Gag Pool 5 Gag 46 Gag 47 Gag 48 Gag 49 Gag 50 Gag 51 Gag 52 Gag 53 Gag 54 Gag 55 Gag 56 Gag 57 
Gag Pool 6 Gag 58 Gag 59 Gag 60 Gag 61 Gag 62 Gag 63 Gag 64 Gag 65 Gag 66 Gag 67 Gag 68 Gag 69 
Gag Pool 7 Gag 70 Gag 71 Gag 72 Gag 73 Gag 74 Gag 75 Gag 76 Gag 77 Gag 78 Gag 79 Gag 80 Gag 81 
Gag Pool 8 Gag 82 Gag 83 Gag 84 Gag 85 Gag 86 Gag 87 Gag 88 Gag 89 Gag 90 Gag 91 Gag 92 Gag 93 
Gag Pool 9 Gag 94 Gag 95 
          
Gag Pool 10 Gag 96 Gag 97 Gag 98 Gag 99 Gag 100 Gag 101 Gag 102 Gag 103 Gag 104 Gag 105 Gag 106 Gag 107 
Gag Pool 11 Gag 108 Gag 109 Gag 110 Gag 111 Gag 112 Gag 113 Gag 114 Gag 115 Gag 116 Gag 117 Gag 118 Gag 119 




Nef Pool 1 Nef 1 Nef 2 Nef 3 Nef 4 Nef 5 Nef 6 Nef 7 Nef 8 Nef 9 Nef 10 Nef 11 Nef 12 
Nef Pool 2 Nef 13 Nef 14 Nef 15 Nef 16 Nef 17 Nef 18 Nef 19 Nef 20 Nef 21 Nef 22 Nef 23 Nef 24 
Nef Pool 3 Nef 25 Nef 26 Nef 27 Nef 28 Nef 29 Nef 30 Nef 31 Nef 32 Nef 33 Nef 34 Nef 35 Nef 36 
Nef Pool 4 Nef 37 Nef 38 Nef 39 Nef 40 Nef 41 Nef 42 Nef 43 Nef 44 Nef 45 Nef 46 Nef 47 Nef 48 
Nef Pool 5 Nef 49 Nef 50 Nef 51 Nef 52 Nef 53 
















Table D2.3. ELISpot plate layout for unmatched data 
 
 
This table shows the ELISpot layout utilized for those individuals screened for consensus group M Gag and HIV-1-specific T-cell responses. Therefore information from 















Table D2.4. ELISpot plate layout for matched data 
 
 
This table shows the ELISpot layout utilized for those individuals screened for consensus group M and clade C HIV-1-specific T-cell responses simultaneously, that is 





























































Figure D3.1. Clical characteristics of study participants for matched and unmatched data. (A) CD4 count 
(cells/μl). (B) Viral load (copies/ml). Mann-Whitney test for unmatched differences between median was used at 

























Appendix D4. Peptide maps for peptides reactive in the study that were classified as 






Figure D4.1. Reactive peptide maps. (A) Peptide maps showing peptides identified as reactive in this study and 
had corresponding peptides/regions whose recognition was classified as beneficial in the Mothe et al (2011) study. 
(B) Peptides that were classified as beneficial peptides (protective ratio, PR>1) in Mothe et al (2011) study. 
Peptides with immd after the peptide number for example p24_p37immd denotes that the peptides was classified as 
immunodominant in this study and olp denotes overlapping with another peptide but with potential for more than 















Appendix E. Functional studies 
Appendix E1. Cytokine panel 
Table E1.1. Cytokine panel and antibodies. 
 
Marker Type and function Antibody Laser 
Viability marker    
Vivid Identification of live/dead cells CD14/CD19 Pac Blue  
    
CD4 T-cell marker FITC  
CD8 T-cell marker PerCP Cy5.5  
    
CD3 T-cell marker APC Cy7  
IFN-γ Cytokine Alexa Flour 700  
IL-2 Cytokine APC  
TNF-α Cytokine PE Cy7  
MIP-1β Chemokine PE  
 
Staining protocol 
1. Add 50μl PBS and spin at 2100 rpm at 40C for 3 minutes and plate blotted on paper 
towel for 1 second and add 150μl of PBS and spin at same speed for 3 minutes 
2. Add 50μl of Vivid, re-suspend and incubate in the DARK for 20 minutes 
3. Add 100μl of FACS wash and spin at 2100 rpm for 3 minutes 
4. Blot on paper towel for 1 second and add 150μl of FACS wash, re-suspend and spin at 
same speed for 3 minutes 
5. Add 50μl of Surface stain mix and re-suspend and incubate for 20 minutes in the DARK 
6. Add 100μl of FACS wash and spin at 2100 rpm for 3 minutes at 40C 
7. Blot on paper towel for 1 second and add 150μl of FACS wash, re-suspend and spin at 
same speed 
8. Add 100μl of Cytofix/Cytoperm, re-suspend and incubate in the DARK for 20 minutes 
9. Add 50μl of Perm Wash and spin at 2100 rpm for 3 minutes at 40C 
10. Blot on paper towel and add 150μl of Perm Wash, re-suspend and spin at same speed 
11. Add 50μl of Intracellular staining mix and incubate in the dark for 20 minutes 
12. Add 100μl of Perm wash and spin at 2100 rpm for 3 minutes at 40C 
13. Blot on paper towel and add 150μl of Perm wash, re-suspend and spin at same speed 
14. Blot on paper towel and add 150μl of Cell fix 

















Flow cytometry results layouts for each individual participant 
 
 




































































































































































































































Figure E1.1. Cytokine profile of CD8+ T-cells from study individual ZA023 after stimulation with peptide 





























































































































































































































































Figure E1.2. Cytokine profile of CD8+ T-cells from study individual ZA033 after stimulation with for peptide 






























































































































































































































































Figure E1.3 Cytokkine profile of CD8+ T-cells from study individual ZA006 after stimularion with peptide 






















































































































































































































































Figure E1.4. Cytokine profile of CD8+ T-cells from study individual ZA021 after stimulation with peptide 
























































































































































































































































Figure E1.5. Cytokine profile of CD8+ T-cells from study individual ZA028 after stimulation with peptide 























































































































































































































































































Figure E1.6. Cytokine profile of CD8+ T-cells from study individual ZA030 after stimulation with peptide 






























































































































































































































































IL-2 MIP-1B TNF-a  
Figure E1.7. Cytokine profile of CD8+ T-cels from study individual ZA029 after stimulation with peptide 


























Appendix E2. Cytotoxic panel 
 
Table E2.1. Cytotoxic panel and antibodies. 
 
Marker Type/function Antibody Laser 
Viability marker    
Vivid Identification of live/dead cells CD14/CD19 Pac Blue violet 
    
CD4 T-cell marker PE Cy7 blue 
CD8 T-cell marker PerCP Cy5.5 blue 
    
CD3 T-cell marker APC Cy7 red 
IFN-γ Cytokine Alexa Flour 700 red 
CD107a Degranulation marker FITC blue 
Perforin Cytotoxic molecule PE blue 





The same protocol for the cytokine panel (Appendix E1) was followed for the cytotoxic panel 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1. Required cells were calculated, approximately 200000 cells/well (four wells/antigen) and 
one extra unstimulated well for Oregon green compensation control. 
2. Fresh RPMI with Penicillin/Streptomycin (5mL) was used. 
3. RPMI with penicillin/streptomycin (200mL) was aliqouted and an aliquot of L-Glutamine 
and Fungin (2mL L-glutamine, 200µl Fungin) was added. This was used to make R10 
(RPMI with 10% FCS or RPMI with 10% Human AB serum). 
4. Cells were washed twice in PBS (no serum). 
5. Oregon Green was diluted 1:10 (add 18µl to a 2µl aliquot). 
6. Oregon Green (10l) was used for 1-10 x 106 cells (in 1mL). If more cells, it was increased 
proportionally. 
7. PBS (990l) was added to 10l of Oregon Green from step five above 
8. This was then added to 1ml of cells (cells resuspended in R10, RPMI with 10% FCS) and 
incubated at RT for 4 mins in the dark. 
9. The cells were mixed and incubated for another 3 mins afterwhich they were vortexed on 
high speed for 10sec. 
10. PBS (1mL) was added and incubated for 3 mins, and then topped up to 15mL with PBS. 
11. Cells were centgrifuged at 1200 rpm for 10 mins and resuspend in R10 (RPMI with 10% 
Human AB serum). 
12. Cells were resuspended such that approximately 200000 cells/well (4 wells/antigen) and one 
extra unstimulated well for Oregon green compensation tube could be plated into a 96-well 
U-bottomed sterile suspension culture plate. 
13. Cells (195µl) and Ag (5µl, final concentration 1ug/ml for each peptide variant). SEB was 
included as positive control and R10 (RPMI with 10% Human AB serum) as negative 
control). No BFA was added 
14. The cells were incubated for 6 days at 37ºC afterwhich wells for each stimulation were 
combined in facs tubes and wells washed to make sure no cells were left. 
15. This was centrifuged at 1800rpm for 5 min and resuspended in 500 µl R10. 
















Table E3.1. Proliferation assay panel and antibodies 
Marker Type/function Antibody Laser 
Vivid Identification of live/dead cells CD14/CD19 Pac Blue violet 
    
CD4 T-cell marker PE blue 
CD8 T-cell marker PerCP Cy5.5 blue 
    
CD3 T-cell marker APC Cy7 red 
Oregon Green Dye taken by diving cells FITC blue 
 
 
 
